Bruce D. Cheson, MD - ESCO

Bruce D. Cheson, M.D. Page 1

CURRICULUM VITAE

Bruce D. Cheson, M.D. 11028 Waycroft Way North Bethesda, MD 20852

Personal Data

Bruce D. Cheson, M.D., FACP, FAAAS, FASCO

Marital Status - Married: Christine M. Cheson, R.N.

Children: Daughter - Sara Elizabeth

Citizenship - United States of America

Education 1963 - 1967 University of Virginia

Charlottesville, Virginia B.A. (B.A. with Distinction - Major: Psychology)

Summer, 1966 Adelphi University

Garden City, New York Research Assistant

1967-1971 Tufts University School of Medicine M.D. 1971 - 1972 University of Virginia Hospital

Charlottesville, Virginia Intern (Internal Medicine)

1972 - 1973 University of Virginia Hospital

Charlottesville, Virginia Junior Assistant Resident (Internal Medicine)

1973 - 1974 University of Virginia Hospital

Charlottesville, Virginia Senior Assistant Resident (Internal Medicine)

1974 - 1975 New England Medical Center Hospital

Boston, Massachusetts Clinical Fellow (Hematology)

1975 - 1976 New England Medical Center Hospital

Boston, Massachusetts Research Fellow (Hematology)


Professional Experience 1975 - 1976 Northeastern University

School of Pharmacy and Allied Medical Sciences Boston, Massachusetts

Lecturer

1975 - 1977 St. John's Hospital and

Lowell General Hospital Lowell, Massachusetts

Consultant

1976 - 1977 St. John's Hospital

Lowell, Massachusetts Department of Medicine (Hematology)

1976 - 1977 Naval Blood Research Laboratory

Boston, Massachusetts Research Associate

1977 - 1979 University of Utah

College of Nursing Salt Lake City, Utah

Masters Thesis Committee

1978 College of Pharmacy Lecturer 1980 - 1982 College of Health Adjunct Assistant Professor 1977 - 1984 University of Utah School

University of Utah Hospital Salt Lake City, Utah

Assistant Professor of Medicine (Hematology/Oncology)

1984 - 1986 Department of Health and

Human Services National Institutes of Health National Cancer Institute Division of Cancer Treatment Cancer Therapy Evaluation Program Clinical Investigations Branch Bethesda, Maryland

Senior Investigator

1986 - 2002 National Cancer Institute

Division of Cancer Diagnosis and Treatment Cancer Therapy Evaluation Program Clinical Investigations Branch

Head, Medicine Section

1988-1990 Veteran's Administration Hospital

Hematology Service Washington, D.C.

Attending Physician


Professional Experience (Continued)

1989-1992 Walter Reed Army Medical Center

Hematology/Oncology Service Washington, D.C.

Attending Physician

1989-2002 Lymphoma Service Division of Cancer Treatment Clinical Oncology Program

Senior Staff Physician

1995-2002 Division of Hematology/Oncology Lombardi Cancer Center Georgetown University College of Medicine

Clinical Professor

2002-1/1/20 Head of Hematology Director of Hematology Research Georgetown University Hospital Lombardi Cancer Center

Professor of Medicine

2011-1/1/20 Deputy Chief, Division of Hematology and Oncology

Professor of Medicine

2013-2019 1/2/2020-present

Georgetown University Hospital, Division of Hematology-Oncology Lymphoid Malignancy Consultant Scientific Advisor, Lymphoma Research Foundation

Fellowship Program Director

Editorial Experience Journal of Clinical Oncology - Editorial Board (1988 – 1990, 2012-2017) Journal of Clinical Oncology - Associate Editor (1997-2008)

Journal of Clinical Oncology, Guest Editor, Classic Papers and Current Comments. Highlights of Malignant Lymphoma Research, 1996. Journal of Clinical Oncology, special issue on Hematologic Malignancies. 2005.

Clinical Advances in Hematology and Oncology. Editor-in-Chief (2002-2016) Supplement on “Recent Advances in the Treatment of Hematologic Malignancies”, 7 (suppl 6), 2009. Cheson BD and Ashforth E. Supplement “A Summer of Hematologic Science” 7 (suppl 15), 2009.



Ashforth E and Cheson BD. Recent Advances in the Management of Hematologic Malignancies: Highlights from the 51st Annual Meeting of the American Society of Hematology, 2010 Ashforth E and Cheson BD, Summer Happenings in Hematology 2011

Annals of Lymphoma, Editor-in Chief (2016-present) Blood and Lymphatic Cancer, Editorial Board (2016-present)

Targeting CD20 in the Treatment of Adults with Indolent and Aggressive B-cell

Lymphomas – in Hematology and Oncology 4 (suppl 8), 2006.

Clinical Care Advances (ASCO publication) – Editor (2007-2008) Hematology/Oncoilogy Clinics of North America “Non-Hodgkin’s Lymphomas: New

Insights and Therapeutic Strategies”, 22 (5), October, 2008. Histone deacetylase inhibition – a novel approach to cancer treatment – Br J Cancer

supplement, December 2006. Clinical Lymphoma and Myeloma – Editor-in-Chief, 2001-2010 Blood and Lymphatic Cancer: Targets and Therapy – Editorial Board 2010-present World Journal of Oncology – editorial board (2010-present) European Journal of Clinical and Medical Oncology – editorial board (2009-present). Mediterranean Journal of Hematology and Infectious Diseases – Reviewer Lancet – reviewer (current) Cancer Research - Associate Editor (1993-1998) Oncology - Associate Editor (1987 - present) Editor - Series on "Biostatistics in Clinical Trials" Editor - "Patient Referral Resource" (1989-2002)

Editor - “Clinical Status and Optimal Use of Newer Therapeutic Agents” Editor - “Highlights from ASH 1998: New developments in the treatment of lymphomas and leukemias”, March, 1999 Editor - “Highlights from ASH 1999: Expanding Role of Monoclonal Antibodies in the Treatment of Hematologic Malignancies”, March 2000 Editor - “Monoclonal Antibodies in Hematologic Malignancies: Clinical Status”, March 2001 Editor - “Monoclonal Antibodies in Hematologic Malignancies: Research and Clinical Developments”, March 2002 Editor - “Monoclonal Antibodies in Hematologic Malignancies: Targeted Approaches to Treatment”, March 2003



Hodgkin lymphoma: advances beyond standard management. Clin Adv Heme Oncol, Jan 2009.

ASCO News - Editor (1994-2004) ASCO Daily News - Editor (1998-2004) Oncology New International – Editorial Board (1989-present) Drugs – Editorial Board (2004-present), reviewer CLL Updates - Editorial Board (2002-2009). NHL Updates – Editorial board (2002-2009) Hematology/Oncology Clinics of North America on Non-Hodgkin’s Lymphoma, October,

2008. Innovations in Hematologic Oncology. Highlights from the 42rd Annual Meeting of the

American Society of Hematology. Innovations in Hematologic Oncology. Highlights from the 43rd Annual Meeting of the

American Society of Hematology. Current and Emerging Research in Lymphoma - Editor. Lymphoma Research

Foundation of America, 2001 Leukemia Research - Reviewer; Assistant Editor (1996-2008) BioOncology Watch - Head, Editorial Board (1998-2006) Seminars in Hematology - Guest Editor, Supplement on “Chronic Lymphocytic Leukemia

in the Purine Analog Era: New Insights and Challenges” (July, 1998) Seminars in Oncology - Guest Editor, Supplement on Bendamustine in Hematologic Malignancies” 29(4)(suppl 13), 2002. Seminars in Oncology. The Role of Alemtuzumab (CAMPATH) in the Treatment of Hematologic Malignancies; 33 (2; suppl 5) April, 2006 Clinical Cancer Research - Editorial Board (1995-1996) Seminars in Oncology - Guest Editor, Supplement on “Low-Grade Non-Hodgkin’s

Lymphomas” (October, 1993) Seminars in Oncology - Guest Editor, Supplement on "Fludarabine" (October, 1990) Series Editor "Basic and Clinical Oncology" - Marcel Dekker Publishers Oncology News International- Associate Editor (1992-2010) Guest Editor - "Biotherapy Reporter", Triclinica Publications, 1991.



Blood – reviewer New England Journal of Medicine - reviewer, book review Journal of Clinical Oncology – reviewer Lancet Oncology – reviewer Lancet Haematology - reviewer Annals of Oncology – reviewer eJHaem – Reviewer Drugs - Reviewer Annals of Internal Medicine – reviewer Cancer – reviewer Leukemia/Lymphoma - reviewer USP-DI “Drug Information for the Health Care Practitioner”, 1993, 1995, 1997, 1998 –

Contributor Clinical Drug Investigation, “The Emerging Role of Idarubicin - a Seminar-in-Print” (1995)

- Peer-review panel AHFS “Drug Information” - American Hospital Formulary Service – reviewer Cancer Chemotherapy and Pharmacology – reviewer The Oncologist – reviewer Indian Journal of Cancer – reviewer Journal of Clinical Outcomes Management – reviewer Editorial advisory board – Versita open access books (2012-2018) Leukemia – section editor (2014-2016) Hematology (ASH 2016) 2016, 2018 – reviewer HemaSphere - reviewer


Reviewing and Editorial Experience (Continued)


Honors

Dean's List, University of Virginia (1964 - 1967) Phi Sigma Society Who's Who in the East, Who's Who in the West National Cancer Institute Merit Award, October 1, 1985 American Men and Women of Science James M. Perelman Visiting Professorship, 11 October 2000 Northern Virginia Magazine – Top Docs: 2007, 2008 ASCO Statesman Award – 2007 Fellow AAAS, 2008-present Patients’ Choice Award, 2009 America’s Top Physicians, 2009 Who’s Who in America, 2009-2018 Lymphoma Research Foundation Freundlich Leadership Award, 2009 Top Doctor in Washington (international Association of Internists) – 2010 Leading Physicians of the World – 2010 Georgetown University Hospital, Division of Hematology/Oncology Teaching Attending of the Year 2010-2011. America’s Top Doctors in Cancer – 2011, 2012 Top Oncologist in Washington, D.C. by International Association of Oncologists - 2012 Leading Physicians of the World – 2012 Top Doctors in Baltimore/Washington, D.C. – 2012 Lymphoma Research Foundation Distinguished Achievement Award (with Christine Cheson) – 2013 Top Doctors, U.S. News and World Report – 2012-2017 Special Coach for Fondazione Italiana Linfomi La Cantera – 5-8 March 2013 Department of Medicine, Research Day, First Place (Ujjani and Cheson), 2013. America’s Top Physicians for Cancer – 2013 Leading Physicians of the World – 2012- Best Doctors in America – 2014- International Association of Oncologists – Leading Oncologists of the World - 2015- Thomas Jefferson Society of Alumni of the University of Virginia 2017-present Top Doctors – 2017-2019 Marquis Who’s Who in the World – 2019 European School of Oncology Senior Faculty – 2020-present Pioneer in Oncology – International Journal of Clinical Research – 2021

Scholarships

New York State Regents Scholarship (1963)

Diplomate

National Board of Medical Examiners American Board of Internal Medicine - 1974 American Board of Internal Medicine - Subspecialty

Examination in Hematology - 1976


Committees and Administrative Experience

University of Utah Hospital Clinical Coordinator - Oncology

Interdisciplinary Applied Nutrition Training Program (1980 - 1982)

University of Utah College of Medicine: Basic Science Elective Committee (1978 - 1980)

Blood Bank Committee (1978 - 1984) Medical Isotopes and Radioactive Drug Research Committee (1980 - 1984) Medicine Clerkship Committee (1982 - 1984) Southwest Oncology Group - Myeloma Study Committee (1982 - 1984) Southwest Oncology Group - Data Monitoring Committee (1985 - present) Cancer and Leukemia Group B - Data Monitoring Committee (1992-2002) NCI-Extramural Clinical Trials in AIDS (Chairman) (1984-1986) Feasibility Conference for National Bone Marrow Transplant

Registry - Planning Committee and NCI Representative (1985)

NIH AIDS Task Force - Endpoints for Clinical Trials (1986)

Bruce D. Cheson, M.D. Page 10 Committees and Administrative Experience (Continued)

AIDS Treatment Evaluation Units, Oncology Subcommittee - NCI AIDS Treatment Cooperative Group, Oncology Subcommittee - NCI

Representative (1988 - 1992) E.O.R.T.C. Protocol Review Committee (1987 - 1990) Office of Technology Assessment of the U.S. Congress – Bone Marrow

Transplantation Using Unrelated Donors: Current Clinical Status and Policy Issues (1987)

National Heart, Lung and Blood Institute, National Blood Resources Educational

Committee (1987 - 1993) NCI Planning Committee for Workshop on the Epidemiology of

Multiple Myeloma (1989)

American College of Physicians, Medical Knowledge Self-Assessment Program – IX Oncology Committee (1989 - 1991)

American College of Physicians, Medical Knowledge Self-Assessment Program -

Subspecialty Examination in Oncology - Co-chairman (1991-1994) American College of Physicians, Medical Knowledge Self-Assessment Program -

Subspecialty Examination in Oncology -Chairman (1996-1998) American College of Physicians/American Society of Clinical Oncology, Medical

Knowledge Self Assessment Examination in Oncology – Chair (2002-2004) American Society of Clinical Oncology-

Public Relations Committee (1987-1994) Chairman (1990-1994)

Education Committee (1989 - 1990) Ad Hoc Committee on Autologous Bone Marrow Transplantation (1991) Special Awards Committee (1991-1995) Program Committee (!988, 1992)-Chairman

Leukemia/Lymphoma Subcommittee - (1992) Health Care Reform Working Group (1992)

Publications Committee (1994-2004) Editor, ASCO News (1994-1999)

Board of Directors (1994-1997) Executive Committee (1996-997) Clinical Trials Task Force (1995-1996)

Strategic Planning Committee (1997-1998) Cancer Communications Committee (2005-2008) IDEA Mentor – 2012 Statesman Award - 2007 Fellow – 2012-present


U.S. General Accounting Office Advisory Board on Bone Marrow Transplantation: An International Comparison of Allocation and Utilization (1992-1994)

American Society of Hematology - Program Committee (1994, 1995, 2009) Reviewer, Educational Book (2009) American Association for Cancer Research - Program Committee, Special

Symposium on Translational Research in Cancer (1994) Special Expert to the Oncologic Drug Advisory Committee, Food and Drug

Administration (1999-2016) Scientific Advisor, German CLL Study Group (2000-2003) Organizing Committee – 1st International Workshop on Waldenström’s Macroglobulinemia - 2000 Oncologic Drug Advisory Committee to the Food and Drug Administration (2002-

2006)

Georgetown University Hospital/Lombardi Comprehensive Cancer Center: Institutional Review Board (2002-2004) Deputy Chair (April, 2003-April, 2004) Data Safety and Monitoring Committee (2002-present) Clinical Research Committee (2006-present) Executive Committee, LCCC (2006-2009) 2 Bles Medical Director (2010-present) Oncology Safety Committee (2010-present) Chair, ResourceAllocation Committee for Investigator Initiated Trials (2011-

present) Strategic Planning Committee (2012-present) Experimental Therapeutics Committee Cancer and Leukemia Group B/Alliance Lymphoma Committee (2002-present)

Chairman, Lymphoma Committee - 2003-2013 Board of Directors (2014-2016)

International Harmonization Committee on Response Assessment in Lymphomas

– Co-chair (2004-2007). American Joint Commission on Cancer, American College of Surgeons,

Co-chair, Lymphoma Subcommittee (2005-2011) 8th Edition Working Group (2012-13) Chair, Lymphoma Subcommittee (2012-13)

NCI Leukemia Advisory Committee on the Chernobyl Project (2006-2012) Scientific Advisory Board – Lyon Synergie Cancer (2007-2010). WHO Clinical Advisory Committee for Classification of Lymphoid Malignancies

(2007)


Scientific Committee 8th International Workshop of the German CLL Study Group (2013)

Scientific Committee – 7th International Symposium on Hodgkin Lymphoma (2006-

2007) Scientific Committee – 8th International Symposium on Hodgkin Lymphoma (2009-

2010) Scientific Committee – 9th International Symposium on Hodgkin Lymphoma (2011-

2012) Scientific Committee – 10th International Symposium on Hodgkin Lymphoma

(2016) Scientific Committee – 11th International Symposium on Hodgkin Lymphoma

(2018) Scientific Committee 3rd International Workshop on PET in Lymphoma (2010) Scientific Committee 4th International Workshop on Pet in Lymphoma (2012) Scientific Committee 5th International Workshop on PET in Lymphoma (2014) Scientific Committee 6th International Workshop on PET in Lymphoma (2016) Scientific Committee 7th International Workshop on PET in Lymphoma (2018)

NCI Lymphoma Steering Committee (2009-2013) Diffuse Large B-cell Subcommittee (2009-2013) Hodgkin Subcommittee (2009-2013) NCI Pediatric Lymphoma Steering Committee (ad hoc reviewer, 19 April 2013)

Co-PI MCCRC/ACCRU, Georgetown/Alliance (2011-2016) PI Alliance Grant, Georgetown University (2012-2016) International Advisory Panel: Cancer Research UK’s Clinical Trials Awards and

Advisory Committee (2011-present) Italian Association for Cancer Research – reviewer (2012) International Committee for the Clinical Research in Cancer (CIR2C), National

Cancer Institute in France – reviewer (2012) Leukaemia and Lymphoma (UK) – reviewer (2012) International Lymphoma Coalition, Diffuse Large B-cell Committee, 2012-present

College of American Pathologists, Hematolymphoid Cancer Protocol Review Panel

(2014) International CTAAC Advisory Board – 2011-2016.

1st Postgraduate Lymphoma Conference – Scientific Committee - 2015 2nd Postgraduate Lymphoma Conference – Scientific Committee – 2016 3rd Postgraduate Lymphoma Conference – Scientific Committee – 2017 4th Postgraduate Lymphoma Conference – Scientific Committee – 2018 5th Postgraduate Lymphoma Conference – Scientific Committee – 2019 6th Postgraduate Lymphoma Conference - Scientific Committee – 2020


Advisory Board – International Conference on Malignant Lymphoma (ICML, Lugano) – 2007- present USERN Advisory Board – 2021-present. European School of Oncology Mentor – 2021-present.


Professional Activities

University of Utah Visiting Cancer Teaching Program (1979 -1983) College of Medicine: Lecturer in Freshman Biochemistry course (1978 - 1983) College of Health: 1. Lecturer in Nutrition Pathophysiology course (1980 - 1982) 2. Preceptor - Graduate Student Clinical Clerkship (1980 - 1982)

3. Graduate Seminar 680R - Nutrition and Cancer (instructor) Summer Quarter, 1980

4. Master Thesis Committee - August 1981 New York University Presidential Fellowship Program - Reviewer (1991) U.S. Pharmacopoeia - drug information reviewer (1992-present) American Society of Hospital Pharmacists - preparation of AHFS Drug Information

material (1992-1995) Medical Education Committee, Meniscus Educational Institute (1998-2004)

Professional Societies

American Association for the Advancement of Science (2008-present) Fellow AAAS (2008-present) American Society of Clinical Oncology (1984 - Present) Associate, American College of Physicians (1971 - 1975) Member, American College of Physicians (1976 - Present) Fellow, American College of Physicians (1979 - Present) American Society of Hematology (1976 - Present) American Federation for Clinical Research (1976 - Present) New York Academy of Sciences (1977 - 1986) Utah State Medical Association (1978 - 1984) Salt Lake County Medical Society (1978 - 1984) Southwest Oncology Group (1978 - 1984) International Association of Oncologists (2012-present)

Licensure

Commonwealth of Massachusetts - License No. 38041 (inactive) State of Utah - License No. 5585 (inactive) State of Maryland - License No. D35917 (active) District of Columbia - License No. 21035 (active)


Foundations

Cure for Lymphoma Foundation, Local Affiliates Board (2000-2001) Lymphoma Research Foundation

Honorary Medical Board (2000-2001) Scientific Advisory Board (2001-present) Executive Committee (2004-present) Public Policy Committee (2004-2006) Chair-elect, Scientific Advisory Board (2008-2010) Chair, Scientific Advisory Board (2010-2012) Board of Directors (2010-2012)

Co-Chair, Lymphoma Research Ride (2006-present) Medical Review Committee (2011-present) Grant Oversight Committee (2015-present) Patient Publications Review Committee (2017-present) Scientific Advisor (2020-present)

Bruce D. Cheson, M.D. Page 16 Publications

1. Cheson BD, Stricker G, and Fry CL. The repression-sensitization scale and

measures of prejudice. J Social Psychol 80:197-200, 1970. 2. Cheson BD, Bluming AZ, and Alroy J. Cogan's Syndrome: A systemic vasculitis.

Amer J Med 60:549-555, 1976. 3. Cheson BD, Christensen RL, Sperling R, Kohler BE, and Babior BM. The origin of

the chemiluminescence of phagocytosing granulocytes. J Clin Invest 58:789-796, 1976.

4. Cheson BD, Curnutte JT, and Babior BM. The oxidative killing mechanisms of the

neutrophil. Prog Clin Immunol 3:1-65, 1977. 5. Cheson BD. Hodgkin's disease, alcohol, and vena caval obstruction. JAMA

239:23-24, 1978. 6. Green JA, Spruance SL, and Cheson BD. Toxoplasmosis in a patient with

untreated Hodgkin's disease. Cancer 45:808-810, 1980. 7. Cheson BD, Plass RR, and Rothstein G. Defective opsonization in multiple

myeloma. Blood 55: 602-606, 1980. 8. Cheson BD, Vaninetti S, Buskjaer L, and Fineman R. Philadelphia chromosome

(Ph1) - associated leukemias: A family study. Cancer Genet Cytogenet 1:321-328, 1980.

9. Cheson BD, and Christiansen RM. Cutis Verticis Gyrata: Unusual

chloromatous disease in acute myelogenous leukemia. Amer J Hematol 8:415-418, 1980.

Bruce D. Cheson, M.D. Page 17 Publications (Continued) 10. Cheson BD, Johnston J, del Junco G, and Kjeldsberg CR. Cytologic

evidence of disseminated immunoblastic lymphoma. Amer J Clin Path 75:621-625, 1981.

11. Cheson BD, and Morris SE. The role of complement and IgG in zymosan opsonization. Int Arch All Appl Immunol 66:48-53, 1981.

12a. Futrell NN, Osborn AG, and Cheson BD. Pineal gland tumors: CT-pathological spectrum. Amer J Neuroradiol 2:415-420, 1981. 12b. Futrell NN, Osborn AG, and Cheson BD. Pineal gland tumors:

CT-pathological spectrum. Amer J Roentgenol 137:951-956, 1981.

13. Mintz SJ, Petersen SR, Cheson BD, Cordell LJ, and Richards RC. Splenectomy for immune thrombocytopenic purpura. Arch Surg

116:645-650, 1981.

14. Cheson BD. Opsonic activity of human myeloma immunoglobulins (M-Ig). Amer J Hematol 11:347-353, 1981.

15. Cheson BD, Schumann GB, and Johnston JL. Urinary cytodiagnosis of renal

involvement in disseminated histiocytic lymphoma. Acta Cytologica 28:148-152, 1984.

16. Cheson BD, Rom WN, and Webber RC. Basophilic stippling of red blood cells A

non-specific finding of multiple etiology. Amer J Indust Med 5:327-334, 1984. 17. Cheson BD, Walker HS, Heath ME, Gobel RJ, and Janatova J. Defective binding

of the third component of complement (C3) to Streptococcus pneumoniae in multiple myeloma. Blood 63:949-957, 1984.

18. Cheson BD, Schumann JJ, and Schumann GB. Urinary cytodiagnostic

abnormalities in 50 patients with non-Hodgkin's lymphomas. Cancer 54:1914-1919, 1984.

19. Cheson BD, Samlowski W, Tang TT, and Spruance SL. Open lung biopsy in 87

immunocompromised patients with pulmonary infiltrates. Cancer 55:453-459, 1985.

20. Ely KR, Peabody DS, Holm TR, Cheson BD, and Edmundson AB. Accessible

intrachain disulfide bonds in hybrids of light chains. Molec Immunol 22:85-92, 1985.

21. Heath ME, and Cheson BD. Defective complement activity in chronic lymphocytic

leukemia. Amer J Hematol 19:63-73, 1985. 22. Cheson BD, DeBellis C, Schumann JL, and Schumann GB. The myeloma cast.

Frequency of observation and clinical correlation in 30 patients with multiple myeloma. Amer J Clin Path 83:421-425, 1985.

Bruce D. Cheson, M.D. Page 18 Publications (Continued) 23. Cheson BD. Clinical utility of body fluid analyses. Clinics Lab Med 5(2):195-208,

1985. 24. Cheson BD, Clegg DO, and Moatamed F. Ultrastructural evidence for persistent

bone marrow gold in aplastic anemia. Arth and Rheum 29:128-132, 1986. 25. Cheson BD, and Curt GA. Bone marrow transplantation: Current perspectives and

future directions. J Natl Cancer Inst 76:1265-1267, 1986. 26. Cheson BD, Wittes RE, Friedman MA. Low-grade non-Hodgkin's lymphoma

revisited. Cancer Treat Rep 70:1051-1054, 1986. 27. Cheson BD, Jasperse DM, Simon R, and Friedman MA. A critical appraisal of low

dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4:1857-1864, 1986.

28. Cheson BD, Jasperse DM, Chun HG, and Friedman MA. Differentiating agents in

human malignancies. Cancer Treat Rev 13:129-145, 1986. 29. Cheson BD and Martin A. Clinical trials in hairy cell leukemia:Current status and

future directions. Ann Intern Med 106:871-878, 1987. 30. Cheson BD and Simon R. Low dose ara-C in acute non lymphocytic leukemia and

myelodysplastic syndromes: A review of 20 years' experience. Sem Oncol 14 (Suppl l):126-133, 1987.

31. Edmundson AB, Ely KR, Herron JN, and Cheson BD. The binding of opioid

peptides to the Mcg light chain dimer: Flexible keys and adjustable locks. Molec Immunol 24:915-935, 1987.

32. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, Rios A, Groopman JE,

Gill P, Volberding PA, Poeisz BJ, Gottlieb MS, Holden H, Volsky D, Silver SS, Hawkins MJ. Suramin therapy in AIDS and related disorders: Report of the U.S. Suramin Working Group. JAMA 258:1347-1351, 1987.

33. Lofters W, Campbell M, Gibbs WN, and Cheson BD. 2'-deoxycoformycin therapy in

adult T-cell leukemia/lymphoma. Cancer 60:2605-2608, 1987. 34. Martin A, Cheson BD. Chronic myelogenous leukemia: New biologic therapies,

endpoints and questions. Oncology 1(7): 12-16, 1987. 35. Nerenstone SR, Archer JI, and Cheson BD. Current status and future directions for

clinical trials in chronic lymphocytic leukemia. Oncology 1(8):31-39, 1987. 36. O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, and Hoth DF. 2'-

Deoxycoformycin (pentostatin) for lymphoid malignancies. Ann Intern Med 108:733-743, 1988.

Bruce D. Cheson, M.D. Page 19 Publications (Continued) 37. O'Dwyer PJ, Cheson BD, Leyland-Jones B, King SA, and Hoth DF.

Deoxycoformycin: An active new drug for indolent lymphomas and hairy cell leukemia. Oncology 2(6):17-22, 1988.

38. Cheson BD. Long-term perspectives of hematologic malignancies. TranAssoc Life

Ins Med Dir of Amer 71:198-219, 1988. 39. Armitage JO, and Cheson BD. Interpretation of clinical trials in diffuse large cell

lymphoma. J Clin Oncol 6:1335-1347, 1988. 40. Grem JL, Cheson BD, King SA, Leyland-Jones B, and Suffness M. Cephalotaxine

esters: Antileukemic advance or therapeutic failure? J Natl Cancer Inst 80:1095-1103, 1988.

41. Sarosy G, Leyland-Jones B, Soochan MP, Cheson BD. The systemic

administration of intravenous melphalan J Clin Oncol 6:1768-1782, 1988. 42. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Boldt DH,

Oken MM, Keating MJ, Kempin SJ, Foon KA. Report of the NCI-Sponsored Working Group on guidelines for clinical protocols for chronic lymphocytic leukemia. Am J Hematol 29:152-163, 1988.

43. Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Cabanillas F, and

Dicke K. Prognostic factors with high dose melphalan therapy for refractory multiple myeloma. Blood 72:2015-2019, 1988.

44. Simon R, Durrleman S, Bloomfield CD, Bonadonna G, Hoppe RT, Rudders R,

Cheson BD, Berard CW. The non-Hodgkin's lymphoma pathologic classification project. Long-term follow-up of 1153 patients with non-Hodgkin's lymphomas. Ann Intern Med 109:939-945, 1988.

45. Cheson BD. Study design in chronic lymphocytic leukemia. Nouvelle Revue

Francaise d' Hematologie 30:407-410, 1988. 46. Cheson BD, Lacerna L, Leyland-Jones B, Sarosy G, Wittes RE. Autologous bone

marrow transplantation:Current status and future directions. Ann Intern Med 110:51-65, 1989.

47. Grem JL, King SA, Cheson BD, Leyland-Jones B, Wittes RE. 2'-Deoxycoformycin

in hairy cell leukemia: Treatment by the special exception mechanism. J Natl Cancer Inst 81:448-453, 1989.

48. Cheson BD. Current approaches to the chemotherapy of B-cell chronic

lymphocytic leukemia. Am J Hematol 32:72-77, 1989. 49. Durrleman S, Grem JL, Cheson BD. 2'-Deoxycoformycin after failure of alpha-

interferon in hairy cell leukemia. Eur J Haematol 43:297-302, 1989.

Bruce D. Cheson, M.D. Page 20 Publications (Continued) 50. Cheson BD. Interferon in the treatment of B-cell malignancies. Biotherapy and

Cancer 2(3):1-7, 1989. 51. Report of the Second International Workshop on Myeloma: Advances in Biology

and Therapy. Cancer Res 49:7172-7175, 1989. 52. Simon R, Durrleman S, Hoppe RT, Bonadonna G, Bloomfield CD, Rudders RA,

Cheson BD, Berard CW. Prognostic factors for patients with diffuse large cell of immunoblastic non-Hodgkin's lymphomas: Experience of the non-Hodgkin's Lymphoma Pathologic Classification Project. Med Ped Oncol 18:89-96, 1990.

53. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD,

Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG. Report of the NCI-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990.

54. Cheson BD. Clinical use of hematopoietic growth factors. Drug News and

Perspectives 3:154-160, 1990. 55. Cheson BD. Current Approaches to the therapy of the Myelodysplastic

Syndromes. Ann Intern Med 112:932-941,1990. 56. Cheson BD. New therapeutic advances in chronic lymphocytic leukemia. Drugs of

Today 26:279-287, 1990. 57. Grem JL, Rubinstein L, King SA, Hawkins MJ, Cheson BD, ShoemakerDD. Clinical

toxicity associated with tiazofurin. Invest New Drugs 8:227-238, 1990. 58. Cheson BD. Cancer Consultation: Aplastic anemia and cytopenias. Primary Care

and Cancer 10(7):44-49, 1990. 59. Cheson BD. Cancer Consultation: Aplastic anemia and secondary leukemia.

Primary Care and Cancer 10(8):18, 1990. 60. Barlogie B, Jagannath S, Cheson B, Smallwood L, Hendrickson A, Gutterman J,

Alexanian R. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 76:677-680, 1990.

61. Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder MS, Hutchins LF,

Coltman CA, Jr, Bonnet JD, Cheson B, Knost JA, Samhouri A, Beckford J, Stock-Novack D. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma. A Southwest Oncology Group Study. J Clin Oncol 8:1575-1584, 1990.

62. Cheson BD. Recent therapeutic advances in B-cell chronic lymphocytic leukemia.

Oncology 4(9):71-84, 1990. 63. Cheson BD. Fludarabine - looking forward. Semin Oncol 17 (suppl 8):1-2, 1990.

Bruce D. Cheson, M.D. Page 21 Publications (Continued) 64. Cheson BD. Strategies for the development of fludarabine. Semin Oncol 17

(suppl 8):71-78, 1990. 65. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic

purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 9:175-188, 1991.

66. Cheson BD. Cancer Consultation: Treatment of early stage chronic lymphocytic

leukemia. Primary Care and Cancer 11:41, 1991. 67. Ayash LJ, Cheson BD, Antman K. A perspective on dose-intensive therapy with

autologous marrow transplantation for solid tumors. Oncology 5(3):25-32, 1991. 68. Cheson BD. Chronic lymphocytic leukemia and hairy cell leukemia. Current

Opinion in Oncology 3:54-62, 1991. 69. Moore TJ, Phillips P, Nerenstone SR, Cheson BD. Systemic treatment of

advanced and recurrent endometrial carcinoma: Current status and future directions. J Clin Oncol 9:1071-1088, 1991.

70. Cheson BD. The value of randomized clinical trials. Contemp Oncol 1:34-36,

1991. 71. Cheson BD. New chemotherapeutic agents for non-Hodgkin's lymphomas. Drugs

of Today 27:157-176. 1991. 72. Cheson BD. New chemotherapeutic agents for non-Hodgkin's lymphomas. Hem

Onc Clinics of North Amer 5:1027-1051, 1991. 73. Cheson BD, New modalities of therapy in chronic lymphocytic leukemia. Crit Rev

Onc/Hematol 11:167-177, 1991. 74. Cheson BD, Vena DA, Sorensen JM, Fallavollita A. Current status of U.S. clinical

trials in chronic lymphocytic leukemia. Leukemia and Lymphoma 5(suppl)119-122, 1991.

75. Cheson BD. Clinical trials programs. Sem Onc Nursing 7:235-242, 1991. 76. Durie BGM, Crowley J, Coltman CA, Jr., Chapman RA, Balcerzak SP, Bonnet JD,

Lipschitz DA, Stephens RL, Cheson BD. Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study. Inv New Drugs 9:329-331, 1991.

77. Cheson BD. Chemotherapy and bone marrow transplantation for the

myelodysplastic syndromes. Sem Oncol 19:85-94, 1992. 78. Cheson BD. Chronic B-cell leukemias. Recent Adv Hematol 6:107-129, 1992. 79. Cheson BD. Treatment of localized gastric lymphomas. Primary Care and Cancer

12(1):6, 1992.

Bruce D. Cheson, M.D. Page 22 Publications (Continued) 80. Cheson BD. Current approaches to the therapy of the myelodysplastic syndromes.

Hematol Reviews and Communications 6:157-171, 1992. 81. Smith MA, Parkinson DR, Cheson BD, and Friedman MA. Retinoids in cancer

therapy. J Clin Oncol 10:839-864, 1992. 82. Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson BD. Quality of life

assessment in cancer treatment protocols: Research issues in protocol development. J Natl Cancer Inst 84:575-579, 1992.

83. Cheson BD. Current therapy for the myelodysplastic syndromes. Drugs of Today

28:103-117, 1992. 84. Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson BD. Building quality of life

assessment into cancer treatment studies: Essential elements in protocol preparation. Oncology 6:25-28, 1992.

85. Cheson BD. Pharmacology of fludarabine. Oncology News Internat 1:20-21,

1992. 86. Cheson BD. New antimetabolites in the treatment of human malignancies. Sem

Oncol 19:695-706, 1992. 87. Cheson BD. Duration of therapy in diffuse large cell lymphoma. Onc News

Internat 1:28, 1992. 88. Parkinson DR, Smith MA, Cheson BD, Stevenson HC, Friedman MA. Trans-

retinoic acid and related differentiation agents. Sem Oncol 19:734-741, 1992. 89. Cheson BD. New purine analogs in the treatment of hematologic malignancies.

Drugs of Today 28:487-500, 1992. 90. Gotay CC, Phillips PH, Cheson BD. Male-female differences in the impact of

cancer therapy. Oncology 7(2):67-74, 1993. 91. Cheson BD. The association between lymphocytopenia and lymphoma.

Primary Care and Cancer 13(1):11-12, 1993. 92. Feigal E, Christian M, Cheson B, Grever M, Friedman M. New chemotherapeutic

agents in non-small cell lung cancer. Sem Oncol 20:185-201, 1993. 93. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe

ES, Herdt J, Cheson BD, Chabner BA. EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin’s lymphoma . J Clin Oncol 11:1573-1582, 1993.

94. Cheson BD. Low-grade non-Hodgkin’s lymphomas: An introduction. Sem Oncol

20 (suppl 5):1-2, 1993.

Bruce D. Cheson, M.D. Page 23 Publications (Continued) 95. Cheson BD. New chemotherapeutic agents for the treatment of low grade non-

Hodgkin’s lymphomas. Sem Oncol 20 (suppl 5):96-110, 1993. 96. Parkinson DR, Sznol M, Cheson BD. Biologic therapies for low-grade lymphomas.

Sem Oncol 20 (suppl 5):111-117, 1993. 97. Cheson, BD. Autologous bone marrow transplantation for follicular non-Hodgkin’s

lymphoma. Primary Care Cancer (in press). 98. Cheson BD. Purine analogs in lymphoproliferative disorders. Leuk Lymph 11

(suppl 2):153-159, 1993. 99. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs. J

Clin Oncol 12:2216-2228, 1994. 100. Vesole D, Barlogie B, Jagannath S, Crowley J, Cheson B, Tricot G. High dose

therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 84:950-956, 1994.

101. Cheson BD. Chronic lymphocytic leukemia and hairy cell leukemia. Curr Opinion

Hematol 1:268-277, 1994. 102. Silberman G, Crosse M, Peterson E, Weston R, Horowitz MM, Appelbaum F,

Cheson BD. An international comparison of the availability and appropriateness of allogeneic bone marrow transplantation in the treatment of chronic myeloid leukemia. New Engl J Med 331:1063-1067, 1994.

103. Grever M, Kopecky K, Foucar MK, Head D, Bennett J, Davey F, Corbett WEN,

Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson BD. A randomized comparison of pentostatin vs alpha-interferon in previously untreated patients with hairy cell leukemia. J Clin Oncol 13:974-982, 1995.

104. Wilson WH, Chabner BA, Bryant G, Fojo A, Bates S, Jaffe ES, Steinberg SM,

Goldspiel BR, Cheson BD, Wittes RE. A phase II study of paclitaxel in relapsed non-Hodgkin’s lymphomas. J Clin Oncol 13:381-386, 1995.

105. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley

J, Barlogie B. Peripheral blood stem cell transplants for multiple myeloma - Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588-596, 1995.

106. Cheson BD. Infectious and immunological complications of purine analogue

therapy. J Clin Oncol 13:2431-2448, 1995. 107. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S, Rai KR.

National Cancer Institute-Sponsored Working Group Guidelines for chronic lymphocytic leukemia - Revisions. Blood 87:4990-4997, 1996.

Bruce D. Cheson, M.D. Page 24 Publications (Continued) 108. Vesole DH, Tricot G, Jagannath S, Desikan KR, Bracy D, Miller L, Cheson B,

Crowley J, Barlogie B. Autotransplants in multiple myeloma: What have we learned? Blood 88:838-847, 1996.

109. Keating M, Cheson B, Gribben JG, Robertson B, Nadler L. Innovative strategies

for the treatment of CLL. Leuk Lymphoma 22 (suppl 2):53-64, 1996. 110. Arbuck SG, Sorensen JM, Christian MC, Ho P, Pluda J, Cheson BD. New drugs in

non-Hodgkin’s lymphoma. Ann Oncol 8 (suppl 1):119-128, 1997. 111. Cheson BD. Perspectives on Purine Analogs, Hematology and Cell Therapy

38:S109-116, 1996. 112. Cheson BD. Introduction: My Back Pages. Classic Papers and Current

Comments: Highlights of Lymphoma Research 1:189-192, 1996. 113. Barlogie B, Jagannath S, Vesole DH, Tricot G, Naucke S, Cheson B, Mattox S,

Bracy D, Salmon S, Jacobson J, Crowley J. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789-793, 1997.

114. Sorensen JM, Vena D, Fallavollita A, Chun HG, Cheson BD. Treatment of

refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C protocol mechanism of the National Cancer Institute: 5-year follow-up report. J Clin Oncol 15:458-465, 1997.

115. Cheson BD. The myelodysplastic syndromes. The Oncologist 2:28-39, 1997. 116. Zwiebel JA and Cheson BD. Chronic lymphocytic leukemia: Staging and

prognostic factors. Semin Oncol 25:42059, 1998. 117. Cheson BD, Frame J, Vena D, Sorensen JM. Tumor lysis syndrome: an

uncommon complication of fludarabine therapy of patients with chronic lymphocytic leukemia. J Clin Oncol 16:2305-2312,1998.

118. Cheson BD. New prospects in the treatment of indolent lymphomas with purine

analogs. Cancer Journal of Scientific American Medicine 4 (suppl 2) S27-36, 1998.

119. Wilson WH, Little R, Pearson D, Jaffe ES, Steinberg SM, Cheson BD, Humphrey

R, Kohler DR, Elwood P. A phase II and dose escalation + G-CSF study of 9-aminocamptothecin in relapsed and refractory lymphomas J Clin Oncol 16:2345-2351, 1998.

120. Cheson BD. Standard and low-dose chemotherapy for the treatment of

myelodysplastic syndromes. Leuk Res 22 (suppl 1)S17-22, 1998.

Bruce D. Cheson, M.D. Page 25 Publications (Continued) 121. Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, Tallman

M, Annino L, Connors JM, Coiffier B, Lauria F. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (Cladribine) via the Group C Protocol mechanism of the National Cancer Institute: Report of 979 patients. J Clin Oncol,16: 3007-3015, 1998.

122. Cheson B. Current approaches to therapy for indolent non-Hodgkin’s lymphomas.

Oncology 12 (suppl 8):25-34, 1998. 123. Cheson B. Chronic lymphocytic leukemia in the purine analog era: new insights

and challenges. Sem Hematol 35 (suppl 3):1-2, 1998. 124. Cheson B. Therapy for previously untreated chronic lymphocytic leukemia: a

reevaluation. Sem Hematol 35 (suppl 3):14-21, 1998 125. O’Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreef M, Giralt S,

Cheson B, Keating M, Freireich E, Rios MB, Talpaz M. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 93:4149-4153, 1999.

126. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G,

Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J, Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999.

127. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Klippenstein D,

Hagenbeek, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Connors JM, Cabanillas F, Hiddemann W. Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s Lymphoma. J Clin Oncol 17:1244-1253, 1999.

128. Cheson BD, Vena D, Barrett J, Freidlin B. Second malignancies as a

consequence of nucleoside analog therapy of chronic lymphoid leukemias. J Clin Oncol 17:2454-2460. 1999.

129. Kreitman RJ and Cheson BD. Treatment of hairy cell leukemia at the close of the

20th century. Hematology 4:283-303, 1999. 130. Cheson BD. Future strategies towards the cure of indolent lymphoid malignancies.

Sem Hematol 36 (suppl 5):1-2, 1999. 131. Cheson BD. New chemotherapeutic strategies for the treatment of indolent

lymphoid malignancies. Sem Hematol 36 (suppl 5):26-33, 1999. 132. Kalil N, and Cheson BD. Chronic lymphocytic leukemia. The Oncologist 4:352-

269, 1999.

Bruce D. Cheson, M.D. Page 26 Publications (Continued) 133. Vey N, Kantarjian H, Tran H, Beran M, O’Brien S, Bivins C, Giles F, Cortes J,

Cheson B, Arbuck S, Estey E. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory of relapsed acute leukemia. Ann Oncol 10:577-583, 1999.

134. Kalil N and Cheson BD. Management of chronic lymphocytic leukemia. Drugs and

Aging 16:9-27, 2000. 135. Grillo-López AJ, Cheson BD, Horning SJ, Peterson BA, Cater WD, Varns CL,

Klippenstein DL, Shen CD. Response criteria for NHL: importance of “normal” lymph node size and correlations with response rates. Ann Oncol 11:399-408, 2000.

136. Cheson BD, Zwiebel JA, Dancey J, Wright J, Murgo A. Novel therapeutic agents

for the treatment of myelodysplastic syndromes. Sem Oncol 27:560-577, 2000. 137. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg

B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Greenberg PL. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000.

138. Rai KR, Peterson BL, Kolitz J, Elias J, Shepherd L, Hines J, Threatte GA,

Appelbaum FR, Larson RA, Cheson BD, Schiffer CA. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New Engl J Med 343:1750-1757, 2000.

139. Cheson BD. Current approaches to therapy for indolent non-Hodgkin’s

lymphomas. Onc Spec Ed 3:43-48, 2000. 140. Flinn I, Kopecky K, Foucar K, Head D, Bennett J, Hutchinson R, Corbett W,

Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever M. Long-term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981-2986, 2000.

141. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S,

Gajewski J, Murgo A, Cheson B, O’Brien S. Homoharringtonine and low-dose cytarabine in the management of late chronic phase chronic myelogenous leukemia. J Clin Oncol 18:351303521, 2000.

142. Cheson BD, Dancey J, Murgo A. New drugs for the treatment of chronic

lymphocytic leukemia. Rev Clin Exper Hematol 4:145-166, 2000. 143. Cheson BD. Chronic lymphocytic leukemia: Emerging therapies and future

directions - chemotherapy. Hematol Cell Ther. 27:41-47, 2000. 144. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo

A, and Wilson WH. The Role of a Doxorubicin-Containing Regimen in Relapsed and Resistant Lymphomas: An 8 year Follow-up Study of EPOCH. J Clin Oncol 18:3633-3642, 2000.

Bruce D. Cheson, M.D. Page 27 Publications (Continued) 145. Cheson B. New drug development in Non-Hodgkin lymphoma. Curr Onc Rep

3:250-259, 2001. 146. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O’Brien S.

Homoharringtonine - history, current research and future directions. Cancer 92:1591-1605, 2001.

147. Mavromatis BH and Cheson BD. New therapies for the indolent non-Hodgkin’s

lymphomas. Onc Spectrums 2:706-716, 2001. 148. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L,

Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps T, Brown PO, Staudt LM. Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia. J Exp Med 194;1639-1647, 2001.

149. Cheson BD. Next new drugs:to the phase II trials. Haematologica 86 (suppl 1 to

n.11):31-35, 2001. 150. Hegde U, Wilson WH, White T, Cheson BD. Rituximab Treatment of Refractory

Fludarabine-associated Immune Thrombocytopenia in Chronic Lymphocytic Leukemia , Blood 100:2260-2262, 2002.

151. Gertz MA, Lacy MQ, Dispenzieri A, Cheson B, Barlogie B, Kyle RA, Palladini G,

Geyer SM, Merlini G. A multicenter phase II trial of 4’-iodo-4’deoxydoxorubicin in primary amyloidosis. Amyloid 9:24-30, 2002.

152. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg

S, Little R, Janik J, Gutierrez M, Raffeld M, Staudt M, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy in untreated large B-cell lymphomas: a novel pharmacodynamic approach with high efficacy. Blood 99:2686-2693, 2002.

153. Cheson B. Rituximab: Clinical development and future directions. Expert Opin

Biol Ther 2:97-110, 2002. 154. Cheson BD. Bexxar. Current Opinion in Investigational Drugs. 3:165-170, 2002. 155. Diehl V and Cheson BD. Bendamustine in the treatment of hematologic

malignancies: Introduction Sem Onc 29 (suppl 13): 1-3, 2002. 156. Cheson BD. Hematologic Malignancies: New Developments and Future

Treatments. Sem Oncol 29 (suppl 13):33-45, 2002. 157. Cheson BD. New Drugs: can they cure chronic lymphocytic leukemia?

Haematologica 87 (Suppl 11 to no. 10):56-58, 2002. 158. Mavromatis BH and Cheson BD. Pre- and post-treatment evaluation of non-

Hodgkin's lymphoma. Best Pract Res Clin Haematol,15:429-47, 2002.

Bruce D. Cheson, M.D. Page 28 Publications (Continued) 159. Cheson BD. Radioimmunotherapy of Non-Hodgkin’s Lymphomas. Blood 101:391-

398, 2003. 160. Mavromatis B and Cheson BD. Monoclonal antibody therapy of chronic

lymphocytic leukemia. J Clin Oncol 212:1874-1881, 2003. 161. Kauh J, Baidas S, Ozdemirli M, Cheson BD. Mantle cell lymphoma: a review of

clinicopathologic features and treatments. Oncology 17:879-896, 2003. 162. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman, CL, Estey EH, Schiffer

CA, Doehner H, Tallman MS, Lister TA, Lo Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003.

163. Mavromatis B and Cheson BD. Novel therapies for chronic lymphocytic leukemia.

Blood Rev 18:137-148, 2004. 164. Cheson BD. What is new in lymphomas? CA – J for Clinicians, 54:260-72, 2004. 165. Cheson BD. What drugs are behind the corner in the treatment of lymphomas?

Haematologica 89 (suppl 9):15-18, 2004. 166. Asatiani E, Cohen P, Ozdemirli M, Kessler CM, Mavromatis B, Cheson BD.

Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol 77:144-146, 2004.

167. Cheson BD and Dutcher BS. Managing malignancy associated tumor lysis

syndrome with rasburicase. J Supportive Oncol 3:117-124, 2005. 168. Cheson BD. The role of radioimmunotherapy with Yttrium 90 (Y90) ibritumomab

tiuxetan in the treatment of non-Hodgkin’s lymphoma (NHL). Biodrugs 19:309-322, 2005

169. Juweid M, Wiseman GA, Vose JM, Ritchie JM, Menda J, Wooldridge JE,

Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol 23:4652-4661, 2005.

170. Pfistner B, Diehl V, Greb A, Cheson BD. International Harmonisation of Trial

parameters in Malignant Lymphoma. Eur J Haematol Suppl, 53-54, July, 2005.

Bruce D. Cheson, M.D. Page 29 Publications (Continued) 171. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng E, Cheson B,

O’Shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:7967-7985, 2005.

172. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link

JM, Guyton KZ, Collins JM, Eckelman WC, Scher HI, O’Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11:2785-2708, 2005.

173. Cheson BD. Combinations of biological agents for non-Hodgkin’s lymphomas.

Haematologica Rep 1:46-51, 2005. 174. Cheson BD. Radioimmunotherapy of Non-Hodgkin’s Lymphomas. Curr Drug

Targets 7:1293-1300, 2006. 175. Binet J-L, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G,

Döhner H, Hallek H, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107:859-861, 2006.

176. Juweid M and Cheson BD. Positron emission tomography (PET) in post-therapy

assessment of cancer. New Engl J Med 354:496-507, 2006. 177. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia.

Cancer Immunol Immunother 55:188-196, 2006. 178. Cheson BD and Canellos GP. The Cancer and Leukemia Group B Lymphoma

Committee. Clin Cancer Res 12 (11 part 2):3572s-3575s, 2006. 179. Cheson BD. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol.

33(2 Suppl 5):2-14, 2006. 180. O’Leary M, Sheaffer J, Keller F, Shu X-O, Cheson B: Lymphomas and

reticuloendothelial neoplasms. In: Bleyer A, O’Leary M, Barr R, Ries LAG (eds): Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006; pp. 25-38.

181. Cheson BD, Greenberg PL, Bennett JM, Lowenberg J, Wijermans PW, Nimer

SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood 108:419-425, 2006.

182. Cheson BD. CLL response criteria. Clin Adv Hematol Oncol 4 (suppl 12):4-5,

2006.

Bruce D. Cheson, M.D. Page 30 Publications (Continued) 183. Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett

NL. Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin’s lymphoma: Results of CALGB 59906. Leuk Lymphoma 47:1511-1517, 2006.

184. Cheson BD. New drugs for peripheral T-cell lymphomas. Haematologica Rep 2

(13) 42-45, 2006. 185. Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC,

Cheson BD. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin’s lymphoma: Results of CALGB study 9153. Cancer 107:2817-2825, 2006.

186. Cheson BD. Histone deacetylase inhibition: a novel approach to cancer

treatment. Br J Cancer 95 (suppl 1):S1, 2006. 187. Czuczman M, Porcu P, Johnson J, Niedzwiecki D, Kelly M, His ED, Cook JR,

Canellos G, Cheson BD. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk and Lymph 48:97-103, 2007.

188. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A,

Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks R, Weber W, Reske SN, Schwaiger M, Siegel BA, Cheson BD. Use of positron eemission tomography (PET) for response assessment of lymphoma: consensus of the Imaging Subcommittee of the International harmonization Project (IHP) in lymphoma. J Clin Oncol 25:571-578, 2007.

189. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Horning SJ, Coiffier B,

Specht L, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007.

190. Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GO, Zelenetz AD,

Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O’Connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, Degennaro LJ, Sigal E, Barker A, Woodcock J. FDG-PET Lymphoma Demonstration Invitational Workshop. Acad Radiol 14:330-339, 2007.

191. Morgan NP, Graves KD, Poggi EA, Cheson BD. Implementing an expressive

writing study in a cancer clinic. The Oncologist 13:196-204, 2007. 192. Cheson BD. Oblimersen for the treatment of patients with chronic lymphocytic

leukemia. Ther Clin Risk Management 3:855-870, 2007. 193. Cheson BD. The International Harmonization Project for Response Criteria in

Lymphoma Clinical Trials. Hematol Oncol Clin North Amer 21:841-854, 2007.

Bruce D. Cheson, M.D. Page 31 Publications (Continued) 194. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien

K, Zelenetz AD, Cheson BD, Canellos GP. Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD), a Salvage Regimen in Relapsed Hodgkin Lymphoma: CALGB 59804. Ann Oncol 18:1071-1079, 2007.

195. Cheson BD. Is BEACOPP superior to ABVD? Curr Hematol Malig Rep 2161-

166, 2007. 196. Cheson BD. Clinical management of T-cell malignancies: Current perspectives,

key issues and emerging therapies. Sem Oncol 34 (6) (suppl 5):S3-S7, 2007. 197. Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon L, Moore J, Czuczman

M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory follicular lymphoma. Ann Oncol 18:1216-1223, 2007.

198. Cheson BD. Revised response criteria for lymphomas. Am J Hematol Oncol

6(suppl 7)11-14, 2007. 199. Cheson BD. Bendamustine: what’s old is new again. Community Oncol 4:733-

734, 2007. 200. Cheson BD, Gregory SA, Marcus R. Emerging treatments for indolent

lymphoma. Clin Adv Hematol Oncol 5 (suppl 8):1-9, 2007. 201. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL.

Single agent bortezomib in the treatment of relapsed Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206. Leuk and Lymph 48:1313-1319, 2007.

202. Seam P, Juweid ME, Cheson BD. The role of PET scans in patients with

lymphoma Blood 110:3507-3516, 2007. 203. Friedberg JW, Cohen P, Chen L, Robinson KS, Forrero-Torres A, La Casce A,

Fayad L, Bessudo A, Camacho ES, Williams ME, van der Jagt R, Oliver J, Loh E, Cheson BD. Bendamustine in patients with rituximab-refractory and alkylator-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II, multi-center, single-agent study J Clin Oncol 28:204-210, 2008.

204. Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL,

Cheson BD. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin’s lymphomas: A phase II study of the CALGB. Br J Haematol 140:313-319, 2008.

205. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H,

Hillmen P, Keating M, Montserrat E, Rai KR, Kipps TJ. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 111:5446-5456, 2008.

Bruce D. Cheson, M.D. Page 32 Publications (Continued) 206. Chanan-Khan A, Cheson BD. Lenalidomide for the treatment of B-cell

malignancies. J Clin Oncol 26:1544-1552, 2008. 207. Fowler N, Asatiani E, and Cheson BD. Needle tract seeding after bone marrow

biopsy in non-Hodgkin’s lymphoma. Leuk and Lymph 49:156-158, 2008. 208. Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner JA,

Demetri GD, Curran WJ, Ganz PA, Kramer B, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey SD, Reaman GH, Sawaya RE, Schuchter LM, Sweetenham J, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS. Clinical cancer advances 2007: Major research advances in cancer treatment, prevent, and screening – a report from the American Society of Clinical Oncology. J Clin Oncol 26:313-325, 2008.

209. Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR,

Randolph SS, Cheson BD. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma. Ann Oncol 19:964-969, 2008.

210. Cheson BD and Leonard JP. Monoclonal antibody therapy of B-cell

malignanices. New Engl J Med 359:613-626, 2008. 211. Lai R, Bartlett N, Mackey J, Jung S-H, Johnson JL, Cook, JR, Jones D, Cass C,

Young JD, Said J, Cheson BD, Hsi E. High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin – a CALGB 59804 correlative study. Leuk Lymph 49:1202-1205, 2008.

212. Cheson BD. New staging and response criteria for non-Hodgkin’s lymphoma.

Radiol Clin North Amer 46 (2):213-223, 2008. 213. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A,

Schwartberg LS, Lemieux B, Cheson BD, Bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma: a phase II, multicenter study J Clin Oncol 26:4473-4479, 2008.

214. Cheson BD. Individualizing therapy for the hematologic malignancies: the stuff of

genes and dreams. Hematol Meeting Rep 2 (5):85-89, 2008. 215. Cheson, BD. Staging and evaluation of the patient with lymphoma. Hematol

Oncol Clin North Amer 22 (number 5):825-837, 2008. 216. Schimmer A, O’Brien S, Kantarjian H, Brandwein J, Cheson B, Minden M, Yee K,

Ravandi-Kashani F, Giles F, Schuh F, Gupta V, Andreef M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14:8295-8301, 2008.

Bruce D. Cheson, M.D. Page 33 Publications (Continued) 217. Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, Devos S, Cheson BD,

Damon LE, Said J. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymph 49:2081-2090, 2008.

218. Cheson BD and Rummel MJ. Bendamustine: Rebirth of an old drug. J Clin

Oncol 27:1492-1501, 2009.

219. O’Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113:299-305, 2009.

220. Kelly JL, Toothaker, SR, Cimenello L, Hoelzer D, Holte H, LaCasce AS, Mead G,

Thomas D, van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW. Outomes of patients with Burkitt lymphoma older than age 40 treated with aggressive chemotherapeutic regimens. Clin Lymph Myeloma 9:307-310, 2009

221. Abedalthagafi M, Rushing EJ, Garvin D, Cheson B, Ozdemirli M. Asymptomatic

diffuse “encephalitic” cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia: case report and review of the literature. Int J Clin Exp Pathol 3:106-109, 2009.

222. Cheson BD. Etiology and management of tumor lysis syndrome in patients with

chronic lymphocytic leukemia. Clin Adv Hematol Oncol 7:263-271, 2009. 223. Jamshed S and Cheson BD. The role of bendamustine in the treatment of

chronic lymphocytic leukemia. Oncotargets and Therapy 2:43-49, 2009. 224. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL,

LaCasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem cell transplant for untreated patients with mantle cell lymphoma: CALGB protocol 59909. J Clin Oncol 27:6101-6108, 2009.

225. Cheson BD. The role of PET in T-cell lymphoma and T-cell specific response

criteria. Hematol Mtg Rep 320-327, 2009. 226. Cheson BD. Novel therapies for the treatment of peripheral T-cell non-Hodgkin’s

lymphomas. Curr Opin Hematol 16:299-305, 2009. 227. Cheson BD. Hodgkin lymphoma: advancing beyond standard management.

Clin Adv Hematol Oncol 7 (suppl 3), 4-11, 2009. 228. Cheson BD. Classification updates and clinical investigations in indolent non-

Hodgkin lymphoma. Clin Adv Hematol Oncol 6:4-6, 2009. 229. Cheson BD. Bendamustine: a new therapeutic option for hematologic

malignancies. Clin Adv Hematol Oncol 6:631-633, 2009.

Bruce D. Cheson, M.D. Page 34 Publications (Continued) 230. Cheson BD and Ashforth E. Newer strategies for overcoming rituximab

resistance in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 7 (2)(suppl 5):8-16, 2009.

231. Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D,

Hurd D, Gockerman JP, Parker B, Prchal J, Peterson BA. Recombinant

interferon-2b added to oral cyclophosphamide either as induction or maintenance in treatment-naïve follicular lymphoma: Final analysis of CALGB 8691. Leuk Lymph 50:1606-17, 2009.

232. Cheson BD. Maintenance therapy is not indicated for the treatment of follicular lymphoma. Nat Rev Clin Oncol 6:622-624, 2009.

233. Cheson BD, Kroll ML. Bendamustine induced neurotoxicity. Clin Adv Hematol

Oncol 7:743-744, 2009. 234. Cheson BD. Bendamustine and rituximab – optimizing dose and schedule, in

Finding the right dose: improving patient outcomes in CLL and NHL. Clin Adv Hematol & Oncol 7 (suppl 16):1-5, 2009.

235. Kahl BS, Bartlett NL, Leonard JP, Ganjoo K, Williams ME, Czuczman MS,

Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin’s lymphoma: Results from a large multicenter study. Cancer, 116:106-114, 2010.

236. Cheson BD, Wendtner C-M, Pieper A, Dreyling M, Friedberg J, Hoelzer D,

Moreau P, Gribben J, Knop S, Montillo M, Rummel M. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin’s lymphomas and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymph Leuk Myeloma 10:21-27, 2010.

237. Cheson BD. Indolent B-cell lymphoma: New therapeutic developments. Clin Adv

Hematol Oncol 8 (1)(suppl 2):10-11, 2010. 238. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Best

Practice & Res Clin Haematol 23:133-143, 2010. 239. Goswami T, Siddique S, Cohen P, Cheson BD. The sarcoid-lymphoma

syndrome, Clin Lymph, Leuk Myeloma 24:156-166, 2010. 240. Ujjani C and Cheson BD. Monoclonal antibody therapy of advanced B-cell

lymphomas. Oncology 24: 156-166, 2010. 241. Cheson BD. Targeted treatment and new agents in follicular lymphoma. Int J

Hematol (e-pub on line, June 2010). 242. Cheson BD. Ofatumumab: a novel anti-CD20 monoclonal antibody for the

treatment of B-cell malignancies. J Clin Oncol 28:3525-3530, 2010.

Bruce D. Cheson, M.D. Page 35 Publications (Continued) 243. Blum KA, Jung S-H, Johnson JL, Lin T, Hsi ED, Lucas DM, Byrd JC, Cheson BD,

Barlett NL. Serious pulmonary toxicity in patients with Hodgkin’s lymphoma treated with the anti-CD30 antibody, SGN-30, and gemcitabine, vonorelbine, and

liposomal doxorubicin (GVD) is associated with a FcRIIIa-158 V/F polymorphism: Results from CALGB 50502. Ann Oncol 21:2246-2254, 2010.

244. Ujjani C and Cheson BD. Bendamustine in chronic lymphocytic leukemia and

non-Hodgkin’s lymphoma. Expert Rev Anti-cancer Ther. 10:1353-1365, 2010. 245. Kim W, Larar JG, Cheson BD, Lee RK, Palmberg PF. Resolution of lymphoma

associated open angle glaucoma by rituximab. J Glaucoma, e-pub ahead of print, 16 September 2010.

246. Gregory SA, Cheson BD, Czuczman MS, Love N. Management of follicular

lymphoma in the up-front and relapsed settings, in “Exploring the clinical decisions of US community-based oncologists and hematologists in the management of multiple myeloma and follicular lymphoma”. Oncology 24(12)(suppl 5):15-23, 2010.

247. Cheson BD, Friedberg JW, Kahl BS, van der Jagt RH, Tremmel L. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory, indolent non-Hodgkin’s lymphoma. Clin Lymph, Leuk and Myeloma 10;452-457, 2010.

248. Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung S-H,

Peterson BA, Nadler LM, Hurd DD, Cheson BD. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplantation: CALGB 9254 Leuk Lymph 52:587-596, 2011.

249. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder

H, Hall NC, Jung S-H, Canellos G, Schwartz LH, Juweid ME, Cheson BD. Results of treatment of early stage non-bulky Hodgkin lymphoma with a novel regimen, doxorubicin, vinblastine and gemcitabine (CALGB 50203) Blood, 117:5314-5320, 2011.

250. Cheson BD. New drugs in follicular lymphoma. Best Practice and Res in

Haematol 24:305-312, 2011 251. Cheson BD, The role of functional imaging in lymphomas. J Clin Oncol 29:1844-

1854, 2011 252. Ujjani C and Cheson BD, Efficacy of bendamustine in rituximab-refractory

indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. Future Oncol 7:9-14, 2011.

253. Cheson BD. Rituximab maintenance for follicular lymphoma – maintaining an open mind. Nat Rev Clin Oncol. E-pub ahead of print, 15 March 2011.

254. Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B,

Williams ME, Swan F, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, and Cheson BD. Bortezomib, Bendamustine, and Rituximab in Patients with

Bruce D. Cheson, M.D. Page 36 Publications (Continued)

Relapsed or Refractory Follicular Lymphoma: The Phase 2 VERTICAL Study. J Clin Oncol 29:3389-3395, 2011.

255. Zeng W, Meck J, Cheson BD, Ozdemirli M. Histiocytic sarcoma transdifferentiated from follicular lymphoma presenting as a cutaneous tumor. J Cutan Pathol 12:999-1003, 2011.

256. Cheson BD. Bendamustine in clinical trials. Clin Adv Hematol Oncol 9 (suppl

17):6-9, 2011. 257. Cheson BD. Highlights from the Pan Pacific Lymphoma Conference. August 15-

19, 2011. Clin Adv Hematol Oncol 9 (10 Suppl 24), 1-24, 2011. 258. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ,

Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz C, Connors JM, Enget A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) for patients with relapsed or refractory Hodgkin Lymphoma. J Clin Oncol 30:2183-2189, 2012.

259. Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 118:3128-3134, 2012.

260. Fitzpatrick K and Cheson B. 90Y-epratuzumab, a humanized Yttrium-raiolabeled anti-CD22mAb for the potential treatment of non-Hodgkin’s lymphoma. Drug Profiles (e-pub, on line), 2012.

261. Wilson WH, Jung S-H, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai

R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz G, Cheson

BD, Hsi E. A Multi-center Trial of Dose-Adjusted EPOCH-Rituximab and Analysis

of Molecular Subtype in Untreated Diffuse Large B-cell Lymphoma: Cancer and Leukemia Group B 50103. Haematologica 97:758-765, 2012.

262. Kostakoglu L, Schoder H, Johnson J, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung S-H, Bartlett NL, Canellos GP, Cheson BD. Interim FDG PET imaging in stage I/II non-bulky Hodgkin lymphoma: would using combined PET and CT criteria better predict response than each test alone? Leuk & Lymph, e-pub ahead of print, 2012.

263. Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon L, Hsi ED, Bucci DM, Linker

CA, Cheson B, Stock W. Detection of Minimal Residual Disease Following

Induction Immunochemotherapy Predicts Progression Free Survival in Mantle Cell

Lymphoma: Final results of CALGB 59909. Haematol 97:79-85, 2012

264. Khozeimeh N, Bhatti T, Ponsky TA, Cheson BD, Brody F, Lin PP. Primary non-

Hodgkin’s lymphoma of the extrahepatic bile duct. J Gastrointest Cancer (e-pub

ahead of print, 2011).


265. Cheson, BD. How I treat patients with Hodgkin Lymphoma. Community Oncol

9:6, 2012.

266. Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD. Phase

II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB

50402): Follicular Lymphoma International Prognostic Index (FLIPI score) is

predictive of upfront immunotherapy responsiveness. Ann Oncol 23:2356-2362,

2012.

267. Koprivnikar JL and Cheson BD. Bortezomib – a proteasome inhibitor with an

evolving role in select subtypes of B-cell Non-Hodgkin’s Lymphoma. Future

Oncology 8:359-371, 2012.

268. Cheson BD, Byrd, JC, Rai KR, Kay NE, O’Brien SM, Flinn IW, Wiestner A, Kipps TJ.

Novel targeted agents and the need to redefine clinical endpoints in chronic

lymphocytic leukemia. J Clin Oncol 30:2820-2822, 2012.

269. Ujjani C, Cheson BD. Chronic lymphocytic leukemia: where are we and where are

we going? Expert Opin Pharmacother 13:1675-1677, 2012.

270. Scott DW, Chan FCC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M,

Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL,

Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ,

Steidl C, Gascoyne RD. A gene expression-based model using formalin-fixed

paraffin embedded biopsies predicts overall survival in advanced stage Hodgkin

lymphoma J Clin Oncol 31:692-700, 2013.

271. Press OW, Unger JM, Rimsza LM, Friedberg JW, Leblanc M, Czuczman MS,

Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR,

Miller TP, Fisher RI. A phase III randomized intergroup trial of CHOP

chemotherapy plus rituximab compared to CHOP chemotherapy plus 131Iodine-

tositumomab for previously untreated follicular non-Hodgkin’s lymphoma

(SWOG S0016) J Clin Oncol 31:314-320, 2013.

272. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H,

Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA,

Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. A randomized phase III trial

of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced

stage Hodgkin’s lymphoma: An intergroup study coordinated by the Eastern

Cooperative Oncology Group (E2496) J Clin Oncol 31:684-691, 2013.

273. Vose JM, Friedberg J, Waller EK, Cheson BD, Trommeshauser D, Fritsch H, Petit C, Munzert G, Younes A. BI 2536 in patients with refractory or relapsed non-Hodgkin’s lymphoma: Phase I, open-label, single dose-escalation study Leuk & Lymph 54:708-713, 2013.


274. Smith S, Schoder H, Johnson JL, Jung SH, Bartlett NL, Cheson BD. The anti-

CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: CALGB 50602 (Alliance) Leuk & Lymphoma, 54:1405-1410, 2013.

275. Ujjani C and Cheson BD. The current status and future directions of targeted therapies in non-Hodgkin lymphomas. Expert Rev Hematol 6:191-203, 2013.

276. Kanakry JA, Li H, Gellert L, Lemas V, Hsieh W, Hing F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl B, Horrning SJ, Ambinder RF. Plasma Epstein-Barr virus DNA oredicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American co-operative group trial, Blood 121:3547-3553, 2013.

277. Rubenstein JL, Hsi ED, Johnston JL, Jung S-H, Grant B, Cheson BD, Kaplan LD. Intensive Chemotherapy and Immunotherapy in Patients with Newly-Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202) J Clin Oncol, 31:3061-3068, 2013. Reprinted in “Best of JCO” p 22-27, 2013.

278. Press O, Unger J, Rimsza L, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski MS, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. A prognostic factor and subset analysis of a phase III trial of CHOP-rituximab vs CHOP+I-131 tositumomab for follicular lymphoma Clin Cancer Res 19:6624-6632, 2013.

279. Khan N and Cheson BD. Peripheral T-cell Lymphomas: A review of treatment and outline of novel therapies. Amer J Therapeutics 20:524-533, 2013.

280. Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of ABVD and Stanford V in elderly Hodgkin lymphoma: A comprehensive analysis from the North American intergroup trial E2496. Br J Haematol, 161:76-86, 2013.

281. Werner W, Herold M, Ruffert K, Merkle K, Brakhage A, Leoni L, Cheson BD. Entwicklungsgeeschichte: Bendamustin gestern, heute, morgen. Onkologie, 36 (suppl 1): 2-10, 2013.

282. Grant BW, Jung S-H, Johnson JL, Kostakoglu L, Hsi E, Byrd JC, Jones J, Leonard JP, Martin SE, Cheson BD. A phase II study of extended induction epratuzumab and rituximab in previously untreated follicular lymphoma: CALGB 50701 Cancer 119:3797-3804, 2013.

283. McCloskey JK, Broome CM, Cheson BD. Safe and effective treatment of aggressive non-Hodgkin lymphoma with rituximab and bendamustine in patients with severe liver failure. Clin Adv Hematol & Oncol 11:184-188, 2013.

284. O’Sullivan C, Ozdemirli M, Bazylewicz M, Cheson BD. Complete Response to Brentuximab vedotin in a transplant naive patient with relapsed CD30+ nodular


lymphocyte predominant Hodgkin lymphoma. Clin Adv Hematol & Oncol 11:382-385, 2013.

285. Kostakoglu L and Cheson BD. Lymphomas: role of molecular and structural imaging for staging, prognostic evaluation and treatment response. Front Oncol 3:212, 2013

286. Ujjani C and Cheson BD. The optimal management of follicular lymphoma: An evolving field. Drugs 73:1395-1403, 2013.

287. Derenzini E, Zinzani PL, Cheson BD. Bendamustine: role and evidences in lymphoma therapy: An overview. Leuk and Lymphoma, e-pub, on line, 2013.

288. Forero-Torres A, Hamadani M, Fanale MA, Bello CM, Verhoef G, Gregory SA, Sonet A, Herbst R, Elgeioushi N, Li J, Ibrahim R, Goswami T, Cheson BD. Phase I study results of MEDI-551 in adults with relapsed or refractory advanced B-cell malignancies (submitted for publication).

289. Cheson BD. How I treat follicular lymphoma: Part 1. Clin Onc News 8:1, 12-13, 2013.

290. Cheson BD. How I treat follicular lymphoma: Part 2. Clin Oncol News 8:20-21, 2013.

291. Hong F, Habermann TM, Gordon LI, Hochster H, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol 25:669-674, 2014.

292. Cheson BD. Bone marrow biopsy for the initial staging of patients with lymphoma: It’s time to eliminate this procedure in selected patients. Oncology 27:1289-1290, 2013.

293. Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattom S, Hoke E, Cheson BD, Larson RA. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B Study 10002, Br J Haematol, 165:102-111, 2014.

294. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettit AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O’Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New Engl J Med 370:997-1007, 2014.

295. Kostakoglu L and Cheson BD. Current role of FDG PET/CT in lymphoma. Eur J Nuc Med Mol Imaging, 41:1004-1027, 2014.

296. Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui A-M, Yu J, Gupta N, Di Bacco A, Shou Y, Martin P. Phase 1 dose-escalation study of


once-weekly IV MLN9708, an investigational proteasome inhibitor, in patients with relapsed or refractory lymphoma. Blood Cancer J 17:e251, 2014.

297. Ujjani C and Cheson BD. Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Opnion on Orphan Drugs 2:617-623, 2014.

298. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchlings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A, Cheson BD. The role of imaging in the staging and response assessment of lymphoma: consensus of the ICML Imaging Working Group. J Clin Oncol, 32:3048-58, 2014

299. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma – the Lugano classification. J Clin Oncol (rapid publication), 32:3059-68, 2014.

300. Hiddemann W and Cheson BD. How I manage follicular lymphoma. Leukemia

28:1388-1395, 2014. 301. Cheson BD. Which Hodgkin’s patients in the United States should be treated

with BEACOPP? Current Hematol Malig Reports (e-pub ahead of print, May, 2014)

302. De Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, Whiting NC, Drachman JG, Advani R. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma. J Hematology and Oncol 7:44, 2014,

303. Ujjani C and Cheson BD. Ofatumumab and Bendamustine in Previously Treated

Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Leuk and Lymphoma June13:1-25, 2014.

304. Morrison V, Jung S-H, Johnson J, LaCasce A, Blum K, Bartlett NL, Pitcher B, Cheson BD. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma. Final results of a phase II trial (CALGB 50501). Leuk Lymph, 58:1814-1822, 2014.

305. Casulo C, Boisvert D, Fine B, Vose JM, Kahl B, Brunvand M, Goy A, Kasamon Y,

Cheson B, Friedberg JW. A phase I study of PRO131921, a novel anti-CD20 antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetic. Clin Imunology 154:37-46, 2014.

306. Venstrom JM, Du J, Verges SL, Pitcher B, Johnseon JL, Jung S-H, Zhou L, Hsu

KC, Czuczman MS, Cheson BD, Kaplan L, Lanier LL. Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-889, 2014.

307. Pfeifer M, McCord R, Koeppen H, Chai A, Grau M, Lenz P, Sandmann T, Polson AG, Dörken B, Chu Y-W, Chen AI, Lebovic D, Salles GA, Czuczman MS,


Palanca-Wessels MC, Advani R, Morschhauser F, Cheson BD, Mundt KE, Lenz G. Anti-CD22 and anti-CD79B antibody-drug-conjugates are active in different molecular diffuse large B-cell lymphoma subtypes Leukemia 29:1578-1586, 2015.

308. Forero-Torres A, Hamadani M, Fanale M, Bello CM, Verhoef G, Gregory SA, Sonet A, Herbgst R, Elgeioushi N, Li J, Eck S, Ibrahim R, Goswami T, Cheson BD. Phase I study results of MEDI-551 in adults with relapsed or refractory advanced B-cell malignancies (submitted for publication).

309. Advani R, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial comparing ABVD + radiotherapy with the Stanford V regimen in patients with stageI/II locally extensive (bulky mediastinal) Hodgkin lymphoma: a subset analysis of the US Intergroup trial E2496. J Clin Oncol 33:1936-1942, 2015.

310. Cheson BD and Crawford J. A phase I study of bendamustine, lenalidomide and

rituximab in relapsed and refractory non-Hodgkin lymphomas. Br J Haematol 169:529-33, 2015.

311. Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart D, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH. Evaluation of the International Prognostic SCORE (IPS-7) and a new prognostic index for patients with advanced Hodgkin lymphoma treated on US Intergroup E2496. Br J Haematol 171:530-538, 2015.

312. Ujjani C and Cheson BD. Advances in the treatment of follicular lymphoma.

Expert Opin on Orphan Drugs 3:207-218, 2015. 313. Cheson BD. Staging and response assessment in lymphomas: the new Lugano

Classification. Chinese Clinical Oncology, special supplement on Lymphomas, 2015.

314. Ujjani C, Paulus A, Gehan E, Jamshed S, Zhuang T, Chitta K, Zhang G, Asmann

Y, Crawford J, Cheson BD. Lenalidomide following fludarabine and rituximab in previously treated CLL. Hematol Leuk, 3: article 2, 2015.

315. Cheson BD. Rethinking clinical response and outcome assessment in a biologic

age. Curr Oncol Rep 17:27, 2015 316. Barr P, Li H, Spier C, Mahadevan D, LeBlanc M, Haq MU, Huber B, Flowers C,

Wagner-Johnston N, Horwitz S, Fisher R, Cheson B, Smith S, Kahl B, Bartlett N, Friedberg J. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol 33:2399-2404, 2015.

317. Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman

M, Giguere JK, Cheson BD. Randomized trial of lenalidomide alone versus


lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol 33:3635-3640, 2015.

318. Chaudhry MM and Cheson BD. What is the status of novel anti-CD20 antibodies

for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows? Expert Rev of Hematol 8:733-742, 2015.

319. Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M,

Weidmann E, Wendtner C-M, ZInzani PL. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel – an update. Leuk and Lymph, 57:766-782, 2016.

320. Nair KS and Cheson BD. The role of idelalisib in the treatment of relapsed and

refractory chronic lymphocytic leukemia. Therap Adv Hematol 7:69-84, 2016. 321. Press OW, Li H, Schöder H, Straus D, Moskowitz CH, LeBlanc M, Rimszo L,

Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahlo BS, Cheson BD, Fisher RI, Friedberg JW. A US Intergroup trial of response-adapted therapy of stage III-IV Hodgkin lymphoma using early interim FDG-PET imaging (SWOG S0816). J Clin Oncol 34:2020-2027, 2016.

322. Barr P, Saylors G, Spurgeon S, Cheson BD, Greenwald D, O’Brien S, Lim A,

McIntyre R, Joshi A, Abella-Dominicus S, Hawkins M, Reddy A, Di Paolo J, Lee H, He J, Hu J, Drelling L, Friedberg J. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed/refractory CLL and NHL. Blood 127:2411-2415, 2016.

323. Ujjani CS, Hill EM, Wang H, Nassif S, Esposito G, Ozdemirli M, Cordova C,

Cheson BD. 18F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma. Br J Haematol 174:410-416, 2016.

324. Cheson BD. Speed Bumps on the Road to A Chemotherapy-Free World for

Lymphoma Patients. Blood 128:325-330, 2016. 325. Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N,

Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg TJ, Franklin N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. GADOLIN. Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in rituximab-refractory indolent non-Hodgkin lymphoma. Lancet Oncol 17:1081-1093, 2016.

326. Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill B, Lamanna N, Skarbnik A, Howlett

CM, Pu JJ, Sehgal A, Strelec L, Vandergrift AM, Fitzpatrick DM, Zent CS, Feldman T, Goy AH, Claxton D, Bachow SH, Kaur G, Svoboda J, Nasta SD, Landsburg D, Schuster S, Porter DL, Cheson BD, Kiselev P, Evens AM. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience. Blood 128:2199-2205, 2016

327. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P. Refinement of the Lugano Classification Response


Criteria for Lymphoma in the Era of Immunomodulatory Therapy. Blood 128:2489-2496, 2016.

328. Ford RR, Ford RW, O’Neal M, Kahl BS, Chen L, Munteanu M, Cheson BD.

Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study. Leuk and Lymph 58:1332-1340, 2017.

329. Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman

MS, Davids MS, Levine E, Smith SE, Bartlett NL, Leonard JP, Cheson BD. Phase I trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood, 128:2510-2516, 2016.

330. Pongas G, Cheson BD. PI3K signaling pathway in normal B cells and indolent B-

cell malignancies. Semin Oncol. 43:647-654, 2016. 331. Maddocks K, Barr PM, Cheson BD, Little RF, Balzer L, Kahl BS, Leonard JP,

Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM. Recommendations for clinical trial development in follicular lymphoma. J Natl Cancer Inst 109, Dec 2016.

332. Chen RW, Hongli L, Bernstein SH, Rimsza LM, Forman SJ, Constine L, Shea

TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. BR but not R-HCVAD is a feasible induction regimen prior to ASCT in front-line MCL: results of SWOG study S1106. Br J Haematol 176:759-769, 2017.

333. Advani R, Lebovic D, Chen A, Brunvand M, Goy A, Chang JE, Hochberg E,

Yalamanchili S, Kahn R, Lu D, Agarwal P, Dere RC, Hsieh H-J, Chu Y-W, Cheson BD. Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with or without rituximab in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Clin Cancer Res 23:1167-1176, 2017.

334. Cheson BD, Trask PC, Gribben JG, Dimier N, Kimby E, Lugtenburg PJ,

Thieblemont C, Fritsch EW, Launonen A, Sehn LH. Health-related quality of life and symptoms in patients with rituximab-refractory, indolent non-Hodgkin lymphoma treated in the Phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Ann Hematol 96:253-259, 2017.

335. Morrison VA, Weller EA, Habermann TM, Li S, Horning SJ, Fisher RI, Cheson

BD, Peterson BA. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leuk Lymph 58:1814-1822, 2017.

336. Smith S, Pitcher BN, Jung S-H, Bartlett N, Wagner-Johnston N, Park S, Richards

K, Cashen A, Jaslowski A, Smith S, Cheson B, Hsi E, Leonard JP. Unexpected and serious toxicity with combined idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphomas: Alliance A051201 and A051202. Lancet Haematol 4:e176-e182, 2017.

Bruce D. Cheson, M.D. Page 44 Publications (Continued) 337. Penne M, Yazdy MS, Sheth Nair K, Cheson BD. Long-term follow-up of patients

treated with bendamustine for lymphoid malignanices. Clin Leuk Lymph Myeloma 17:637-644, 2017.

338. Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg

JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, Vander Walde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds, AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP. Long-term outcomes, secondary malignancies, and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol 178:250-256, 2017.

339. Cheson BD and Kostakoglu L. FDG-PET for early response assessment in

lymphomas. Part 1: Hodgkin Lymphoma. Oncology 31:45-49, 2017. 340. Cheson BD and Kostakoglu L. FDG-PET for early response assessment in

lymphomas. Part 2: Diffuse large B-cell lymphoma. Oncology 31:71-76, 2017. 341. Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C,

Skarbnik AP, Cheson B, Zent CS, Pu JJ, Kiselev P, Bachow SH, Winter AM, Cruz A-L, Claxton DF, Daniel C, Isaack K, Kennard KH, Timlin C, Fanning M, Yacur M, Svoboda J, Schuster SJ, Nabhan C. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: Results from a large multi-center study of 683 US patients. Ann Oncol 28:1050-2056, 2017.

342. Zhang L, Ghielmini M, Cheson BD, Ujjani C. Pros and cons of rituximab

maintenance in follicular lymphoma. Cancer Treat Rev 58:34-40, 2017. 343. Nanni C, Cottereau AS, Lopci E, Bodet-Milan C, Coronado M, Pro B, Kim WS,

Trotman J, Barrington S, Duhrsen U, Vander Borght T, Zamagni E, Kraeber-Bodere F, Messioiu C, Rahmouni A, Buvat I, Andre M, Mertzberg M, Oyen W, Casasnovas O, Luminari S, Garderet L, Montavers F, Kobe C, Kluge R, Versari A, Zucca E, Moreau P, Cheson B, Haioun C, Gallamini A, Meignan M. Report of the 6th international workshop on PET scan in lymphoma and myeloma. Leuk Lymph 58:2298-2303, 2017.

344. Cheson BD. What is the role of chemotherapy in chronic lymphocytic leukemia?

Clin Lymph, Leuk, Myeloma 17;723-727, 2017. 345. Cheson BD, Enschede SH, Cerri E, Desai M, Potluri J, Lamanna N, Tam C.

Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist 22:1283-1291, 2017.

346. Yazdy MS and Cheson BD. Impact of obinutuzumab alone and in combination

for follicular lymphoma. Blood and Lymphatic Cancer: Targets and Therapy e-pub on line, 2017.

347. Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruanb J,

Smith SE, Leonard JP, Cheson BD. A phase II trial of lenalidomide plus


rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 28:2806-2812, 2017.

348. Cheson BD. PET-CT in lymphoma: Current overview and future directions. Sem

Nuc Med 48:76-81, 2018. 349. Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah, Fowler N,

Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg P, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma receiving obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study J Clin Oncol 36:2259-2266, 2018.

350. Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM,

Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW. Continued excellent outcomes in previously untreated follicular lymphoma patients after treatment with CHOP plus rituximab or CHOP plus 131Iodine-tositumomab – Long-term follow-up of phase III randomized study SWOG 0016. J Clin Oncol 36:697-703, 2018.

351. Mato A, Nabhan C, Thompson M, Brander D, Skarbnik A, Cheson BD, Ujjani CS,

Barr P, Zent C, Isaac KM, Kennard K, Timlin C, Landsburg D, Nasta S, Schuster S, Svoboda J. Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real world analysis. Haematologica 103:874-879, 2018.

352. Straus DJ, Jung S-H, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schoder H,

Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Smith SE, Leonard JP, Freidberg JW, Kahl BS, Cheson BD, Bartlett NL. CALGB 50604: Risk-adapted treatment of non-bulky early stage Hodgkin lymphoma based on interim PET Blood 132:1013-1021, 2018.

353. Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR,

Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: a multicentre, open-label phase 2 trial. Lancet Oncol 19:65-75, 2018.

354. Tallarico M, Foster J, Seisler D, Lafky J, Hurria A, Jatoi A, Cohen HJ, Muss H,

Bartlett NL, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C. Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (Alliance A151611). J Geriatr Oncol 9:321-328, 2018.

355. Gopal AJ, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou J-Z, Yacoub A, Lill

M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GS, Wang S-S, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. Ibrutinib as treatment for chemoimmunotherapy-refractory patients with follicular lymphoma: results from the open-label multicenter, phase II DAWN study. J Clin Oncol 36:2401-2412, 2018.

Bruce D. Cheson, M.D. Page 46 Publications (Continued) 356. Ujjani C, Wang H, Skarbnik A, Trivedi N, Ramzi P, Kahn N, Cheson BD. A

phase I study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. Blood Advances 2:762-768, 2018.

357. Antic D, Biljana M, Milic N, Cheson B, Narkhede M, Panovska I, Trajkova S, Popova M, Llamas P, Raso AG, Delluc A, Ianotto JC, Gerotziafas GT, Fareed J. Internal and external validation of THROLY (Thrombosis lymphoma) score. Thrombosis Res, 164 (Suppl 1), S187, 2018.

358. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H,

Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood 131:2745-2760, 2018.

359. Narkhede MS and Cheson BD. Surrogate endpoints and risk adaptive strategies

in previously untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk 18:447-451, 2018.

360. Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N,

Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenberg PJ, Fingerle-Rowson G, Mattielo F, Knapp A, Sehn LH. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 36:2259-2266, 2018.

361. Cheson BD. Speaking volumes about volumes. Blood 131:2408-2409, 2018. 362. Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT,

Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker E, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 103:1511-1517, 2018.

363. Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD,

Furman RR, Lamanna N, Tam CSL, Handunetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal A, Zent CS, Tuncer HH, Schuster S, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trials. Am J Hematol 93:1394-1401, 2018.

364. Narkhede M, Yazdy MS, Cheson BD. Determining the sequence of novel

therapies in the treatment of relapsed Hodgkin’s lymphoma. Expert Rev Hematol. 11:773-780, 2018.

Bruce D. Cheson, M.D. Page 47 Publications (Continued) 365. Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H,

Heffner L, Zhou L, Verdugo M, Potluri J, Choi M. Venetoclax for chronic lymphocytic leukemia progressing after more than one B-cell receptor pathway inhibitor. Br J Haematol 185:961-966, 2019.

366. Chitalia A, Swoboda D, McCutcheon JN, Ozdemerli M, Khan N, Cheson BD.

Descriptive analysis of genetic alterations and cell of origin in Richter transformation. Leuk Lymph 60:971-979, 2019.

367. Rosenbaum CA, Jung S-H, Pitcher B, Bartlett NL, Smith SM, His E, Wagner-

Johnston N, Thomas SP, Leonard JP, Cheson BD. Phase 2 multi-center study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). Br J Haematol185:53-64, 2019.

368. Bartlett NL, Wilson WH, Jung S-H, Hsi ED, Maurer MJ, Pederson LD, Polley M-

YC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Matthew S, Fisher RI, Richards KL, Schoder H, Zelenetz A, Leonard JP. Dose adjusted EPOCH-R compared to R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the phase 3 intergroup trial Alliance/CALGB 50303. J Clin Oncol 37:1790-1799, 2019.

369. Yazdy MS, Mato AR, Cheson BD. Combinations or sequences of targeted

agents in CLL: Is the whole greater than the sum of its parts (Aristotle, 360 BC)? Blood, 133L:121-129, 2019.

370. Lansigan F, Barak I, Pitcher B, Jung S-H, Cheson BD, Czuczman M, Grant B,

Martin P, Hsi E, Schoder H, Smith S, Bartlett N, Leonard JP, Blum KA. Early relapse of follicular lymphoma after ritiuximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB studies 50402, 50701, and 50803 (Alliance) Cancer Med 8:165-173, 2019.

371. Cheson BD, O’Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, Yu A,

Fisher RI, Zinzani PL, Dreyling M. Optimal management of adverse events from copanlisib in the treatment of patients with non-Hodgkin lymphomas. Clin Lymph, Myeloma, Leuk 19:135-141, 2019.

372. Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press

OW, Salles G, Tilly H, Chen AJ, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Lu D, Pewnuel E, Hirata J, Wenger M, Chu Y-W, Sharman J. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol, 6:e256-e265, 2019.

373. Sharman JP, Coutre SE, Furman RR, Cheson BD, Paagel JM, Hillmen P,

Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettit AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O’Brien SM, Stilgenbauer S. Final results of a randomized, controlled, phase 3 study of rituximab with or without idelalisib followed by an open-label


idelalisib extension in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol, 37:1391-1402, 2019.

374. Mato AR, Wierda WG, Davids MS, Cheson BD, COutre SE, Furman RR, Heffner

L. Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC. Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica, 104:2258-2264, 2019.

375. Narkhede M, Yazdy MS, Cheson BD. Targeting biology in non-Hodgkin

lymphoma. Heme Onc Clin North Amer, 33:727-738, 2019. 376. Blum KA, Polley M-Y, Jung S-H, Dockler TJ, Anderson S, Hsi ED, Wagner-

Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib in previously untreated patients with high-risk follicular lymphoma. CALGB50904 (Alliance). Cancer 125:3378-3389, 2019.

377. Roeker LE, Fox CP, Eyre TA, Brander D, Allan JN, Schuster SJ, Nabhan C, Hill

BT, Shah NN, Lansigan F, Sarraf Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson LK, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax treated CLL patients in routine clinical practice. Clin Cancer Res, 25:4264-4270, 2019.

378. Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill bT, Brander DM, Barr

PM, Lansigan F, Cheson BD, Singavi AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibocy in R/R CLL. Blood Adv 3:1568-1573, 2019.

379. Ujjani C and Cheson BD. Targeted therapies in CLL: Is two (or three) better than

one? The Cancer J, J of Principles and Practice of Oncol 25:449-454, 2019. 380. Ghia P, Coutre SE, Cheson BD, Barrientos JC, Hillmen P, Pettit AR, Zelenetz

AD, Shreay S, Hallek M, Furman RR. Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized clinical trial. Haematologica 105:e19, 2020.

381. Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pewarson L, Pagel JM, Jacobs R, Mato AR. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukemia. Br J Haematol 188:918-923, 2020.

Bruce D. Cheson, M.D. Page 49 Publications (Continued) 382. Owen RG, McCarthy H, Rule S, D’Sa S, Thomas SK, Tournilhac O, Forconi F,

Kersten MJ, ZinZani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicenter, phase 2 study. Lancet Haematol 7:e112-e121, 2020.

383. Eyre TA, Lamanna N, Roeker LE, Ujjani CS, Hill BT, Barr PM, Lansigan E, Cheson BD, Yazdy M, Allan JN, Rhodes J, Schuster SJ, Nabhan C, Skarbnik A, Leslie L, Islam P, Whitaker K, Coombs CC, Tuncer HH, Pagel JM, Jacobs R, Winter AM, Bailey N, Sitlinger A, Schuhj AH, Follows G, Fox CP, Brander DM, Shadman M, Mato AR. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica Feb 20, 2020.

384. Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E, Danesi D, Fingerle-Rowson G, Harbron C, Mundt K, Wassner-Fritsch E, Cheson BD. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia 34:522-532, 2020.

385. Cheson BD. Predicting the future of diffuse large B-cell lymphoma. Blood

135:1308-1309, 2020.

386. Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N., Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Illizaliturri F, Leonard JP, Cheson BD. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol 95:583-593, 2020.

387. Mato A, Roeker L, Jacobs R, Hill B, Lamanna N, Brander D, Shdman M, Ujjani C, Yazdy MS, Perini G, Pinilla-Ibarz J, Barrientos J, Skarbnik A, Torka P, Pu J, Pagel J, Gohil S, Fakhri B, Choi M, Coombs C, Rhodes J, Barr P, Portell C, Perry H, Garcia C, Whitaker K, Winter A, Sitlinger A, Khajavian S, Grajales-Cruz, A, Isaac K, Shah P, Akhtar O, Pocock R, Lam K, Voorhees T, Schuster S, Rodgers T, Fox C, Martinewz-Calle N, Munir T, Bhavsar E, Bailey N, Lee J, Weissbrot H, Nabhan C, Goodfriende J, King A, Zelenetz A, Dorsey C, Bigelow K, Cheson B, Allan J, Eyre T. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res 26:3589-3596, 2020.

388. Cheson BD, Morschhauser F, Martin P. Management of adverse events from the combination of rituximab and lenalidomide in the treatment of patients with follicular and low-grade non-Hodgkin lymphomas. Clin Lymph, Myeloma and Leuk 20:563-571, 2020.

389. Schöder H, Polley MY, Knopp MV, Hall NC, Kostakoglu L, Zhang J, Higlewy HR,

Kelloff G, Liu H, Zelenetz A, Cheson BD, Wagner-Johnston ND, Kahl B, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL.


Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 trial. Blood 135:2224-2234, 2020.

390. Holstein SA, Suman VJ, Owzar K, Santo K, Benson DM, Jr., Shea TC, Martin T,

Silverman M, Isola L, Vij R, Cheson BD, Linker C, Anderson KC, Richardson PG, McCarthy PL. Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma. Biol Blood Marrow Transplant 26:1414-1424, 2020.

391. Chauhan A, Viruni N, Liu TYA, Cheson BD. Successful treatment of ocular

chronic lymphocytic leukemia with ibrutinib: Case report and review of the literature. Leuk Res Rep April 20, 2020, on line.

392. Narkhede M and Cheson BD. Copanlisib in the treatment of non-Hodgkin

lymphoma. Future Oncology, 16:1947-1955 , 2020. 393. Narkhede M and Cheson BD. Tafasitamab: A novel and effective new antibody

for the treatment of B-cell malignancies. Drugs of the Future (in press, 2020). 394. Cheson BD and Mato AR. The evolving use of minimal residual disease (MRD)

assessment in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 18 (suppl 6):3-19. 2020.

395. Cheson BD. Monumental progress in the treatment of diffuse large B-cell

lymphoma. ASCO Post, 25 July 2020. 396. Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J,

Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tan CS, Shadman M. The impact of age on survival in CLL patients receiving ibrutinib as initial therapy. Blood and Lymphatic Cancer: Targets and Therapy 10:1-5, 2020.

397. Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B, Diefenbach

CS, Feldman TA, Ansell SM. Nivolumab and brentuximab vedotin as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multi-centre, phase 2 trial. Lancet Haematol 7:e808-e815, 2020.

398. Mato AR, Ghosh N, Schuster SJ, Lamanna N, Pagel JM, Flinn IW, Barrientos J,

Rai KR, Reeves JA, Cheson BD, Barr PM, Kambhampati S, Lansigan F, Pu JJ, Skarbnik AP, Roeker LE, Fonseca G, Sitlinger A, Hamadeh IS, Dorsey C, LaRatta N, Weissbrot H, Luning Prak ET, Tsao PY, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Svoboda J, Brander DM. Phase 2 atudy of the safety and

efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K inhibitor therapy. Blood (e-pub ahead of print).

399. Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, Bartlett NL,

Czuczman MS, Martin P, Rosenbaum CA, Jung S-H, Leonard JP, Cheson BD, Hsi ED. Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803) Amer J Surg Pathol 45:384-393, 2021.


400. Chauhan A and Cheson BD. Copanlisib in the treatment of relapsed Follicular

Lymphoma: Utility and experience from the clinic. Cancer Management and Research 13:677-692, 2021.

401. Cheson BD, Nowakowski GS, Salles G. Diffuse large B-cell lymphoma: New targets and novel therapies. Blood Cancer Journal 11:68, 2021(in press).

402. Balasubramanian S, Hodkinson B, Schuster SJ, Fowler NH, Trotman J, Hess G,

Cheson BD, Schaffer M, Sun S, Deshpande S, Vermeulen J, Salles G, Gopal AK. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial (submitted for publication, 2020).

403. Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA,

Knopinska-Posluszny, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Sabu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P,

O’Connor OA. Umbralisib, a dual PI3K/CK1 inhibitor in patients with relapsed/refractory indolent lymphoma. J Clin Oncol 39:1609-1618, 2021.

404. Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Wang MH, Kipps TJ. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica (e-pub ahead of print, March, 2021).

405. Moving towards the chemo-free treatment of lymphoma: Hype or reality?

(submitted for publication, 2021). 406. Sehn LH, Trneny M, Bouabdallah K, Dueck G, Gribben JG, Lugtenburg PJ,

Salles G, Knapp A, Nielsen TG, Bu L, Cheson BD. Sustained overall survival benefit with obinutuzumab plus bendamustine vs rituximab plus bendamustine in patients with rituximab-refractory indolent non-Hodegkin lymphoma: final analysis of the randomized, phase III GADOLIN study (submitted for publication, 2021).

407. Cheson BD and Meignan M. Current role of functional imaging in the

management of lymphoma. Current Oncology Reports (in pess, 2021). 408. Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD,

Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Wang MH, Kipps TJ. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukaemia. Haematologica (on line ahead of print).

409. Davids M, O’Connor O, Jurczak W, Samaniego F, Fenske T, Zinzani PL, Patel

M, Ghosh N, Cheson B, Derenzini E, Brander D, Reeves J, Knopinska-Posluszny W, Allan J, Phillips JT, Caimi P, Lech-Maranda E, Burke J, Agajanian R, Pettengell R, Leslie L, Cheah C, Fonseca G, Essell J, Chavez J, Pagel J, Sharman J, Hsu Y, Miskin H, Sportelli P, Weiss M, Flinn I. Integrated safety


analysis of umbralisib, a dual PI3KCK inhibitor, in relapsed/refractory lymphoid malignancies. Blood Advances (in press).

410. Pongas G and Cheson BD. Recent advances in the management of follicular

lymphoma. Blood and Lymphatic Cancer (in press). 411. Rutherford S, Jang H, Kim S, Patel K, Bartlett NL, Maleck M-K, Watlins M, Bond

DA, Feldman T, Magarelli G, Advani RH, Spinner M, Evens AM, Shah MR, Ahmed S, Stephens DM, Allen P, Tees M, Karmali R, Cheson BD, Strouse C, Bailey N, Pagel JM, Ramchandren R. Outcomes among classical Hodgkin lymphoma patients after an interim PET scan: A real world experience. (submitted for publication).


Books 1. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Progress, BD

Cheson, ed. Marcel Dekker Publishers, New York, 1993. 2. Nucleoside Analogs in the Treatment of Human Malignancies. BD Cheson, MJ

Keating, W Plunkett, eds. Marcel Dekker Publishers, New York, 1997. 3. The Chronic Lymphoid Leukemias, BD Cheson, ed. Marcel Dekker Publishers,

New York, 2001. 4. Monoclonal Antibody Therapy of Hematologic Malignancies, BD Cheson ed, Darwin Scientific Publications, Oxfordshire, UK, 2001. 5. Zevalin radioimmunotherapy, BD Cheson, ed. COAB Publishing Co., New York,

2003. 6. Hoffman and Abeloff’s Hematology-Oncology Review, C. Isaacs, SS Argawala. BD

Cheson, AD Ma, JL Marshall, NA Rizvi, eds. Elsevier, Philadelphia, PA, 2017. Book Chapters 1. Curt GA, Allegra C, and Cheson BD. “Infusional Therapy Using Cytosine

Arabinoside”, In: Infusional Therapy in the Treatment of Cancer (J Lokich, ed.). Precept Press, Chicago, IL, p. 161-166, 1987.

2. Cheson, BD. “Therapy of Adult Acute Leukemias”, In Manual of Oncologic

Therapeutics (RE Wittes, ed.), J.B. Lippincott Co., Philadelphia, p 345-358, 1988. 3. Cheson, BD. “Therapy of Chronic Leukemias”, In Manual of Oncologic

Therapeutics (RE Wittes, ed.), J.B. Lippincott Co., Philadelphia, p 359-367, 1988. 4. Cheson, BD. “Therapy of Plasma Cell Dyscrasias”, In Manual of Oncologic

Therapeutics (RE Wittes, ed.), J.B. Lippincott Co., Philadelphia, p 382-388, 1988. 5. Cheson, BD. “Therapy of Adult Acute Leukemias”, In Manual of Oncologic

Therapeutics (RE Wittes, ed.), J.B. Lippincott Co., Philadelphia, second edition, p 251-260, 1991.

6. Cheson, BD. “Therapy of Chronic Leukemias”, In Manual of Oncologic


7. Cheson, BD. “Therapy of Plasma Cell Dyscrasias”, In Manual of Oncologic


Bruce D. Cheson, M.D. Page 54 Book Chapters (Continued) 8. Cheson BD. “Autologous Bone Marrow Transplantation for Miscellaneous

Tumors”, In High Dose Cancer Therapy: Pharmacology, Hematopoietins and Stem Cells (JO Armitage and KH Antman, eds.), Williams and Wilkins, Baltimore, p. 763-771, 1992.

9. Cheson BD. “Preface”. In Chronic Lymphocytic Leukemia: Scientific Advances

and Clinical Progress (BD Cheson, ed.), Marcel Dekker, Inc., New York, 1993. 10. Cheson BD. “Chronic Lymphocytic Leukemia: Staging and Prognostic Factors”, In

Chronic Lymphocytic Leukemia: Scientific Advances and +*Clinical Developments (BD Cheson, ed.), Marcel Dekker, Inc., New York, p. 253-279, 1993.

11. Miller BA, Linet MS, Cheson BD. “Leukemias”, in SEER Cancer Statistics Review:

1973-1990, (Miller BA, Gloeckler Ries LA. Kosary CL, Harras A, Devesa SS, and Edwards BK, eds.), NIH Publication No. 93-2789, p. XIII.1-23, 1993.

12. Harras A, Pottern LM, Cheson BD. “Multiple Myeloma”, in SEER Cancer Statistics

Review: 1973-1990, (Miller BA, Gloeckler Ries LA. Kosary CL, Harras A, Devesa SS, and Edwards BK, eds.), NIH Publication No. 93-2789, p. XVII.1-17, 1993.

13. Gloeckler Ries LA, Zahm SH, Cheson BD. “Non-Hodgkin’s Lymphoma”, in SEER

Cancer Statistics Review: 1973-1990, (Miller BA, Gloeckler Ries LA. Kosary CL, Harras A, Devesa SS, and Edwards BK, eds.), NIH Publication No. 93-2789, p. XVI1I.1-24, 1993.

14. Cheson BD. “Chronic Lymphocytic Leukemia”, In Current Therapy in Oncology (JF

Foley, JM Vose, JO Armitage, eds.), W.B. Saunders, Inc., Philadelphia, p. 327-330, 1994.

15. Cheson BD. “The Chronic Lymphoid Leukemias”, In Clinical Oncology (MD

Abeloff, JO Armitage, AS Lichter, JE Neiderhueber, eds.), Churchill Livingstone, New York, p. 1999-2022, 1995.

16. Cheson BD, Wilson WH. “Paclitaxel in Hematological Malignancies”, In Paclitaxel

in Cancer Treatment (WP McGuire and EK Rowinsky, eds.), Marcel Dekker, Inc., New York, p. 295-305, 1995.

17. Cheson BD. “Chronic Leukemias”, In Manual of Oncologic Therapeutics (3rd

edition) (JS MacDonald, D Haller, and RJ Mayer, eds), J.B. Lippincott Co., Philadelphia, PA, p 282-289, 1995.

18. Cheson BD. “The Acute Leukemias”, In Manual of Oncologic Therapeutics (3rd

edition) (JS MacDonald, D Haller, and RJ Mayer, eds), J.B. Lippincott Co., Philadelphia, PA, p 272-281, 1995.

19. Cheson BD. “High Dose Chemotherapy for Miscellaneous Solid Tumors”, in High

Dose Cancer Therapy: Pharmacology, Hematopoietins and Stem Cells (JO Armitage and KH Antman, eds.), Williams and Wilkins, Baltimore, second edition, p.889-899, 1995.

Bruce D. Cheson, M.D. Page 55 Book Chapters (Continued) 20. Cheson BD, Huntley C, Montello M. “Fludarabine”, in Therapeutic Drugs (CT

Dollery, ed), Churchill Livingstone, Edinburgh, UK, 1996. 21. Cheson BD. “Non-Hodgkin’s Lymphomas”, in Conn’s Current Therapy, 1996

Edition (RE Rakel, ed), W.B . Saunders Co. Philadelphia, PA, p. 413-419, 1996. 22. Cheson BD. “Autografting for Miscellaneous Tumors”, in Autologous Stem Cell

Transplantation: Biological and Clinical Results in Malignancies (A Carella, ed.), Harwood Academic Publishers, p. 385-395, 1997.

23. Cheson BD. “Toxicities of Nucleoside Analogues” in Nucleoside Analogues in

Cancer Therapy (BD Cheson, MJ Keating, W Plunkett, eds), Marcel Dekker, Inc. P 415-459, 1997.

24. Cheson BD, Grever MR. “Clinical Development of 2’-Deoxycoformycin”, in

Nucleoside Analogues in Cancer Therapy (BD Cheson, MJ Keating, W Plunkett, eds), Marcel Dekker, Inc., p 95-112, 1997.

25. Cheson BD. “The Myelodysplastic Syndromes”, in The Chemotherapy

Sourcebook, Second Edition (MC Perry, ed) WIlliams & Wilkins, p. 1409-1422, 1996.

26. Cheson BD. “Miscellaneous Chemotherapy Drugs”, in Principles and Practice of

Oncology, 5th edition (VT DeVita, Jr., S Hellman, SA Rosenberg, eds) Lippincott-Raven, Philadelphia, 490-498. 1997.

27. Cheson BD. “Chronic Lymphocytic Leukemia”, In Current Therapy in Oncology,

Second Edition (JF Foley, JM Vose, JO Armitage, eds.), W.B. Saunders, Inc., Philadelphia. p. 39904904, 1999.

28. Cheson BD. “The Chronic Lymphoid Leukemias”, In Clinical Oncology (MD

Abeloff, JO Armitage, AS Lichter, JE Neiderhueber, eds.), second edition, Churchill Livingstone, New York. 2536-2563, 2000.

29. Cheson BD. “High Dose Chemotherapy for Miscellaneous Solid Tumors”, in High

Dose Cancer Therapy: Pharmacology, Hematopoietins and Stem Cells (JO Armitage and KH Antman, eds.), Williams and Wilkins, Baltimore, third edition, 909-920, 2000.

30. Cheson BD, “Chronic Lymphocytic Leukemias and the Plasma Cell Dyscrasias”, in

Scientific American Medicine, 1999. 31. Cheson BD. “Miscellaneous Chemotherapy Drugs”, in Principles and Practice of

Oncology, 6th edition (VT DeVita, Jr., S Hellman, SA Rosenberg, eds) Lippincott-Raven, Philadelphia p 452-459, 2001.

32. Cheson BD. “The Myelodysplastic Syndromes”, in The Chemotherapy

Sourcebook, Third Edition (MC Perry, ed) Lippincott. WIlliams & Wilkins, Philadelphia, p 849-857, 2001.

Bruce D. Cheson, M.D. Page 56 Book Chapters (Continued) 33. Cheson BD. “Hodgkin’s Disease and the Non-Hodgkin’s Lymphomas”, in The

American Cancer Society Textbook of Oncology (Lenhard RE, Osteen RT, and Gansler T, eds), p 497-516, American Cancer Society, Atlanta, GA, 2000.

34. Cheson BD, Demakos EP, “Fludarabine”, in Oncology Therapeutics: A Quick

Reference Guide”, Ratain MJ, Tempero M, C. Skosey, eds, W.B. Saunders, Inc., Philadelphia, PA, p 70, 2001.

35. Cheson BD. “The Initial Approach to the Treatment of Chronic Lymphocytic

Leukemia”, in The Chronic Lymphoid Leukemias, (Cheson BD, ed.), Marcel Dekker Publishers, New York, p 261-273, 2001.

36. Cheson BD. New Developmental Agents and Directions in the Treatment of Acute

Myelogenous Leukemia, in Acute Leukemias IX (Hiddemann W, Büchner T, Ritter J, Unterhalt M, Haferlach T, eds.), Springer-Verlag, Berlin, p.153-160, 2003.

37. Cheson BD. “Chronic Lymphocytic Leukemia and Hairy Cell Leukemia”, in Clinical

Practice of Hematology and Oncology (Furie B, Cassileth PA, and Atkins M, Mayer RJ, eds), Churchill Livingstone, Philadelphia, PA , p. 688-700, 2003.

38. Cheson BD, Fisher RI. “Monoclonal Antibodies in the Treatment of Hematologic

Malignancies: Future Directions”, in Cheson BD, Monoclonal Antibody Therapy of Hematologic Malignancies. Darwin Scientific Publications, Oxford, England p 259-273, 2001.

39. Cheson BD. “Response Criteria in Myelodysplastic Syndromes”, in Bennett JM,

ed., The Myelodysplastic Syndromes. Marcel Dekker Publishers, New York, NY p 251-263, 2002.

40. Cheson BD, “Chronic Lymphocytic Leukemias and the Plasma Cell Dyscrasias”, in

Scientific American Medicine, 2001. 41. Cheson BD. “Radioimmunotherapy with Yttrium90 Ibritumomab Tiuxetan

(Zevalin®): Future Directions”. In Radioimmunotherapy with Yttrium90 Ibritumomab Tiuxetan (Zevalin®) (Cheson BD, ed), COAB Publishers, New York, NY p. 70-90, 2003.

42. Cheson BD. “Chronic Lymphoid Leukemias and Plasma Cell disorders”. In

Scientific American Medicine (Dale DC and Federman DD, eds), Scientific American, Inc. p. 2431-2441 (volume 2), New York, NY, 2003.

43. Abbasi S and Cheson BD. “Chronic Lymphocytic Leukemia”, in Bethesda

Handbook of Clinical Hematology (Rodgers GP and Young NS, eds), Lippincott Williams & Wilkins, Philadelphia, p. 177-186, 2004.

44. Cheson BD, Mavromatis BH. “Maintenance Therapy With Rituximab”, in

Therapeutic Strategies in Lymphoid Malignancies (Hillmen P and Witzig TE, eds), Clinical Publishing, Oxford, UK, p. 69-77, 2005.

Bruce D. Cheson, M.D. Page 57 Book Chapters (Continued) 45. Cheson BD. “The Approach to the Patient With Malignant Lymphoma”, in The

Lymphomas (Canellos GP, Lister TA, and Young B, eds) Saunders-Elsevier, Philadelphia, PA, p. 148-157, 2006.

46. Abbasi S and Cheson, BD. “Chronic Lymphocytic Leukemia”, in Hematology-

Oncology Therapy (Boyiadzis MM, Lebowitz PF, Frame JN, and Fojo T), McGraw Hill New York, NY, 236-247. 2006.

47. Cheson BD. “Treatment approach to follicular lymphomas”, in Clinical Malignant

Hematology (Sekeres MA, Kalaycio ME, and Bolwell BJ, eds.), McGraw-Hill, New York, NY, 531-542, 2007.

48. Asatiani E and Cheson BD. “Treatment of myelodysplastic syndromes”, in The

Chemotherapy Source Book (MC Perryl, ed.) Lipincott Williams & Wilkins, Philadelphia, PA, p 552-559, 2007.

49. Cheson BD and Coiffier B. “Non-Hodgkin lymphoma”, in Atlas of Clinical

Hematology (JO Armitage, ed), Springer, Philadelphia, PA, 1-52, 2008. 50. Cheson BD. “Chronic Lymphocytic Leukemia”, in Evidence-based Hematology

(Crowther M, Ginsberg J, Lottenberg R, Meyer R, Schünemann H), Blackwell, 294-299, 2008.

51. Cheson BD, Rummel MJ, “PET und Ansprechkriterien zur Beurteilung des

Therapieerfolgs” in NHL Diagnostik und Therapie – State of the Art 2007 (MJ Rummel, ed), Agileum Verlag, Germany, p 27-36, 2008.

52. Jamshed S and Cheson BD. “Chronic Lymphoid Leukemias” in The Bethesda

Handbook of Clinical Oncology, Third Edition (J Abraham, JL Gulley and CJ Allegra, eds), Wolters Kluwer, Lippincott, Williams and Wilkins, Philadelphia, PA, p. 313-317, 2009.

53. Cheson BD, “Restaging and Response Criteria”, in The Non-Hodgkin Lymphomas

(Mauch P, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, eds), Lippincott-Williams-Wilkins, Philadelphia, PA, p. 172-183, 2009.

54. Cheson BD. “Response Assessment and Follow-up of the Patient With Malignant

Lymphoma”, in The Lymphoid Neoplasms (Magrath I, Diehl V, eds), Hodder Arnold Publishers, London, p 910-921, 2010.

55. Cheson BD, Armitage JO, Anderson KC, Fisher RI, Ghobrial I, Gospodarowicz M,

Harris NL, Hoppe RT, Hussong JW, Juweid M, Kyle RA, LeBlanc M, Lister TA, Murphy S, Rosen ST, Sandlund J, Tybinkowski K. “Lymphoid Neoplasms” in AJCC Cancer Staging Manual, Seventh Edition, Springer, New York, p. 599-628, 2010.

56. El-Shami K and Cheson BD. “The Chronic Leukemias” in Handbook of Cancer

Chemotherapy (Skeel RT and Khleif SN, eds), Lippincott, Williams and Wilkins, Philadelphia, PA, 2011 (in press).

Bruce D. Cheson, M.D. Page 58 Book Chapters (Continued) 57. Cheson BD. “International Staging and Response Criteria for Lymphomas”, in

Management of Hematologic Malignancies (O’Brien SM, Vose JM, Kantarjian HM, eds), Cambridge University Press, Cambridge, UK p. 277-285, 2011.

58. Armitage JO, Cheson BD (Co-chairs). Lymphoid Neoplasms. AJCC Cancer Staging Manual, 7th Edition. Springer, New York, p. 599-615, 2010.

59. Cheson BD (ed), Lymphoid Neoplasms. AJCC Cancer Staging Atlas, Second Edition, Springer, New York, p. 601-617, 2012.

60. Ujjani C and Cheson BD. Chemotherapy Modalities and Algorithms, In Non-Hodgkin Lymphomas: Advanced Diagnostics and Personalized Therapies. Future Science, London, UK p 139-149, 2013.

61. Ujjani C and Cheson BD. Bendamustine: A New Generation of Alkylators for Lymphoid Malignancies, in Novel Targeted Drugs in the Treatment of Lymphomas (Springer Clinical Medicine ebooks) (in press, 2013).

62. Ujjani C and Cheson BD. The Chronic Lymphoid Leukemias in The Bethesda Manual of Clinical Oncology (Abraham, Gulley, Allegra eds), Wolters Kluwer, Philadelphia, PA, p 321-327, 2014.

63. Ujjani C and Cheson BD. The Increased Spectrum of Bendamustine. In Principles and Practice of Oncology Updates (DeVita VT, Jr, Lawrence TS, and Rosenberg SA, eds) 28 (1):1-9, 2014.

64. Cheson BD. Life Is Like Riding A Bicycle. In The Big Casino (Winokur S and Coppola V, eds), p. 136-140, 2014.

65. Ujjani C and Cheson BD. Chronic Leukemias in Skeel Handbook of Hematology

and Oncology (Khlief SN, Rixw O, Skeel R, editor), Wolters Kluwer, Philadelphia. P 479-505, 2016.

66. Gallamini A, Cheson B, Hutchings M. Functional Imaging in Hodgkin Lymphoma in (Younes A and Engert A, eds), Hodgkin Lymphoma, Springer Nature, 2020.


Editorials/Commentaries

1. Cheson BD. Function of the National Marrow Donor Program - The Article Reviewed. Oncology 3(2):72-74, 1989.

2. Cheson BD, Simon R. A guide to interpreting reports of clinical trials. Oncology

3(7):41, 1989. 3. Cheson BD. The purine analogs - A therapeutic beauty contest. J Clin Oncol

10:868-871, 1992. 4. Cheson BD. The maturation of differentiation therapy. New Engl J Med 327:422-

424, 1992. 5. Cheson BD. Ennui or not ennui, that is the question. Ann Oncol 7:767-769, 1996. 6. Cheson BD. Clinical status and optimal use of newer therapeutic agents.

Oncology 11:1609-1610. 1997. 7. Cheson BD. The curious case of the baffling biological. J Clin Oncol 18:2007-

2009, 2000. 8. Cheson BD. Some like it hot! J Clin Oncol 19:3908-3911, 2001. 9. Cheson B. CHOP Plus Rituximab: Balancing facts and opinion. New Engl J Med,

2002 346:280-282, 2002. 10. Juweid ME and Cheson BD. Role of Positron Emission Tomography in Lymphoma.

J Clin Oncol. April 18 (epub ahead of print), 2005 11. Cheson BD, Haller D, Horning SJ. Serving interests in hematologic malignancies

in the Journal of Clinical Oncology 23:3666-3667, 2005. 12. Cheson BD, Overcoming mechanisms of RECISTance in lymphoma. Leuk and

Lymp 48:447-448, 2007. 13. Cheson BD. Anti-CD20 monoclonal antibodies in the treatment of indolent

lymphoma and CLL. Clin Adv Hematol Oncol 5 (2 suppl 3):1-16, 2007 14. Cheson BD. Non-Hodgkin’s lymphomas: New insights and therapeutic strategies:

Preface. Hematol Oncol Clin North Amer 22 (5):xiii-xiv, 2008. 15. Cheson BD. Burkitt Lymphoma: Too soon to declare victory. Oncology 32:1518-

1519, 2008. 16. Cheson BD. The case against heavy PETing. J Clin Oncol 27:1742-1743, 2009. 17. Cheson BD. Recent advances in the treatment of hematologic malignancies:

Introduction. Clin Adv Hematol Oncol 7 (suppl 6):4-5. 2009.


18. Cheson BD. Commentary in “A Summer of Hematologic Science”, Clin Adv Hematol & Oncol 7 (9)(suppl 15): 19-22, 2009.

19. Cheson BD, Cortés JE, Jagannath S. Expanding our mission: Cliniical Lymphoma,

Myeloma & Leukemia. 9:266, 2009. 20. Cheson BD. Syk [sic] of the same old chemotherapy? Blood 115:2561-2562, 2010. 21. Cheson BD. Commentary in “Recent Advances in the Management of

Hematologic Malaignancies”, Clin Adv Hematol Oncol 8 (4)(suppl 7):17-22, 2010. 22. Cheson BD. Commentary in “Chronic Lymphocytic Leukemia: A Case-base

Discussion of Recent Advances in Patient Management”, Clin Adv Hematol Oncol 8 (supple 12): 11-13, 2010.

23. Cheson BD. Commentary in “Recent Advances in the Treatment of Leukemia,

Lymphoma, and Myeloma: Clin Adv Hematol Oncol 9 (suppl 7): 19-23, 2011. 24. Cheson BD. Commentary in Summer Happenings in Hematology 2011. Clin Adv

Hematol Oncol, 9 (8)(suppl 17):20-22, 2011. 25. Cheson BD. Genetic abnormalities in CLL: prognostic factors or their own

disease? Oncology 25 (8):706-708, 2011. 26. Cheson BD. Introduction to bendamustine, in “Bendamustine: Mechanims of

action and clinical data”. Clin Adv Hematol Oncol 9 (supple 19):2, 2011. 27. Cheson BD. Time to remember to forget dose-intensification in lymphoma. J Clin

Oncol 29:3954-3956, 2011.

28. Cheson BD. Brentuximab vedotin ushers in a new era in treating lymphomas. Community Oncology 9:3-4, 2012.

29. Cheson BD. Waiting is the hardest part. J Clin Oncol 20:1-2, 2012.

30. Cheson BD. Hodgkin Lymphoma: Protecting the victims of our success. J Clin Oncol, 30:4456-4457, 2012 (selected for podcast).

31. Cheson BD. Therapy for diffuse large B-cell lymphoma: getting personal. Lancet, e-pub on line, April 2013.

32. Federico M, Bellei M, Cheson BD. BEACOPP or no BEACOPP? Lancet Oncol 14:e487-488, 2013.

33. Cheson BD. A summer of change in hematologic malignancies: Highlights in B-cell malignancies from the 2013 ASCO, EHA, and ICML meetings. Clin Adv Hematol Oncol 11:748-750, 2013.

34. Cheson BD. Response assessment in Hodgkin Lymphoma: Size matters! J Clin Oncol (2013 – podcast).


35. Cheson BD. CLL and NHL: the end of chemotherapy? Blood 123:3368-3370, 2014.

36. Cheson BD. PET-CT scans in restaging follicular lymphoma: a surrogate too late?

Lancet Haematology 1:e2-3, 2014.

37. Cheson BD. Bendamustine in CLL: How quickly will today’s consensus become tomorrow’s memory? Leuk Res (e-pub ahead of print), 2014.

38. Cheson BD. Highlights from the 2014 congress of the European Hematology

Association. Clin Adv Hematol Oncol 12:619-622, 2014. 39. Cheson BD and Zhu J. Lymphoma: looking from the present to the future.

Chinese Clinical Oncology, special supplement on Lymphoma, 2015. 40. Cheson BD. Surveillance scans in lymphoma. HemeOnc Today 16 (10):60, 2015. 41. Cheson BD. Small molecules, big changes. Oncology 29:308-309, 2015. 42. Tefferi A + 100 coauthors (including Cheson B). In support of a patient-driven

initiative and petition to lower the price of cancer drugs. Mayo Clin Proc 90:996-1000, 2015.

43. Cheson BD. Ibrutinib in Waldenström’s Macroglobulinemia: Revamping the

landscape. Lancet Oncol 18:165-166, 2017.

44. Cheson BD. Staying Ahead of The Rapidly Evolving World of Chronic Lymphocytic Leukemia. The Cancer J. J of Principles and Practice of Oncol 25:373, 2019.

45. Cheson BD and Gutierrez ME. Growing (Up) Together: Understanding Lymphoma

in the AYA Population. Ann Lymph (in press). Patient Referral Resource 1. Cheson BD. Clinical trials with adjuvant therapy of breast cancer. Oncology

3(6):70-75, 1989. 2. Cheson BD. Clinical trials in advanced breast cancer. Oncology 3(7):113-123,

1989. 3. Cheson BD. Clinical trials in colon cancer. Oncology 3(9):98-108, 1989. 4. Cheson BD. Clinical trials in non-Hodgkin's lymphoma. Oncology 3(10):37-50,

1989. 5. Cheson BD. Clinical trials in prostate cancer. Oncology 3(11):65-78, 1989. 6. Cheson BD. Clinical trials in small cell lung cancer. Oncology 4(1):43-56, 1990. 7. Cheson BD. Clinical trials in non-small cell lung cancer. Oncology 4(2):51-63,

1990.


8. Cheson BD. Clinical trials in soft tissue sarcomas. Oncology 4(3):42-58, 1990. 9. Cheson BD. Adjuvant therapy for colon cancer. Oncology 4(4):67-84, 1990. 10. Cheson BD. Adjuvant therapy for rectal cancer. Oncology 4(6):58-71, 1990. 11. Cheson BD. High dose chemotherapy for acute myeloid leukemia. Oncology

4(7):69-84, 1990. 12. Cheson BD. Clinical trials in ovarian cancer. Oncology 4(8):69-75, 1990. 13. Cheson BD. Clinical trials at the National Cancer Institute: NCI-Navy. Oncology

4(9)129-133, 1990. 14. Cheson BD. Clinical trials at the National Cancer Institute: Biological Response

Modifiers Program. Oncology 4(10):42-53, 1990. 15. Cheson BD. Clinical trials at the National Cancer Institute: Surgery Branch.

Oncology 4(11):72, 1990.

Bruce D. Cheson, M.D. Page 63 16. Cheson BD. Clinical Trials at the National Cancer Institute: Radiation Oncology

Branch. Oncology 4(12):34-36, 1990. 17. Cheson BD. Clinical Trials at the National Cancer Institute: Pediatric Oncology

Branch I. Oncology 5(1):41-53, 1991. 18. Cheson BD. Clinical Trials at the National Cancer Institute: Pediatric Oncology

Branch II. Oncology 5(2):116-118, 1991. 19. Cheson BD. Clinical Trials in Malignant Gliomas. Oncology 5(3):87-89, 1991. 20. Cheson BD. Clinical Trials in Advanced Colorectal Cancer. Oncology 5(4):61-80,

1991. 21. Cheson BD. Clinical Trials in the Adjuvant Therapy of Rectal Cancer. Oncology

5(5):61-64, 1991. 22. Cheson BD. Clinical Trials in Malignant Melanoma. Oncology 5(6):95-98, 1991. 23. Cheson BD. Clinical Trials for the Adjuvant Therapy of Breast Cancer I. Oncology

5(7):115-118, 1991. 24. Cheson BD. Clinical Trials for the Adjuvant Therapy of Breast Cancer II. Oncology

5(8):96-113, 1991. 25. Cheson BD. Clinical Trials in Gastric and Esophageal Cancer Oncology 5(8):96-

113, 1991. 26. Cheson BD. Autologous Bone Marrow Transplant Trials for Breast Cancer.

Oncology 5(9):55-63, 1991. 27. Cheson BD. Clinical Trials in Gastric and Esophageal Cancer. Oncology 5(10):71-

84, 1991. 28. Cheson BD. Clinical Trials in Elderly Patients with Acute Myeloid Leukemia.

Oncology 5(11):61-65, 1991. 29. Cheson BD. Clinical Trials in Multiple Myeloma. Oncology 5(12):43-48, 1991. 30. Cheson BD. Clinical Trials in Bladder Cancer. Oncology 6(1):105-120, 1992. 31. Cheson BD. Clinical Trials with Taxol. Oncology 6(3):67-70, 1992. 32. Cheson BD. Clinical Trials With All-trans Retinoic Acid. Oncology 6(4):67-76,

1992. 33. Cheson BD. Clinical Trials with 2-Chlorodeoxyadenosine. Oncology 6(5):95-98,

1992.

Bruce D. Cheson, M.D. Page 64 34. Cheson BD. Clinical Trials in Cervical Cancer. Oncology 6(6):56-63, 1992. 35. Cheson BD. Clinical Trials in Non-small Cell Lung Cancer. Oncology 6(7):44-49,

1992. 36. Cheson BD. Clinical Trials in Head and Neck Cancer. Oncology 6(8):49-50,1992. 37. Cheson BD. Clinical Trials in Rhabdomyosarcoma. Oncology 6(9):57-63, 1992. 38. Cheson BD, Ungerleider RS. NCI High Priority Trials I. Oncology 6(10):57-60,1992. 39. Cheson BD, Ungerleider RS. NCI High Priority Trials II. Oncology 6(11):30-36,

1992. 40. Cheson BD, Ungerleider RS. NCI High Priority Trials III. Oncology 6(12):46-50,

1992. 41. Cheson BD, Arbuck S.G. Update on Taxol Trials. Oncology 7(1):63-67, 1993. 42. Cheson BD. Clinical Trials with Topotecan. Oncology 7(2):49-51, 1993. 43. Cheson BD, Ungerleider RS. NCI High Priority Trials IV. Oncology 7(3):55-59,

1993. 44. Cheson BD, Feigal EG. Clinical Trials for AIDS-related Non-Hodgkin’s

Lymphomas. Oncology 7(4):37-38, 1993. 45. Cheson BD. Clinical Trials in Adult Acute Lymphoblastic Leukemia. Oncology

7(5):31-34, 1993. 46. Cheson BD, Carter CL, Sznol M. Clinical Trials with Interleukin-6. Oncology

7(6):43-44, 1993. 47. Cheson BD, Sorenson JM, Phillips PH. Clinical Trials Using Edatrexate. Oncology

7(7):33-34, 1993. 48. Miller LL, Cheson BD, Phillips P. NCI-sponsored Trials of PIXY321. Oncology

7(8):56-62, 1993. 49. Cheson BD, Arbuck SG, Phillips PH. Clinical Trials With Docetaxel (Taxotere).

Oncology 7(9):51-52, 1993. 50. Cheson BD, Feigal EG, Phillips PH. Clinical Trials in Limited Small Cell Lung

Cancer. Oncology 7(10):43-47, 1993. 51. Cheson BD, Feigal EG, Phillips PH. Clinical Trials in Extensive-Stage Small-Cell

Lung Cancer. Oncology 7(11):60-64, 1993. 52. Cheson BD, Phillips PH, Abrams JS. Clinical Trials in Metastatic Breast Cancer.

Oncology 7(12):43-44, 1993.

Bruce D. Cheson, M.D. Page 65 53. Cheson BD, Abrams JS, Arbuck SG, Phillips PH. Paclitaxel in Metastatic Breast

Cancer. Oncology 8(1):72-77, 1994. 54. Cheson BD, Phillips PH, Feigal EG. Clinical Trials in Non-small Cell Lung Cancer.

Oncology 8(2):56-56-66, 1994. 55. Cheson BD, Trimble E, Phillips PH. Phase III Clinical Trials in Ovarian Cancer.

Oncology 8(3):56-64, 1994. 56. Cheson BD, Phillips PH, Trimble E. Phase II Ovarian Cancer Trials. Oncology

8(4):73-74, 1994. 57. Cheson BD, Smith MA, Phillips PH. Pediatric Trials. Oncology 8(5):41-45, 1994. 58. Cheson BD, Kaplan R, Phillips PH. Pancreatic Cancer Trials. Oncology 8(6):40-

44, 1994. 59. Cheson BD, Phillips PH. Clinical Trials in Multiple Myeloma and Waldenström’s

Macroglobulinemia. Oncology 8(7):45-50, 1994. 60. Cheson BD, Kaplan R, Phillips PH. Clinical Trials in Colon Cancer. Oncology 8

(8):43-47, 1994. 61. Cheson BD, Kaplan R, Phillips PH. Clinical Trials in Rectal Cancer. Oncology

8(9):63-67, 1994. 62. Cheson BD, Kaplan R, Phillips PH. Clinical Trials in Primary Central Nervous

System Tumors. Oncology 8(10):51-55, 1994. 63. Cheson BD, Phillips PH, Abrams J. Adjuvant Therapy of Breast Cancer. Oncology

8(11):55-65, 1994. 64. Cheson BD, Kaplan RS, Phillips PH. Clinical Trials in Prostate Cancer. Oncology

8(12):35-41, 1994. 65. Cheson BD, Kaplan RS, Phillips PH. Clinical Trials in Prostate Cancer II.

Oncology 9(1):50-55, 1995. 66. Cheson BD, Phillips PH, Pluda JM, Christian M. Clinical Trials of Suramin.

Oncology 9(2):161-163, 1995. 67. Cheson BD, Phillips PH, Arbuck SG. Clinical Trials with Topotecan. Oncology

9(3):220-226, 1995. 68. Cheson BD, Wittes RE, Phillips PH. Clinical Trials at the Medicine Branch of the

NCI - Part I. Oncology 9(4):292-294, 1995. 69. Cheson BD, Rosenberg SA, Phillips PH. Clinical Trials at the Surgery Branch of

the NCI. Oncology 9(5):453-454, 1995.

Bruce D. Cheson, M.D. Page 66 70. Cheson BD, Wilson WH, Phillips PH. Clinical Trials at the Medicine Branch of the

NCI II. Oncology 9(6):506-509, 1995. 71. Cheson BD, Foss FM, Phillips PH. Clinical Trials in Mycosis Fungoides/Sézary

Syndrome. Oncology 9(7):645-646, 1995. 72. Cheson BD, Arbuck SG, Phillips PH. Clinical Trial with 9-Amino Camptothecin.

Oncology 9(8):727-731, 1995. 73. Cheson BD, Phillips PH. Clinical Trials in Myelodysplastic Syndromes. Oncology

9(9):821-825, 1995. 74. Cheson BD, Sznol M, Phillips PH. Clinical Trials with Tumor Vaccines. Oncology

9(10):929-931, 1995. 75. Cheson BD, McCabe MS, Phillips PH. Clinical Trials Assessing Quality of Life.

Oncology 9(11):1171-1178, 1995. 76. Cheson BD, Abrams J, McCabe MS, Crosson K. High Priority Clinical Trials in

Breast Cancer. Oncology 9(12):1292-1298, 1995. 77. Brawley OW, Phillips PH, Cheson BD. Cancer Chemoprevention Trials I.

Oncology 10 (3):324-327, 1996. 78. Brawley OW, Cheson BD, Phillips PH. Cancer Chemoprevention Trials II.

Oncology 10 (4):499-503, 1996. 79. Pluda J, Cheson BD, Phillips PH. Clinical Trials Using Bryostatin-1. Oncology 10

(5):740-742, 1996. 80. Sorensen JM, Phillips PH, Cheson BD. Clinical Trials Using Gemcitabine.

Oncology 10 (6):855-861, 1996. 81. Sorensen JM, Cheson BD, Phillips PH. Clinical Trials with Tolmudex. Oncology 10

(7):1041-1042, 1996. 82. Kaplan RS, Phillips PH, Cheson BD. Clinical Trials in the CNS Consortia.

Oncology 10 (8):1183-1184, 1996. 83. Phillips PH, Pluda JM, Cheson BD. Clinical Trials Using Thalidomide. Oncology

10 (10):1498-1501, 1996 84. Smith MA, Phillips PH, Cheson BD. Clinical Trials for Children with Acute

Leukemia. Oncology 10 (11):1662-1666, 1996. 85. Ho PTC, Cheson BD, Phillips PH. Clinical Trials with Compound 506U78.

Oncology 10 (12):1831-1832 , 1996 86. Sznol M, Phillips PH, Cheson BD. Clinical Trials Using Tumor Vaccines.

Oncology 11 (1):81-90 , 1996.

Bruce D. Cheson, M.D. Page 67 87. Cheson BD, Phillips PH. Clinical Trials: New Autologous Stem-Cell Transplant

Protocols. Oncology 11 (2):178-180, 1997. 88. Feigal E, Phillips PH, Cheson BD. Clinical Trials in AIDS-Related malignancies.

Oncology 11(3):337-341, 1997. 89. Cheson BD, Nelson A. Clinical Trials with PSC-833. Oncology 11(4):490-493,

1997. 90. Wright J, Ho PTC, Phillips PH, Cheson BD. Clinical Trials Using CI-980 (Mivobulin

Isethionate). Oncology 11(5) 643-644, 1997. 91. Cheson BD, Nelson A. Clinical Trials in Elderly Patients. Oncology 11(6):838-844,

1997. 92. Murgo AJ, Cannon D, Christian MC, Cheson BD, Nelson A. Clinical Trials with

Pyrazoloacridine. Oncology 11 (7):991-994, 1997. 93. Cheson BD, Abrams JS, Nelson A. High Priority Trials. Oncology 11 (8):1144-

1150, 1997. 94. Kaplan RS, Cheson BD, Nelson AP. Clinical Trials in Bladder and Urothelial

Cancers. Oncology 11(9):1348-1351, 1997. 95. Conley BA, Cheson BD. Clinical Trials in Head and Neck Cancer. Oncology

11(10):1527-1530, 1997. 96. Feigal EG, Cheson BD, Nelson AP. Clinical Trials in Lung Cancer. Oncology

11(11):1686-1694, 1997. 97. Zwiebel J, Ho P, Sepelak SB, Saunders J, Cheson BD, Nelson A. Clinical Trials

with Perillyl Alcohol. Oncology 11(12):1817-1817-1823, 1997. 98. McCabe MS, Cheson BD, Nelson AP. Clinical Trials Assessing Quality of Life.

Oncology 12 (1):69-71, 1998. 99. Cheson BD, Nelson AP. Clinical Trials in Adult Acute Myelogenous Leukemia.

Oncology 12 (2):224-227, 1998. 100. Smith MA, Cheson BD, Nelson AP. Clinical Trials in Children with Brain Tumors.

Oncology 12 (3):393-396, 1998. 101. Abrams JA, Cheson BD, Smiley JK. Clinical Trials in Metastatic Breast Cancer.

Oncology 12 (4):527-533, 1998. 102. Streicher H, Sznol M, Blatner G, Cheson BD. Clinical Trials with Tumor Vaccines.

Oncology 12 (5):684-693, 1998. 103. Conley BA, Smiley JK, Cheson BD. Clinical Trials in Multimodality Approaches for

Advanced Esophageal Cancer. Oncology 12 (6):856-865, 1998.

Bruce D. Cheson, M.D. Page 68 104. Wright J, Blatner GL, Cheson BD. Clinical Trials With Flavopiridol. Oncology 12

(7):1018-1024, 1998. 105. Zwiebel JA, Nagler C, Smiley JK, Cheson BD. Clinical Trials with Adenovirus-p53

Gene Therapy. Oncology 12 (8):1172-1175, 1998. 106. Cheson BD, Smiley JK. Clinical Trials in Non-Hodgkin’s Lymphomas. Oncology

12 (9):1321-1329, 1998. 107. Davis T, Streicher H, Blatner G, Cheson BD. Clinical Trials with Monoclonal

Antibodies. Oncology 12(10):1479-1487, 1998. 108. McCabe M, Blatner GL, Cheson BD. Integrating Economic Analysis into

Cooperative Group Trials. Oncology 12(11):1589-1594, 1998. 109. Conley BA, Smiley JK, Cheson BD. Clinical Trials in Gastric Cancer. Oncology

12(12):1751-1752, 1998. 110. Wright JJ, Blatner G, Cheson BD. Clinical Trials of Dolostatin-10. Oncology

13(1):68-75, 1999. 111. Murgo A, Cannon DJ, Blatner G, Cheson BD. Clinical trials of MGI-114. Oncology

13(2):233-8, 1999. 112. Kaplan RS, Smiley JK, Cheson BD. Multicenter phase I and II trials in adults with high-grade gliomas. Oncology 13(4):532-537, 1999. 113. Ivy SP, Blatner G, Cheson BD. Clinical Trials with Gadolinium-Texaphyrin and

Lutetium-Texaphyrin. Oncology 13(5):671-676, 1999. 114. Conley BA, Smiley J, Cheson B. Clinical Trials in Colon Cancer. Oncology

13(6):814-820, 1999 115. Ivy SP, Blatner G, Cheson BD. Clinical Trials with Single-Agent Oxaliplatin.

Oncology 13(7):966-970, 1999. 116. Ivy SP, Blatner G, Cheson BD. Combination Regimens Containing Oxaliplatin.

Oncology 13(8):1116-1118, 1999. 117. Saxman SB, Smiley JK, Cheson BD. Clinical Trials in Melanoma. Oncology

13(9):1239-1242, 1999. 118. Saxman SB, Blatner GL, Cheson BD. Clinical Trials in Non-Small Cell Lung

Cancer. Oncology 13(10):1384-1388, 1999. 119. Wright J, Blatner GL, Cheson BD. Clinical Trials with the Farnesyl Transferase

Inhibitor R115777. Oncology 13(11):1527-1533, 1999. 120. Anderson B, Blatner GL, Cheson B. Clinial Trials in Pediatric Sarcomas.

Oncology 13(12):655-662, 1999.

Bruce D. Cheson, M.D. Page 69 121. Murgo AJ, McBee WL, Cheson BD. Clinical Trials with Arsenic Trioxide. Oncology

14(2):206-219, 2000 122. Kaplan RS, Gore-Langton RE, Cheson BD. Clinical Trials in Prostate Cancer.

Oncology 14(3):399-404, 2000. 123. Trimble E, Valmonte CM, Cheson BD. Clinical Trials in Epithelial Ovarian Cancer.

Oncology 14 (5):678-690, 2000. 124. Trimble E, Valmonte CM, Cheson BD. Clinical Trials in Cervical Cancer.

Oncology 14 (7):1045-1050, 2000. 125. Zwiebel JA, Nagler C, Smiley JK, Cheson BD. Current Clinical trials of Adenovirus

p53 Gene Therapy. Oncology 14 (8):1172-1175, 2000 126. Davis T, Gore-Langton RE, Cheson BD. Current Clinical Trial of the Anti-CD20

monoclonal Antibody Rituximab. Oncology 14 (10):1437-1443, 2000. 127. Wright J, Hillsamer VL, Gore-Lagngton RE, Cheson BD. Current Cliniical Trials for

the Proteosome Inhibitor PS-341. Oncology 14 (11):1589-1597, 2000. 128. Smith M, Newsome SY, Cheson BD. Current Clinical Trials in Acute

Lymphoblastic Leukemia. Oncology 14 (12):1720-1725, 2000. 129. Cheson BD, Valmonte CM. Current Clinical Trials in Myelodysplastic Syndromes.

Oncology 15(1):52-57, 2001. 130. Cheson BD, Abrams J, Gravell A. Clinical Trials in Early-stage Breast Cancer.

Oncology 15(2):176-185, 2001. 131. Saxman SB, West PJ, Cheson BD. Current Clinical Trials in Small-cell Lung

Cancer. Oncology 15(3):318-323, 2001. 132. Murgo A, Wood KF, Gravell AE, Cheson BD. Clinical Trials with STI-571.

Oncology 15 (7):885-886, 2001. 133. Chen HX, Gore-Langton RE, Cheson BD. Current clinical trials of the anti-VEGF

monoclonal antibody bevacizumab. Oncology 15 (8):117-126, 2001. 134. Colevas AD, West PJ, Cheson BD. Current clinical trials of epothilone B analog

(BMS-247550). Oncology 15 (9):1172-1175, 2001.

Bruce D. Cheson, M.D. Page 70 Monographs 1. Cheson BD. CLL: Prognosis and Treatment. Triton Biosciences, Inc., 1988. 2. Cheson BD. Treatment Options for Hematologic Malignancies: Chronic

Myelogenous Leukemia, Hairy-cell Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma. Triclinica Communications, 1990.

3. Cheson BD. Regulation of Hematopoiesis, Sources for Bone Marrow

Transplantation, and the Potential of PCR Technology: Focus of the Thirty-second Annual Meeting of the American Society of Hematology. Biotherapy Reporter 1(1):1-8, 1990.

4. Cheson BD. Accrual to Clinical Trials in Urologic Malignancies. Urologic Oncology

Update, Winter, 1991. 5. Cheson BD. Chronic Lymphocytic Leukemia: New Therapies and Future

Prospects. Biologic and Clinical Characteristics of Chronic Lymphocytic Leukemia. Advances in Leukemia and Lymphoma 2:3-11, 1991.

6. Cheson BD. Alternative schedules and indications for fludarabine, in “Purine

Analogs: Current Status in Hematological Malignancies”, Physicians’ Education Resource, 1998.

7. Cheson BD. Current approaches to therapy for indolent non-Hodgkin’s

lymphomas. Oncology Special Edition, 2000. 8. Cheson BD, Hillmen P, Österborg A. Subcutaneous administration of

alemtuzumab. Clinical Advances in Hematology & Oncology, June 2003. 9. Cheson BD. Anti-CD20 monoclonal antibodies in the treatment of indolent

lymphoma and CLL. Clin Adv Heme Onc 5 (2)(suppl 7), 2007. 10. Cheson BD, Rai KR, Obrien S. Chronic lymphocytic leukemia: current and

emerging treament approaches. Clin Adv Hematol Oncol 6 (suppl):1-10, 2008. 11. Rai KR, Knauf WU, Cheson BD. Chronic lymphocytic leukemia: A case-base

discussion of recent advances in patient management. Clin Adv Hematol Oncol 8 (suppl 12): 3-15, 2010.

12. Cheson B. Adverse events in chronic lymphocytic leukemia and non-Hodgkin

lymphoma: importance of accurate reporting and long-term follow-up, in “Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol 9 (suppl 15):7-8, 2011.


Meeting Programs/Syllabus/Compendia 1. Hematology, 1986. Educational Session on Non-Hodgkin's Lymphomas, American

Society of Hematology, 1986. 2. ASCO Educational Booklet. Educational Session on Myelodysplastic Syndromes,

American Society of Clinical Oncology, 1988. 3. ASCO Educational Booklet. Educational Session on Chronic Lymphocytic

Leukemia, May, 1990. 4. ASCO Educational Booklet. Educational Session on Chronic Lymphocytic

Leukemia, November, 1991. 5. Eighth Annual ROSE Seminar, “Future of Bone Marrow Transplantation”, August,

1992. 6. Ninth Annual ROSE Seminar, “Advances in Cancer Therapy - 1993”, August,

1993. 7. Cancer Medicine 1993, Dana Farber Cancer Institute, “Myelodysplastic

Syndromes”, October, 1993. 8. ASCO Educational Booklet. Educational Session on New Drugs, November, 1993. 9. Hematology Board Review Course, “Myelodysplastic Syndromes”, George

Washington University, October, 1994. 10. Eleventh Annual ROSE Seminar, “High Dose Chemotherapy for Breast Cancer”,

August, 1995. 11. Oncology Board Review Course, “Non-Hodgkin’s Lymphomas”, George

Washington University, October, 1995. 12. Education Programme of the 26th Congress of the International Society of

Haematology, “Therapy of the Myelodysplastic Syndromes”, August, 1996. 13. Hematology Board Review Course, “Myelodysplastic Syndromes”, George

Washington University, October, 1996. 14. ASCO Education Book, Multiple Myeloma: Treatment, May, 1997. 15. Cancer Medicine and Hematology Board Review Course, Harvard University,

Chronic Lymphocytic Leukemias and Lymphoplasmacytic Disorders, September, 1997.

16. Hematology Board Review Course, George Washington University, Non-Hodgkin’s

Lymphomas, October, 1997.

Bruce D. Cheson, M.D. Page 72 Meeting Programs/Syllabus/Compendia (Continued) 17. International Society of Hematology/European Hematology Association, Education

Book, “Treatment Strategies for Aggressive Non-Hodgkin’s Lymphomas”, July, 1998.

18. Medical Oncology - State of the Art. Myelodysplasia; Chronic Lymphocytic

Leukemia, September, 1999. 19. Cancer Medicine and Hematology Board Review Course, Harvard University, CLL

and Variants, October, 1999. 20. Hematology Board Review Course, George Washington University, The Chronic

Lymphoid Leukemias; Myelodysplastic Syndromes, October, 1999. 21. American Society of Hematology Education Book. Educational Session on

Indolent Non-Hodgkin’s Lymphomas, December, 1999. 22. American Society of Hemtaology Hematology Education Book. Education Session

on Targeted Therapies for Hematologic Malignancies. December, 2001. 23. American Society of Hematology Education Book. Education Session on

Epidemiology and New Therapeutic Approaches for Non-Hodgkin’s Lymphomas. December, 2002.

Letters 1. Cheson BD. BCG and uriticaria. Ann Intern Med, 83:738, 1975. 2. Cheson BD, and Garovoy MR. Cogan's Syndrome and Bw 17 revisited. New Engl

J Med 397:62-63, 1977. 3. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM,

Keating MJ, Boldt DH, Kempin SJ, Foon KA. Chronic lymphocytic leukemia: Recommendations. Ann Intern Med 110:664-665, 1989.

4. Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F.

Intermediate-dose melphalan for refractory myeloma: Response. Blood 74:1177, 1989.

5. Cheson BD. Immunosuppression with fludarabine therapy: Response. Oncology

5(2):12, 1991. 6. Cheson BD. Elevated erythrocyte sedimentation rate in a patient with Hodgkin’s

disease. Primary Care and Cancer (in press). 7. Cheson BD, Abrams J, Friedman MA. Breast cancer trials not floundering.

American Medical News, p. 29, June 7, 1993.

Bruce D. Cheson, M.D. Page 73 Letters (Continued) 8. Cheson BD. Autologous bone marrow transplantation in acute myeloid leukemia.

Onc News Internat 2(7):36-37, 1993. 9. Grever M, Bennett JM, Habermann T, Rai K, Eisenhauer E, Cheson BD. Optimal

treatment for untreated patients with hairy cell leukemia? Reply. J Clin Oncol 13:2677-2678, 1995.

10. Cheson BD. Prolonged cyclophosphamide therapy in chronic lymphocytic

leukemia. Primary Care & Cancer. 16 (5):1 & 7, 1996. 11. Cheson BD. Treatment of primary refractory lymphoma. Onc News Int. 5 (2):36-

37, 1996. 12. Cheson BD. Mammography in a woman treated for non-Hodgkin’s lymphoma.

Onc News Int 5:17, 1996. 13. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg

B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Greenberg PL. MDS Standardized Response Criteria: Further Definition. Blood 98:1985, 2001.

14. Ozdemirli M, Cheson BD, Jaffe ES. What is anaplastic large cell lymphoma? Am J

Surg Pathol, 26:1664-1665, 2004. 15. Cheson BD, Leonard JP. Monoclonal antibody therapy and non-Hodgkin’s

lymphoma. New Engl J Med 360:192-193, 2009.

16. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillman P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes. Blood 119 (June 4):5348, 2012.

17. Federico M, Bellei M, Cheson BD. BEACOPP or no BEACOPP? Lancet Oncol 14:87-88, 2013

18. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillman P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. Clarifications of iwCLL criteria for a partial response to therapy. Blood (e-pub on line, 2013)

19. Barrington SF, Mikhaeel G, Meignan M, Hutchings M, Mueller S, Schwartz LH,

Zucca E, Risher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD. Reply to B. Bennani et al, Adams et al, E. Laffon et al, and E. Hawkes et al. J Clin Oncol 33:1221-1223, 2015.

20. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S,

Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A, Cheson BD. Reply to Karamida et al. J Clin Oncol 33:4121-4122, 2015.

Bruce D. Cheson, M.D. Page 74 Letters (Continued) 21. Ujjani CS and Cheson BD. Overestimated value of FDG-PET based bone marrow

evaluation in lymphoma: Response to Adams and Kwee. Br J Haematol (e-pub ahead of print, 2016).

Book Reviews 1. Chronic and Acute Leukemias in Adults. C.D. Bloomfield, ed. Cancer Treat Rep

70:317-319, 1986. 2. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. R.P. Gale

and K.R. Rai, eds. J Natl Cancer Inst 80:65-66, 1988. 3. A Colour Atlas of Haematological Cytology. F.G.J.Hayhoe and R.J. Flemens, eds.

Hematol Rev and Comm 7:237-238, 1993. 4. Myeloma: Biology and Management. J.S. Malpas, D.E. Bergsagel, R.A. Kyle, eds.

New Engl J Med 333:672-673, 1995. 5. Non-Hodgkin’s Lymphomas. PM Mauch, JO Armitage, B Coiffier, R Dalla-Favera,

NL Harris, eds. New Engl J Med 351:2351-2352, 2004.


Abstracts 1. Cheson BD, Christensen R, Sperling R, Kohler B, and Babior BM. The Origin of

the chemiluminescence of phagocytosing granulocytes. Blood 46:1016A, 1975. 2. Cheson BD, Plass RR, and Rothstein G. Defective opsonization in multiple

myeloma. Blood 52:219A, 1978. 3. Cheson BD. Chemotherapy of hepatomas. Proc Snowbird Conf on Advances in

Hepatobiliary Disorders, 1978. 4. Morris SE, and Cheson BD. Role of serum factors in zymosan opsonization. Clin

Res 28:35A, 1980. 5. Cheson BD, and Morris SE. Serum factors required for zymosan (Z) opsonization.

Clin Res 28:306A, 1980. 6. Cheson BD. Opsonic activity of multiple myeloma immunoglobulins (MM-Ig). Clin

Res 28:306A, 1980. 7. Mintz SJ, Petersen SR, Cheson BD, Cordell LJ, and Richards RC, Splenectomy for

idiopathic (immunologic) thrombocytopenic purpura. Proc Western Surgical Soc, 1980.

8. Weiss BJ, Petersen SR, Mintz SJ, and Cheson BD. Is staging laparotomy for

Hodgkin's disease obsolete? Proc Southwestern Surg Cong, 1981. 9. Mineau DE, Miller FJ, Datz FL, Lee RG, and Cheson BD. Partial splenic ablation

using transcatheter ethanol. Proc 67th Scientific Assembly of the Radiologic Society of North America, 1981.

10. Walker HS, and Cheson BD. Defective complement function in multiple myeloma.

Clin Res 30:48A, 1982. 11. Walker HS, Janata J, and Cheson BD. S. pneumoniae (SP) infections in Multiple

Myeloma (MM): Role for a complement defect. Clin Res 30:381A, 1982. 12. Tang TT, Samlowski WE, Cheson BD, and Spruance SL. Value of open lung

biopsy in immunocompromised patients with pneumonitis. Clin Res 31:52A, 1983. 13. Heath ME, Cheson BD, and Millikan CH. Ischemic cerebrovascular episodes

during aspirin therapy. Clin Res 31:63A, 1983. 14. Cheson BD, Schumann JJ, and Schumann GB. Urinary cytodiagnostic

abnormalities in 50 patients with non-Hodgkin's lymphoma. Acta Cytologica 27:555, 1983.

15. Heath ME, and Cheson BD. Defective complement activity in chronic lymphocytic

leukemia. Clin Res 32:33A, 1984.

Bruce D. Cheson, M.D. Page 76 Abstracts (Continued) 16. Cheson BD, DeBellis CC, Schumann GB, and Schumann JL. The "Myeloma Cast":

A unique pathologic finding in patients with multiple myeloma. Amer J Clin Path 83:266, 1985.

17. Cheson BD, Jasperse DM, Simon R, and Friedman MA. Is the use of low dose

ara-C (LoA) warranted in acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS)? Proc ASCO 5:582, 1986.

18. Cheson BD, Levine A, Mildvan D, Kaplan L, Rios A, Wolfe P, Groopman J,

Hawkins M. Suramin Therapy in AIDS and Related Diseases: Initial report of the U.S. Suramin Working Group. Proc Int Conf on AIDS, 1986.

19. Lofters W, Campbell M, Gibbs WN, and Cheson BD. Phase II trial of 2'-

deoxycoformycin (DCF) in adult T-cell lymphoma (ATL). Proc ASCO 6:739, 1987. 20. Cheson BD. Study Design in Chronic Lymphocytic Leukemia (CLL). Proc 4th

International Workshop on CLL, 1988. 21. Cheson BD, Barlogie B, Bergsagel D, Cooper MR, Greipp P, Mackenzie M, Oken

MM, Salmon SE, Schiffer CA. Report of the National Cancer Institute (NCI)-sponsored workshop on therapeutic strategies in multiple myeloma. Proc Second International Workshop on Advances in Biology and Therapy of Myeloma, 1989.

22. Chun HG, Grem J, Vena D, Fallavollita A, Cheson BD. Treatment of active hairy

cell leukemia (HCL) refractory or intolerant to alpha-interferon (IFN-A) with pentostatin under the Group C protocol. Proc ASCO 9:828, 1990.

23. Cheson BD. Fludarabine phosphate: an active new drug for the treatment of

lymphoproliferative disorders (LPD). J Cancer Res and Clin Oncol 116:1000 (abstr 11.28.06), 1990.

24. Sorenson JM, Chun HG, Vena D, Fallavollita A, Cheson BD. Pentostatin (DCF)

therapy for hairy cell leukemia (HCL): Update of a Group C protocol of 208 patients (pts) who have failed interferon alpha (IFNa). Proc ASCO 10:232 (abstr. 787), 1991.

25. Cheson BD. U.S. clinical trials in chronic lymphocytic leukemia. Proc 5th

International Workshop on CLL, p. 63, 1991. 26. Grever M, Kopecky K, Head DR, Cassileth P, Rai K, Eisenhauer E, and Cheson B.

A randomized comparison of deoxycoformycin (DCF) versus alpha-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): An NCI-sponsored intergroup study (SWOG, ECOG, CALGB, NCIC CTG), Proc ASCO 11:264 (abstr 868), 1992.

27. Gotay C, Phillips P, Cheson B. Male-female differences in the impact of cancer

therapy. Proc ASCO 11:157 (abstr 447), 1992.

Bruce D. Cheson, M.D. Page 77 Abstracts (Continued) 28. Sorenson JM, Vena D, Fallavollita A, Cheson BD. Treatment of refractory chronic

lymphocytic leukemia (CLL) with fludarabine monophosphate (FAMP) under the Group C protocol. Proc ASCO 11:264 (abstr 867), 1992.

29. Cheson BD. Nucleoside analogues: Which wins the beauty contest? Proc

“Leukemia...the next questions”, 1993. 30. Sorensen JM, Vena DA, Montello MJ, Christian MC, Cheson BD. Treatment of

hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine (CDA) under the group C mechanism. Proc ASCO 12:302 (abstr 988), 1993.

31. Vena DA, Phillips PH, Carter CL, Cheson B. Database management of NCI-

sponsored cancer treatment trials. Proc ASCO 12:186 (abstr 537), 1993. 32. Phillips PH, Vena DA, Carter CL, Cheson BD. Database management of National

Cancer Institute-sponsored cancer treatment trials. Proc Soc Clin Trials, 1993. 33. Cheson BD. New chemotherapeutic agents for multiple myeloma (MM). Proc IV

International Workshop on Multiple Myeloma, p. 84, 1993. 34. Grever M, Kopecky K, Head D, Foucar K, Cassileth P, Golomb H, Habermann T,

Rai K, Eisenhauer E, Appelbaum F, Cheson B. A randomized comparison of deoxycoformycin (DCF) versus alpha-2a interferon (IFN) in previously untreated patients (PTS) with hairy cell leukemia (HCL): An updated report on the NCI-sponsored intergroup study. Blood 82 (suppl 1) 199a (abstr 782), 1993.

35. Frame JN, Sorensen JM, Qashu N, Vena D, Christian M, Chun HG, Cheson BD.

Tumor lysis syndrome (TLS) in patients receiving fludarabine (F) for chronic lymphocytic leukemia (CLL). Blood 82 (suppl 1):139a (abstr 540), 1993.

36. Cheson BD. Recent initiatives in the treatment of CLL. Proc “Hematologic

Malignancies...New Strategies and Targets” , 1994. 37. Cheson BD. New therapeutic approaches in chronic lymphocytic leukemia. Proc

AACR Special Conference: Translational Research in Cancer: New Opportunities for Progress, 1994.

38. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley

J, Barlogie B. Peripheral blood stem cell transplants (PBSC) for multiple myeloma (MM) - identification of favorable variables for rapid engraftment in 225 patients. Blood 84 (suppl 1): 180a (abstr 707), 1994.

39. Barlogie B, Jagannath S, Vesole D, Miller L, Cheson B, Bracy D, Tricot G. Total

therapy (TT) for 202 newly diagnosed patients (pts) with multiple myeloma (MM). Blood 84 (suppl 1): 386a (abstr 1531), 1994.

40. Vesole D, Jagannath S, Tricot G, Miller L, Cheson B, Bracy D, Barlogie B.

Autotransplants (AT) for multiple myeloma (MM). Blood 84 (suppl 1): 535a (abstr 2126), 1994

Bruce D. Cheson, M.D. Page 78 Abstracts (Continued) 41. Munshi NC, Wijdenes J, Fassas A, Vesole D, Jagannath SJ, Cheson B, Butch A,

Dhodapkar M, Tricot G, Barlogie B. Anti-IL-6 monoclonal antibody (BE-8) and suramin for treatment of Castleman’s disease (CD). Blood 86 (suppl 1):189a (abstr 745), 1995.

42. Rai KR, Peterson B, Kolitz J, Elias J, Shephard L, Hines J, Cheson B, Schiffer C.

Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). A randomized inter-group study. Blood 66:607a (abstr 2414), 1995.

43. Arbuck SG, Cheson BD. New drugs for treatment of malignant lymphoma. Ann

Oncol 7 (suppl 3):32 (abstr 102), 1996. 44. Rai KR, Peterson B, Elias L, Shepherd L, Hines J, Nelson D, Cheson B, Kolitz J,

Schiffer CA. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG intergroup study. Blood 88 (suppl 1):141a (abstr 552), 1996.

45. Cheson BD, Vena D, Freidlin B, Barrett J, Sorensen JM. The risk of secondary

malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Proc ASCO 16:15a (abstr 52), 1997.

46. Horning S, Cheson B, Peterson B, Grillo-Lopez AJ, Carter W, Varns C,

Klippenstein D, Kossman C, Kortman K, Rosen PJ, Morrison V, Just R, Parkeer E, Dallaire BK. Response criteria (RC) and quality assurance (QA) of responses in the evaluation of new therapies for patients with low-grade lymphoma (LGNHL). Proc ASCO 16:18a (abstr 62), 1997.

47. Grillo-López AJ, Horning S, Cheson B, Peterson B, Coiffier B, Hiddemann W,

Marcus R, Lister TA, Gianni AM, ahd García-Conde J. Development of response criteria (RC) for low-grade or follicular lymphomas (LG/F NHL) and application in a 166 patient study. Exper Hematol, 25(8):732 (abstr 17), 1997.

48. Cheson BD. New drugs for the treatment of CLL. Hematol and Cell Ther 39 (suppl

1): S61, 1997. 49. Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett

WEN, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum FR, Cheson BD, Grever M. Long-term results in hairy cell leukemia (HCL) treated with pentostatin. Blood 90 (suppl 1):578a (abstr 2575), 1997.

50. Cheson BD. Purine analogues in the treatment of low grade lymphomas. Ann

Hematol 77 (suppl 1):A5 (abstr 20), 1998.

Bruce D. Cheson, M.D. Page 79 Abstracts (Continued) 51. O’Brien S, Kantarjian H, Cortes J, Giles FJ, Beran M, Rios M-B, Mallard S, Cheson

B, Murgo A, Talpaz M. Simultaneous homoharringtonine (HHT) and interferon alpha (IFN ) therapy as an effective regimen in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Blood 92 (suppl 1, part 1):251a (abstr 1028), 1998.

52. Kantarjian H, O’Brein S, Rios M-B, Cortes J, Giles FJ, Gajewski J, Beran M,

Kornblau S, Mallard S, Keating M, Cheson B, Murgo A, Talpaz M. Homoharringtonine (HHT) and low-dose cytosine arabinoside (LD-ara-C) is effective and safe for the treatment of Philadelphia chromosome (Ph)-positive late chronic phase (CP) chronic myelogenous leukemia. Blood 92 (suppl 1, part 2):246b (abstr 4056.5), 1998.

53. Vey N, Kantarjian H, Beran M, O’Brien S, Cortes J, Giles FJ, Cheson B, Arbuck S,

Estey E. Phase I study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Blood 92 (suppl 1, part 1):235a (abstr 962), 1998.

54. Grillo-López AJ, Cheson B, Horning S, Peterson B, Carter W, Varns C, Shen D,

Klippenstein D. Response criteria (RC) for NHL: importance of “normal” lymph node (LN) size and correlations with response. Blood 92 (suppl 1, part 1):412a (abstr 1701), 1998.

55. Grillo-López AJ, McLaughlin P, Cheson BD, Czuczman M, Maloney DG, Horning

S, Link BK, Davis TA, Cabanillas, F, White CA. Final report on the application of the new Response Criteria (RC) proposed for NHL: the rituximab pivotal trial. Proc ASCO 18:13a (abstr 44), 1999.

56. Cheson BD. Mabthera in the next millenium. Proc 4th International Workshop on

Lymphomas, Lugano, Switzerland, 1999. 57. Kantarjian HM, Talpaz M, Cortes J, Rios MB, Giles FJ, Mallard S, Bramble D,

Murgo A, Cheson B, Kornblau S, Keating M, O’Brien S. Homoharringtonine and low-dose cytosine (Ldara in late chronic phase chronic myelogenous leukemia (CML). Blood 94:274b-275b (abstr 4439), 1999.

58. Kantarjian HM, Talpaz M, Cortes J, Rios MB, Giles FJ, Tjomas D, Andreeff M,

Mallard S, Lim J, Murgo A, Cheson B, Keating M, O’Brien S. Triple combination therapy with interferon-alpha (IFN- ), low-dose cytarabine (Ldara and homoharringtonine (HHT) in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) in early chronic phase. Blood 94:275b (abstr 4439), 1999.

59. Gertz MA, Lacy MQ, Dispenzieri A, Cheson B, Barlogie B, Kyle RA, Pajjadini G,

Geyer S, Merlini G. A multicenter phase II trial of 4’-iodo-4’-deoxydoxorubicin (IDOX) in primary amyloidosis. Blood 96:288b (abstr 4985), 2000.

60. Cheson BD. New chemotherapy agents in acute leukemia. Ann Hematol 80

(suppl II)S3 (abstr 10), 2001.

Bruce D. Cheson, M.D. Page 80 Abstracts (Continued) 61. Hegde UP, Wilson WH, White T, Fogarty P, Rick M, Cheson B. Rituximab for the

treatment of fludarabine (FAMP)-associated autoimmune thrombocytopenia (AT) in chronic lymphocytic leukemia (CLL): report of three cases from a single institution. Proc ASCO 20:305a (abstr 1218), 2001.

62. Wilson WH, Frankel SR, Drbohlav N, Hegde U, Gutierrez M, Janik J, Davis T, Little

R, Steinberg S, Grillo-Lopez A, Cheson B, Jaffe E, Grossbard M, Chabner B. Phase II study of dose-adjusted EPOCH-Rituximab in untreated high risk large B-cell lymphomas. Proc ASCO 20:290a (abstr 1158), 2001.

63. Cheson BD. New drugs for the treatment of chronic lymphocytic leukemia. Leuk

and Lymph 42 (suppl 1):10-12 (abstr S17), 2001. 64. Cheson BD. New drugs for the treatment of non-Hodgkin’s lymphoma. 8th

International Conference on Malignant Lymphoma. Ann Oncol 13 (suppl 2), 37 (abstr 108), 2002.

65. Hegde U, White T, Stetler-Stevenson M-A, Marti G, Janik J, Pittaluga S, Kingma D,

Steinberg S, Cheson B, Jaffe E, Wilson WH. Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma, Blood 100 (suppl 1):358a (abstr 1389), 2002.

66. Mavromatis BH, Asatiani E, Cheson BD, Hartmann Dm Liu M-L, Kessler C, Cohen

P, Ozdemerli. Indolent large granular lymphoproliferative disorders (LGLD) posing as myelodysplastic syndrome (MDS). Blood 100 (suppl 1):242b (abstr 4489), 2002.

67. Mavromatis BH, Ozdemirli M, Cheson BD. A case of reactive T-cell lymphoid

aggregates causing persistent F18 FDG uptake in a patient with treated diffuse large B-cell non-Hodgkin’s lymphoma. Blood 100 (suppl 1):289b (abstr 4689), 2002.

68. Cheson BD. New drugs for lymphoma. Proc. Pan Pacific Lymphoma Conference,

2003. 69. Asatiani E, Cohen P, Ozdemirli M, Kessler C, Mavromatis B, Cheson BD.

Monoclonal gammopathy in extranodal subtypes of marginal zone lymphoma (ENMZL) correlates with advanced diseas withb involvement of bone marrow. Blood 102 (suppl 1):633a (abstr 2337), 2003.

70. Zantek ND, Cheson BD, Hartmann D-P, Mavromatis B, Abbasi S, Ozdemirli M.

Zap-70 expression in lymphoid tissue of B-cell lymphomas using immunohistochemistry. Blood 102 (suppl 1):283b (abstr 4854), 2004.

71. Gordon LI, Moore JO, Cheson BD, Czuczman M, Younes A, Leonard JP, Forero-

Torres A, Sweetenham JW, Chieffo N, thall A, Leigh BR. Phase I results from a multiceneter trial of galiximab (anti-CD80 antibocy, IDEC-114) in combination with rituximab for the treatment of follicular lymphoma. Blood 102 (suppl 1):307b (abstr 4951)), 2003.

Bruce D. Cheson, M.D. Page 81 Abstracts (Continued) 72. Abbasi SY, Mavromatis BH, Ozdemirli M, hartmann DP, Cohen P, Cheson BD.

Correlation of CD38 expression and cytogenetic abnormalities in chronic lymphocytic leukemia (CLL). Blood 102 (suppl 1):350b (abstr 5125), 2003.

73. Zafer E, Abbassi S, Cheson B, Ozdemirrli M, Hartmann D, Meck J. Chronic

lymphocytic leukemia: a prospective study using FISH, CD38, and ZAP-70. Proc Amer Soc Human Genetics, pp 82 (abstr 334), 2004.

74. Cheson BD. PET-CT in non-Hodgkin Lymphoma – International Response

Criteria – Is It Time For a Change? Eur J Haematol 73 (suppl 65):27-28 (abstr D-01), 2004.

75. Damon L, Niedzwiecki D, Cheson B, Hurd D, Bartlett N, Kelly M, Linker C,

Canellos G. Intense chemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909. Blood 104 (suppl 1):255-256a (abstr 895), 2004.

76. Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett

NL. Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: Results of CALGB 59906, a phase II study of doxorubicin and topotecan. Blood 104 (suppl 1):685a (abstr 2500, 2004

77. Sher D, Johnson, J, Siddiqui M, Damon L, Linker C, Cheson B, Stock W.

Eradication of minimal residual disease during treatment of mantle cell lymphoma: CALGB 59909. Blood 104 (suppl 1):459a (abstr 1652), 2004.

78. Mavromatis BH, Cheson BD, Ozdemirli M, Hartmann D-P, Abbasi S, Zafer E,

Zantek N, Cooksey J, Meck J. Deletion of 13q14 is independent of CD38 expression in chronic lymphocytic leukemia (CLL). Blood 104 (suppl 2):285b (abstr 4811), 2004.

79. Leonard JP, Rosenblatt JD, Bartlett NL, Gopal A, Younes A, Fisher D, Foss F,

Forero A, Bernstein S, Cheson B, Carabasi MH, Bociek RG, Hart B, McDonald M. Phase II study of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent Hodgkin’s disease. Blood 104 (suppl 1):721a (abstr 2635), 2004.

80. Forero-Torres A, Bernstein S, Gopal A, Foss F, Leonard J, Rosenblatt J, Bartlett

N, Younes A, Fisher D, Cheson B, Carabasi M, Bociek G, hart B, McDonald M, SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Blood 104 (suppl 1):721a (abstr 2637), 2004.

81. Grinblatt D, Johnson J, Niedzwicki D, Rizzieri DA, Bartlett N, Cheson BD. Phase II

study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (SLL): CALGB study 50002. Blood 104 (suppl 1):897-898a (abstr 3284), 2004.

Bruce D. Cheson, M.D. Page 82 Abstracts (Continued) 82. Mavromatis BH, Cheson BD, Zantek ND, Hartmann D-P, Kessler C, Cohen P,

Gehan E, Ozdemirli M. ZAP-70 expression in chronic lymphocytic leukemia (CLL) is independent of Rai stage: a retrospective review of 38 patients (pts). Blood 104 (suppl 2):285-286b (abstr 4811), 2004.

83. Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Canellos GP, Cheson BD.

Results of a phase II study of 506U78 in CTCL and PTCL. Blood 104 (suppl 1):682a (abstr 2486), 2004.

84. Wilson WH, Porcu P, Hurd D, Martin SE, Czuczman M, Niedzwiecki D, Saint Louis

JD, Johnson JL, Cheson B, Canellos GP, Zelenetz AD. Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma – CALGB 50103. Proc ASCO 567s (abstr 6530), 2005.

85. Leonard JP, Friedberg J, Younes A, Fisher D, Gordon L, Moore J, Czuczman M,

Miller T, Stiff P, Cheson B, Forero-Torres A, Nasizadeh H, Whitely M, Leigh BR. Results from a phase I/II study of galiximab (anti-CD80) in combination with rituximab (anti-CD20) for relapsed or refractory follicular lymphoma. Ann Oncol 16 (suppl 5), p v71 (abstr 115), 2005.

86. Cheson BD. New Drugs for Lymphomas. Ann Oncol 16 (suppl 5), p v66 (abstr

101), 2005. 87. Cheson BD. Response assessment in lymphoma. Proc Pan-Pacific Lymphoma

Conference, 2005. 88. Friedberg J, Cohen P, Cheson B, Robinson KS, Foran J, Fayad L, LaCasce A,

Bessudo A, Camacho E, Williams M, van der Jagt R, Oliver J, Benaim E. Treanda™ (Bendamustine HCL, SDX-105) produces durable response in patients with rituximab-resistant indolent B-cell non-Hodgkin’s lymphoma (NHL). Proc 2005 Pan-Pacific Lymphoma Conference, 2005.

89. Forero-Torres A, Bernstein SH, Gopal AK, Foss F, Leonard JP, Rosenblatt JD,

Bartlett NL, Cheson BD, Epner E, Hernandez-Illizaliturri FJ, Proctor SJ, Brice P, Tilly H, Haioun C, Jerkeman M, Bosly A, Lorenz JM, Barton J. SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractoryt or recurrent systemic anaplastic large cell lymphoma (ALCL). Blood 106 (suppl 1) 938a (abstr 3356), 2005.

90. Friedberg JW, Leonard JP, Younes A, Fisher DC, Gordon LI, Moore JO,

Czuczman MS, Miller TP, Stiff PJ, Cheson BD, Forero-Torres A, Finucane DM, Leigh BR, Molina A. Updated results from a phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular NHL. Blood 106 (suppl 1) 685a (abstr 2435), 2005.

Bruce D. Cheson, M.D. Page 83 Abstracts (Continued) 91. Cella D, Webster K, Cashy J, Kutikova L, Burgess MF, Lin BK, Bowman L, Liepa

AM, Gauthier JE, Gregory SA, Johnson SA, Cheson BD. Development of a measure of health-related quality of life for non-Hodgkin’s lymphoma clinical research: the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym). Blood 106 (suppl 1) abstr 750, 2005.

92. Friedberg JW, Cohen P, Cheson BD, Robinson KS, Forero-Torres A, Fayad L, La

Casce AS, Bessudoo A, Camacho ES, Williams ME, van der Jagt RH, Oliver J, Benaim E. Bendamustine HCL (TREANDA) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-ceell non-Hodgkin’s lymphoma (NHL): Results from a phase II multicenter single-agent study. Blood 106 (suppl 1) abstr 229, 2005.

93. Friedberg JW, Ciminello L, Kelly J, Clawson S, Hoelzer D, Holte H, LaCasce A,

meade G, Thomas D, van Imhoff GW, Cheson B, Magrath IT, Fisher RI. Outcome of patients > age 40 with Burkitt Lymphoma (BL) treated with aggressive chemotherapeutic regimens: Results from the International Burkitt Lymphoma Collaborative Group. Blood 106 (suppl 1), abstr #928, 2005.

94. O’Brien S, Kipps TJ, Faderl S, Crump M, Keating MJ, Anderson B, Soho C, Bole J,

Turner R, Viallet J, Cheson BD. A phase I trial of the small molecule pan-bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL). Blood 106 (suppl 1) abstr 446, 2005.

95. Jordan JL, Asatiani E, Hartmann DP, Cheson BD, Ozdemirli M. Flow cytometric

analysis in myeloddysplastic syndrome (MDS). Blood 106 (suppl 1) abstr 4932, 2005.

96. Acs P, Mavromatis B, Ozdemirli M, Hartmann D, Cheson BD. Treatment

outcomes in patients (pts) with transformed chronic lymphocytic leukemia (CLL) in one institution. Blood 106 (suppl 1) abstr 5031, 2005.

97. Acs P, Mavromatis B, Ozdemirli M, Hartmann D, Mmeck J, Zafer E, Slack R,

Cheson B. A prognostic model using ZAP-70, CD38 and cytogenetics to better predict need for early therapy and response to treatment in chronic lymphocyic leukemia (CLL). Blood 106 (suppl 1) bstr 2114, 2005.

98. Cheson BD, Pfistner B, Juweid ME, Specht L, Rosen ST, Gascoyne R, Stroobants

S, Diehl V. Revised response criteria for malignanct lymphomas. From the members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma. Blood 106 (suppl 1) abstr 18, 2005.

99. O’Brien S, Claxton D, Crump M, Faderl S, Kipps T, keating M, Cheson B. Small

molecule pan-bcl2 family inhibitor obatoclax (GX15-070): Final results of a single agent phase I trial in patients with refractory chronic lymphocytic leukemia (CLL). Proc European Hematol Assoc, 2006.

Bruce D. Cheson, M.D. Page 84 Abstracts (Continued) 100. Cheson BD. Updating response criteria in non-Hodgkin’s lymphoma. Proc 4th

International Workshop on Nuclear Oncology, 2006. 101. Cheson BD, Pfistner B, Juweid ME, Horning SJ, Coiffier B, gascoyne RD, Fisher

RI, Rosen ST, hagenbeek A, Hoppe RT, Vose JM, Diehl V. Recommendations for revised response criteria for malignant lymphoma. J Clin Oncol 24 (18S, part I):423s (abstr 7507), 2006.

102. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. A

phase II study of Bortezomib in relapsed Hodgkin lymphoma: preliminary results of CALGB 50206. J Clin Oncol 24 (suppl 18, part I):440s (abstr 7576), 2006.

103. Lai R, His ED, Mackey J, Jung S, Johnson JL, Cook JR, Jones D, Said JW,

Cheson BD, Bartlett NL. High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin – a CALGB correlative study. J Clin Oncol 24 (suppll 18, part I):442s (abstr 7581), 2006.

104. Juweid M, Stroobants S, Mottaghy F, Dietlein M, Guermazi A, Wiseman G,

Scheidhauer K, Hoekstra OS, Buck A, Naumann R, Spaepen K, Kostakoglu L, Reske S. Schwaiger M, Pfistner B, Diehl V, Cheson BD. Recommendations of the Imaging Committee of the International harmonization project (IHP) for FDG-PET (PET) use in patients with lymphoma. Proc Soc Nuc Med, 2006 (in press).

105. Juweid M, Stroobants S, Mottaghy F, Hoekstra O, Guermazi A, Dietlein M,

Wiseman G, Scheidhauer K, Buck A, Naumann R, Hicks R, Reske S, Schwaiger M, Diehl V, Cheson B. Recommendations of the imaging committee of the International Harmonization Project (IHP) for FDG-PET (PET) use in patients with lymphoma. Proc Eur Soc Nuc Med (in press, 2006).

106. Pfistner B, Diehl V, Specht L, Coiffier B, Hoppe R, Cheson B. New reponse

criteria for aggressive non-Hodgkin lymphoma. Proc German Lymphoma Study Group Meeting (in press, 2006).

107. Forero-Torres A, Cohen P, Cheson BD, Robinson KS, La Casce AS, Fayad L,

Camacho ES, Williams ME, van der Jagt RH, Friedberg JW. A phase II study of single-agent bendamustine in rituximab-refractory B-cell non-Hodgkin’s lymphoma. Proc ESMO 2006 (in press).

108. van der Jagt RH, Cohen P, Cheson B, Tulpule A, Herst JA, Lemieux B,

Schwartzberg LS, Robinson KS, Oliver JW, Williamas ME. Phase II results of bendamustine in combination with rituximab in relapsed mantle-cell lymphoma. Proc ESMO 2006.

109. van der Jagt RH, Cohen P, Cheson B, Tulpule A, Herst JA, Lemieux B,

Schwartzberg LS, Robinson S, Oliver JW, Williams ME. Phase II results of bendamustine in combination with rituximab in relapsed indolent non-Hodgkin’s lymphoma. Proc ESMO, 2006.

Bruce D. Cheson, M.D. Page 85 Abstracts (Continued) 110. Damon L, Johnson J, Niedzwiecki D, Cheson BD, Hurd D, Bartlett N, Byrd J, Kelly

M, Linker C, Canellos G. Immuno-chemotherapy (IC) and autologous stem cell transplantation (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL). Blood 108 (part 1): 774a (abstr 2737), 2006.

111. Van der Jagt R, Cohen P, Cheson BD, Tulpule A, Herst JA, Lemieux B,

Schwartzberg LS, Robinson KS, Oliver JW, Williams ME. Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin’s lymphoma. Blood 108 (part 1): 766a (abstr 2710), 2006.

112. Forero-Torres A, Bernstein SH, Gopal A, Foss F, Leonard JP, Rosenblatt JD,

Bartlett NL, Cheson BD, Epner E, Hernandez-Ilizaliturri FJ, Procor SJ, Brice P, Tilly H, Haious C, Jerkeman M, Bosly A, Gianni AM, Holte H, Mahendra P, Uharek L, Lorenz J, Barton J, Sievers E. SGN-30 (anti-CD30 mAb) has a single-agent response rate of 21% in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). Blood 108 (part 1): 768a (abstr 2718), 2006.

113. Mavromatis BH, Gaughan EM, Cheson BD, Attinger C, Cupps T, Couch K, Picken

K, Kessler C. Hyperhomocysteinemia (HHCY) increases the risk for lower extremity ulcers (LEUs). Blood 108 (part 2): 104ba (abstr 4099), 2006.

114. Mavromatis BH, Kessler CM, Cheson BD, Sein A, Sharp SA. The impact of GM-

CSF on arsenic trioxide (As2O3) therapy in patients with myelodysplastic syndrome (MDS): preliminary results of a phase II study. Blood 108 (part 2):299b (abstr 4856), 2006.

115. Cheson BD. Monoclonal antibodies against B cells and their role in the

management of chronic lymphocytic leukemia (CLL). Leuk and Lymph 48 (suppl 1)S15-S17, 2007.

116. Cheson BD. Revised response criteria for malignant lymphoma. Proc 2007

Lymphoma Symposium, Tokyo, Japan. 117. Cheson BD. New agent development: Update in 2007. Proc 2007 Lymphoma

Symposium, Tokyo, Japan. 118. Cheson BD. Development of ABVD as standard treatment for Hodgkin’s

lymphoma. Proc VII International Symposium on Hodgkin’s Lymphoma, 2007. 119. Cheson BD. Current role and future of PET in Hodgkin’s lymphoma. Proc VII

International Symposium on Hodgkin’s Lymphoma, 2007. 120. Kahl BS, Bartlett NL, Leonard JP, Ganjoo K, Williams ME, Czuczman MS,

Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Safety and efficacy of bendamustine in patients with rituximab-refractory, indolent B-cell non-Hodgkin’s lymphoma Blood 110 (part 1):406-407a (abstract 1351) 2007.

Bruce D. Cheson, M.D. Page 86 Abstracts (Continued) 121. Straus D, LaCasce A, Bartlett N, Juweid M, Kostakoglu L, Hall N, Johnson J, Jung

S-H, Canellos G, Cheson B. Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin’s lymphoma (HL): Results of CALGB 50203. Blood 110 (part 1):70-71a (abstract 214), 2007.

122. SchimmerAD, Brandwein J, O’Brien SM, Kantarjian H, Cheson BD, Minden MD,

Yee K, Schuh A, Gupta V, Viallet J, Borthakur G. A phase I trial of the small molecule pan-Bcl-2 family inhibitor obatoclax mesyalte (GX15-070) administered by continuous infusion for up to four days to patients with hematological malignancies. Blood 110 (part 1):272a (abstract 892), 2007.

123. Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph

SS, Cheson BD. Phase II trial of oral vironostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma. Proc ECCO (in press).

124. Cheson BD. Antibodies against B cells and their role in the management of

chronic lymphocytic leukemia. Leuk and Lymphoma 48 (suppl 1):S15-S17, 2007. 125. van der Jagt RH, Cohen P, Cheson B, Tulpule A, Herst JA, Lemieux B,

Schwartzberg LS, Robinson KS, Oliver JW, Williams ME. Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin’s lymphoma. Proc Chemotherapy Foundation, 2007.

126. Cheson BD. Development of ABVD as standard teatment for Hodgkin’s

lymphoma. Haematologica 92 (suppl 5):8 (abstr 1025), 2007. 127. Cheson BD. Current role and future of PET in Hodgkin’s lymphoma.

Haematologica 92 (suppl 5):21 (abstr 1068), 2007. 128. Cheson BD. New Drugs for B-cell Non-Hodgkin’s Lymphomas. Ann Oncol 19

(Suppl 4): abstr 133, 2008. 129. Cheson BD. Controversy: Has PET changed the approach to lymphoma patients:

Con. Ann Oncol 9 (suppl 4):abstr 121, 2008. 130. Czuczman MS, Johnson J, Jung S, Cheson BD. A phase II trial of extended

induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab in previously untreated follicular lymphoma (FL): initial report of CALGB 50402. Ann Oncol 9 (suppl 4): abstr 143, 2008.

131. Wilson WH, Zelenetz AD, Niedzwiecki D, Hurd D, Martin SE, Czuczman M,

Johnson JL, Canellos GP, Cheson BD. Multi-center study of doise-adjusted EPOCH-R in untreated diffuse large B-cell lymphoma-CALGB 50103. Ann Oncol 9 (suppl 4): abstr 206, 2008.

132. De Vos S, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN,

Kaplan H, Dornan D, Whiting N, Drachman J, Forero-Torres A. A phase 2 cliinical trial of SGN-40 monotherapy in relapsed difuse large B-cell lymphoma. Blood 112 (11):368 (abstract 1000), 2008.

Bruce D. Cheson, M.D. Page 87 Abstracts (Continued) 133. Friedberg JW, Younes A, Fisher DC, Gordon LI, Moore JO, Czuczman MS, Miller

TP, Stiff PJ, Cheson BD, Forero-Torres A, McKinney B, Leonard JP. Durable responses in patients treated with galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular lymphoma: long-term follow-up of a phase II clinical trial. Blood 112 (11)369-370 (abstract 1004), 2008.

134. Kostakoglu L, Straus DJ, Schoder H, LaCasce AS, Bartlett NL, Hall N, Johnson JL,

Jung S-H, Canellos GP, Schwartz LH, Cheson BD. Validation of the International Harmonization Project (IHP) guidelines in early stage Hodgkin lymphoma (HL) treated with adriamycin, vinblastine and gemcitabine (AVG) (CALGB 50203): eaerly results. Blood 112 (11):520 (abstract 1460), 2008.

135. Hsi ED, Said J, Jung S, Lai R, Jones D, Chadburn A, Cheson BD, Wilson WH.

Biologic prognostic markers in diffuse large B-cell lymphoma patients treated with dose-adjusted EPOCH—R: a CALGB 50103 correlative science study. Blood 112 (11):181 (abstract 476), 2008.

136. Czuczman MS, Leeonard JP, Johnson JL, Jung S-H, Hsi E, Byrd JC, Cheson BD.

FLIPI score is applicable and predictive of response to upfront immunotherapy in CALGB 50402: phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab [R]. Blood 112 (11):369 (abstract 1003), 2008.

137. Vose JM, Young A, Friedberg JW, Waller EK, Cheson BD, Trommeshauser D,

Munzert G. Phase I dose-esalation trial of BI 2536, a Polo-like kinase inhibitor in relapsed and refractory non-Hodgkin’s lymphoma. Blood 112 (11):93 (abstract 233), 2008.

138. Blum KA, Johnson JL, Jung S-H, Cheson BD, Bartlett NL. Serious pulmonary

toxicity with SGN-30 and gemcitabine, vinorelbine, and liposomal doxorubicin in patients with relapsed/refractory Hodgkin lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. Blood 112 (11):92-93 (abstract 232), 2008.

139. Advani R, De Vos S, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR,

Winter JN, Kaplan H, Dornan D, Whiting N, Drachman J, Forero-Torres A. A phase 2 clinical trial of SGN-40 monotherapy in relapsed diffuse large B-cell lymphoma. Blood 112 (11) 368 (abstract 1000), 2008.

140. Matous J, Letzer J, Rosen P, Noga S, Fowler N, Smith S, Amin B, Shi H,

Parasuraman S, Cheson B. Bortezomib (V), bendamustine (B), and rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): dose finding results of the VERTICAL study. J Clin Oncol 27:446s (abstract 8550), 2009.

141. Cheson BD, Vose JM, Bartlett NL, van der Jagt RH, Lopez A, Tolcher AW,

Weisenburger DD, Seiz AL, Shamsili S, Keating AT. Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 27 (15s):434s (abstract 8502), 2009.

Bruce D. Cheson, M.D. Page 88 Abstracts (Continued) 142. Cheson BD, Friedberg J, Kahl BS, vsn der Jagt RH. Bendamustine produces

durable responses in rituximab-refractory patients with non-Hodgkin’s lymphoma regardless of prior alkylator or purine analog sensitivity. Proc Pan Pacific Lympoma Conf, 2009.

143. Cheson BD. Bendamustine in the treatment of chronic lymphocytic leukemia

(CLL). Proc Chemotherapy Foundation, 115-117, 2009. 144. Cheson BD. Improving On The Anatomic Staging of Lymphomas: The Role of

Metabolic Imaging. Proc AJCC Annual Conference on Anatomic Staging Meets Molecular Markers (in press).

145. Cheson BD, Friedberg JW, Kahl BS, van der Jagt RH, Tremmel L, Zaks T.

Bendamustine produces durable responses with an acceptable long-term safety profile in patientse with rituximab-refractory non-Hodgkin’s lymphoma: A pooled analysis. Blood 114: abstract #2681, 2009.

146. Fowler N, Kahl BS, Rosen P, Matous J, Cashen A, Jacdobs S, Letzer J, Amin B,

Williams M, Ross M, Smith S, Saleh A, She H, Parasuraman S, Cheson BD. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the phase 2 VERTICAL study. Blood 114: abstract #933, 2009.

147. Friedberg JW, Vose JM, Kahl BS, Brunvand MW, Goy A, Kasamon YL, Burington

B, Li J, Ho W, Cheson BD. A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with arelapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. Blood 114: abstract #3742, 2009.

148. Gaidarova S, Li JW, Corral LG, Glezer E, Schafer PH, Xie W, Lopez-Girona A,

Cheson BD, Bennett B. Lenalidomide alone and in combination with rituximab enhances NK cell immune synapse formation in chronic lymphocytic leukemia (CLL) cells through activation of Rho and Rac1 GTPases. Blood 114L abstract #3441, 2009.

149. Kaplan LD, Jung S-H, Johnson JL, Linker CA, Byrd JC, Stock W, Hsi ED, Cheson

BD. A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma. J Clin Oncol 28 (15S):57s (abstract # TPS306), 2010.

150. Smith SM, Bartlett N, Johnson JL, Lister J, Cashen AF, Jung S, Schoder H, Egan

K, Cheson BD. Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602. J Clin Oncol 28 (15S): 582s (abstract #8039), 2010.

151. Morrison VA, Johns JL, Jung S, Leonard JP, Cheson BD. A phase II trial of

bortezomib plus lenalidomide for relapsed/refractorytmantle cell lymphoma (MCL) (CALGB 50501). J Clin Oncol 28 (15S):599s (abstract # 8106), 2010.

Bruce D. Cheson, M.D. Page 89 Abstracts (Continued) 152. Love N, Gregory SA, Cheson BD, Czuczman MS, Elder M, Paley D, Ziel K.

Tolerance and response to initial systemic therapy in older patients with follicular lymhoma (FL): observations from 186 unselected recent cases in the practices of US-based medical oncologists (MOs). Blood abstract #3842, 2010.

153. Smith SM, Bartlett N, Johnson JL, Cashen A, Lister J, Jung, S, Schoder H, Egan

K, Cheson BD. Galiximab, an anti-CD80 primatizied monoclonal antibody, in relapsed Hodgkin lymphoma (HL): Final results of CALGB 50602. Haematologica 95 (suppl 4), S32 (abstract 108), 2010.

154. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H,

Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl B, Friedberg JW, Blum KA, Habermann TM, Tuscano J, Hoppe R, Horning SJ. A randomized phase III trial of ABVD vs Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin’s lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Blood, abstract 415, 2010.

155. Advani R, Hong F, Fisher RI, Bartlett NL, Robinson S, Gascoyne RD, Wagner H,

Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl B, Friedberg JW, Blum KA, Habermann TM, Tuscano J, Hoppe R, Horning SJ. Randomized phase III trial comparing ABVD + radiotherapy and the Stanford V regimen in patients with stage I/II bulky mediastinal Hodgkin lymphoma: a subset analysis of the US Intergroup Trial E2496. Blood , abstract # 416, 2010.

156. Grant B, Leonard JP, Johnson JL, Kostakoglu L, His E, Byrd JC, Jones JA, Jung

S-H, Cheson BD. Combination biologic therapy as initial treatment for follicular lymphoma: initial results from CALGB 50701 – a phase II trial of extended induction epratuzumab (anti-CD22) and rituximab (anti-CD20). Blood, 116 (21): 191 (abstract #427), 2010.

157. Morrison VA, Hong F, Habermann TM, Fisher RI, Cheson BD, Kahl B, Horning SJ,

Peterson BA. R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients (pts): long-term follow-up of intergroup E4494/C9793. Blood, abstract #589, 2010.

158. Rubenstein JL, Johnson JL, Jung S-H, Cheson BD, Kaplan LD. Intensive

chemotherapy and immunotherapy, without brain irradiation, in newly diagnosed patients with primary CNS lymphoma: Results of CALGB 50202. Blood, abstract #763, 2010.

159. Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Powell BL, Shea TC, Nattom S,

Hoke E, Cheson BD, Larson R. Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002. Blood, abstract #858, 2010.

160. Cheson BD. Bendamustine and other new agents in NHL. Curr Treatment

Options in Oncol 11 (suppl 1):36-45, 2010. 161. Cheson BD. The role of PET/CT in T-cell lymphoma (T-NHL). Proc T-cell

lymphoma forum p 38, 2011.

Bruce D. Cheson, M.D. Page 90 Abstracts (Continued) 162. Cheson BD. Problems of the design and interpretation of very early clinical trials in

hemato-oncology. Proc ESO advanced courses, seminars and symposia on Leukemia and Lymphoma, Ascona, Switzerland, 2011.

163. Morrison, VA, Cheson BD. A phase II trial of bortezomob plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501). J Clin Oncol 29 (15S): 37s (TPS223), 2011.

164. Ujjani CS, S. Jamshed, K. W. Fitzpatrick, E. A. Gehan, J. Crawford, C. M. Broome, P. Cohen, C. Kessler, Cheson BD. Lenalidomide following rituximab and fludarabine in untreated CLL. J Clin Oncol 29 (15S):433S (abstract 6558), 2011.

165. Evens AM, et al. Efficacy and tolerability of ABVD and Stanford V for elderly

advanced-stage Hodgkin lymphoma (HL): analysis from the phase III randomized U.S. intergroup trial E2496. J Clin Oncol 29 (15S):512S (abstract 8035), 2011.

166. Cheson BD, Ujjani CS, Karim SM, Goswami T, Crawford J, Gehan EA,

Bendamustine and lenalidomide in relapsed/refractory lymphoid malignancies. J Clin Oncol 29 (15S):520S (abstract 8066), 2011.

167. Cheson BD. Promising new drugs in lymphoma – opportunities for changing

practice. Proc 7th Annual NCRI Meeting, p. 97, 2011.

168. Ujjani CS, Karim SM, Goswami T, Crawford J, Gehan EA, Kessler C, Cheson BD. Bendamustine and lenalidomide in relapsed/refractory CLL. Clin Lymph Myeloma and Leuk, 11 (suppl 2), S245, 2011.

169. Ujjani CS, Ramzi P, Gehan EA, Broome CM, Cheson BD. Ofatumumab and bendamustine in previously treated CLL and SLL. Clin Lymph Myeloma and Leuk, 11 (suppl 2), S245-246, 2011.

170. Ujjani C and Cheson BD. Bendamustine and lenalidomide in relapsed and refractory lymphoid malignancies. Ann Oncol 22 (suppl 4): abstract 507, 2011.

171. Press OW, Unger JM, Rimza LM, Friedberg J, LeBlanc M, Czuczman MS, Kaminski MS, Braziel RM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab Vs. CHOP chemotherapy plus Iodine-131-tositumoimab for the treatment of newly diagnosed follicular non-Hodgkin’s lymphoma. Blood 118 (21): 48 (abstract 98), 2011.

172. Ujjani C and Cheson BD. Bendamustine and lenalidomide in relapsed and refractory CLL. Blood 118: abstract 4618, 2011.

173. Ujjani C and Cheson BD. Ofatumumab and benddamustine in previously treated CLL. Blood 118: abstract 4615, 2011.

174. Advani R, Hong F, Gordon LI, Gascoyne RD, Wagner H, Hoppe RT, Fisher RI, Bartlett NL, Kahl BS, Stiff P, Cheson BD, Belch AR, Friedberg JW, Kassis J, Blum KA, Habermann TM, Tuscano J, Horning SJ. Patterns of failure in patients with stage I/II bulky mediastinal Hodgkin Lymphoma (HL) treated with ABVD +

Bruce D. Cheson, M.D. Page 91 Abstracts (Continued)

radiotherapy or the Stanford V regimen in the randomized phase III North American Intergroup trial, E2496. Blood 118 (21):696-697 (abstract #1603), 2011.

175. Kostakoglu L, Schoder H, Hall N, Straus DJ, Johnson JL, Schwartz L, LaCasce A, Jung S-H, Bartlett NL, Canellos GP, Cheson BD. Interim FDG-PET imaging in CALGB 50203 trial of stage I/II non-bulky Hodgkin lymphoma: would using combined PET and CT criteria better predict response than each test alone? Blood 118 (21):1556 (abstract #3644), 2011.

176. Cheson BD. Problems in the design and interpretation of early clinical trials in hematooncology. Proc 7th International Waldenstrom’s Macroglobulinemia Workshop, 2012.

177. Press OW, Unger JM, LeBlanc ML, Rimsza LM, Friedberg JW, Czuczman MS, Kaminski MS, Braziel RM, Spier CM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab WITH CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: results of subset analyses and a comparison of prognostic models. J Clin Oncol 30 (suppl):abstract 8001, 2012.

178. Leonard JP, Jung S-H, Johnson JL, Bartlett N, Blum KA, Cheson BD. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 30 (suppl): abstract 8000, 2012.

179. Goswami T, Forero A, Hamadani M, Sonet A, Verhoef G, Fanale MA, Bello CM, Huang W, Cheson BD. Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. J Clin Oncol 30 (suppl): abstract 8065, 2012.

180. Morrison VA, Jung S-H, Johnson J, LaCasce A, Blum KA, Bartlett NL, Cheson BD. Salvage therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Initial results of a phase II trial (Alliance/CALGB 50501), Blood abstr 3696, 2012.

181. Habermann TM, Hong F, Morrison VA, Dakhil SR, Jacobson SO, Weick JK, Frankel S, Gascoyne RD, Fisher RI, Cheson BD, Weller EA, Kahl BS, Horning SJ, Peterson BA, Hochster HS> (ECOG E4494, CALGB 9793, E1496). Differences in outcomes in males and females with diffuse large B-cell lymphoma and follicular lymphoma treated with rituximab. Blood (abstract 3705), 2012.

182. Rubenstein JL, Hsi ED, Johnson JL, Jung S-H, Cheson BD, Kaplan LD. BCL-6

expression and treatment delay correlate with outcome in newly diagnosed primary CNS lymphoma: Final report of CALGB 50202 (Alliance). Blood (abstract 301) 2012.

183. Ujjani C, Gehan E, Jamshed S, Crawford J, Broome C, Cohen P, Cheson BD. Lenalidomide following rituximab and fludarabine in untreated CLL. Blood (abstract 3924), 2012.

Bruce D. Cheson, M.D. Page 92 Abstracts (Continued) 184. Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui A-M,

Gupta JY, Di Bacco A, Shou Y, Martin P. Results of a phase I dose-escalation study of once-weekly MLN9708, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. Blood (abstract 3646), 2012.

185. Khan N, Chitalia A, Ozdemirli M, Ray G, Gehan E, Cheson BD. Cell of origin of Richter’s transformation in CLL. Blood (abstract 53342), 2012.

186. Advani R, Lebovik D, Brunvand M, Chen A, Goy A, Chang J, Madea L, Ho W, Kahn R, Lu D, Chu Y-W, Cheson BD. A phase I study of DCDT2980S, an antibody-drug conjugate (ADC) targeting CD22, in relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Blood (abstract 59), 2012.

187. Forero-Tores A, Gregory S, Federico M, Bello C, Sonet A, Kipps T, Cuneo A, Fanale M, Goswami T, Assouline S, Cheson BD. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractory advanced B-cell malignancies: Results from a phase I/II study. Blood (abstract 3677), 2012.

188. Karaturi MS, Arai S, Chen R, Gopal A, Feng L, Yuan Y, Smith S, Ansell S, Rosenblatt J, Savage KJ, Ramchandren R, Bartlett N, Cheson BD, Forero-Torres A, Moskowitz CH, Connors JM, Fanale M, deVos S, Engert A, Illidge T, Borchmann P, Morschhauser F, Horning SJ, Younes A. Overall survival benefit for patients with relapsed Hodgkin Lymphoma treated with brentuximab vedotin after autologous stem cell transplant. Blood (abstract 3701), 2012

189. Hamadani M, Forero A, Kipps TJ, Fanale MA, Cuneo A, Perez de Oteyza J, Gladstone D, Goswami T, Ibrahim RA, Liang M, Eck S, Elgeioushi N, Herbst R, Cheson BD. MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab. J Clin Oncol 31 (suppl), abstract 7045, 2013.

190. Kaplan LD, Jung S, Bartlett N, Johnson J, Byrd J, Blum KA, Stock W, LaCasce

AS, Hsi ED, Hurd D, Czuczman M, Cheson BD. Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB 50403 (oral presentation). Hematological Oncology 31 (suppl 1):126 (abstract 89), 2013.

191. Advani R, Chen A, Lebovic D, Brunvand M, Goy A, Chang J, Hochberg E, Yalamanchili S, Kahn R, Lu D, Chai A, Chiu Y, Cheson B. Phase I study of the anti-CD22 antibody-drug conjugate (ADC) DCDT2980S with or without rituximab (RTX) in patients (PTS) with relapsed or refractory (R/R) B-cell non_hodgkin’s lymphoma (NHL). Hematological Oncology 31 (suppl 1):108 (abstract 39), 2013.

192. Martin P, Jung S, Johnson J, Elstrom R, Bartlett N, Blum K, Shea T, Leonard JP, Cheson B. CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Hematological Oncology 31 (suppl 1):117 (abstract 63), 2013.

193. Press OW, LeBlanc M, Rimsza LM, Schoder H, Friedberg JW, Evens AM, Li H, Bartlett NL, LaCasce AS, Sweetenham JW, Straus DJ, Noy A, Kostakoglu L,


Grewal RK, Hsi ED, Gascoyne RD, Cheson BD, Kahl BS, Miller TP, Fisher RI. A phase II trial of response-adapted therapy of stages III-IV Hodgkin lymphoma using early interim FDG-PET imaging: US Intergroup S0816. Hematological Oncology 31 (suppl 1):137-138 (abstract 124), 2013.

194. Cheson BD, Fisher RI, Barrington S, Zucca E, Cavalli F, Lister TA. Follow-ip of the 11-ICML Workshop on lymphoma staging and restaging in the PET era. Hematological Oncology 31 (suppl 1):139 (abstract 128), 2013.

195. Wagner H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Desjardins P, Gascoyne RD, Stiff P, Cheson BD, Caplan S, Advani R, Kahl B, Friedberg J, Blum KA, Habermann T, Tuscano J, Hoppe RT, Fitzgerald TJ, Laurie F, Horning SJ. Patterns of failure in a randomized phase III trial of ABVD versus Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin’s lymphoma: an entergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Hematological Oncology 31 (suppl 1):182 (abstract 256), 2013.

196. Mundt K, McCord R, Koeppen H, Fu L, Wong C, Do A, Sumiyoshi T, Wang Y, Bourgon R, Polson A, Chai A, Chu W, Palance-Wessels MC, Advani RH, Morschhauser F, Cheson BD. Exploratory analysis of the relationship between target ewxperssion and efficacy of anti-CD22-MMAE and Anti-CD79B-MMAE antibody drug conjugates in phase I studies. Hematological Oncology 31 (suppl 1):192 (abstract 287), 2013.

197. Cheson BD, Crawford JG. A dose-finding study of bendamustine, rituximab and lenalidomide in relapsed and refractory lymphoma. Hematological Oncology 31 (suppl 1):193 (abstract 289), 2013.

198. Martin P, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui A, Yu J, Gupta N, Di Bacco A, Shou Y, Assouline SE. Weekly MLN9708, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma: phase I dose-escalations tudy. Hematological Oncology 31 (suppl 1):197 (abstract 301), 2013.

199. Ujjani C, Jung S-H Cheson BD, A phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance study A051103. Hematological Oncology 31 (suppl 1):275 (abstract 562), 2013.

200. Leonard JP, Jung S-H, Cheson BD. Alliance A051202: A phase I trial of lenalidomide, rituximab and GS-1101 (idelalisib) in recurrent follicular lymphoma. Hematological Oncology 31 (suppl 1):276 (abstract 563), 2013.

201. Cheson BD.Current and future Alliance (CALGB) trials for lymphoma. Proc Lymphoma Symposium Tokyo 2013.

202. Cheson BD. New drugs for lymphoma. Proc Lymphoma Symposium Tokyo 2013.

203. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson MS, Joyce R, van der Jagt RH, Munteanu MC, Brown PD, Cheson BD. Comparison of response by independent review committee (IRC) with response by investigators in an open-label, phase 3 North American study of bendamustine in


patients with rituximab-refractory, indolent B-cell Non-Hodgkin’s Lymphoma (NHL). Proc Chinese Soc Clin Oncol, 2013 (oral presentation).

204. Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart D, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH. Prospective evaluation of the utility of the International Prognostic Score (IPS) for patients with advanced Hodgkin Lymphoma (HL) treated with comtemporary therapy: results from US intergroup trial E2496. Haematologica 98 (suppl 2), 4 (abstract P010 – poster presentation), 2013.

205. Press O, Li H, Schoder H, LeBlanc M, Rimsza L, Friedberg JW, Bratlett NL, LaCasce A, Sweetenham J, Evens A, Straus D, Knopp M, Noy A, Hsi E, Cook J, Mittra E, Lechowicz MJ, Gascoyne RD, Miller TP, Kahl B, Cheson BD, Fisher RI. Response-adapted therapy of stage III-IV Hodgkin lymphoma based on interim FDG-PET imaging:L early results of US intergroup S0816 (oral presentation). Haematologica 98 (suppl 2), 36 (abstract T108), 2013.

206. Forero-Torres A, Hamadani M, Kipps T, Fanale M, Cuneo A, Perez de Oteyza J, Gladstone D, Andre M, Bellam N, Goswami T, Ibrahim R, Schneider A, Liang M, Eck , Elgeioushi N, Herbst R, Cheson BD. Safety and disease response to MEDI-551, an anti-CD19, in CLL patients previously treated with rituximab. 28th Annual Soc Immunother Cancer, 10 November 2013, National Harbor, MD (poster presentation).

207. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Hallek M, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, O’Brien SM. A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Proc ASH Abstract # LBA-6 (oral presentation), 2013

208. Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H, Jr., Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano J, Hoppe RT, Horning SJ, Advani RH. Evaluation of a novel 3 factor prognostic score (PS-3) for patients with advanced Hodgkin lymphoma (HL) treated on US Intergroup E2496. Proc ASH abstract #4277 (poster presentation), 2013

209. Advani RH, Hong F, Habermann TM, Li H, Kahl BS, Morrison VA, Weller EA, Varma G, Fisher RI, Peterson BA, Cheson BD, Gascoyne RD, Horning SJ, Bousetta S, Coiffier B, Ziepert M, Pfreundschuh M. Improved risk stratification with addition of male sex (S) to the elderly international prognistc index (S-EIPI) for DLBCL patients > 60 years treated with R-CHOP: an international collaboration of the US intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d’Etude De Lumphome d’Adultes. Proc ASH, abstract #3045 (poster presentation), 2013.

210. Forero-Torres A, Hamadani M, Fanale MA, Bello CM, Kipps TJ, Offner F, Verhoef G, Federico M, Gregory SA, Sonet A, Assouline S, Perez de Oteyza J, Tomas JF,


Cuneo A, Elgeioushi N, Goswami T, Ibrahim R, Herbst R, Cheson BD. Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase ½ study in adults with relapsed or refractory advanced B-cell malignancies. Proc ASH, abstract1810 (poster presentation), 2013.

211. Malnassy G, Geyer S, Fulton N, Koval G, Niedzwiecki D, Carlton V, Weng L, Kaplan LD, Marcucci G, Damon LE, Larson RA, Stone RM, Cheson BD, Faham M, Stock W. Comparison of deep sequencing and allele-specific oligonucleotide PCR methods for MRD quantificataion in acute lymphopblastic leukemia and mantle cell lymphoma: CALGB 10403 and CALGB 59909 (Alliance). Proc ASH, abstract 2547 (poster presentation), 2013.

212. Advani R, Chen AI, Lebovic D, Brunvand MW, Goy A, Chang JE, Hochberg E, Yalamanchili S, Kahn R, Lu D, Chai A, Chu Y-W, Cheson BD. Final results of a phase I study of the anti-CD22 antibody-drug conjugate (ADC) DCDT2980S with or without rituximab (RTX) in patients (pts) with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). Proc ASH, abstract #4399 (poster presentation), 2013.

213. Hong F, Habermann TM< Gordon LI, Hochster HS, Gascoyne RD, Morrison V, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahn BS. The role of Body Mass Index in survival outcome for lymphoma patients : the US intergroup experience. Proc ASH, abstract #3060 (poster presentation), 2013.

214. Fulton N, Johnson J, Kaplan LD, Koval G, Malnassy G, Jung S-H, Devine S, Shea TC, Leonard JP, Cheson BD, Stock W. Minimal residual disease (MRD) status following induction chemo-immunotherapy predicts progression-free survival in mantle cell lymphoma (MCL): CALGB 50403 (Alliance). Proc ASH, abstract #3002 (posterpresentation), 2013.

215. Ujjani CS, Hill E, Nassif S, Wang H, Wang Y, Ozdermili M, Esposito G, Chewon BD. The utility of 18f-FDG PET/CT in assessing bone marrow involvement in lymphoma. Proc ASH, abstract #2981 (poster presentation), 2013.

216. Cheson BD. Identifying the control arm in randomized T-cell studies: Opportunities to expedite accrual in upfront studies of T-cell lymphoma (TCL). Proc 6th Annual T-cell Forum, p. 64, 2014.

217. Furman RR, Sharman J, Coutre SE, Cheson BD, Pagel JM, Barrientos JC, Zelenetz AD, Kipps TP, O’Brien SM. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL). Proc Brit Soc Haematol (oral presentation), April, 2014.

218. Coutre SE, Furman RR, Sharman JP, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps Tj, Flinn I, Ghia P, Eradat HA, Ervin TJ, Lamanna N, Coiffier B, Pettitt A, Kim Y, Jahn TM, O’Brien SM, Hallek MJ. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. J Clin Oncol 32: 5s, abstract 7012, 2014.

Bruce D. Cheson, M.D. Page 96 Abstracts (Continued) 219. Barr PM, Saylors GB, Spurgeon SEF, Cheson BD, Greenwald DR, O’Brien SM,

Liem AKD, McIntyre R, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Pacio J, Wu M, Melchor-Khan F, Jin F, Friedberg JW. Phase 2 trial of GS-9972, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s abstract #7059, 2014.

220. Martin P, Jung S-H, Johnson JL, Pitcher B, Elstrom R, Bartlett N, Blum KA, Richards KL, Leonard J, Cheson BD. CALGB 50803 (ALLIANCE): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. J Clin Oncol 32:5s abstract #8521, 2014.

221. Barr PM, Li H, Spier CM, Mahadevan D, Friedberg JW, LeBlanc ML, Haq MU, Flowers C, Wagner-Johnston ND, Cheson BD, Horwitz SM, Miller TP, Fisher RI. U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL). J Clin Oncol 32:5s abstract 8523, 2014.

222. Morschhauser F, Flinn I, Advani R, Sehn L, Kolibaba K, Press O, Salles G, Diefenbach C, Tilly H, Assouline S, Chen A, Dreyling M, Hagenbeek A, Zinzani PL, Cheson BD, Yalamanchii S, Lu D, Chai A, Chu Y-W, Sharman J. Preliminary results if a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. J Clin Oncol 32:5s, abstract 8519, 2014.

223. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Hallek MJ, Coiffier B, O’Brien SM, Tausch E, Kreuzer KA, Jiang W, Jahn TM, Lazarov M, Stilgenbauer S. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randeomized, double-blind, placebo-controlled trial. J Clin Oncol 32:5s abstract 7011, 2014.

224. Ghia P, O’Brien SM, Furman RR, Coutre SE, Sharman JP, Cheson BD, Pagel JM, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Eradat HA, Lamanna N, Hallek MJ, Coiffier B, Pettitt A, Ye W, Jahn TM, Wagner LI. Health-related quality of life (HRQL) impact of idelalisib (IDEAL) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. J Clin Oncol 32:5s abstract 7099, 2014.

225. Hillmen P, Furman RR, Coutre SE, Sharman JP, Pagel JM, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat HA, Ervin TJ, Lamanna N, Coiffier B, Pettitt A, Ye W, Jahn TM, Dubowy R, O’Brien SM, Hallek M, Cheson BD. Pre-treatment with idelalisib markedly reduces rituximab infusion-related reactions and infusion interruptions in patients with CLL. Proc EHA, 2014.

226. Stilgenbauer S, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Hallek MJ, Coiffier B, O’Brien SM, Kreuzer KA, Jiang W, Jahn TM, Lazarov M, Sharman JP. Effect of idelalisib/rituximab combination treatment of relapsed CLL on the BCR signaling related chemokines CCL3 and CCL4: Data from a phase 3, randomized, double-blind, placebo-controlled trial. Proc EHA, 2014.

Bruce D. Cheson, M.D. Page 97 Abstracts (Continued) 227. Eradat HA, Ghia P, O’Brien SM, Hillmen P, Furman RR, Coutre SE, Sharman JP,

Cheson BD, Pagel JM, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Lamanna N, Hallek MJ, Coiffier B, PPettitt A, Kim Y, Jahn TM, Wagner LI. Health-related quality of life impact of idelalisib (IDELA) in patients with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. Proc EHA, 2014.

228. Hillmen P, Furman RR, Coutre SE, Sharman JP, Pagel JM, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat HA, Lamanna N, Coiffier B, Pettitt A, Ye W, Jahn TM, Dubowy R, O’Brien SM, Hallek MJ, Cheson BD. Pre-treatment with idelalisib markedly reduces rituximab infusion-related reactions and infusion interruptions in patients with CLL. Proc EHA, 2014.

229. Ghia P, Coutre SE, Furman RR< Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Hallek MJ, Coiffier B, O’Brien SM, Stilgenbauer S, Jiang W, Jahn TM, Wong M, Lazarov M, Sharman JP. Effect of idelalisib/rituximab combination treatment of relapsed CLL on the BCR signaling-related chemokines CCL3 and CCL4: data from a phase 3, randomized, double-blind, placebo-controlled trial. Proc EHA, 2014.

230. Morschhauser F, Flinn I, Advani R, Sehn L, Kolibaba K, Press O, Salles G, Diefenbach C, Tilly H, Assouline S, Chen A, Dreyling M, Hagenbeek A, Zinzani PL, Cheson BD, Yalamanchii S, Lu D, Chai A, Chu Y-W, Sharman J. Preliminary results if a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. Proc EHA, June, 2014.

231. Coutre SE, Furman RR, Sharman JP, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps Tj, Flinn IW, Ghia P, Eradat HA, Lamanna N, Coiffier B, Pettitt A, Li X, Jaahn TM, O’Brien SM, Hallek MJ. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. Proc EHA 2014.

232. Stilgenbauer S, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Hallek MJ, Coiffier B, O’Brien SM, Tausch E, Kreuzer KA, Jiang W, Janh TM, Lazarov M, Sharman JP. Efficacy of idelalisib in CLL subpopulations harboring del (17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial. Proc EHA, 2014.

233. Morschhauser F, Flinn I, Advani R, Sehn L, Kolibaba K, Press O, Salles G, Diefenbach C, Tilly H, Assouline S, Chen A, Dreyling M, Hagenbeek A, Zinzani PL, Cheson BD, Yalamanchii S, Lu D, Chai A, Chu Y-W, Sharman J. Preliminary results if a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. Proc Pan Pacific Lymphoma Conf, July, 2014.

234. Ghia P, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Eradat HA, Lamanna N, Coiffier B, Pettitt A, Li X, Jahn TM, O’Brien SM, Hallek MJ. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia.


Proc 14th Conference of the International Society of Geriatric Oncology, Lisbon, Portugal, 24 October 2014.

235. Pagel JM, Coutre SE, Furman RR, Sharman JP, Cheson BD, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Paolo G, Eradat HA, Ervin T, Lamanna N, Coiffier B, Pettitt A, Li X, Jahn TM, O’Brien SM, Hallek MJ. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia (CLL). Society of Hematologic Oncology, Houston, TX, 18 September 2014.

236. Ujjani C, Hill E, Nassif S, Wang H, Ozdemirli M, Esposito G, Cordova C, Wang Y, Cheson B. The utility of 18F-FDG PET/CT in assessing bone marrow involvement in lymphoma. Proc 5th International Workshop on PET in Lymphoma, Menton France, 19 September 2014.

237. Pagel JM, Coutre SE, Furman RR, Sharman JP, Cheson BD, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Paolo G, Eradat HA, Ervin T, Lamanna N, Coiffier B, Pettitt A, Li X, Jahn TM, O’Brien SM, Hallek MJ. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia (CLL). Proc Int Soc Geriatric Oncol, Lisbon, Portugal, 23 October 2014.

238. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Hallek M, Coiffier B, O’Brien S, Tausch E, Kreuzer K-A, Jiang W, Lazarov M, Li D, Jahn TM, Stilgenbauer S. Second interim analysis of a phase 3 study of idelalisib (Zydelig®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in subpopulations with del (17p) and other adverse prognostic factors. Blood Proc ASH abstr #330, 2014.

239. Morschhauser F, Flinn I, Advani RH, Diefenbach CS, Kolibaba K, Press OW, Sehn LH, Chen AI, Salles G, Tilly H, Cheson BD, Assouline S, Dreyling M, Hagenbeek A, ZinZani PL, Yalamanchili S, Lu D, Jones C, Jones S, Chu Y-W, Sharman JP. Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. Blood Proc ASH abstr #4457, 2014.

240. Smith SM, Pitcher B, Jung S-H, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Cheson BD, Leonard JP. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202. Blood Proc ASH abstr #3091, 2014.

241. Sehn LH, Chua N, Mayer J, Dueck G, Trněny M, Bouabdallah K, Fowler N, Delwail

V, Press O, Salles G, Gribben J, Leonard A, Lugtenberg PJ, Franklin N, Wassner-Fritsch E, Fingerle-Rowson, Cheson BD. Gadolin: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. J Clin Oncol 33 (suppl):LBA8502, 2015.

Bruce D. Cheson, M.D. Page 99 Abstracts (Continued) 242. Advani RH, Flinn I, Sharman JP, Diefenbach CSM, Kolibaba KS, Press OW, Sehn

LH, Chen AI, Salles GA, Tilly H, Cheson BD, Assouline SE, Dreyling MH, Hagenbeek A, Zinzani PL, Jones C, Chu Y-W, Hirata J, Wenger M, Morschhauser F. Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose elvel. J Clin Oncol 33 (suppl): abstract 8503, 2015.

243. Sehn LH, Chua N, Mayer J, Dueck G, Trněny M, Bouabdallah K, Fowler N, Delwail

V, Press O, Salles G, Gribben J, Leonard A, Lugtenberg PJ, Franklin N, Wassner-Fritsch E, Fingerle-Rowson, Cheson BD. Gadolin: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Proc EHA, June, 2015.

244. Sharman J, Flinn I, Advani R, Diefenbach C, Kolibaba K, Press O, Sehn L, Chen

A, Salles G, Tilly H, Cheson B, Assouline S, Dreyling M, Hagenbeek A, Zinzani PL, Jones C, Jones S, Chu W, Hirata J, Wenger M, Morschhauser F. Two doses of polatuzumab vedotin (POV, anti-CD79b antibody-drug conjugate) plus rituximab (R) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): durable responses at lower dose levels. Proc EHA (poster presentation), June, 2015.

245. Cheson BD, Chua N, Mayer J, Dueck G, Trněny M, Bouabdallah K, Fowler N,

Delwail V, Press O, Salles G, Gribben J, Leonard A, Lugtenberg PJ, Franklin N, Wassner-Fritsch E, Fingerle-Rowson, Sehn LH. Primary results from the phase III GADOLIN study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Proc ICML, June, 2015.

246. Sharman J, Flinn I, Advani R, Diefenbach C, Kolibaba K, Press O, Sehn L, Chen

A, Salles G, Tilly H, Cheson B, Assouline S, Dreyling M, Hagenbeek A, Zinzani PL, Jones C, Jones S, Chu W, Hirata J, Wenger M, Morschhauser F. Two doses of polatuzumab vedotin (POV, anti-CD79b antibody-drug conjugate) plus rituximab (R) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): durable responses at lower dose levels. Haematol Oncol 33 (suppl 1): 177-8 (abstr 143), June, 2015.

247. Barr PM, Saylors G, Spurgeon SE, Cheson BD, Greenwald DR, O’Brien SM, Liem

AK, McIntyre R, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, Hu J, Dreiling L, Friedberg JW. SYK and PI3Kδ pathway inhibition resulted in increased rates of pneumonitis: implications for developing future small molecule combinations. Haematol Oncol 33 (suppl 1) 121: abstr 42, June 2015.

248. Cheson BD, Chua N, Mayer J, Dueck G, Trnent M, Bouabdallah K, Fowler N,

Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Franklin N, Wassner-Fritsch EZ, Fingerle-Rowson G, Sehn L. Primary results from the phase III GADOLIN study of obinutuzumab plus bendamustine versus bendamustine alone in rituximab-refractory indolent non-Hodgkin lymphoma. Haematol Oncol 33 (suppl 1) 167 (abstr 123), June 2015.

Bruce D. Cheson, M.D. Page 100 Abstracts (Continued) 249. Cheson BD. Bendamustine and emerging new effective tretments for B-cell

lymphoma and CLL. Proc Japanese Soc Lymphoreticular Research. July, 2015 250. Cheson BD. New Lugano Classification for staging and response evaluation:

What are the most important changes? Proc Japanese Soc Lymphoreticular Research. July, 2015.

251. Mato A, Nabham C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett

C, Pu JJ, Seghal AR, trelec LE, Vandegrift A, Rago A, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nassta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Evens AM. Favorable outcomes in CLL patients with alternate kinase inhibitors following ibrutinib or idelalisib discontinuation: results from a large multi-center study. Blood 126: abstract 719, 2015.

252. Martin P, Chen Z, Cheson BD, Ellis T, Robinson KS, Williams ME, Rajguru SA,

Friedberg JW, van der Jagt RH, La Casce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, Vander Walde AM, Herst JA, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Smith MR, Leonard JP. Long-term outcomes, secondary malignancies, and stem cell collection following bendamustine in patients with previously treated indolent non-Hodgkin lymphoma. Blood 126: abstract 3961, 2015.

253. Chen R, Li H, Bernstein SH, Rimsza LM, Forman SJ, Constine L, Shea TC,

Cashen AF, Blum KA, Fenske TS, Barr PM, LeBlanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. Pre-transplant R-bendamustine induces high rates of minimal residual disease in MCL patients: updated results of S1106: US intergroup study of a randomized phase II trial of R-HCVAD vs R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma. Blood 126: abstract 518, 2015.

254. Straus DJ, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schoder H, Jung S-H,

Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnson N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL. Initial results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL)(CALGB/Alliance 50604). Blood 126:abstract 578, 2015.

255. Kaplan LD, Jung S-H, Stock W, Bartlett NL, Pitcher B, Byrd JC, Blum KA, LaCasce

AS, Fulton N, Hsi ED, Hurd DD, Czuczman M, Leonard JP, Cheson BD. Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (Alliance) 50403. Blood 126: abstract 337, 2015.

256. Brown JR, Cheson BD, Furman RR, Ghia P, Hallek M, Hillmen P, O’Brien S,

Sharman JP, Dubowy RL, Valesco B, Waldapfel CC, Zelenetz AD. Patterns of lymphocytosis in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) treated with idelalisib. Blood 126: abstract 2952, 2015.

Bruce D. Cheson, M.D. Page 101 Abstracts (Continued) 257. Ujjani CS, Jung S-H, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman

MS, Davids MS, Leonard JP, Cheson BD. Phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma (Alliance 051103). Blood 126: abstract 471, 2015.

258. Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben JC, Harbron C, Hoster

E, Kahl BS, Mundt K, Sebban C, Sehn LH, Cheson BD. Analysis of minimal residual disease in follicular lymphoma patients in GADOLIN, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory indolent non-Hodgkin lymphoma. Blood 126: abstract 3978, 2015.

259. Sohani AR, Pitcher B, Chadburn A, Said JW, Martin P, Czuczman MS, Bartlett NL,

Rosenbaum CA, Leonard JP, Cheson BD, Hsi ED. Interfollicular CD10 expression and follicular PD1 tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: an Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401). Blood 126: abstract 334, 2015.

260. Rosenbaum CA, Pitcher B, Bartlett NL, Smith SM, Liu JJ, Hsi ED, Jung S-H,

Leonard JP, Cheson BD. Phase II trial of ofatumumab (OFA) in previously untreated follicular non-Hodgkin lymphoma (NHL): CALGB 50901 (Alliance). Blood 126: abstract 2741, 2015.

261. Cheson BD, Trask PC, Gribben JC, Dimier N, Kimby E, Lugtenburg PJ,

Thieblemont C, Fritsch EW, Sehn LH. Primary results of the health-related quality of life assessment from the phase III Gadolin study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory, indolent non-Hodgkin lymphoma. Blood 126: abstract 1532, 2015.

262. Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben JC, Harbron C, Hoster

E, Kahl BS, Mundt K, Sebban C, Sehn LH, Cheson BD. Minimal residual disease analysis in patients with follicular lymphoma treated with obinotuzumab plus bendamustine versus bendamustine alone in GADOLIN, a phase III study of relapsed/refractory indolent non-Hodgkin lymphoma. 36th World Congress of the International Society of Haematology, 2016.

263. Penne M, Sheth K, Yazdy M, Jiang J, Cheson BD. Long-term follow-up of patients

(pts) treated with bendamustine (B) for lymphoid malignancies. Proc ASCO, abstract e14027, 2016.

264. Timlin C. Banerjee C, Howlett C, Ujjani CS, Skarbnik AP, Fanning M, Schuster SJ,

Svoboda J, Porter D, Nasta S, Stadtmauer E, Landsburg DJ, Feldman T, Rago A, Dorsey C, Capozzi DL, Morganroth J, Cheson B, Mato A. Comparable outcomes in chronic lymphocytix leukemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-center study. Proc ASCO, abstract 7529, 2016.

265. Jones JA, Wierda WG, Choi MY, Davids MS, Cheson BD, Furman RR, Lamanna

N, Barr PM, Eradat HA, Halwani AS, Heffner LT, Chyla B, Zhu M, Potluri J, Verdugo ME, Humerickhouse R, Mato AR, Coutre S. Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. Proc ASCO, abstract #7519, 2016.

Bruce D. Cheson, M.D. Page 102 Abstracts (Continued) 266. Ghia P, Cheson BD, Furman RR, Hallek M, Hillmen P, O’Brien SM, Sharman JP,

Dubowy RL, Velasco B, Waldapfel CC, Zelenetz AD, Brown JR. Patterns of idelalisib treatment-emergent lymphocytosis in patients with CLL or SLL. EHA, 2016.

267. Banerjee R, Timlin C, Fitzpatrick D, Howlett C, Ujjani CS, Flanning M, Schuster

SJ, Svoboda J, Porter DL, Stadtmauer EA, Cheson BD, Skarbnik AP, Feldman T, Goy A, Dorsey C, Capozzi DL, Landsburg D, Nasta S, Mato AR. Comparable outcomes in chronic lymphocytic leukemia patients treated with reduced-dose ibrutinib: results from a multi-center study. EHA (submitted), 2016.

268. Coutre S, Desai M, Cerri E, Potluri J, Busman T, Verdugo M, Humerickhouse RA,

Best A, Mobasher M, Vosganian G, Lin Y-L, Cheson B. Gradual 5-week ramp up of venetoclax along with prophylaxis and monitoringeffectively mitigates tumor lysis syndrome in patients with chronic lymphocytic leukemia. Proc Pan Pacific Lymphoma Conference, 2016.

269. Coutre S, Wierda W, Choi M, Davids MS, Cheson BD, Furman RR, Lamanna N,

Barr PM, Awan FT, Halwani A, Heffner L, Chyla B, Zhu M, Potluri J, Verdugo M, Humerickhouse RA, Mato AR, Jones J. Veneteoclax is active in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. Proc Pan Pacific Lymphoma Conference, 2016.

270. Ghia P, Cheson BD, Furman RR, Hallek M, Hillmen P, O’Brien SM, Sharman JP,

Dubowy RL, Velasco B, Waldapfel C, Zelenetz ad, Brown JR. Patterns of idelalisib treatment-emergent lymphocytosis in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Proc EHA, 2016.

271. Trněný M, Bouabdallah K, Dueck G, Gribben J, Lugtenburg PJ, Press O, Salles G,

Sehn LH, Fingerle-Rowson G, Matiello F, Wassner-Fritsch E, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine alone in patients with rituximab-refractory follicular lymphoma: results from the GADOLIN study. Proc EHA, 2016

272. Timlin C. Banerjee C, Howlett C, Ujjani CS, Skarbnik AP, Fanning M, Schuster SJ,

Svoboda J, Porter D, Nasta S, Stadtmauer E, Landsburg DJ, Feldman T, Rago A, Dorsey C, Capozzi DL, Morganroth J, Cheson B, Mato A. Comparable outcomes in chronic lymphocytic leukemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-center study. Proc EHA 2016.

273. Schoder H, Hall N, Knopp MV, Zhang J, Pitcher B, Jung S-H, Kelloff G, Dehdashi

F, Kurdziel K, Lamonica D, Esposito G, Manzone T, Higley H, Schwartz L, Bartlett N, Cheson B, Leonard J, Wilson W. Semi-quantitative FDG-PET assessment of interim and end of treatment response in the CALGB/Alliance phase III study of R-CHOP vs dose-adjusted EPOCH-R in untreated DLBCL: A blinded, arm-pooled, initial analysis of correlation with outcomes. Proc 6th International Workshop on PET in Lymphoma, September 2016.

Bruce D. Cheson, M.D. Page 103 Abstracts (Continued) 274. Friedberg JW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza L,

Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowica MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Press OW. Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin lymphoma using early interim FDG-PET imaging. Haematologica 101 s5, p. 19, abstract T0003, 2016.

275. Straus D, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schoder H, Jung S-H,

Pollplewell L, Chang JE, Moskowitz C, Wagner-Johnson N, Leonard J, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL. Results of US Intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB/Alliance 50604). Haematologica 101 s5, p. 10, abstr T012, 2016.

276. Mato AR, Lamanna N, Ujjani CS, Brander DM, Hill BT, Howlett C, Skarbnik AP,

Cheson B, Zent CS, Pu JJ, Bachow SH, Winter AM, Cruz A-L, Claxton DF, Daniel C, Isaack K, Kennard KH, Timlin C, Yacur M, Fanning M, Strelec LE, Landsburg DJ, Nasta SD, Schuster SJ, Porter DL, Nabhan C, Barr PM. Toxicities and outcomes of ibrutinib-treated patients in the United States: large retrospective analysis of 621 real world patients. Blood 128 (suppl):abstract 3222, 2016.

277. Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C,

Skarbnik AP, Cheson B, Zent CS, Pu JJ, Kiselev P, Bachow SH, Winter AM, Cruz A-L, Claxton DF, Daniel C, Isaack K, Kennard KH, Timlin C, Fanning M, Yacur M, Svoboda J, Schuster SJ, Nabhan C. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in CLL: results from a large multi-center study of 683 US patients. Blood 128 (suppl): abstract 4400, 2016.

278. Wilson WW, Jung S-H, Pitcher BN, Hsi ED, Friedberg J, Cheson B, Bartlett NL,

Smith S, Wagner-Johnston N, Kahl BS, Staudt LM, Blum K, Abramson J, Press OW, Fisher RI, Richards KL, Schoder H, Chang JE, Zelenetz AD, Leonard JP. Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303. Blood 128 (suppl): abstract 469, 2016.

279. Kanakry JA, Hong F, Martinez-Maza O, Horning SJ, Gordon LI, Gascoyne RD,

Gellert LL, Lemas MV, Cheson B, Advani RH, Pohlman B, Kenkre VP, Winter JN, Stiff PJ, Tusano J, Friedberg J, Dreosti L, Fisher RI, Laneuville P, Kahl BS, Ambinder RF. Serum biomarkers predict outcomes in advanced Hodgkin lymphoma independent of International Prognostic Score (IPS) and treatment: correlative analysis from a large North American cooperative group trial. Blood 128 (suppl): abstract 2992, 2016.

280. Jones J, Choi MY, Mato AR, Furman RR, Davids MS, Heffner LT, Cheson BD,

Lamanna N, Barr PM, Eradat H, Halwani A, Chyla B, Zhu M, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Coutre SE. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood 128 (suppl): abstract 637, 2016.

Bruce D. Cheson, M.D. Page 104 Abstracts (Continued) 281. Salles GA, Trotman J, Lill M, Cheson B, Schuster SJ, Hou J-Z, Radford JA,

Spencer A, Schaffer M, Damle R, Gartenberg GJ, Vermeulen J, Balasubramanian S, Deshpande S, Caballero D. Pseudo-progression among patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. Blood 128 (suppl): abstat 2980, 2016.

282. Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM,

Gopal AJ, Maloney DG, Cheson B, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press O. Continued excellent outcomes in previously untreated follicular lymphoma patients after treatment with CHOP plus rituximab or CHOP plus (!#!) iodine-tositumomab - long term follow-up of phase III randomized study SWOG S0018. Blood 128 (suppl 1): abstract 616, 2016.

283. Lansigan F, Barak I, Pitcher BN, Jung S-H, Cheson B, Czuczman MS, Grant BW,

Martin P, Hsi ED, Schoder H, Smith SE, Bartlett NL, Leonard JP, Blum K. Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB studies 50402, 50701, and 50803 (Alliance). Blood 128 (suppl): abstract 2953, 2016.

284. Tallarico M, Foster J, Seisler D, Lafky J, Hurria A, Jatoi A, Cohen HJ, Muss H,

Bartlett NL, Cheson B, Jung S-H, Byrd JC, Leonard JP, Nabhan C. Toxicities and related outcomes of elderly patients (pts)(>65 years) with hematologic malignancies in the contemporary era (Alliance A151611). Blood 128 (suppl): abstract 536, 2016.

285. Cheson BD, Trnĕny M, Bouabdallah K, Dueck G, Gribben J, Lugtenburg PJ, Press

O, Salles GA, Fingerle-Rowson G, Mattiello F, Wassner-Fritsch E, Sehn LH. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN study. Blood 128 (suppl): abstract 615, 2016.

286. Salles GA, Morschhauser F, Cheson B, Rule SA, Fegan C, Guillaume C, Nelson

C, Yang Y, Mitra S, Starodub A, Dyer MJS. Preliminary results of a phase 1b dose escalation and dose expansion study of GS-4059 in combination with idelalisib in subjects with B-cell malignancies. Blood 128 (suppl): abstract 2961, 2016.

287. Jones J, Choi MY, Mato AR, Furman RR, Davids MS, Heffner LT, Cheson BD,

Lamanna N, Barr PM, Eradat H, Halwani A, Chyla B, Zhu M, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Coutre SE. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Austrian Society of Hematology and Medical Oncology, 2016.

288. Dyer MJS, Morschhauser F, Cheson B, Rule SA, Fegan C, Cartron G, Nelson C,

Yang Y, Mitra S, Starodub A, Salles G. Preliminary results of a phase 1b dose escalation study of GS-4059 in combination with idelalisib in subjects with B-cell malignancies. Proc British Soc Haematol, 2016 (BSH2017-357), 2017.

Bruce D. Cheson, M.D. Page 105 Abstracts (Continued) 289. Cheson BD. Response criteria in lymphoma – imaging criteria and guidelines.

Proc. NCI Quantitative Imaging Network, 2017. 290. Fowler N, Gopal AK, Schuster SJ, Trotman J, Hess G, Hou J, Yacoub A, Lill M,

Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Osmanov D, Caballero D, Deshpande S, Vermeulen J, Damle R, Schaffer M, Balasubramanian S, Cheson B, Salles G. Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. Hematol Oncol 35 (S2):210-211, 2017.

291. Martin P, Jung S, Pitcher B, Bartlett NL, Blum KA, Shea T, Ruan J, Smith SE,

Leonard JP, Cheson BD. Final results of CALGB 50803 (ALLIANCE): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Hematol Oncol 35 (S2):51, 2017.

292. Pott C, Belada D, Danesi N, Fingerle-Rowson GR, Gribben J, Harbron CG, Hoster

E, Kahl BS, Kehden B, Mundt KE, Nicolas-Virelizier E, Sehn LH, Cheson BD. Minimal residual disease and outcomes in relapsed/refractory follicular lymphoma (FL) in the phase III GADOLIN trial of obinutuzumab and bendamustine vs bendamustine. Hematol Oncol 35 (S2):216-217, 2017.

293. Burke JM, Bibeau K, Kahl B, Carson KR, Zelenetz AD, Brander DM, Maddocks KJ,

Gerecitano JF, Pathak AK, Cheson BD. Evidence of low incidence of myelodysplastic syndrome (MDS) in patients exposed to bendamustine treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). J Clin Oncol 35 (suppl): abstr e19008), 2017.

294. Dorsey C, Paskalis D, Brander DM, Lansigan F, Barr PM, Lamanna N, Cheson

BD, Pu JJ, Schreeder MT, Pagel JM, Sportelli P, Flanning MJ, Miskin HP, Zimmer T, Walsh K, Schuster SJ, Luning-Prak ET, Wileyto P, Weiss MS, Mato AR. KI intolerance study: a phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy. J Clin Oncol 35 (suppl): abstr TPS7569), 2017.

295. Salles G, Gopal A, Schuster S, Trotman J, Hess G, Hou J-Z, Yacoub A, Lill M,

Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Osmarov D, Caballero D, Desphande S, Vermeulen J, Damle R, Schaffer M, Balasubramanian S, Cheson B, Fowler N. Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. EHA proceedings, abstract E1129, 2017.

296. Mato AR, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR,

Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Beach DF, Pu JJ, Sehgal AR, Winter AM, Zent CS, Tuncer HH, Singavi AK, Schuster SJ, Pickens PV, Shah NN, Williams A, Howlett C, Weissbrot H, Ali N, Patel B, Isaac K, Rhodes J, Hughes ME, Khajavian S, Chatburn ET, Sitlinger A, Tranchito E, Bhavsar EB, Bailey N, Burns TF, Yacur N, Malhotra M, Handunnetti S, Kennard K, Nabhan C, Ujjani CS. Front-line ibrutinib therapy for chronic lymphocytic leukemia (CLL) in the real world: responses, toxicity, outcomes and subsequent therapies. Blood 130 (suppl 1), abstr 3011, 2017.

Bruce D. Cheson, M.D. Page 106 Abstracts (Continued) 297. Mato AR, Tam CS, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna

N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Winter AM, Kennard K, Isaac K, Dorsey C, Vandergrift AM, Singavi AK, Williams A, Howeltt C, Weissbrot H, Ali N, Sitlinger A, Tranchito E, Rhodes J, Bhavsar EB, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Handunnetti S, Svoboda J, Furman RR, Nabhan C. Disease and patient characteristics, patterns of care, toxicities, and outcomes of chronic lymphocytic leukemia (CLL) patients treated with venetoclax: a multicenter stody of 204 patients. Blood 130 (suppl 1), abstract 4315, 2017.

298. Davids MS, Flinn IW, Mato AR, O’Connor OA, Brander DM, Lunning MA< Vose

JM, Nastoupil L, Fowler N, Flowers C, Brown JR, Schreeder MT, Ghosh N, Lansigan F, Cheson BD, Barr PM, Pagel JM, Danilov A, Ibarz JP, Deng C, Burke JM, Siddiqi T, Patel MR, Farber CM, Venugopal P, Gribben JG, ZinZani PL, Miskin HP, Sportelli P, Weiss MS, O’Brien SM. An integrated safety analysis of the next generation PI3Kδ inhibitor umbralisib (TGR-1202) in patients with relapsed/refractory lymphoid malignancies. Blood 130 (suppl 1): abstract 4037, 2017.

299. Brander DM, Rhodes J, Pagel JM, Nabham C, Tam CS, Jacobs R, Hill BT,

Lamanna N, Lansigan F, Shadman M, Ujjani CS, Skarbnik AP, Cheson BD, Pu JJ, Sehgal AR, Barr PM, Allan JN, Beach DF, Patel B, Pickens PV, Nasta SD, Kennard K, Tuncer HH, Koch B, Furman RR, Mato AR. Applicability of the chronic lymphocytic leukemia (CLL)-IPI on patients treated with front-line ibrutinib in the real world: the case for new prognostic models. Blood 130 (Suppl 1): abstract 1719, 2017.

300. Rhodes J, Barr PM, Ujjani CS, Nabham C, Tam CS, Jacobs R, Lansigan F, Hill

BT, Brander DM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Pagel JM, Allan JN, Kennard K, Cheson BD, Beach DF, Patel B, Isaac K, Tuncer HH, Furman RR, Mato AR. The impact of front-line ibrutinib dose reduction and interruption on outcomes in chronic lymphocytic leukemia (CLL) patients. Blood 130 (suppl 1):abstract 4313, 2017.

301. Bange E, Nabhan C, Brander DM, Lamanna N, Ujjani CS, Howlett C, Skarbnik AP,

Hill BT, Cheson BD, Zent CS, Pu JJ, Winter AM, Isaac K, Kennard K, Timlin C, Dorsey C, Nasta SD, Svoboda J, Landsburg DJ, Schuster SJ, Parr PM, Mato AR. Real-world evidence for durable treatment responses after toxicity related discontinuation of idelalisib. Blood 130 (suppl 1):abstract 4325, 2017.

302. Mato AR, Cheson BD, Lamanna N, Pagel LM, Lansigan F, Barr PM, Pu JJ, Dorsey

C, Chatburn ET, Svoboda J, Schuster SJ, Luning-Prak E, Tsao P, Sitlinger A, Ujjani CS, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Brander DM. KI intolerance study: a phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-δ inhibitor therapy. Blood 130 (suppl 1):abstract 4314, 2017.

303. Herrera AF, Patel MR, Burke JP, Advani RH, Cheson BD, Sharman JP, Penuel E,

Polaon AC, Leng N, Li C, Schuth E, Vaze A, Samineni D, Elstrom R, Diefenbach CS. A phase I study of the anti-CD79b THIOMABTM-drug conjugate DCDS0780A


in patients (pts) with relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL). B;ood 130 (suppl 1):abstract 4129, 2017.

304. Antic D, Biljana M, Milic M, Cheson BD, Narkhede M, Panovska I, Trajkova S,

Popova M, Llamas P, Raso AG, Delluc A, Ianotto J-C, Gerotziafas GT, Fareed J. Development and external validation of thrombosis lymphoma/Throly/Score-interim analysis. Blood 130 (suppl 1):abstract 558, 2017.

305. Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre S, Choi M, Furman RR,

Heffner L, Barr PM, Eradat H, Zhou L, Verdugo M, Potluri J, Jones J. Analysis of PET-CT to identify Richter’s transformation in 167 patients with disease progression following kinase inhibitor therapy. Blood 130 (suppl 1):abstract 834, 2017.

306. Wierda WG, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L,

Jones J, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Choi M. Venetoclax (VEN) is active in chronic lymphocytic leukemia (CLL) relapsed of refractory to more than one B-cell receptor pathway inhibitor (BCRi). Blood 130 (suppl 1):abstract 3025, 2017.

307. Ujjani CS, Wang H, Skarbnik AP, Trivedi N, Ramzi P, Khan N, Cheson BD. Phase

1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL and SLL. Blood 130 (suppl 1): abstract 4324, 2017.

308. Cheson BD. Indolent Lymphomas and Hodgkin Lymphoma: My Treatment and

Emerging Therapies. Proc 15th Annual Indianapolis Hematology Review. 309. Koffman B, Dennison B, Kennard K, Byrd JC, Pagel JM, Davids MS, Nabhan C,

Kaye NE, Brander DM, Stephens DM, Hill BT, Pinilla-Ibarz J, Cheson BD, Rosen ST, Awan FT, Choi MY, Mato AR. A U.S-based survey: The experience of 1147 chronic lymphocytic leukemia (CLL) patients (pts). J Clin Oncol 36: abstract 7532, 2018.

310. Thompson M, Nabhan C, Cheson BD, Allan JN, Parr PM, Skarbnik AP, Jacobs R,

Ujjani CS, Furman RR, Schuster SJ, Shah NN, Pagen LM, Hill BT, Brander DM, Shadman M, Zent C, Lamanna N, Tunder HH, Lansigan F, Mato AR. Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies. J Clin Oncol 36: abstract 6577, 2018.

311. Hamlin PA, Cheson BD, Farber CM, Feldman T, Fenske TS, Hess BT,

Khatcheressian JL, Miller CB, Munoz J, Patel MR, Smith SM, Smith SD, Stevens DA, Ye JC, Steele A, Pandey A, Birrell M, Leeds J, Coffey G, Curnutte JT. The dual SYK/JAK inhibitor cderdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 36: abstract 7511, 2018.

312. Mato AR, Schuster SJ, Lamanna N, Flinn I, Barrientos JC, Kambhampati S,

Cheson BD, Barr PM, Pagel JM, Reeves JA, Lansigan F, Pu JJ, Skarbnik AP, Fonseca GA, Dorsey C, Prak EL, Paskalis D, Sportelli P, Miskin HP, Brander DM. A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts


with CLL who are intolerant to prior BTK or PI3K inhibitor therapy. J Clin Oncol 36: abstract 7530, 2018.

313. Mato AR, Schuster SJ, Lamanna N, Barrientos JC, Rai KR, Reeves JA, Flinn IW,

Kambhampati S, Pagel JM, Cheson BD, Barr PM, Lansigan F, Skarbnik AP, Fonseca GA, Pu JJ, Ujjani C, Svoboda J, Sitlinger A, Dorsey C, Weissbrot H, Mark A, Luning Prak AT, Tsao P, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Brander DM. A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3kδ inhibitor therapy. Proc 23rd Congress of EHA, abstract 2119, 2018.

314. Koffman B, Dennison B, Kennard K, Furman R, Byrd J, Pagel J, Davids M,

Nabhan C, Kay N, Siddiqi T, Brander D, Wierda W, Stephens D, Hill B, Pinila-Ibarz J, Cheson B, Rosen S, Awan F, Choi M, Mato A. A U.S.-based survey: The experience of 1147 chronic lymphocytic leukemia (CLL) patients. Proc 23rd Congress of EHA, abstract # 1888, 2018.

315. Davids MS, Flinn IW, Mato AR, O’Connor OA, Brander DM, Lunjing MA< Vose JM,

Nastoupil L, Fowler N, Flowers CR, Brown JR, Schreeder MT, Ghosh N, Lansigan F, Cheson BD, Barr PM, Pagel JM, Danilov A, Pinilla-Ibarz J, Deng C, Venugopal P, Gribben JG, Zinzani PL, Miskin HP, Sportelli P, Weiss MS, O’Brien SM. Long term integrated safety analysis of umbralisib (TGR-1202), a PI3kdelta/CK1-epsilon inhibitor with a differentiated safety profile in patients with relapsed/refractory lymphoid malignancies. Proc 23rd Congress of EHA, abstract 3740, 2018.

316. Hamlin PA, Cheson BD, Farber CM, Feldman T, Fenske TS, Hess BT,

Khatcheressian JL, Miller CB, Munoz J, Patel MR, Smith SM, Smith SD, Stevens DA, Ye JC, Steele AJ, Pandey A, Birrell MR, Leeds JM, Coffey GP, Curnutte JT. Proc 23rd Congress of EHA, abstract # 2671, 2018.

317. Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr

PM, Lansigan F, Cheson B, Singavi AK, Yazdy M, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy A, Cooms CC, Tuncer HH, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Kirkwood AA, Fox CP. Venetoclax as monotherapy or in combination: patterns of use and predictors of outcomes in an international multicenter study on CLL patients. Blood 132 (suppl 1): abstract #3142, 2018.

318. Roeker LE, Fox CP, Eyre TA, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN,

Lansigan F, Yazdy M, Lamanna N, Cheson B, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Tuncer HH, Ujjani CS, Winter AM, Rhodes J, Dorsey C, Morse H, Pagel JM, Williams AM, Jacobgs R, Goy A, Muralikrishnan S, Pearson Lm Sitlinger A, Bailey N, Schuh A, Brander DM, Kirkwood AA, Mato AR. Adverse events, patterns of tumor lysis syndrome prophylaxis and management, and dosing patterns in a large cohort of venetoclax treated CLL patients in community and academic settings. Blood 132 (suppl 1): abstract #4410, 2018.

319. Mato AR, Yazdy MS, Hill BT, Shadman M, Tuncer H, Winter AM, Kennard K, Allan

JN, Ujjani CS, Brander DM, Nabhan C, Barr PM, Brown JR, Fox CP, Rhodes J, Schuh A, Eyre TA, Lamanna N, Jain N, Wierda WG, Skarbnik AP, Roeker LE,


Bannerji R, Evens AM, Lansigan F, Samp JC, Nielsen J, Pauff JM, Kipps TJ, Schuster SJ, Follows GA, Cheson B, Eichhorst B. Treatment patterns and outcomes of patients with CLL treated with chemoimmuno and novel agent-based therapy: a multicenter study. Blood 132 (suppl 1): abstract #4759, 2018.

320. Younes A, Burke JM, Cheson B, Diefenbach C, Ferrari S, Hahn U, Hawkes E,

Khan C, Lossos IS, Masuraka G, Tani M, Vitolo U, Yuen S, Oestergaard MZ, Chitra S, Wenger M, Nielsen T, Seliam G, Sharman J. Safety and efficacy of atezolizumab in combination with rituximab plus CHOP in previously untreated patients with diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase I/II study. Blood 132 (suppl 1): abstract #2969, 2018.

321. Koffman B, Dennison B, Kennard K, Byrd JC, Furman RR, Pagel JM, Davids MS,

Nabhan C, Kay NE, Siddiqi T, Brander DM, Wierda WG, Stephens DM, Hill BT, Ibarz JP, Cheson B, Rosen ST, Awan FT, Choi MY, Henry TE, Roeker LE, Mato AR. Factors that influence treatment decision-making: perspectives of 1147 chronic lymphocytic leukemia (CLL) patients in the United States. Blood 132 (suppl 1): abstract 4414, 2018.

322. Antic D, Milic N, Mihaljevic B, Cheson B, Narkhede M, Abdel-Razeq H, Panovska

I, Trajkova S, Popova M, Aurer I, Boban A, Ghielmini M, Gerotziafas GT, Fareed J. External validation and revision of thrombosis lymphoma/Throly/ score. Blood 132 (suppl 1): abstract #140, 2018.

323. Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum

KA, LaCasce AS, Hurd DD, Ruppert AS, Hernandez-Illizaliturri FJ, Leonard JP, Cheson B. Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8 year follow up of CALGB 50403 (Alliance). Blood 132 (suppl 1): abstract #146, 2018.

324. Balasubramanian S, Hodkinson B, Schuster SJ, Fowler NH, Trotman J, Hess G,

Cheson B, Schaffer M, Wang S-S, Deshpande S, Vermeulen J, Salles G, Goral AK. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the Dawn phase 2 trial. Blood 132 (suppl 1): abstract #4147. 2018.

325. Witzig T, Maddocks K, de Vos S, Lyons R, Edenfield W, Sharman J, Vose J, Yimer

H, Wei H, Chan E, Patel P, Di Simone C, Gandhi M, Vaugh J, Kolibaba K, Cheson B, Saramaniego F. Phase 1/2 trial of acalabrutinib plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma. J Clin Oncol 38: abstract #7519, 2019.

326. Allan JN, Coleman M, Sharman JP, Cheson BD, Izumi R, Frigault MM, Quah CS,

Raman RK, Wang MH, Kipps TJ. Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory chronic lymphocytic leukemia (CLL) J Clin Oncol 38: abstract 7530, 2019.

327. Witzig T, Maddocks K, de Vos S, Lyons R, Edenfield W, Sharman J, Vose J, Yimer

H, Wei H, Chan E, Patel P, Di Simone C, Gandhi M, Vaugh J, Kolibaba K, Cheson


B, Saramaniego F. Phase 1/2 trial of acalabrutinib plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma. Proc EHA, 2019.

328. Rogers K, Thompson PA, Allan JN, Coleman M, Sharman JP. Cheson BD, Izumi

R, Frigual MM, Quah C, Raman RK, Wang MH, Kipps TJ. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Proc EHA, 2019.

329. Rhodes J, Sail K, Sarraf Yazdy M, Hill B, Shadman M, Tuncer H, Winter A,

Kennard K, Allan J, Ujjani C, Brander D, Cho S, Sharmokh S, Jiang DD, Nabhan C, Barr P, Brown J, Fox C, Schuh A, Eyre T, Lamana N, Wierda W, Skarbnik A, Roeker L, Bannerji R, Evens A, Pauff J, Schuster S, Follows G, Cheson B, Eichhorst B, Mato A. Factors impacting treatment selection in treatment-naïve patients with CLL: A multicenter study. Proc EHA, 2019.

330. Roeker L, Yazdy M, Gashonia L, Goodfriend J, Narkhede M, Rhodes J, Kennard

K, Morse H, Dorsey C, Battiato K, Peterson M, Carver J, Schuster S, Cheson B, Mato A. Hypertension in patients treated with ibrutinib for chronic lymphocytic leukemia (CLL). Proc EHA, 2019.

331. Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Izumi

R, Frigault MM, Quah C, Raman RK, Wang MH, Kipps TJ. Phase 2 study of acalabrutinib in ibvrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Hematol Oncol 37 suppl 1, 60-61, abstract 029, 2019.

332. Mato AR, Schuster SJ, Lamanna N, pagel JM, Flinn IW, Barrientos J, Reeves JA,

Cheson BD, Barr PM, Kambhampati S, Lansigan F, Pu JJ, Skarbnik A, Fonseca G, Dorsey C, LaRatta NM, Weissbrot H, Svoboda J, Luning Prak ET, Tsao P, Sitlionger A, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Brander DM. A phase 2 study to assess the safety and efficacy of umbralisib in patients with chronic lymphocytic leuykemia (CLL) who are intolerant to prior BTK or PI3k delta inhibitor therapy. Hematol Oncol 37 suppl 1 88, abstract 050, 2019.

333. Yazdy MS, Roeker L, Gashonia L, Goodfriend J, Narkhede M, Rhodes J, Kennard

K, Morse H, Dorsey C, Battiato K, Deonarine I, Carver J, Schuster SJ, Cheson BD, Mato A. Hematol Oncol 37 suppl 1, 212-213, abstract 164, 2019.

334. Witzig TE, Maddocks K, de Vos S, Lyons R, Edenfield W, Sharman J, Vose J,

Yimer H, Wei H, Chan E, Patel P, Di Simone C, Gandhi M, Vaughn J, Kolibaba K, Cheson B, Samaniego F. Acalabrurtinib plus pembrolizumab in relapsed/refractory diffuse large B-cell lymphoma: a phase 1/2 study. Hematol Oncol 37 suppl 1, 327-328, abstract 275, 2019.

335. Ujjani C, Wang H, Leslie L, Johnson M, Cheson BD. Phase IB/II study of ibrutinib

and venetoclax in relapsed and refractory follicular lymphoma. Hematol Oncol 37 suppl 1, 569-570, abstract OT24, 2019.

336. Rogers KA, Thompson PA, Allan JA, Coleman M, Sharman JP, Cheson BD, Izumi

R, Frigault MM, Quah C, Raman RK, Wang MH, Kipps TJ. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Proc SOHO, 2019.


337. Rogers KA, Thompson PA, Allan JA, Coleman M, Sharman JP, Cheson BD, Izumi

R, Frigault MM, Quah C, Raman RK, Wang MH, Kipps TJ. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Proc IWCLL, 2019.

338. Rhodes J, Sail K, Sarraf Yazdy M, Hill B, Shadman M, Tuncer H, Winter A,

Kennard K, Allan J, Ujjani C, Brander D, Cho S, Sharmokh S, Jiang DD, Nabhan C, Barr P, Brown J, Fox C, Schuh A, Eyre T, Lamana N, Wierda W, Skarbnik A, Roeker L, Bannerji R, Evens A, Pauff J, Schuster S, Follows G, Cheson B, Eichhorst B, Mato A. Factors impacting treatment selection in treatment-naïve patients with CLL: A multicenter study. Proc IWCLL, 2019.

339. Ujjani C, Mato A, Hill B, Allan J, Lansigan E, Skarbnik A, Jacobs R, Thompson M,

Svoboda J, Tuncer HH, Pagel J, Brander D, Cheson BD, Barr P, Zent CS, Rhodes J, Roeker L, Pu J, Handunnetti S, Nabhan C, Shah N, Goy A, Pickens P, Schuster S, Lamanna N, Sehgal A, Tam C, Shadman M. The impact of age on survival in CLL patients receiving ibrutinib as initial therapy. Proc IWCLL 2019.

340. Mato AR, Sail K, Yazdy MS, Hill BT, Shadman M, Manzoor BS, Tuncer HH, Allen

4311, 2019.JN, Ujjani CS, Sharmokh S, Jiang DD, Pena G, Marshall T, Nielsen J, Barr PM, Brown JR, Schuh A, Eyre TA, Wierda WG, Skarbnik A, Roekner LE, Bannerji R, Pauff JM, Schuster SJ, Follows GA, Cheson BD, Eichhorst BF, Brander DM, Pivneva I, Lamanna N. Treatment sequences and outcomes of patients with CLL treated with venetoclax and other agents post introduction of novel therapies. Blood 134 (suppl 1), abstract 1756, 2019.

341. Yazdy MS, Mato AR, Roeker LE, Jarral U, Ujjani CS, Shadman M, Skarbnik A,

Whitaker KJ, Deonarine I, Kabel C, Stump SE, Goodfriend J, Pagel JM, Bailey N, Patel K, Jacobs R, Feldman T, Leslie LA, Goy A, Coombs CC, Muluneh B, Khajavian S, Lamanna N, Weissbrot H, Weiss J, Cheson BD. Toxicities and Outcomes of acalabrutinib-treated patients with chronic lymphopcytic leukemia: a retrospective analysis ofreal world patients. Blood 134 (suppl 1): abstract 4311, 2019.

342. Mato AR, Roeker LE, Eyre TA, Jacobs R, Hill BT, Lamanna N, Brander DM,

Shadman M, Ujjani C, Yazdy M, Perini GF, Ibarz JP, Barrientos JC, Skarbnik A, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi MY, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac K, Shah P, Akhtar OS, Pocock R, Lam K, Vorhees TJ, Schuster SJ, Rogers D, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weisbrott H, Nabhan C, Goodfriend J, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Fox CP, Allan JN. Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies. Blood 134 (suppl 1): abstract 502, 2019.

343. Younes A, Burke JM, Cheson BD, Diefenbach C, Ferrari S, Hahn UH, Hawkes EA,

Khan C, Lossos IS, Musuraca G, Tani M, Vitolo U, Yuen SLS, Raval A, Mahesh R, Shivhare MR, Nielsen TG, Sellam G, Sharman JP. Safety and efficacy of atezolizumab in combination with rituximab plus CHOP in previously untreated


patients with diffuse large B-cell lymphoma (DLBCL): Updated analysis of a phase I/II study. Blood 134 (suppl 1): abstract 2874, 2019.

344. Burke JM, Andre M, Cheson BD, Duell J, Nowakowski G, Rosenwald A, Salles

GA, Sharman JP, Staber PB, Trneny M, Westin JR, Brugger W, Fingerle-Rowson G, Klanova M, Wurth G, Truemper L. A phas 1b, open-label, randomized study to assess safety and preliminary efficacy of tafasitamab (MOR-208) or tafasitamab+lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma: The First-Mind trial. Blood 134 (suppl 1): abstr 2877, 2019.

345. Yazdy MS, Jarral U, Yin C, Kuhr F, Jacob AP, Cheson BD. Long-term follow-up of

follicular lymphoma (FL) patients (pts) demonstrating undetectable minimal residual disease (MRD) using a next generation based DNA assay: support for FL as a curable disease. Blood 134 (suppl 1): abstr 2813, 2019.

346. Shadman M, Sail K, Manzoor BS, Yazdy MS, Hill BT, Tuncer HH, Allan JN, Ujjani

CS, Emechebe N, Kamalakar R, Sharmokh S, Jiang DD, Pena G, Marshall T, Nielsen J, Barr PM, Brown JR, Schuh A, Eyre TA, Lamannas N, Wierda WG, Skarbnik A, Roeker LE, Bannerfji R, Pauff JM, Schuster SJ, Follows GA, Cheson BD, Eichhorst BF, Brandser DM, Pivneva I, Guerin A, Mato AR. Treatment discontinuation patterns for patients with CLL in real-world settings: Results from a multi-center study. Blood 134 (suppl 1): abstract 3048, 2019.

347. Sehn LH, Trneny M, Bouabdallah K, Dueck G, Gribben JG, Lugtenburg PJ, Salles

GA, Knapp A, Nielsen TG, Liu W, Cheson BD, Sustained overall survival benefit of obinutuzumab plus bendamustine followed by obinutuzumab maintenance compared with bendamustine along in patients with rituximab-refractory indolent non-Hodgkin lymphoma: final results of the Gadolin study. Blood 134 (suppl 1): abstract2822, 2019.

348. Hamid MS, Rutherford SC, Kim S, Bafrtlett NL, Malecek M-K, Watkins M,

Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Ahmed S, Stephens DM, Allen P, Patel K, Teers MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Pagel JM, Ramchandren R. North American practice patterns for PET-2 positive Hodgkin lymphoma. Blood 134 (suppl 1): abstract 1553, 2019.

349. Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian BA, Diefenbach

CS, Feldman TA, Ansell SM. Phase II, Multi-center Trial of Nivolumab (Nivo) and Brentuximab Vedotin (BV) in Patients (Pts) with Untreated Hodgkin Lymphoma (HL) > age 60 Years or Unable to Receive Standard ABVD Chemotherapy: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU051505I. JCO 38 (suppl): abstract 8014, 2020..

350. Rutherford SC, Yin J, Pederson LD, LaPlant B, Shadman M, Li H, LeBlanc ML,

Kenkre V, Hong F, Blum KA, Dockter T, Martin P, Jung S-H, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger J, Cheson BD, Mandfrekar SJ, Bartlett NL, Kahl B, Friedberg JW, Leonard JP. Relevance of bone marrow biopsies for response assessment in National Clinical Trials Network follicular lymphoma clinical trials. JCO 38 (suppl): abstract 8038, 2020.

Bruce D. Cheson, M.D. Page 113 Abstracts (Continued) 351. Patel K, Maris MB, Cheson BD, Zonder JA, Lesokhin AM, Von Keudell G,

Seymour EK, Lin GHY, Catalano T, Shou Y, Iyer SP Ramchandren R. Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma. JCO 38 (suppl): abstract 3030, 2020.

352. Batchelor T, Giri S, Ruppert AS, Bartlett NL, Hsi ED, Cheson BD, Nayak L,

Leonard JP, Rubenstein JL. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101. JCO 38 (suppl): abstract 8042, 2020.

353. Chauhan A, Dreta B, Sackstein P, Ahn J, Cheson B. Role of baseline PET SUVmax in predicting early progression in follicular lymphoma (FL): A single- center retrospective analysis. Proc ESMO, 2020.

354. Narang J, Bajpai S, Jarecha RR, Caplan C, Macdonald D, Padrella G, Sharma M,

Cheson BD. The clinical relevance of residual, persistent and elongated abnormal sized nodes by longest diameter (LDi) in patients (pts) with chronic lymphocytic leukemia (CLL), otherwise in a complete remission (CR). Blood 136 (suppl 1): abstract 2227, 2020.

355. Zinzani PL, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA,

Knopinska-Posluszny W, Cheah CY, Phillips TJ, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca GA, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, O’Connor OA, Miskin HP, Sportelli P, Weiss MS, Fowler NH. Umbralisib, the once daily dual inhibitor of

PI3k ande casein kinase-1 demonstrates clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 2 global Unity-NHL trial. Blood 136 (suppl 1): abstract 2934, 2020.

356. Patel K, Ramchandren R, Maris M, Lesokhin AM, von Keudell GR, Cheson BD,

Zonder J, Seymour EK, Catalano T, Lin GHY, Uger B, Petrova PS, Roberge K, Shou Y, Iyer SP. Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study. Blood 136 (suppl 1): abstract 1191, 2020.

357. Ujjani CS, Lai C, Leslie LA, Ramzi P, Tan M, Wang S, Wanfg H, Shim E, Swanson

N, Broome CM, Gopal AK, Smith SD, Warren EH, Blue K, Kdiry S, Till BG, Lynch RC, Shadman M, Johnson M, Coye H, Shelby M, Tseng YD, Shustov A, Maloney DG, Cheson BD. Ibrutin ib and venetoclax in relapsed and refrctory follicular lymphoma. Blood 136 (suppl 1): abstract 2943, 2020.

358. Batchelor T, Giri S, Ruppert AS, Bartlett NL, Hsi ED, Cheson BD, Nayak L,

Leonard JP, Rubenstein JL. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy imn Alliance 51101. Proc ASCO, abstr# 8042, 2021.

Bruce D. Cheson, M.D. Page 114 Abstracts (Continued) 359. Patel K, marids MB, Cheson BD, Zonder JA, Lesokhin AM, Von Keudell G,

Seymour EK, Lin GHY, Catalano T, Shou Y, Iyer SP, Ramchandren R. Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma. Proc ASCO abstr #3030, 2021.

360. LaCasce AS. Dockter T, Ruppert AS, Kostakoglu L, Schoder H, Hsi ED, Bogart

JA, Cheson BDm Wagner-Johnston N, Abramson JS, Maddocks KJ, Leonard JP, Bartlett NL. CALGB 50801 (Alliance): {ET adapted therapy in bulky stage I/II classic Hodgin Lymphoma (cHL). Proc ASCO abstr #7507, 2021.

361. Rutherford SC, Yin J, Pederson L, LaPlant B, Shadman M, Li H, LeBlanc M, Blum

KA, Dockter T, Martin P, Jung S-H, Grant BW, Rosenbaum CA, Ujjani CS, Barr PM, Unger JM, Cheson BD, Bartlett NL, Friedberg JW, Leonard JP. Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials. Proc ASCO abstr #8038, 2021.

362. LaCasce AS, Dockter T, Ruppert AS, Peterson S, Kostakoglu L, Schoder H, Hsi E,

Bogart JA, Cheson BD, Wagner-Johnston ND, Abramson JS, Maddocks KJ, Leonard JP, Bartlett NL. CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL). Proc ICML, 2021.

Presentations To Meetings 1. The Origin of the Chemiluminescence of Phagocytosing Granulocytes. Cheson

BD, Christensen RL, Sperling R, Kohler BE, and Babior BM. (BD Cheson presenting) Boston Blood Club, Boston, Massachusetts, 6 November 1975.

2. The Origin of the Chemiluminescence of Phagocytosing Granuloctes. Cheson BD,

Christensen RL, Sperling R, Kohler BE, and Babior BM (BD Cheson presenting) American Society of Hematology, Dallas, Texas, 8 December 1975.

3. Chemiluminescence - A Measure of Granulocyte Function. University of Utah

Hospital, Hematology/Oncology Research Conference, Salt Lake City, Utah (Invited Speaker), 13 January 1977.

4. Chemotherapy of Hepatomas. Advances in Hepatobiliary Disorders. Snowbird,

Utah (Invited Speaker), 16 March 1978. 5. Role of Serum Factors in Zymosan Opsonization. SE Morris and BD Cheson (SE

Morris presenting). American Federation for Clinical Research (Western Section), Carmel, California, 7 February 1980.

Bruce D. Cheson, M.D. Page 115 Presentations To Meetings (Continued) 6. Defective Opsonization by Myeloma Serum as Determined by Chemiluminescence. American Society for Photobiology, Workshop on Biological Chemiluminescence, Colorado Springs, Colorado (Invited Speaker), 23 February 1980. 7. Hematologic and Oncologic Disorders in Refinery Workers. 40th Annual AMA

Congress on Occupational Health, Salt Lake City, Utah (Invited Speaker), 11 September 1980.

8. Splenectomy for Idiopathic (Immunologic) Thrombocytopenic Purpura. SJ.

Mintz,SR Petersen, BD Cheson, LJ Cordell, and RC Richards (SJ Mintz Presenting) Western Surgical Society, 18 November 1980.

9. Impact of Nutrition on Cancer. National Symposium: Nutrition in

Contemporary Medicine, Park City, Utah (Invited Speaker), 2 March 1981. 10. Nutrition in Cancer Management. Sixth Annual Advances in Internal Medicine

Post-graduate Conference, Snowbird, Utah (Invited Speaker), 3 March 1981. 11. Partial Splenic Ablation Using Transcatheter Ethanol. DE Mineau, FJ Miller, FL

Datz, RG Lee, and BD Cheson (DE Mineau presenting). 67th Scientific Assembly and Annual Meeting of the Radiologic Society of North America, Chicago, Illinois, 16-20 November 1981.

12. Defective Complement Function in Multiple Myeloma. HS Walker and BD Cheson

(HS Walker presenting). American Federation for Clinical Research (Western Section), Carmel, California, 17 February 1982.

13. S. Pneumoniae Infections in Multiple Myeloma: Role for a Complement Defect. HS

Walker, J Janata and BD Cheson (BD Cheson presenting) American Federation for Clinical Research, Washington, D.C, 7 May 1982.

14. Value of Open Lung Biopsy in Immunocompromised Patients with Pneumonitis.

TT Tang, WE Samlowski, BD Cheson, and SL Spruance (BD Cheson presenting). American Federation for Clinical Research, Plenary Session, Carmel, California, 9 February 1983.

15. Theory and Application of Chemiluminescence and Chemiluminogenic Probing of

Phagocyte Oxygenation Activity. 83rd Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana (Invited Speaker), 9 March 1983.

16. Defective Complement Activity in Chronic Lymphocytic Leukemia (CLL). ME

Heath and BD Cheson. American Federation for Clinical Research (Western Section), Carmel, California, 9 February 1984.

17. Clinical Trials in Unfavorable Histology Non-Hodgkin's Lymphomas (Invited

speaker). Cancer and Leukemia Group B, Montreal, Canada, 17 April 1986.

Bruce D. Cheson, M.D. Page 116 Presentations To Meetings (Continued) 18. Is the Use of Low Dose Ara-C Warranted in Acute Myelogenous Leukemia and

Myelodysplastic Syndromes? BD Cheson, DM Jasperse, R Simon, and MA Friedman. American Society of Clinical Oncology, Los Angeles, California, 5 May 1986.

19. Suramin Therapy in AIDS and Related Diseases: Initial Report of the U.S.

Suramin Working Group. BD Cheson, A Levine, D Mildvan, L Kaplan, A Rios, P Wolfe, J Groopman, and MJ Hawkins. International Conference on AIDS, Paris, France, 24 June 1986.

20. Low Dose Ara-C in Acute Non-Lymphocytic Leukemia and Myelodysplastic

Syndromes: A Review of 20 Years' Experience. BD Cheson and R Simon. Third Ara-C Symposium: "CYTOSAR-U - A Review of the Past with a Look to the Future." Kalamazoo, MI, 1-2 December, 1986.

21. Non-Hodgkin's Lymphomas. Educational Session, American Society of

Hematology, San Francisco, California, 6-7 December, 1986. 22. The Role of the Cooperative Groups, CTEP, and Industry in Clinical Trials. Upjohn

- MSL Neoplastic Diseases Unit, Washington, D.C, 22 September, 1987. 23. The Potential for Cure of Hematologic Malignancies in Adults (Invited speaker).

Ninety-sixth Annual Meeting of the Association of Life Insurance Medical Directors of America, Minneapolis, Minnesota, 13 October 1987.

24. Myelodysplastic Syndromes: Pathobiology and Management, 1988 (Invited

speaker). Educational Symposium, American Society of Clinical Oncology, New Orleans, Louisiana, 22 May 1988.

25. Study Design in Chronic Lymphocytic Leukemia. Fourth International Workshop on

CLL. Paris, France, 6 September 1988. 26. Report of the NCI-sponsored Workshop on Therapeutic Strategies in Multiple

Myeloma. Second International Workshop on Myeloma. Houston, Texas, 8 April 1989.

27. Report of the NCI-sponsored Workshop on Therapeutic Strategies in Multiple

Myeloma (Invited speaker). Southwest Oncology Group, MyelomaCommittee Meeting. San Antonio, Texas, 12 April 1989.

28. Myelodysplastic Syndromes: Current Status and Future Prospects (Invited

speaker). A Symposium on Leukemia: Current Laboratory and Clinical Issues, Leukemia Society of America (Maryland Chapter) and University of Maryland Cancer Center, 14 April 1989.

29. Chronic Lymphocytic Leukemia - 1992: Biology, Immunology, Clinical and

Prognostic Factors. Educational Symposium, American Society of Clinical Oncology, Washington, D.C., 20 May 1990.

Bruce D. Cheson, M.D. Page 117 Presentations To Meetings (Continued) 30. Biochemical Drug Targeting - Fludarabine - An Active New Drug For the Treatment

of Lymphoproliferative Disorders. 15th International Cancer Congress (UICC). Hamburg, F.R. Germany, 22 August 1990.

31. New Approaches to the Treatment of Chronic Lymphocytic Leukemia. Big Sky

Cancer Conference. Big Sky Montana, 8 September 1990. 32. Adjuvant Therapy of Colon Cancer. Big Sky Cancer Conference, 9 September

1990. 33. Therapeutic Strategies for the Chronic Leukemias. Southwest Oncology Group,

Columbus, Ohio, 3 October 1990. 34. Clinical and Biologic Characteristics of Chronic Lymphocytic Leukemia.

Educational Symposium - "Chronic Lymphocytic Leukemia: New Therapies and Future Prospects". In conjunction with Annual Meeting of the American Society of Hematology, Boston, Massachusetts, 30 November 1990.

35. New Therapies of Chronic B-Cell Leukemias. The Johns Hopkins Oncology

Center's 17th Annual Symposium on the Diagnosis and Treatment of Neoplastic Disorders. Baltimore, Maryland, 22 March 1991.

36. Chronic Lymphocytic Leukemia. "Meet the Professor" Session, Annual Meeting of

the American Society of Clinical Oncology, Houston, Texas, 19 and 21 May 1991. 37. Purine Analogues in the Treatment of Lymphoid Malignancies. Cancer and

Leukemia Group B Fall Meeting, Oncology Nursing Committee, Memphis, TN, 31 October 1991.

38. Chronic Lymphocytic Leukemia: New Perspective on Biology and Therapy.

Educational Session, Fall Meeting of the American Society of Clinical Oncology, Miami, FL, 9 November 1991.

39. Purine Analogs in the Treatment of Hematologic Malignancies. Invited discussant

at Adult Leukemia session, Annual Meeting of the American Society of Clinical Oncology, San Diego, CA, 18 May 1992.

40. Treatment of refractory chronic lymphocytic leukemia (CLL) with fludarabine

monophosphate (FAMP) under the Group C protocol (J.M. Sorenson presenting). Poster presentation at the Annual Meeting of the American Society of Clinical Oncology, San Diego, CA, 18 May 1992.

41. Future of Bone Marrow Transplantation. Medical Directors Workshop, Eigth

Annual Northwestern National Life ROSE Symposium, Minneapolis, MN, 2 August 1992.

42. Advances in Oncology and Bone Marrow Transplantation. Guest speaker. Eighth

Annual Northwestern National Life ROSE Symposium, Minneapolis, MN, 3 August 1992.

Bruce D. Cheson, M.D. Page 118 Presentations To Meetings (Continued) 43. Conventional Therapy for Multiple Myeloma: The U.S. Experience. Health

Insurance Association of American Forum on Investigational and Experimental Modalities: The Role of Bone Marrow Transplantation in the Treatment of Multiple Myeloma, Washington, D.C., 9 September 1992

44. Optimal Clinical Setting for Autologous Bone Marrow Transplantation. Health

Insurance Association of American Forum on Investigational and Experimental Modalities: The Role of Bone Marrow Transplantation in the Treatment of Multiple Myeloma, Washington, D.C., 9 September 1992

45. Chronic Lymphocytic Leukemia. “Frontiers in Oncology 1992”, Pennsylvania

Oncology Society, Pittsburgh, PA, 25 September, 1992. 46. Chronic Lymphocytic Leukemia in the 1990’s, “Chronic Leukemias in the 1990’s”,

Leukemia Society of America Medical Symposium, Philadelphia, Pennsylvania, 21 October 1992.

47. New Therapies for the Treatment of Low Grade Non-Hodgkin’s Lymphomas, -

“New Concepts in the Biology and Therapy of Indolent B-cell Non-Hodgkin’s Lymphomas”, Educational symposium in conjunction with the American Society of Hematology Annual Meeting, Anaheim, CA, 4 December 1992.

48. Nucleoside Analogs: Which Wins the Beauty Contest?, “Leukemia: The Next

Questions”, Houston, Texas, 25 March 1993. 49. Purine Analogues for Lymphoproliferative Disease: An Overview, “The Purine

Analogues: New Chemotherapy for Lymphoma and Leukemia”, The National Cancer Institute of Canada Clinical Trials Group, Montreal, Canada, 16 April 1993.

50. Are Results With Autologous Bone Marrow Transplant for Favorable Histology

Non-Hodgkin’s Lymphoma Better Than Standard Therapy? “Controversies in Bone Marrow Transplantation”, Methodist Hospital, San Antonio, TX, 23 April 1993.

51. “Treatment of hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine (CDA) under

the group C mechanism”. 29th Annual Meeting of the American Society of Clinical Oncology, Adult Leukemia/Lymphoma Poster Session, Orlando, FL, 18 May 1993.

52. Myelodysplastic Syndromes: Biology and Prognosis. “Myeloproliferative Disorders

and Myelodysplastic Syndromes: A Clinical Update”, Hilton Head, SC, 19 June 1993.

53. Myelodysplastic Syndromes: Principles of Therapy. “Myeloproliferative Disorders

and Myelodysplastic Syndromes: A Clinical Update”, Hilton Head, SC, 19 June 1993.

54. Recent Advances in Cancer Therapy. Ninth Annual ROSE Seminar, Minneapolis

MN, 2 August 1993.

Bruce D. Cheson, M.D. Page 119 Presentations To Meetings (Continued) 55. Indolent Lymphoma. “Lymphoma Symposium”, Lenox Hill Hospital, New York, NY,

29 September 1993. 56. Prognostic Factors and Therapy in Non-Hodgkin’s Lymphoma. Ninth Annual

“Toward 2000” Symposium, Fox Chase Cancer Center, Philadelphia, PA, 1 October 1993.

57. New Drugs for the Treatment of Multiple Myeloma (MM). IV International Workshop

on Multiple Myeloma, Rochester, MN, 4 October 1993. 58. New Antimetabolites for the Treatment of Human Malignancies, ASCO Fall

Educational Conference, Symposium on “New Agents”, St. Louis, MO, 13 November 1993.

59. Frame JN, Sorensen JM, Qashu N, Vena D, Christian M, Chun HG, Cheson BD.

Tumor lysis syndrome (TLS) in patients receiving fludarabine (F) for chronic lymphocytic leukemia (CLL)(JN Frame, poster presentation). American Society of Hematology, St. Louis, MO, 6 December 1993

60. Cheson BD. NCI-sponsored research and new drug development in multiple

myeloma. International Myeloma Foundation, Tysons Corners, VA, 22 January 1994.

61. Cheson BD. The use of the new purine analogues in treating low-grade

lymphoma. “Low Grade Non-Hodgkin’s Lymphoma: A Canadian Consensus Conference”, Toronto, Ontario, Canada, 19 September 1994.

62. Cheson BD. Recent initiatives in the treatment of CLL. “Hematologic

Malignancies...New Strategies and Targets”, Atlanta, GA, 27 October 1994. 63. Cheson BD. New therapeutic approaches in chronic lymphocytic leukemia. AACR

Special Conference: Translational Research in Cancer: New Opportunities for Progress, Ashville, NC, 12 December 1994.

64. Cheson BD. Is “more” better therapy for breast cancer? Society of Utah Medical

Oncologists, Semi-Annual Meeting, Salt Lake City, UT, 25 February 1995. 65. Cheson BD. “Indolent non-Hodgkin’s lymphomas”, Copely Memorial Hospital,

Seventh Annual Cancer Symposium, Aurora, IL, 19 April, 1995. 66. Cheson BD. “Myelodysplastic syndromes”, Leukemia Society of America,

Louisiana Chapter symposium on “Apoptosis and Chronic Leukemias”, New Orleans, LA, 14 June 1995.

67. Cheson BD. “New drugs for the treatment of chronic lymphocytic leukemia”, The

Oxford Forum, Key Issues and Concerns in the Treatment of CLL. Somerville College, Oxford, England, 25 June 1995.

Bruce D. Cheson, M.D. Page 120 Presentations To Meetings (Continued) 68. Cheson BD. “Paying for treatment in clinical trials”, American Society for Blood

and Marrow Transplantation, Assessing Outcome of Blood and Marrow Transplantation, Milwaukee, WI, 27 July 1995.

69. Cheson BD. “NCI Clinical Trials: What, Why, and for Whom?” Keynote speaker,

United Resource Networks Annual Meeting: “Dimensions in Disease Management”. Minneapolis, MN, 18 September 1995.

70. Cheson BD. “Which New Drugs Have a Role in the Treatment of Low Grade Non-

Hodgkin’s Lymphomas?”, at “Lymphoma...the next questions”, San Antonio, TX, 20 October 1995.

71. Cheson BD. “What Does This Mean for the Practicing Clinician?”, at

“Lymphoma...the next questions”, San Antonio, TX, 20 October 1995. 72. Cheson BD. Lymphoid malignancies: Clinical experience and toxicity of purine

analogues. NIH Clinical Staff Conference on “Newer Purine Analogues Bridging the Gap Between Indolent Lymphoid Malignancies and Systemic Autoimmune Diseases”, Bethesda, MD, 31 January 1996.

73. Cheson BD. Biology and Natural History of CLL. Chronic Lymphocytic Leukemia

and Associated Disorders, Baylor University Medical Center, Dallas, TX, 2 March 1996.

74. Cheson BD. Fludarabine in Non-Hodgkin’s Lymphoma. Clinical Implications of the

R.E.A.L. Classification. Boston, MA, 6 March 1996. 75. Cheson BD. New Therapies for Indolent Non-Hodgkin’s Lymphomas. Leukemia

Society of America, South Florida Chapter, Miami, FL, 14 March 1996. 76. Cheson BD. Mechanism of Action and Pharmacology of Fludarabine, Agrupación

Mexicana par el Estudio de la Hematologica (AMEH), XXXVII Annual Meeting, Mazatlán, Mexico, 29 April 1996.

77. Cheson BD. Treatment Options in Chronic Lymphocytic Leukemia, Symposium on

Current Treatment of CLL - Objectives, Options and Patient Expectations, Second Meeting of the European Haematology Association, Paris, France, 30 May 1996.

78. Cheson BD. Therapy of the Myelodysplastic Syndromes. Education Session of

the 26th Congress of the International Society of Haematology, Singapore, 25 August 1996

79. Cheson BD. Low Grade Lymphoma.Lymphomas and Hodgkin’s Disease:

Strategies for Cure. Jaffar Annual Oncology Conference. Southfield, MI, 27 September 1996.

80. New Chemotherapeutic Approaches and Future Directions, at “New Concepts in

Indolent Non-Hodgkin’s Lymphomas”, Chicago, IL 30 September 1996.

Bruce D. Cheson, M.D. Page 121 Presentations To Meetings (Continued) 81. New Chemotherapeutic Approaches and Future Directions, at “New Concepts in

Indolent Non-Hodgkin’s Lymphomas”, Miami, FL, 30 October 1996. 82. Therapy for Previously Untreated CLL: A Reevaluation, at “Chronic Lymphocytic

Leukemia in the Purine Analog Era: New Insights and Challenges”, American Society of Hematology Thirty-eighth Annual Meeting, Orlando, FL, 6 December 1996.

83. Topoisomerase I Inhibitors in the Treatment of Multiple Myeloma and Lymphomas,

at “Topoisomerase I-Inhiubitors in the Treatment of Hematologic Malignancies”, Orlando, FL, 7 December 1996.

84. Symposium on Evidence-Based Practice of Oncology, University of Louisville.

“Evidence-based Management of Chronic Lymphocytic Leukemia”, Louisville, KY, 26 February 1997.

85. Stanford University Symposium on “Current Treatment and Future Directions in the

Management of Non-Hodgkin’s Lymphomas and Lung Cancers”. “New Drugs in Lymphomas”, 15 March 1997.

86. Thirty-third Anuual Meeting of the American Society of Clinical Oncology,

Educational Session, “Multiple Myeloma: Biology and Therapy”, Denver, CO, 17 and 18 May 1997.

87. Thirteenth Annual ROSE Seminar, ReliaStar Insurance Company, “High Dose

Chemotherapy for Breast Cancer: An Update”, Minneapolis, MN, 4 August 1997. 88. Lymphoma, the Next Questions, “Are There Any New Useful Drugs for

Lymphoma?”, New Orleans, LA, 3 October 1997. 89. Lymphoma, the Next Questions, “What Does All This Mean to the Practicing

Clinician?”, New Orleans, LA, 3 October 1997. 90. Lymphoma, the Next Questions, “Evaluation of a Patient With a CD5-negative

Chronic Lymphocytic Leukemia-like Disorder”, New Orleans, LA, 3 October 1997. 91. Therapeutic Strategies and Supportive Care in Myelodysplastic Syndromes:

Yesterday, Today and Tomorrow, “Standard and Low-dose Chemotherapy of MDS”, American Society of Hematology Annual Meeting, San Diego, CA, 5 December 1997.

92. Emerging Issues and Future Perspectives in Managing Indolent Lymphoma, “New

Prospects in the Treatment of Indolent Lymphoma with Purine Nucleoside Analogues”, American Society of Hematology Annual Meeting, San Diego, CA, 5 December 1997.

Bruce D. Cheson, M.D. Page 122 Presentations To Meetings (Continued) 93. New Advances in the Treatment of Hematologic Malignancies: Focus on

Topoisomerase I Inhibitors, “Topoisomerase I Inhibitors in the Treatment of Lymphoma”, American Society of Hematology Annual Meeting, San Diego, CA, 5 December 1997.

94. Novel Applications of Purine Analogs: Opportunities in Immunology, “Purine

Analogs in Non-malignant Disease”, American Society of Hematology Annual Meeting, San Diego, CA, 5 December 1997.

95. Alternative Schedules and Indications for Purine Analogs. Second Annual Winter

Oncology Conference: Advances in Hematological Malignancies, Mont-Tremblant, Canada, 11 March 1998.

96. Treatment Options for Patients with Lymphoma, “The Use of Newer Therapeutic

Approaches in the Treatment of Low-Grade Lymphoma: Future Directions”, Sundance, UT, 13 March 1998.

97. The Role of Interferon in the Treatment of Indolent Non-Hodgkin’s Lymphomas,

Discussant at oral session on Adult Non-Hodgkin’s Lymphoma, Thirty-fourth Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, 18 May 1998.

98. Therapeutic Strategies for Intermediate and High-Grade Non-Hodgkin’s

Lymphomas. Educational Session on Non-Hodgkin’s Lymphomas, International Society of Hematology/European Hematology Association, Amsterdam, the Netherlands, 5 July 1998.

99. Indolent Non-Hodgkin’s Lymphomas. ASCO Symposium on “Non-Hodgkin’s

Lymphomas”, 17th Meeting of the UICC International Cancer Congress, Rio de Janeiro, Brazil, 27 August 1998.

100. New Drugs for the Treatment of Chronic Lymphocytic Leukemia. 2Nd International

Workshop of the German CLL Study Group, Kloster Benediktbeuern, Germany, 25 September 1998.

101. Purine Analogs in the Treatment of Indolent Non-Hodgkin’s Lymphomas. 2nd

International Symposium on Malignant Lymphomas, Munich, Germany, 27 September 1998.

102. New Agents Under Development at the National Cancer Institute for Hematologic

Malignancies/Proposed Clinical Trials for New Drugs. Hematologic Malignancies...the Next Questions. Chicago, IL, 10 October 1998.

103. Myelodysplastic Syndromes. George Washington University

Hematology/Oncology Board Review Course, Washington, D.C., 16 October 1998. 104. Chronic Lymphocytic Leukemia. George Washington University

Hematology/Oncology Board Review Course, Washington, D.C., 16 October 1998.

Bruce D. Cheson, M.D. Page 123 Presentations To Meetings (Continued) 105. New Developments in the Use of Topoisomerase I Inhibitors in the Treatment of

Hematologic Malignancies, in “Hematologic Malignancies: Is There a Role for Topoisomerase I Inhibitors?”, American Society of Hematology Annual Meeting, Miami, FL, 4 December 1998.

106. New Drugs for Lymphoma, in “Non-Hodgkin’s Lymphoma: Contemporary

Challenges for the Clinician”, American Society of Hematology Annual Meeting, Miami, FL, 4 December 1998.

107. New Chemotherapeutic Strategies for Indolent B-cell Malignancies, in “Toward the

Cure of Indolent B-cell Malignancies”, American Society of Hematology Annual Meeting, Miami, FL, 4 December 1998.

108. Mabthera in the Next Millennium, in Mabthera: Future Applications in CD20+

Malignancies. International Lymphoma Congress. Lugano, Switzerland, 1 June 1999.

109. Low-grade Non-Hodgkin’s Lymphoma. “Living Well With Lymphoma Forum”. Cure

for Lymphoma Foundation, Washington, D.C., 25 September, 1999. 110. Myelodysplastic Syndromes. “Medical Oncology - State of the Art”, Atlanta, GA, 29

September 1999. 111. Chronic Lymphocytic Leukemia. “Medical Oncology - State of the Art”, Atlanta,

GA, 29 September 1999. 112. Apoptosis. “National Lymphoma Awareness Week Educational Forum”,

Lymphoma Research Foundation of America, Los Angeles, CA, 16 October 1999. 113. New Chemotherapy Agents for Lymphoma. “National Lymphoma Awareness

Week Educational Forum”, Lymphoma Research Foundation of America, Los Angeles, CA, 16 October 1999.

114. Other Indolent Non-Hodgkin’s Lymphomas. “National Lymphoma Awareness

Week Educational Forum”, Lymphoma Research Foundation of America, Los Angeles, CA, 16 October 1999.

115. Unconjugated Antibody Therapy of Indolent Hematologic Malignancies.

“Immunotherapy in Non-Hodgkin’s Lumphoma: New Treatment Advances” at the 41st Annual Meeting of the American Society of Hematology, 3 December 1999.

116. All Leukemias and Lymphomas Are Not the Same: How to Select the Ideal

Patients for New Drug Studies. “Novel Therapeutic Agents and Strategies in Hematologic Malignancies” at the 41st Annual Meeting of the American Society of Hematology, 3 December 1999.

Bruce D. Cheson, M.D. Page 124 Presentations To Meetings (Continued) 117. Emerging Therapies and Future Directions in Chemotherapy. “Scientific Advances

and Clinical Development in Chronic Lymphocytic Leukemia: an IWCLL Perspective” at the 41st Annual Meeting of the American Society of Hematology, 3 December 1999.

118. New Treatment Approaches for Indolent Lymphomas. “Management of Indolent

Non-Hodgkin’s Lymphomas” at the 41st Annual Meeting of the American Society of Hematology, 4 and 5 December 1999.

119. Fludarabine in CLL. Advances in Hematological Malignancies, Whistler, British

Columbia, Canada, 15 March 2000. 120. Rituximab, New Applications and Future Directions. Advances in Hematological

Malignancies, Whistler, British Columbia, Canada, 16 March 2000. 121. New Agents for the Treatment of Myelodysplastic Syndromes. Advances in

Hematological Malignancies, Whistler, British Columbia, Canada, 15 March 2000. 122. Innovations for Indolent Lymphoma for the New Millennium. German Cancer

Congress, Berlin, Germany, 22 March 2000. 123. New Therapies for the Treatment of Non-Hodgkin’s Lymphomas. Cancer and

Leukemia Group B Spring Meeting, New Orleans, LA, 10 June 2000. 124. Other New Antibodies in CLL. IIIrd International Workshop of the German CLL

Study Group. Kloster Irsee, Germany, 23 September 2000. 125. Front-line Therapy of Chronic Lymphocytic Leukemia. Challenging Cases in

Leukemia and Lymphoma, American Society of Hematology 42nd Annual Meeting. 1 December 2000.

126. Management of Previously Untreated Patients with CLL. Defining Optimal

Treatment Strategies in Hematologic Malignancies, American Society of Hematology 42nd Annual Meeting. 1 December 2000.

127. Current Therapies in the Treatment of Non-Hodgkin’s Lymphomas: Biologics.

Managing Non-Hodgkin’s Lymphoma in the New Millennium, American Society of Hematology 42nd Annual Meeting. San Francisco, CA, 1 December 2000.

128. Radioimmunotherapy in Hematologic Malignancies: Future Directions.

Radioimmunotherapy of Low-Grade Non-Hodgkin’s Lymphoma, American Society of Hematology 42nd Annual Meeting. San Francisco, CA, 1 December 2000.

129. New Developmental Agents and Directions in the Treatment of Acute Leukemias.

Acute Leukemias IX. Munich, Germany, 24 February 2001. 130. Review of Interferon Therapy for NHL. Pan Pacific Lymphoma Conference. Maui,

HI 20, June, 2001.

Bruce D. Cheson, M.D. Page 125 Presentations To Meetings (Continued) 131. What’s New in the Pipeline for Lymphomas? Lymphoma...the Next Questions,

Washington, D.C. 12 October 2001. 132. New Therapeutic Options for the Treatment of Low Grade Non-Hodgkin’s

Lymphoma. Lymphoma...the Next Questions, Washington, D.C. 12 October 2001. 133. Other Indolent Non-Hodgkin’s Lymphomas, at the Lymphoma Research

Foundation of America Educational Forum on Lymphomas, Itaska, IL, 13 October 2001.

134. New Agents, at the Lymphoma Research Foundation of America Educational

Forum on Lymphomas, Itaska, IL, 13 October 2001. 135. Future Directions with Bendamustine in the Treatment of Hematological

Malignancies. Bendamustine in the Treatment of Hematological malignancies, satellite symposium for European Congress of Clinical Oncology, Lisbon, Portugal, 21 October 2001.

136. Next New Drugs...to the Phase I Trials. New Drugs in Hematologic Malignancies.

12 November 2001, Bologna, Italy. 137. Chronic Lymphocytic leukemia in First Relapse, in Challenging Cases in

Hematology. American Society of Hematology 43rd Annual Meeting, Orlando, FL, 7 December 2001.

138. Rational Approaches to Design of Therapeutic Targeting Molecular Markers.

Inhibiting Cell Cycle Progression and Proteasome Degradation Pathways. American Society of Hematology 43rd Annual Meeting, Orlando, FL, 8 December 2001.

139. Development of Rituximab Combination Regimens. New Directions in Biological

Therapy: Applications in Oncology and Immunology. Maui, Hawaii, 26 January 2002.

140. Is There Still a Role for Chemotherapy in the Treatment of Non-Hodgkin’s

Lymphomas? German Cancer Congress, Berlin, Germany, 11 March 2002. 141. New Drugs for the Treatment of CLL. IX International Workshop on CLL, San

Diego, CA, 23 March 2002. 142. Meet the Professor:CLL. American Society of Clinical Oncology, 38th Annual

Meeting, 18 and 20 May 2002, Orlando, FL. 143. “Is there a Role for Interferon in Indolent Non-Hodgkin’s Lymphoma?”, American

Society of Clinical Oncology, 38th Annual Meeting, 19 May 2002, Orlando, FL. 144. “Management of Transformed NHL”, 8th International Conference on Malignant

Lymphomas, Lugano, Switzerland, 11 June 2002.

Bruce D. Cheson, M.D. Page 126 Presentations To Meetings (Continued) 145. “New Drugs for Lymphomas”, 8th International Conference on Malignant

Lymphomas, Lugano, Switzerland, 15 June 2002. 146. “New Monoclonal Antibodies for the treatment of Chronic Lymphocytic Leukemia”,

German CLL Group Meeting, Kloster Irsee, Germany, 14 September 2002. 147. “New Drugs for Lymphomas”, United States-Japan Clinical Trials Summit on

Lymphoma, Kauai, Hawaii, 21 September 2002. 148. “New Drugs for Lymphomas”, Lymphoma/Myeloma 2002. New York, New York, 4

October 2002. 149. “New Drugs: Can They Cure Chronic Lymphocytic leukemia?” Chronic

Lymphocytic Leukemia: Is it a Curable Disease? Bologna, Italy, 11 October 2002. 150. “New Therapeutic and Biologic Approaches in Indolent Lymphoma (Including CLL),

in Innovative Current and Future Strategiew for Hematologic Malignancies, American Society of Hematology, Philadelphia, PA, 6 December 2002.

151. “Novel Agents for Non-Hodgkin’s Lymphomas”, in Update on Epidemiology and

Therapeutics for Non-Hodgkins Lymphomas, American Society of Hematology, Philadelphia, PA, 7 December 2002.

152. “New Strategies for Patients with Non-Hodgkin’s Lymphomas”, in Progress in

Lymphoma Therapy (Keynote Speaker), Tokyo, Japan, 19 April 2003. 153. “Chronic Lymphocytic Leukemia”, at First Annual Southern Symposium on

Hematologic Malignancies, Atlanta, GA, 3 May 2003. 154. “Clinical Trials: What Do They Tell Us About Future Treatments for CLL?”.

Lymphoma Research Foundation and Scripps Cancer Center Symposium: Lymphoma Treatment Today and Tomorrow. San Diego CA, 14 June 2003.

155. “New Drugs for Lymphoma”, Pan pacific Lymphoma Conference, Kona, Hawaii, 25

July 2003. 156. “Chronic Lymphocytic Leukemia” Dana Farber/Partners Cancer Medicine and

Hematology Course, Boston, MA, 23 September 2003. 157. “Diagnosis and Treatment of Lymphomas”, Chinese American Medical Association,

Washington, D.C., 28 September 2003. 158. “Is There Still a Need for Chemotherapy in the treatment of Indolent B-Cell

malignancies?” in Developing Immunotherapy for Effective Management of Leukemia and Lymphoma, at 45th Annual Meeting of the American Society of Hematology, San Diego CA, 5 December 2003.

Bruce D. Cheson, M.D. Page 127 Presentations To Meetings (Continued) 159. “Advances in the Treatment of Low-Grade Non-Hodgkin’s Lymphomas, in Non-

Hodgkin’s Lymphoma Update. Roslyn, NY, 17 March 2004. 160. “Response Criteria for Lymphoma - Is it Time for a Change?”, International Society

of Cutaneous Lymphoma, Symposium on Staging/ Classification of Cutaneous Lymphomas and Response Criteria/Endpoints in Clinical Trials of Cutaneous T-Cell Lymphomas. Washington, D.C., 5 February 2004,

161. “Chronic Lymphocytic Leukemia: An ASH Update”, ASH Updates. Washington,

D.C., 28 February 2004.

162. “New Drugs for Lymphomas”, Lymphoma Research Foundation Patient Education Forum, Washington, D.C., 28 February 2004.

163. “The Need for a Paradigm Change in the Treatment of Chronic Lymphoid Malignancies” (Keynote Speaker), Towards a Change of Care in Chronic Lymphoid Malignancies, Prague, Czech Republic, 24 April 2004.

164. Poster Discussion, Lymphomas, 40th Annual Meeting, American Society of Clinical Oncology, 5 June 2004.

165. “New Therapies for Lymphoid Malignancies”, International Symposium on Lymphomas, 40th Annual Meeting of the American Society of Clinical Oncology, 7 June 2004.

166. “Developing Combinations of Biological Agents for Lymphomas”, Therapeutic Advances in the Treatment of Hematological Malignancies, Kauai, Hawaii, 11 August 2004.

167. “Therapy for CLL: Advances Over the Last 25 Years” (Keynote Speaker). The Role of Immunotherapy in NHL: Optimising Treatment Outcomes. Prague, Czech Republic, 12 September 2004.

168. “PET-CT in non-Hodgkin Lymphoma – International Response Criteria – Is It Time For a Change?”, Sixth International Symposium on Hodgkin’s Lymphoma, Cologne, Germany, 20 September 2004.

169. “New Drugs Behind the Corner”, Ten Years After the REAL Classification: Open Issues. Bologna, Italy, 6 October 2004.

170. “Follicular Lymphoma: Where Are We Going?”, Lymphoma & Myeloma 2004, New York, NY, 16 October 2004.

171. New Drugs in Lymphoma, Lymphoma Research Foundation Patient Education Symposium, New York, NY, 16 October 2004.

Bruce D. Cheson, M.D. Page 128 Presentations To Meetings (Continued)

172. Response Criteria in Lymphomas. Nordic Lymphoma Group Meeting (Plenary Speaker), Helsinki, Finland, 22 October 2004.

173. Chronic Lymphocytic Leukemia in “Prognostic Assessment and Treatment Strategies for B-cell Malignancies”, 56th Annual Meeting of the American Society of Hematology, San Diego, CA, 3 December 2004.

174. Chronic Lymphocytic Leukemia: Meet the Professor. 56th Annual Meeting of the American Society of Hematology, San Diego, CA, 4 December 2004.

175. Response Criteria: Is It Time For a Change? NCI Cancer Imaging Program - The Role of FDG-PET in the Evaluation of Therapeutic Response in Cancer. Washington, D.C., 11 January 2005.

176. Life Beyond Rituximab. International Workshop on Malignant Lymphomas. Laguna Beach, CA, 30 January 2005.

177. Emerging Treatment Optiions for Lymphoma, “Lymphoma…the Next Questions”, Ft. Lauderdale, FL, 8 April 2005.

178. B-cell Malignancies: Innovations. 8th Annual Moll Pavilion Cancer Symposium, Cleveland, OH, 13 April 2005.

179. Monoclonal Antibodies – Promising Prognoses in CLL, “MabThera in NHL/CLL: Bringing Science To Life”, 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 7 June 2005.

180. New Drug Development in Diffuse Large B-Cell Lymphoma, “Aggressive Lymphomas: Life After CHOP-Based Therapies”, 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 7 June 2005.

181. How To Develop New Drugs for Lymphomas, 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 11 June 2005.

182. What Clinical Trials Would Enhance the Utility of Radioimmunotherapy? Radioimmunotherapy for Non-Hodgkin’s Lymphoma: Why Should We Use It? Why Don’t We Use It? Pan Pacific Lymphoma Conference, Kauai, Hawaii,14 July 2005.

183. Response Criteria in Lymphoma: A Work in Progress. Pan Pacific Lymphoma Conference, Kauai, Hawaii, 15 July 2005.

184. Update on B-Cell Lymphoma. Third Annual Conference on Therapeutic Advances in the Treatment of Hematological Malignancies. Santa Monica, CA, 6 August 2005.

185. Great Debates in Hematology, Colorado Springs, CO, 26 August 2005.


a. Stem Cell Transplanttaion for Early Relapse Follicular Lymphoma b. Stem Cell Transplantation for First Remission, High-Risk Large Cell Lymphoma c. Fludarabine-based Regimens for the Initial Thearpy of Follicular Lymphoma d. Treatment of Relapsed Mantle Cell Lymphoma in Elderly patients e. ABVD Therapy for Hodgkin’s Lymphoma

186. Follicular Lymphoma and New Drugs. Post-Lugano Lymphoma Synposium. Washington, D.C., 10 September 2005.

187. Response Criteria in CLL: Historical Perspectives. XI International Workshop on CLL. Brooklyn, N.Y., 18 September 2005.

188. Recent CALGB Trials for Lymphoma and New Agent Development Other Than Antibody Therapy, 2005 Lymphoma Symposium, Tokyo, Japan, 1 October 2005.

189. Combinations of Biological Response Modifiers in Non-Hodgkin’s Lymphomas, New Drugs in Hematology, Italian Society of Hematology, Bologna, Italy, 10 October 2005.

190. New Approaches to NHL: Radioimmunotherapy, Richmond Blood Club, Richmond, VA, 18 October 2005.

191. Measuring Treatment Benefits: Revised NHL and CLL Response Criteria. Life Beyond NHL: Investigator Forum. Hamburg, Germany, 22 October 2005.

192. Monoclonal Antibodies. Clinical Pharmacology of Anticancer Agents. Leesburg, VA, 31 October 2005.

193. Does CR Matter in First-Line Therapy for CLL? Current Treatment Strategies for B-Cell malignancies. American Society of Hematology 47th Annual Meeting. Atlanta, GA, 9 December 2005.

194. Treatment Strategies For A Patient Who Has Relapsed After Fludarabine. Current Treatment Strategies for B-Cell malignancies. American Society of Hematology 47th Annual Meeting. Atlanta, GA, 9 December 2005.

195. Revised Response Criteria for Malignant Lymphomas. Oral Session on B-Cell Lymphoma: Clinical Chemotherapy Trials. American Society of Hematology 47th Annual Meeting. Atlanta, GA, 11 December 2005.

196. Defining Critical Clinical Endpoints in Follicular Lymphoma: International Response Critiera and Optimal Endpoints, 2006 International Workshop on Lymphoid Malignancies, Laguna Beach, CA, 21 January 2006.

197. Guidelines for response in Malignant Lymphoma. 1st International Workshop of the German Competence Network Malignant Lymphoma, Cologne, Germany, 7 March 2006.


198. Historical recap of response assessment in aggressive NHL, recent revision of International Workshop staging criteria to incorporate FDG-PET for response assessment. FDG-PET Lymphoma Demonstration Project Invitational Workshop, Bethesda, MD, 20 March 2006.

199. Updating response assessment criteria in non-Hodgkin’s lymphoma. 4th International Workshop on Nuclear Oncology, Prague, Czech Republic, 20 May 2006

200. Great Debates in Hematology, Colorado Springs, CO, 8 September 2006. a. Radioimmunotherapy for relapsed follicular lymphoma in elderly patients b. Role of radiation therapy in stage I-II Hodgkin lymphoma c. The role of PET scans in the management of lymphoma

201. Chronic Lymphocytic Leukemia. ASH State-of-the-Art Symposium: Hematologic Malignancies: Recent Advances in Therapy. Las Vegas, NV, 15 September 2006.

202. Chronic Lymphocytic Leukemia. Dana Farber/Partners Cancer Medicine and Hematology Course. Boston, MA, 19 September 2006.

203. Indolent NHL – The Role of Standardised Response Criteria. Maintaining The Right Course For Maximal Survival in NHL. Valencia, Spain 7 October 2006.

204. Eliminating Minimal Residual Disease in CLL: A Realistic Goal. CME Lecture Series. Bethesda, MD, 12 October 2006.

205. New New Drugs For Peripheral T-Cell Lymphomas. It’s Time to Take Care of T-cell Lymphomas, Bologna, Italy, 23 October 2006.

206. International Working Group (Cheson) Criteria – The History, Drug Development Applications and Advances for the Future. Center for Business Intelligence 4th Annual Medical Imaging for Cliinical Trials, Tysons, Virginia, 26 October 2006.

207. Lymphoma Research Foundation Annual patient Education Forum, Los Angeles, CA, 28 October 2006. a. Overview of Lymphomas, b. Follicular Lymphoma c. Targeted Therapies

208. Best Practices in Oncology 2007:Advances in Hematologic Malignancies. Update on the Management of Lymphomas. Bethesda, MD, 30 January 2007.

209. Current Trends in Leukemia, Lymphoma and Myeloma. What’s New in the Management of CLL? Crystal City, VA, 10 February 2007.

210. International Follicular Lymphoma Meeting. Small Molecule Treatment of Follicular Lymphoma. North Berwick, Scotland, 20 March 2007.


211. Bendamustine: Mechanism of Action and Preclinical Data, in “Novel Cytotoxic and Targeted Agents in Lymphoproliferative Disorders”, Pan Pacific Lymphoma Conference, Maui, Hawaii, 14 June 2007.

212. Novel Approaches to Chronic Lymphocytic Leukemia: Combining Monoclonal Antibodies with Novel Cytotoxic Agents, in Novel Cytotoxic and Targeted Agents in Lymphoproliferative Disorders”, Pan Pacific Lymphoma Conference, Maui, Hawaii, 14 June 2007.

213. How Do PET Scans Change the Response Criteria for Non-Hodgkin’s Lymphoma? Pan Pacific Lymphoma Conference, Maui, Hawaii, 14 June 2007.

214. Revised Response Criteria. Lymphoma Symposium 2007, Tokyo, Japan, 8 September 2007.

215. New Agent Development: Update in 2007. Lymphoma Symposium 2007, Tokyo, Japan, 8 September 2007.

216. Antibodies Against B Cells and Their Role in the Management of CLL. XII International Workshop on CLL, London, England, 15 September 2007.

217. Chronic Lymphocytic Leukemia and Variants. Dana Farber/Partners Cancer Medicine and Hematology Course. Boston, MA, 25 September 2007.

218. The US Experience With Bendamustine in Indolent Lymphomas. German, Austrian, Swiss Hematology and Oncology Association Meeting, Satellite Symposium, Basel, Switzerland, 6 October 2007.

219. New Therapies Coming Forward to the Clinic for Relpased CLL, Lymphoma Research Foundation, Indolent Lymphoma Workshop, Crystal City, VA, 11 October 2007.

220. New Antibodies and Role of RIT. Lymphoma Research Foundation, Indolent Lymphoma Workshop, Crystal City, VA, 11 October 2007.

221. New Strategies in the Treatment of Follicular Lymphoma. Lymphoma and Myeloma: 2007, New York

222. , NY, 22 October 2007.

223. Overview of Current and Future Treatment of Indolent Lymphomas. SymBios Investigators Meeting, Tokyo, Japan, 27 October 2007.

224. Development of ABVD As Standard Treatment for Hodgkin’s Lymphoma. 7th International Symposium on Hodgkin’s Lymphoma, Cologne, Germany, 3 November 2007.

225. Current Role and Future of PET in Hodgkin’s Lymphoma. 7th International Symposium on Hodgkin’s Lymphoma, Cologne, Germany, 6 November 2007.


226. What’s New In the Management of Chronic Lymphocytic Leukemia. Current Trends in Leukemia, Lymphoma, and Myeloma. Arlington, VA, 9 February 2008.

227. PET as Remission Criteria for Aggressive Lymphomas, European Congress on Hematologic Malignancies, Paris, France, 23 February 2008.

228. Updates from the American Society of Hematology Meetings, LRF “Ask the Doctor”, Washington D.C., 26 March 2008.

229. Standard Approach to the Treatment of Hodgkin’s Lymphoma, “Hodgkin’s Lymphoma: Advancing Beyond Standard Management”, 10th-International Conference on Malignant Lymphoma, 3 June 2008, Lugano Switzerland.

230. New Strategies for Overcoming Refractory or Resistant NHL and CLL, in “The Evolving Role of Multyifunctional Agents in Lymphoid Malignancies”, 10th-International Conference on Malignant Lymphoma, 3 June 2008, Lugano, Switzerland.

231. New Response Criteria for Malignant Lymphoma (Meet the Professor), 10th-International Conference on Malignant Lymphoma, 4 June 2008 (twice), Lugano, Switzerland.

232. Has PET Changed the Approach to Lymphoma Patients? 10th-International Conference on Malignant Lymphoma, 6 June 2008, Lugano Switzerland.

233. New Drugs for B-Cell Non-Hodgkin’s Lymphoma, 10th-International Conference on Malignant Lymphoma, 7 June 2008, Lugano Switzerland.

234. Implications of Response-Adapted Therapy: Differences in HD and DLCL Biology and Response Assessment Strategies, Society of Nuclear Medicine 2008 Annual Meeting, 17 June 2008, New Orleans, LA.

235. Lenalidomide and Other Biological Agents in Lymphoma. 2008 Amgen Australia Clinical Hematology Symposium, 26 July 2008, Sydney, NSW, Australia.

236. PET in Lymphoma. 2008 Amgen Australia Clinical Hematology Symposium, 27 July 2008, Sydney, NSW, Australia.

237. Follicular Lymphoma and New Agents. Advances in the Clinical Management of Lymphoma: An Update of the Lugano Meeting. 15 September 2008, Washington, D.C.

238. Chronic Lymphocytic Leukemia and Variants. Dana Farber/Partners Cancer Medicine and Hematology Course. Boston, MA, 23 September 2008.

239. Individualizing Therapy for the Hematologic Malignancies: the Stuff of Genes and Dreams. New Drugs in Hematology, Bologna, Italy, 6 October 2008.


240. Broadening the Scope of Treatment for CLL, NHL and MM: An Update on Research and Treatment Options. Third Party Patient Advocacy Summit, Washington, D.C., 20 October 2008.

241. PET Scans in Lymphoma. Dinner Lecture, Montreal, Canada, 22 January 2009.

242. CLL. ION Hematology Review Meeting, Amelia Island, FL, 24 January 2009.

243. What’s New in the Management of Chronic Lymphocytic Leukemia. Current Trends in Leukemia, Lymphoma and Myeloma, Washington, D.C., 31 January 2009.

244. Role of PET in T-cell Lymphoma and T-cell Specific Response Criteria. 2006…2009: Now We Know T-cell Lymphomas Better, Bologna, Italy 16 March 2009.

245. When MabThera-FC Is Not An Option, “New Advances in CLL and NHL: From Clinical Trials to Clinical Practice”, Vienna, Austria, 29 March 2009.

246. Latest Advances in the Treatment of Follicular Lymphoma, “Advances in Targeted Therapy in Lymphoproliferative Disorders”, Madrid, Spain, 16 April 2009.

247. CLL and Follicular Lymphoma. Johns Hopkins 14th Annual Update in Hematologic Malignancies, Baltimore, MD, 1 May 2009.

248. Novel Targets in B-cell Malignancies, at “Pipeline Drugs Become Clinical Reality”, American Society of Clinical Oncology, Orlando, FL, 30 May 2009.

249. Safety and Efficacy of YM155 in Diffuse Large B-cell Lymphoma (DLBCL), American Society of Clinical Oncology, Orlando, FL, 1 June 2009.

250. Treatment Options for a Patient With Follicular Lymphoma: Current Standards of Care and Future Directions, in “Defining a Standard of Care for Indolent NHL and CLL: A 2009 Perspective:, Pan Pacific Lymphoma Conference, Kohala Coast, HI, 23 June 2009.

251. When Should Rituximab Maintenance Be Used? Pan Pacific Lymphoma Conference, Kohala Coast, HI, 24 June 2009.

252. Ask the Doctor About Lymphoma. Washington, D.C., 14 September 2009.

253. Role of PET in Clinical Trials of Novel Therapeutics in Haematology, ECCO/ESMO, Berlin, Germany, 22 September 2009.

254. Novel Agents in Low-grade Lymphoma: More Than We Can Handle? Lymphoma & Myeloma 2009, New York, NY, 23 October 2009.

255. Old and New Alkylating Agents. 14th Annual Lymphoma Research Foundation Educational Forum on Lymphoma, Brooklyn, NY, 24 October 2009.


256. Monoclonal Antibodies. Cancer Education Consortium, Clinical Pharmacology of Anti-Cancer Drugs. Leesburg, VA, 9 November 2009.

257. Bendamustine in Chronic Lymphocytic Leukemia. Chemotherapy Foundation Symposium XXVII. New York, NY, 11 November 2009.

258. Cheson BD. Poster Discussion: CLL. State of the Art Therapy for Hematologic Malignancies. 51st Annual meeting of the American Society of Hematology, 5 December 2009.

259. Cheson BD. Indolent B-cell lymphoma: New therapeutic developments. In Augmenting Clinical Responses Through Intracellular Pathways in B-cell Malignancies. 51st Annual meeting of the American Society of Hematology, 4December 2009.

260. Cheson BD, Friedberg JW, Kahl BS, van der Jagt RH, Tremmel L, Zaks T. Bendamustine produces durable responses with an acceptable long-term safety profile in patientse with rituximab-refractory non-Hodgkin’s lymphoma: A pooled analysis (poster presentation) 51st Annual meeting of the American Society of Hematology, 6 December 2009.

261. Cheson BD. New Drugs for Lymphoma. LyFE Meeting. Melbourne, Australia, 12 March 2010.

262. Cheson BD. 8th Annual Hematology & Oncology Targeted Therapies (HOTT) Symposium, Melbourne, Australia,12-14 March 2010.

a. Prognostic Factors in CLL b. New Drugs in CLL c. What I Learned About CLL at ASH

263. Cheson BD. Follicular Lymphoma – the CALGB study. Second International Workshop on Interim PET in Lymphoma. Menton, France, 9 April 2010.

264. Cheson BD. Personalizing therapies or patients with chronic lymphocytic leukemia: What are the optimal clinical applications of chemotherapies and targeted therapies in the first-line setting. First Annual Symposium on Personalized Therapies for Hematological Malignancies. Arlington, VA, 1 May 2010.

265. Cheson BD. Highlites of the Day: Lymphoma. 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 6 June 2010.

266. Cheson BD. Management of newly diagnosed follicular lymphoma in “Re-exploring the clinical decisions of community based oncolgists and hematologists in the management of multiple myeloma and follicular lymphoma”. ASCO Satellite, Chicago, IL, 6 June 2010.

267. Cheson BD. Difficult decisions in a patient with refractory non-Hodgkin’s lymphoma, in “Clinical case study conundrums in the management of indolent


lymphomas and myeloma”, 15th Congress of the European Hematology Association, Barcelona, Spain, 10 June 2010.

268. Cheson BD. Role of Bendamustine in CLL. VIIIth International Workshop of the German CLL Study Group in Cologne. Bonn, Germany, 4 September 2010.

269. Cheson BD. US Studies with Bendamustine as Front-Line in CLL. VIIIth International Workshop of the German CLL Study Group in Cologne (Satellite Symposium). Bonn, Germany, 4 September 2010.

270. Cheson BD. Recent modifications of the International Response Criteria for lymphoma. 8th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 23 October 2010.

271. Cheson BD. PET for lymphoma staging. 8th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 26 October 2010.

272. Cheson BD. Cancer and Leukemia Group B Trials for Malignant Lymphoma. 2010 Lymphoma Symposium, Tokyo, Japan, 6 November 2010.

273. Cheson BD. New Agent Development for Malignant Lymphoma; Recent Trends. 2010 Lymphoma Symposium, Tokyo, Japan, 6 November 2010.

274. Cheson BD. Bendamustine and Other Active Agents in NHL. Chemotherapy Foundation Symposium XXVIII, New York, NY, 10 November 2010.

275. Cheson BD. Prognostic Value of FDG-PET. Aggressive Lymphomas Workshop. Bologna, Italy, 15 November 2010.

276. Cheson BD. Current and Future Bendamustine Therapies in the Treatment of Follicular and Other Lymphomas. Bendamustine Special Seminar Meeting (Symbios), at the 52nd Annual Meeting of the Amerian Society of Hematology, Orlando, FL, 4 December 2010.

277. Cheson BD. The Role of PET Imaging in Lymphoma. Spotlight Session on “Issues in Imaging in Lymphoma” (Co-chair), 52nd Annual Meeting of the Amerian Society of Hematology, Orlando FL, 6 December 2010.

278. Cheson BD. Non-Hodgkin’s Lymphoma: An ASH Update. Highlights of ASH 2010, the Leukemia & Lymphoma Society, Pittsburgh, PA, 21 January 2011.

279. Cheson BD. Hodgkin’s Lymphoma: An ASH Update. Highlights of ASH 2010, the Leukemia & Lymphoma Society, Pittsburgh, PA, 21 January 2011.

280. Cheson BD. Chronic Lymphocytic Leukemia: An ASH Update. Falls Church, VA, 22 January 2011.

281. Cheson BD. The Role of PET/CT in T-cell Lymphomas. Third Annual T-cell Lymphoma Forum, San Francisco, CA, 28 January 2011.


282. Cheson BD. The potential of bendamustine in B-cell malignancies. 42nd Nordic Hematology Meeting, Bergen, Norway, 4 May, 2011.

283. Optimal treatment of CLL. What is the stadard of care? Symposium on Ribomustine in B-cell Malignancies, Peterhof, Russia, 19 May 2011.

284. Optimal use of bendamustine in B-cell malignancy iNHL patients refractory to rituximab: definition and frequency. Treatment options for patients with relapsed.refractory iNHL. Symposium on Ribomustine in B-cell Malignancies, Peterhof, Russia, 19 May 2011.

285. Optimal use of bendamustine in B-cell malignancies. Treatment recommendations. International Almazov Scientific Conference 2011. St. Petersburg, Russia, 21 May 2011.

286. Optimal treatment of B-CLL. International Almazov Scientific Conference 2011. St. Petersburg, Russia, 21 May 2011.

287. Discussant, Lymphoma Oral Session: Are We Ready for Risk-Adapted Therapy in Lymphoma? 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, 4 June 2011.

288. Lymphoma. Highlites of ASCO. 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, 5 June 2011.

289. Problems in the Design and Interpretation of Very Early Clinical Trials in Hemato-Oncology. European School of Oncology, Leukaemia and Lymphoma. Ascona, Switzerland, 14 June 2011.

290. How I Treat Mantle Cell Lymphoma. 11th International Conference on Malignant Lymphoma, Satellite Symposium. Lugano, Switzerland, 14 June 2011.

291. How Can We Best Combine Immunotherapies With Chemotherapy in Lymphoma? 11th International Conference on Malignant Lymphoma, Satellite Symposium. Lugano, Switzerland, 16 June 2011.

292. New Drugs for Treating Patients With Follicular Lymphoma. 11th International Conference on Malignant Lymphoma, Satellite Symposium. Lugano, Switzerland, 17 June 2011.

293. Ask the Doctor, LRF Symposium, Washington, D.C., 6 July 2011

294. Is Follicular Lymphoma Curable – NO? 2011 Pan Pacific Lymphoma Conference, Kauai, JI, 17 August 2011.

295. Biological Endpoints in Lymphoma, in “Non-Hodgkin’s Lymphoma: Optimizing Individualized Treatment Challenging Cases. Pan Pacific Lymphoma Conference, Kauai, HI, 18 August 2011.


296. Chronic Lymphocytic Leukemia, Lymphoma Research Foundation North American Educational Forum on Lymphoma, Brooklyn, NY, 1 October 2011.

297. New/Old Drugs for Lymphoma, Lymphoma Research Foundation North American Educational Forum on Lymphoma, Brooklyn, NY, 1 October 2011.

298. Lymphoma Pretreatment Assessment and Response Criteria. 73rd Annual Meeting of the Japanese Society of Hematology, Nagoya, Japan, 15 October 2011.

299. Optimal Use of Bendamustine. 73rd Annual Meeting of the Japanese Society of Hematology, Nagoya, Japan, 15 October 2011.

300. New Trends in the Diagnosis and Therapy of Lymphoid Malignancies. 73rd Annual Meeting of the Japanese Society of Hematology, Nagoya, Japan, 15 October 2011.

301. Promising new drugs in lymphoma – opportunities for changing practice. 7th Annual NCRI Meeting, Liverpool, England, 8 November 2011.

302. The Hemato-Oncologist’s Perspective On The Use of PET-CT in Clinical Practice and Clinical Trials. Society of Nuclear Medicine, Mid-Eastern Section, Hyattsville, MD, 21 April 2012.

303. Should Rituximab-Bendamustine Be Utilized As Front-line Therapy for Symptomatic CLL or Held in Reserve for Salvage Therapy? Great Debates and Updates in Hematologic Malignancies, New York, 28 April 2012.

304. Which CLL Patients Do I Refer for Allogeneic-BMT? Great Debates and Updates in Hematologic Malignancies, New York, 28 April 2012.

305. U.S. Clinical Trials in CLL: 2012 – New Drugs On The Horizon. CLL Expert Forum, Stockholm, Sweden, 7 May 2012.

306. Opportunities and Challenges of Mentoring Relationships, Georgetown University, Washington, D.C., 6 June 2012.

307. How To Treat Patients with DLBCL Who Have a Poor Ejection Fraction. Pan Pacific Lymphoma Conference, Maui, Hawaii, 18 July 2012.

308. Putting Lymphoma Patients On Clinical Trials – How Do Patients and Physicians Benefit? Pan Pacific Lymphoma Conference, Maui, Hawaii, 20 July 2012.

309. Challenges in New Drug Development: Clinical Trials and Tribulations. Special Guest Speaker, 7th International Workshop on Waldenström’s Macroglobulinemia, Goat Island, Rhode Island, 24 August 2012.

310. Treanda – The US Story. Hamatologie im Spiegel Der Zeit. Innovative Substanzen Gewinnen Mit Einem Bewahrten Partner Jubilaums-Symposium “50 Jahre Bendamustin”, Jena, Germany, 8 September 2012.


311. Chemotherapy for Lymphoma: Nearing An End. Cancer Clinics of Excellence Clinical Summit, Washington, D.C., 15 September 2012.

312. Role of PET in T-cell Lymphoma and T-cell Specific Response Criteria. T-cell Lymphomas: Work in Progress. Bologna, Italy, 17 September 2012.

313. Has Bendamustine-Rituximab Replaced FCR as the Standard of Therapy in CLL? Lymphoma & Myeloma 2012. New York, NY, 26 October 2012.

314. Ask the Doctor, LRF Patient Symposium. Fairfax, VA, 17 October 2012.

315. Change of Treatment Paradigm for Indolent Lymphoma: What is New? Controversies in Follicular Non-Hodgkin’s Lymphoma 2012, Lucerne, Switzerland, 2 November 2012.

316. Treatment Options. 17th Annual Lymphoma Research Foundation North American Patient Education Forum, Manhattan Beach, CA, 10-11 November 2012.

317. Who Regulates Clinical Trials. 17th Annual Lymphoma Research Foundation North American Patient Education Forum, Manhattan Beach, CA, 10-11 November 2012.

318. The Lymphoma Research Foundation Research Program and Scientific Avisory Board. 17th Annual Lymphoma Research Foundation North American Patient Education Forum, Manhattan Beach, CA, 10-11 November 2012.

319. New Drugs in Follicular and Other Indolent Lymphomas. 17th Annual Lymphoma Research Foundation North American Patient Education Forum, Manhattan Beach, CA, 10-11 November 2012.

320. Bendamustine, Amore a Prima Vista and Closing remarks. Bendamustina: Ruolo ed Evidenze Cliniche Nella Terapia Dei Linfomi. Bologna, Italy, 28 January 2013.

321. Hematologic Malignancies – What’s New? ION Solutions’ National Meeting, San Diego, CA, 9 Februry 2013.

322. New Directions in Follicular Lymphoma. 17th Annual International Congress on Hematologic Malignancies. New York, NY, 16 February 2013.

323. Stem Cell Transplantation in Follicular Lymphoma: Comment. 17th Annual International Congress on Hematologic Malignancies. New York, NY, 16 February 2013.

324. Non-Hodgkin’s Lymphomas: state of the Art of Treatment. New Drugs in Hematology, Bologna, Italy, 16 April 2013.

325. State of the Art: Staging, Restaging and Response Evaluation in Lymphoma. Keynote Lecture, 10th International Chicago Lymphoma Symposium. Chicago, IL, 27 April 2013.


326. Follow-up of the Closed Workshop on Lymphoma Staging and Restaging in the PET Era. Closed Workshop on Staging and Restaging of Lymphoma. 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18 June 2013.

327. Potential for Eliminating Chemotherapy in Indolent Lymphoma. Advances in the Treatment of B-cell Malignancies. 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18 June 2013.

328. Why Should We Exploit the Synergy of Lenalidomide and Anti-CD20 Antibody as a Backbone for Future Treatment Combinations in NHL? Potential for Eliminating Chemotherapy in Indolent Lymphoma. Advances in the Treatment of B-cell Malignancies. 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18 June 2013.

329. A Peek Through the Looking Glass: What Does the Future Promise? Making Sense of the Rapidly Changing World of Lymphoma. 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 19 June 2013.

330. Do We Need Maintenance After Front-Line Treatment of Follicular Lymphoma? Potential for Eliminating Chemotherapy in Indolent Lymphoma. Advances in the Treatment of B-cell Malignancies. 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 21 June 2013.

331. Report of the Closed Workshop on Lymphoma Pretreatment Assessment and Response Criteria in the New Millennium: Beyond Ann Arbor. 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 21 June 2013.

332. Ask the Doctor. Lymphoma Research Foundation. Washington, D.C., 16 September 2013.

333. How I Treat Mantle Cell Lymphoma. 6th Annual City of Hope Conference on How the Experts Treat Hematologic Malignancies. Santa Monica, CA, 19 September 2013.

334. Progress in Lymphoma: An Historical Perspective and the Future of Treatment. Keynote Speaker at the Lymphoma Research Foundation Annual Patient Edeucation Forum, Brooklyn, NY, 29 September 2013.

335. Hodgkin Lymphoma, T-cell Lymphoma and Diffuse Large B-cell Lymphoma. Year in Review. New York, NY, 5 October 2013.

336. Prognostic Indices and PET, Milestones in Hodgkin Lymphoma. 9th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 15 October 2013.

337. Current and Future Alliance (CALGB) Trials for Lymphoma. Lymphoma Symposium Zenyaku Japan. Tokyo, Japan, 2 November 2013.

338. Chemotherapy for Lymphoma: The End is in Sight. Lymphoma Symposium Zenyaku Japan. Tokyo, Japan, 2 November 2013.


339. Therapeutic Advances in CLL. Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow (The Greenspan Meeting XXXI). New York, NY, 6 November 2013.

340. Advances in Lymphomas and CLL. Bernstein Oncology Day. New York, NY, 15 November 2013.

341. Systemic Treatment of Cutaneous Lymphomas. Cutaneous Lymphoma Foundation Patient Education Forum. North Bethesda, MD, 16 Novembert 2013.

342. Advances in the Treatment of Indolent B-cell Lymphomas. Stirling, Scotland, 18 November, 2013.

343. Advances in the Treatment of Indolent B-cell Lymphomas. Chilworth Manor Hotel, Shouthampton, England, 19 November 2013.

344. US Experience – Indolent Lymphomas. Royal College of Pathologists, Current Treatment Options in Haematological Malignancies. Bristol, England, 21 November 2013.

345. Diffuse Large B-cell Lymphoma, “Challenging Cases in Non-Hodgkin Lymphoma:

Expert Strategies in Disease Management”, New Orleans, LA, 6 December 2013.

346. Identifying the control arm in randomized T-cell studies: Opportunities to expedite accrual in upfront studies of T-cell lymphoma (TCL). 6th Annual T-cell Forum, San Francisco, CA, 25 January 2014.

347. Progress in indolent lymphoma: Is chemotherapy dead? International Waldenstrom’s Macroglobulinemia Foundation, Annual Patient Education Forum (Keynote Speaker). Tampa, FL,16 May 2014.

348. CLL: Ask the Doctor. Lymphoma Research Foundation. Washington, D.C., 5 June 2014.

349. Lymphoma and CLL: Is chemotherapy dead? Annual Meeting, Medical Addairs, Gilead Sciences, San Francisco, CA, 19 June 2014.

350. Staging, Restaging, Response Criteria. Pan Pacific Lymphoma Conference. Kona, HI 21 July 2014.

351. Consolidative Therapy for Indolent NHL: Ready for Prime Time? In Reshaping the Treatment Algorithm for Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma. Pan Pacific Lymphoma Conference, Kona HI 21 July 2014.

352. Key Clinical Advances for Relapsed Patients with CLL That Have Clonal Evolution of Chemoresistance. Redefining the Therapeutic Landscape for Relapsed/Refractory Chronic Lymphocytic Leukemia. Pan Pacific Lymphoma Conference, Kona, HI 22 July 2014.


353. Need for New Response Assessment Considerations in CLL. Redefining the Therapeutic Landscape for Relapsed/Refractory Chronic Lymphocytic Leukemia. Pan Pacific Lymphoma Conference, Kona, HI 22 July 2014.

354. Update on Antibody-Conjugates for NHL. Pan Pacific Lymphoma Conference. Kona, HI, 24 July 2014.

355. Do We Need Maintenance Afrter Front-Line Therapy? No! Follicular Lymphomas Workshop, Bologna, Italy, 17 September 2014.

356. Bendamustine in relapsed/Refractory Follicular Lymphoma. Follicular Lymphomas Workshop, Bologna, Italy, 17 September 2014.

357. Special Lecture: Response Evaluation Criteria in Lymphoma. Korean Society of Hematology Lymphoma Study Group. Seoul, Korea, 24 October 2014.

358. Frontline Treatment of Follicular Lymphoma. Korean Society of Hematology Lymphoma Study Group. Seoul, Korea, 24 October 2014.

359. State of the Art: Staging, Restaging and Response Evaluation in Lymphomas. ALLIANCE Lymphoma Committee Meeting. Rosemont, IL, 7 November 2014.

360. New Treatments for Lymphoma. Keynote Speaker. Hong Kong Society of Haematology. Hong Kong, 18 November 2014.

361. The Changing Landscape in Lymphoid Malignancies. Keynote Speaker. 2nd Haematology Debates. Barcelona, Spain, 22 January 2015.

362. Key Challenges in Indolent Lymphoma Treatment. 1st Middle East and Sub-Saharan Africa (MENA/SSA) Oncology and Hematology Summit. Dubai, UAE, 6 March 2015.

363. Current Management and Recent Advances in Relapsed or Therapy-resistant CLL. 1st Middle East and Sub-Saharan Africa (MENA/SSA) Oncology and Hematology Summit. Dubai, UAE, 6 March 2015.

364. Who Is the Winner Among Chemotherapy Regimens in Addition To Rituximab in Front-line Follicular Lymphoma? 1st Postgraduate Lymphoma Conference, Rome, Italy, 26 March 2015.

365. The Role of PET-CT and T-cell Specific Response Criteria. 2102…2015, T-cell Lymphomas: We Are Illuminating the Darkest of Tunnels. Bologna, Italy 27 April 2015.

366. State of the Art: Staging, Restaging and Response Evaluation in Lymphomas. 15th Anniversary Mabthera Symposium, Chongqing, China, 8 May 2015.


367. State of the Art: Staging, Restaging and Response Evaluation in Lymphomas. Alliance for Clinical Trials in Oncology, Spring Meeting. Rosemont, IL, 15 May 2015.

368. New Approaches to the Treatment of Follicular Lymphoma: Is Chemotherapy Dead? Immune-based Strategies Towards Advancing the Treatment of B-cell Malignancies. 13th ICML, Lugano, Switzerland, 18 June 2015.

369. GADOLIN: Primary Results From a Phase III Study of Obinutuzumab Plus Bendamustine Compared With Bendamustine Alone in Patients With Rituximab-refractory Indolent non-Hodgkin Lymphoma. 13th ICML, Lugano, Switzerland, 19 June 2015.

370. New Lugano Classification for Staging and Response Evaluation: What Are The Most Important Changes? 55th Annual Meeting of the Japanese Society for Lymphoreticular Research. Okayama, Japan, 10 July 2015.

371. Bendamustine and New Effective Treatments for Lymphoma. 55th Annual Meeting of the Japanese Society for Lymphoreticular Research. Okayama, Japan, 10 July 2015.

372. Making the Diagnosis of Lymphoma. Lymphoma Research 20th Annual Patient Education Forum, Brooklyn, New York, 3 October 2015.

373. Chronic Lymphocytic Leukemia. Lymphoma Research 20th Annual Patient Education Forum, Brooklyn, New York, 3 October 2015.

374. Is There a Role for Maintenance Therapy? No. Lymphoma Research 20th Annual Patient Education Forum, Brooklyn, New York, 3 October 2015.

375. The Lugano Classification: New Recommendations for Staging and Response Assessment of Lymphomas. Israel Society of Hematology and Blood Transfusion. Haifa, Israel, 29 October 2015.

376. The Integration of Novel Immune and Targeted Therapies in the Management of Lymphoma. Israel Society of Hematology and Blood Transfusion. Haifa, Israel, 30 October 2015.

377. Meet the Professor. Israel Society of Hematology and Blood Transfusion. Haifa, Israel, 29 October 2015.

378. Treatment of Indolent Lymphoma Patients – The Role of Anti-CD20: Past, Present and Future. ASH Update (Roche). Lisbon, Portugal. 27 February 2016.

379. BTK Inhibitors. 2nd Postgraduate Lymphoma Conference. Rome, Italy, 17 March 2016.

380. The New Concept of Chemotherapy-free Treatment Regimens. 2nd Postgraduate Lymphoma Conference. Rome, Italy, 17 March 2016.


381. Bendamustine. New Drugs in Hematology. Bologna, Italy, 10 May 2016.

382. State of the Art of Treatment of Non-Hodgkin Lymphoma. New Drugs in Hematology. Bologna, Italy, 10 May 2016.

383. Should Lymphomas Be Staged With PET and What Follow-up Scans are Needed? Pan Pacific Lymphoma Conference. Kauai, Hawaii, 19 July 2016.

384. The Evolving Treatment Paradigm in Front-line CLL Management: Implication of 2016 Data Sets. Pan Pacific Lymphoma Conference, Kauai, Hawaii, 21 July 2016.

385. Anti-CD20 Therapy for B-cell Malignancies. Santaigo, Chile, 9 August 2016.

386. Therapeutic Options in Rituximab Refractory Patients. Chilean Society of Hematology, Puerto Mont, Chile, 11 August 2016.

387. Perspectives in Lymphoma. Society of Hematologic Oncology, Houston, TX, 9 September 2016.

388. Imaging in Lymphoma from 1999 to Lugano: what next? 6th International Workshop on PET in Lymphoma. Menton, France, 20 September 2016.

389. Role of Chemotherapy in CLL Management. Lymphoma & Myeloma 2016. New York, NY, 14 October 2016.

390. PET Update – 2016. 10th Meeting of the International Society of Hodgkin Lymphoma, Cologne, Germany, 24 October 2016.

391. CLL – 2016. Lymphoma Reesarch Foundation Annual Patient Education Forum, Chicago, IL, 29 October 2016.

392. Immunotherapy and monoclonal antibodies. Lymphoma Reesarch Foundation Annual Patient Education Forum, Chicago, IL, 29 October 2016.

393. New concepts in the research and management of chronic lymphocytic leukemia. 17th Annual Conference of Virginia Oncology Associates. Virginia Beach, VA, 5 November 2016.

394. Recommendations for Initial Evaluation, Staging and Response Assessment in Lymphomas. Brazilian Congress of Hematology, Hemotherapy and Cellular Therapy. Florionopolis, Brazil 10 November 2016.

395. The Role of PET in Lymphoma. Brazilian Congress of Hematology, Hemotherapy and Cellular Therapy. Florionopolis, Brazil 10 November 2016.

396. Follicular Lymphoma: Is Chemotherapy Dead. Brazilian Congress of Hematology, Hemotherapy and Cellular Therapy. Florionopolis, Brazil 11 November 2016.


397. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN study. American Society of Hematology, San Diego, CA, 5 December 2016.

398. Follicular Lymphoma: Targeted, Maintained, and Cured. 14th Annual Indy Hematology Conference (T. Howard Lee Keynote Lecture), Indianapolis, IN, 11 March 2017.

399. Lymphoma Overview. Lymphoma Research Foundation, Lymphoma Workshop, Washington, D.C., 18 March 2017.

400. Immunotherapy of Lymphoma. Lymphoma Research Foundation, Lymphoma Workshop, Washington, D.C., 18 March 2017.

401. Response Criteria on Check Point Inhibitor Therapy. 3rd Postgraduate Lymphoma Conference. Rome, Itlay, 23 March 2017.

402. New Biological Agents in Follicular Lymphoma: BTK Inhibitors. 3rd Postgraduate Lymphoma Conference. Rome, Italy, 24 March 2017.

403. New Agents for Patients With Relapsed/Refractory Follicular Lymphoma. 8th Brazilian Lymphoma Conference/XV Lymphoma Interchange Meeting. São Paulo, Brazil, 1 April 2017.

404. New Approaches to the Treatment of Relapsed and Refractory Follicular and Low-grade lymphoma: The GADOLIN Trial. 8th Brazilian Lymphoma Conference/XV Lymphoma Interchange Meeting. São Paulo, Brazil, 1 April 2017.

405. The Use of PET-CT in Diffuse Large B-cell Lymphoma. 8th Brazilian Lymphoma Conference/XV Lymphoma Interchange Meeting. São Paulo, Brazil, 1 April 2017.

406. Recommendations for Staging, Response Assessment and Follow-up of Lymphomas. NCI Quantitative Imaging Network Meeting. Rockville, MD, 10 April 2017.

407. Future Directions in Management of Indolent Non-Hodgkin Lymphomas. 5th Annual Hematology Experience Exfchange. Dubai, UAE, 5 May 2017.

408. Case Discussions: Waldenström’s Macroglobulinemia. 5th Annual Hematology Experience Exfchange. Dubai, UAE, 6 May 2017.

409. Development of the Staging and Response Criteria for Adult Lymphomas. 3rd International Symposium: Childhood, Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL). Washington, D.C., 11 May 2017.

410. Treatment of Follicular Lymphoma in First Relapse: The US Perspective. Indolent Lymphoma Workshop. Bologna, Italy, 15 May 2017.


411. Endpoints of Clinical Trials. Clinical Trials Workshop. 14th ICML, Lugano, Switzerland, 13 June 2017.

412. Management Issues in Follicular Lymphoma. Symposium on Progress in the Management of Follicular Lymphoma. 14th ICML, Lugano, Switzerland, 13 June 2017.

413. Treatment Options for Patients with Relapsed/Refractory Hodgkin Lymphoma. Improving Treatment Strategies for Patients With Follicular Lymphoma: How to Translate Novel Study Data Into Clinical Practice. Lugano, Switzerland, 13 June 2017.

414. Follicular Lymphoma. Lymphoma Research Foundation Annual North American Patient Education Forum, Brooklyn, NY, 21 October 2017.

415. Immunotherapy. Lymphoma Research Foundation Annual North American Patient Education Forum, Brooklyn, NY, 21 October 2017.

416. The GADOLIN Study: Implications for the Future of Response Assessment. XIII Annual Meeting of the Argentine Society of Hematology. Mar del Plata, Argentina, 18 November 2017.

417. A Case Based Discussion on Follicular Lymphoma. Targeted Oncology Symposium. Fort Lauderdale, FL. 1 March 2018.

418. Emerging Therapies in Lymphoma (Patient Perspective). 15th Annual Indianapolis Hematology Review. Indianapolis, IN, 9 March 2018.

419. Emerging Therapies in Lymphoma (Nursing Perspective). 15th Annual Indianapolis Hematology Review. Indianapolis, IN, 10 March 2018.

420. Indolent Lymphomas and Hodgkin Lymphoma: My Treatment and Emerging Strategies. 15th Annual Indianapolis Hematology Review. Indianapolis, IN, 10 March 2018.

421. Untangeling the complexities of FL: current treatment challenges in frontline. 4th Postgraduate Lymphoma Conference, Rome, Italy, 15 March 2018.

422. PI3 kinase inhibitors in follicular lymphoma. 4th Postgraduate Lymphoma Conference, Rome, Italy, 15 March 2018.

423. With the advent of targeted agents is there a role for transplant in FL? . 4th Postgraduate Lymphoma Conference, Rome, Italy, 15 March 2018

424. How I treat follicular lymphoma. Chinese School of Oncology. Shanghai, China, 22 March 2018.

425. With a wealth of therapeutic options in CLL: combinations or sequencing? 5th Annual Shenzou International Lymphoma Forum, Suzhou, China, 25 March 2018.


426. Should DEL patients be treated differently? 5th Annual Shenzou International Lymphoma Forum, Suzhou, China, 25 March 2018.

427. Treatment of Indolent Lymphomas. Delaware Society of Oncology. Wilmington, DE, 12 April 2018.

428. Aggressive Non-Hodgkin Lymphomas. NHL oncoMAP Washington Meeting. Washington, D.C., 30 April 2018.

429. PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be. 2015…2018 T-cell Lymphomas: we are close to the finalization. Bologna, Italy, 7 May 2018.

430. Treatment of Relapsed and Aggressive B-cell Lymphomas. Regional Summit on B-cell and Plasma Malignancies. Boston, MA, 12 May 2018.

431. Toward a Chemo-free Future in Lymphoid Malignancies. Lymphoma and CLL Session, ASCO Annual Meeting. Chicago, IL, 3 June 2018.

432. How do we incorporate PET-CT In to Standard of Care and Research Studies? Pan Pacific Lymphoma Conference, Maui HI, 17 July 2018.

433. Bendamustine: New Data On An Old Drug. New Drugs in Hematology. Bologna, Italy, 2 October 2018.

434. Bendamustine For Relapsed and Refractory Follicular Lymphoma. New Drugs in Hematology. Bologna, Italy, 2 October 2018.

435. Initial Treatment of CLL. New Drugs in Hematology. Bologna, Italy, 2 October 2018.

436. Clinical and Biological Criteria for Treatment Decisions in Follicular Lymphoma. 5th Postgraduate Course in Lymphoma. Rome, Italy, 14 March 2019.

437. Double Expressor Lymphomas. Aggressive Lymphomas. Bologna, Italy, 13 May 2019.

438. The Lugano Classification 5 Years After: Should We Change Anything? 15th ICML, Lugano, Switzerland, 20 June 2019.

439. Research to Practice Year in Review: CLL and Lymphomas. Houston, TX, 11 January 2020.

440. Phase II, Multi-center Trial of Nivolumab (Nivo) and Brentuximab Vedotin (BV) in Patients (Pts) with Untreated Hodgkin Lymphoma (HL) > age 60 Years or Unable to Receive Standard ABVD Chemotherapy: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU051505I. Amerifcan Society of Clinical Oncology Annual Meeting, 29 May 2020 (poster discussion, virtual).


441. New Therapies for Lymphoma. Lymphoma Research Foundation Lymphoma Workshop. 16 July 2020 (virtual).

442. Follicular and Other Indolent Lymphomas. Lymphoma Research Foundation Lymphoma Workshop. 16 July 2020 (virtual).

443. Follicular and Other Indolent Lymphomas and Hodgkin Lymphoma. 17th Annual Indy Hematology Review. 15 August 2020 (virtual).

444. Who, When and How to Treat: The Paradox of Watching and Waiting, Treatment and Retreatment of Indolent Lymphomas. 17th Annual Indy Hematology Review. 15 August 2020 (virtual).

445. ASH Review 2020: CLL and NHL. ION Multiple Myeloma Summit and ASH Review. 6 February 2021 (virtual).

446. Oral, Non-chemotherapy Options in CLL and NLL. ION Oral Oncolytics Meeting. 13 March 2021 (virtual).


Invited Lectures 1. University of Nevada - Reno College of Medicine. "The Neutrophil - Development,

Kinetics, and Function", 12 February 1979. 2. University of California at Irvine - Medicine Grand Rounds. "Clinical Evaluation of

Defects in Neutrophil Function, " 13 November 1980. 3a. Medical College of Virginia - Hematology/Oncology Research Seminar.

"Bactericidal Defects in Multiple Myeloma," 3 March 1982. 3b. Medical College of Virginia - Multidisciplinary Tumor Board."Multiple Myeloma:

Current concepts of Immunology and Treatment," 4 March 1982. 4. University of California - Los Angeles, Sepulveda Veterans Administration Hospital

- Medical Staff Conference. "Multiple Myeloma, Current Concepts of Immunology and Treatment", 20 June 1983.

5a. Texas Technological University Medical School (Amarillo), Harrington Cancer

Center. Hematology/Oncology Clinical Conference. "Value of Open Lung Biopsy in Immunocompromised Patients", 23 June 1983.

5b. Hematology/Oncology Research Seminar "Bactericidal Defects in Multiple

Myeloma", 24 June 1983. 5c. Medical Grand Rounds. "Multiple Myeloma: Current Concepts of Immunology and

Therapy", 24 June 1983. 6. City of Hope National Medical Center - Hematology Research Conference. "Bactericidal Defects in Multiple Myeloma," 21 July 1983. 7. Louisiana State University - Shreveport, Hematology/Oncology Conference.

"Multiple Myeloma: Current Concepts of Immunology and Therapy", 9 September 1983.

8. Southern Illinois University School of Medicine, General Medicine Conference

"Multiple Myeloma: Current Concepts of Immunology and Therapy", 14 September 1983.

9. University of Kansas College of Health Sciences, Division of Clinical Oncology

Research Seminar. "The Pneumococcus versus Multiple Myeloma: Novel Approach to an Uncomplementary Situation", 20 March 1984.

10. Washington Hospital Center, Multi-disciplinary Tumor Board. "Controversies in the

Treatment of Low-grade Non-Hodgkin's Lymphomas", 24 April 1987. 11. University of Maryland, Hematology Conference. "Low Dose Ara-C Therapy", 18

January 1988.

Bruce D. Cheson, M.D. Page 149 Visiting Lectureships (Continued) 12. Duke University, Hematology-Oncology Research Seminar. "Therapy of

Myelodysplastic Syndromes", 11 February 1988. 13a. McGill University, Royal Victoria Hospital, Hematology ResearchConference.

"Therapy of Favorable Histology Non-Hodgkin' Lymphomas", 24 February 1988. 13b. McGill University, Royal Victoria Hospital, Medical Grand Rounds.

"Myelodysplastic Syndromes - Therapeutic Challenge", 24 February 1988. 14a. McGill University, Hopital Juif, Medical Grand Rounds, Ross Silverstein Memorial

Lecturer. " Current Approaches to the Therapy of Myelodysplastic Syndromes", 21 March 1988.

14b. McGill University, Hôpital Juif, Hematology/Oncology Seminar. "The Role of the

NCI in U.S. Clinical Cancer Trials", 22 March 1988. 15. University of Chicago, Hematology/Oncology Seminar. "Therapy of

Myelodysplastic Syndromes", 2 May 1988. 16. University of North Carolina, Hematology/Oncology Seminar. "Current Treatment

Strategies in Myelodysplastic Syndromes", 11 July 1988. 17. Walter Reed Army Medical Center, Hematology/Oncology Seminar.

"Therapy of Myelodysplastic Syndromes", 6 January 1989. 18. Washington Hospital Center, Medicine Lecture Series. "The Bone Marrow Goes

Awry - Myelodysplastic Syndromes", 14 April 1989. 19. Rush Medical Center, Oncology Division, Distinguished Special Lecturer. "GM-

CSF Therapy in the Myelodysplastic Syndromes", 28 June 1989. 20. Roswell Park Memorial Institute, Department of Medicine Seminar. "Current

Therapeutic Strategies in Myelodysplastic syndromes", 6 February 1990. 21. Medical College of Virginia, Hematology-Oncology Seminar. "Current Therapeutic

Strategies in Myelodysplastic Syndromes", 18 April 1990. 22. Rush Medical Center, Oncology Division, Wadsworth Memorial Lecturer. "Chronic

Lymphocytic Leukemia: Current Status and Future Perspectives", 25 April 1990. 23. Washington Hospital Center, Hematology-Oncology Grand Rounds. "Chronic B-

cell Leukemias", 13 November 1990. 24. Leukemia Society of America, Illinois Chapter, Annual Speaker. "Chronic

Lymphocytic Leukemia", 15 November 1990. 25. Memorial Hospital and Medical Center, Cumberland Maryland, Internal Medicine

Grand Rounds. "Chronic Lymphocytic Leukemia", 20 November 1990.

Bruce D. Cheson, M.D. Page 150 Visiting Lectureships (Continued) 26. Johns Hopkins Oncology Center, Multidisciplinary Clinical Conference. "Chronic

Lymphocytic Leukemia: State of the Art", 13 December 1990. 27. University of Maryland Cancer Center, Hematology Conference. "Myelodysplasia",

18 March 1991. 28. Cardeza Foundation for Hematologic Research, Thomas Jefferson University.

"Chronic Lymphocytic Leukemia: Current Status and Future Directions", 6 May 1991.

29. Mayo Clinic Foundation, Findling Memorial Lectureship, Department of Internal

Medicine. "Chronic Lymphocytic Leukemia: New Directions", 30 September 1991. 30. Mayo Clinic Foundation, Division of Hematology. "Myelodysplastic Syndromes:

Current Status and Future Directions", 1 October 1991. 31. Northwestern University Medical School. "Chronic Lymphocytic Leukemia in the

1990's", 18 October 1991. 32. Cleveland Clinic Cancer Center, Grand Rounds. "Chronic Lymphocytic Leukemia:

1991", 3 December 1991. 33. Washington Hospital Center Cancer Institute, "Clinical Trials: Why and How?", 3

April 1992. 34. Hackensac Medical Center, "Chronic Lymphocytic Leulemia in the 1990's", 21 April

1992. 35. Georgetown University Hospital, "Chronic Lymphocytic Leukemia in the 1990's", 26

May 1992. 36. Loyola University, Hematology/Oncology Grand Rounds, "Chronic Lymphocytic

Leukemia: Current Status and Future Directions", 12 June 1992. 37. Holy Cross Hospital, Ft. Lauderdale, FL, Medical Grand Rounds, "Chronic

Lymphocytic Leukemia in the 1990's", 18 June 1992. 38. Brooklyn Veterans Administration Hospital, Brooklyn, NY, Hematology/Oncology

Seminar, "Chronic Lymphocytic Leukemia in the 1990's", 26 June 1992. 39. Illinois Masonic Medical Center, Chicago, IL, Department of Medicine Grand

Rounds, “Chronic Lymphocytic Leukemia in the 1990’s”, 7 August 1992. 40. Dana Farber Cancer Institute, Boston, Massachusetts, Divison of Oncology

Seminar, “Chronic Lymphocytic Leukemia in the 1990’s”, 16 September 1992. 41. Boston University Hospital, Boston, Massachusetts, Hematolog/Oncology

Research Seminar, “Chronic Lymphocytic Leukemia in the 1990’s”, 16 September 1992.

Bruce D. Cheson, M.D. Page 151 Visiting Lectureships (Continued) 42. Brown University, Rhode Island Hospital, Providence, RI, Department of Medicine

Grand Rounds, “Chronic Lymphocytic Leukemia in the 1990’s”, 23 September 1992.

43. Brown University, Roger Williams Hospital, Providence, RI, Department of

Medicine Grand Rounds, “Chronic Lymphocytic Leukemia in the 1990’s”, 10 November, 1992.

44. Cornell Medical Center, New York Hospital, New York, NY, Hematology Oncology

Seminar, “Chronic Lymphocytic Leukemia in the 1990’s”, 17 November 1992. 45. Clinical Oncology Association of Georgia, Atlanta, GA, “Chronic Lymphocytic

Leukemia in the 1990’s”, 18 November 1992. 46. Columbia-Presbyterian Medical Center, New York, NY, Hematology/Oncology

Seminar, “Chronic Lymphocytic Leukemia in the 1990’s”, 7 January 1993. 47. Lahey Clinic, Burlington, Massachusetts, Hematology/Oncology Seminar, “Chronic

Lymphocytic Leukemia in the 1990’s”, 17 March 1993. 48. Howard University Cancer Center, Washington, D.C., Tumor Conference, “Chronic

Lymphocytic Leukemia in the 1990’s”, 20 May 1993. 49. Washington Hospital Center, Washington, D.C., Department of Medicine Grand

Rounds, “Chronic B-Cell Malignancies”, 25 May 1993. 50. Boston Veterans Administration Hospital, Jamaica Plains, MA, Department of

Medicine Grand Rounds, “Chronic Lymphocytic Leukemia in the 1990’s”, 1 June, 1993.

51. UCLA, Harbor General Hospital, Torrance, CA, Department of Medicine Grand

Rounds, “Chronic Lymphocytic Leukemia in the 1990’s: An Update”, 15 June 1993. 52. The Medical Center at Princeton, Princeton, NJ, Department of Medicine Grand

Rounds, “Chronic Lymphocytic Leukemia in the 1990’s: An Update”, 22 June 1993.

53. Vanderbilt University Medical Center, Nashville, TN, Hematology/Oncology

Seminar, “Chronic Lymphocytic Leukemia in the 1990’s: An Update”, 22 July 1993.

54. Nashville Oncology Society, Nashville, TN, “Purine Analogs in Hematologic

Malignancies”, 22 July 1993. 55. University of Medicine and Dentistry of New Jersey, Hematology/Oncology

Seminar, Newark, NJ, “Chronic Lymphocytic Leukemia in the 1990’s: An Update”13 September 1993.

Bruce D. Cheson, M.D. Page 152 Visiting Lectureships (Continued) 56. Tri-state Hematology/Oncology Conference, Evansville, IN, “Chronic Lymphocytic

Leukemia in the 1990’s: An Update”, 16 September 1993. 57. Hematology Seminar, Methodist Hospital, Houston , TX “Chronic Lymphocytic

Leukemia in the 1990’s: An Update”, 22 September 1993. 58. Gulf Coast Hematology Society, Houston, TX, “New Insights Into the Biology and

Therapy of Chronic Lymphocytic Leukemia”, 22 September 1993. 59. Cancer Medicine - 1993 , offered by Harvard University, School of Medicine, Dana

Farber Cancer Institute, Division of Medical Oncology, Boston, MA, “Myelodysplastic Syndromes”, 6 October 1993.

60. Michigan State University, East Lansing, MI, Department of Medicine Grand

Rounds, “Chronic Lymphocytic Leukemia”, 12 October 1993. 61. West Virginia University, Charleston Medical Center, Tumor Board, “Chronic

Lymphocytic Leukemia”, 18 October 1993. 62. Bowman Gray School of Medicine, Winston-Salem, NC, Hematology/Oncology

Seminar, “Chronic Lymphocytic Leukemia: An Overview”, 22 October 1993. 63. St. Joseph’s Hospital, Milwaukee, WI, Department of Medicine Grand Rounds,

“Chronic Lymphocytic Leukemia in the 1990’s”, 27 October 1993. 64. Medical College of Wisconsin, Milwaukee, WI, Hematology/Oncology Seminar,

“Chronic Lymphocytic Leukemia in the 1990’s”, 27 October 1993. 65. Princess Margaret Hospital, Toronto, Canada, Grand Rounds, “Chronic

Lymphocytic Leukemia in the 1990’s”, 10 November 1993. 66. London Regional Cancer Center, London, Ontario, Canada, Hematology Lecture,

“Chronic Lymphocytic Leukemia in the 1990’s”, 10 November 1993. 67. McMaster University Medical Center, Hamilton, Ontario, Canada,

Hematology/Oncology Grand Rounds, “Chronic Lymphocytic Leukemia in the 1990’s”, 11 November 1993.

68. University of Pittsburgh, Montefiore Hospital, Pittsburgh, PA,

Hematology/Lymphoma Seminar, “Chronic Lymphocytic Leukemia in the 1990’s”, 16 November 1993.

69. Mt. Sinai Medical Center, New York, NY, Hematology Seminar, “Chronic

Lymphocytic Leukemia in the 1990’s”, 9 December 1993. 70. Dartmouth/Hitchcock Medical Center, Lebanon, NH, Hematology/Oncology

Seminar, “Chronic Lymphocytic Leukemia in the 1990’s”, 16 December 1993.

Bruce D. Cheson, M.D. Page 153 Visiting Lectureships (Continued) 71. Washington Hospital Center Cancer Institute, Washington, D.C.

Hematology/Oncology Seminar, “New Insights into the Biology and Therapy of Indolent Non-Hodgkin’s Lymphomas”, 7 January 1994.

72. Overlook Hospital, Summit, NJ, Department of Medicine Grand Rounds, “Chronic

Lymphocytic Leukemia in the 1990’s”, 14 January 1994. 73. Tufts-New England Medical Center Hospital, Boston, MA, Hematology/Oncology

Grand Rounds, “Chronic Lymphocytic Leukemia in the 1990’s: An Update”, 4 February 1994.

74. Franklin Hospital Medical Center, Valley Stream, NY, Hematology/Oncology

Conference, “Chronic Lymphocytic Leukemia in the 1990’s: An Update”, 7 February 1994.

75. University of California at Los Angeles, Hematology/Oncology Seminar, “Chronic

Lymphocytic Leukemia in the 1990’s: An Update”, 16 February 1994. 76. Brigham and Women’s Hospital, Boston, MA, Hematology/Oncology Ground

Rounds, “Chronic Lymphocytic Leukemia in the 1990’s: An Update”, 11 March 1994.

77. Cottage Hospital, Santa Barbara, CA, Hematology/Oncology Seminar, “Chronic

Lymphocytic Leukemia in the 1990’s: An Update”, 19 April 1994. 78. University of British Columbia, Vancouver, B.C., Department of Hematology and

Bone Marrow Transplantation, Clinical Seminar, “Chronic Lymphocytic Leukemia in the 1990’s: An Update”, 16 June 1994.

79. Takoma General Hospital, Takoma, WA., Department of Medicine Grand Rounds,

“Chronic Lymphocytic Leukemia”, 17 June 1994. 80. Emory University Hospital and Clinics, Atlanta, GA, Hematology/Oncology

Seminar, “Recent Advances in Chronic Lymphocytic Leukemia”, 29 June 1994. 81. Howard University Cancer Center, Washington, D.C., “Seminars in Oncology”

lecture series, “Indolent Non-Hodkgin’s Lymphomas”, 8 September 1994. 82. Medical College of Ohio, Toledo, OH, Department of Medicine Grand Rounds,

“Indolent Non-Hodkgin’s Lymphomas”, 10 September 1994. 83. University of Texas, Southwestern Medical Center, Dallas, TX,

Hematology/Oncology Lecture Series, “Indolent Non-Hodkgin’s Lymphomas”, 16 September 1994.

84. Ingalls Memorial Hospital, Harvey, IL, Tumor Board, “Indolent Non-Hodkgin’s

Lymphomas”, 3 October 1994.

Bruce D. Cheson, M.D. Page 154 Visiting Lectureships (Continued) 85. University of South Alabama, Mobile, AL, Department of Medicine, Medical Grand

Rounds, “Indolent Non-Hodkgin’s Lymphomas”, 6 October 1994. 86. Mobile Infirmary, Mobile, AL, Tumor Conference, “Indolent Non-Hodkgin’s

Lymphomas”, 6 October 1994. 87. Manitoba Cancer Treatment and Research Foundation, Manitoba, Winnepeg,

Canada, “Chronic Lymphocytic Leukemia in the 1990’s”, 11 October 1994. 88. Hematology Board Review Course, offered by George Washington University,

Division of Hematology/Oncology, “The Myelodysplastic Syndromes”, 13 October 1994.

89. Princess Margaret Hospital, Toronto, Canada, Department of Medicine Grand

Rounds. “Indolent Non-Hodkgin’s Lymphomas”, 19 October 1994. 90. City-wide Tumor Conference, Toronto, Canada, “Chronic Lymphocytic Leukemia in

the 1990’s”, 19 October 1994. 91. Daniel Freeman Memorial Hospital, Inglewoood, CA, Grand Rounds, “Indolent

Non-Hodkgin’s Lymphomas”, 12 December 1994. 92. Cedars/Sinai Medical Center, Los Angeles, CA, Oncology Grand Rounds, “Indolent

Non-Hodkgin’s Lymphomas”, 13 December 1994. 93. Washington Hospital Center Cancer Center, Washington D.C., Oncology

Conference, “Indolent Non-Hodkgin’s Lymphomas”, 14 December 1994. 94. Allegheny General Hospital, Pittsburgh, PA, Hematology/Oncology Grand Rounds,

“Indolent Non-Hodkgin’s Lymphomas”, 21 December 1994. 95. Maimonides Medical Center, Brooklyn, New York, Department of Medicine Grand

Rounds, “Indolent Non-Hodkgin’s Lymphomas”, 11 January 1995. 96. Princeton Medical Center, Princeton, New Jersey, Department of Medicine Grand

Rounds, “Indolent Non-Hodkgin’s Lymphomas”, 17 January 1995. 97. Henry Ford Hospital, Detroit Michigan, Hematology/Oncology Conference,

“Indolent Non-Hodkgin’s Lymphomas”, 20 January 1995. 98. Strong Memorial Hospital, University of Rochester, Rochester, New York,

Oncology Seminar, “Indolent Non-Hodkgin’s Lymphomas”, 24 January 1995. 99. Brookdale Hospital Medical Center, Brooklyn, New York, Department of Medicine

Grand Rounds, “Indolent Non-Hodkgin’s Lymphomas”, 1 February 1995. 100. Portsmouth Naval Medical Center, Portsmouth, VA, Department of Medicine Grand

Rounds, “Indolent Non-Hodkgin’s Lymphomas”, 10 February 1995.

Bruce D. Cheson, M.D. Page 155 Visiting Lectureships (Continued) 101. Walt Disney Memorial Cancer Center, Orlando, FL, Hematology/Oncology

Seminar, “Indolent Non-Hodkgin’s Lymphomas”, 16 February 1995. 102. University of Pennsylvania, Philadelphia, PA, Hematology/Oncology Seminar,

“Indolent Non-Hodkgin’s Lymphomas”, 22 February 1995. 103. Society of Utah Medical Oncologists, Salt Lake City, UT, Guest Lecture Series,

“Indolent Non-Hodkgin’s Lymphomas”, 24 February 1995. 104. Lenox Hill Hospital, New York, NY, Hematology/Oncology Seminar, “Indolent Non-

Hodkgin’s Lymphomas”, 28 February, 1995. 105. Dalhousie University, Halifax, Nova Scotia, Canada, Hematology/Oncology Guest

Lecture, “Indolent Non-Hodkgin’s Lymphomas”, 9 March, 1995. 106. Dalhousie University, Halifax, Nova Scotia, Canada, Hematology/Oncology Grand

Rounds, “Chronic Lymphocytic Leukemia in the 1990’s”, 10 March 1995. 107. University of Connecticut, Farmington, CT, Department of Medicine Grand

Rounds, “Indolent Non-Hodkgin’s Lymphomas”, 15 March, 1995. 108. Holy Cross Hospital, Fort Lauderdale, FL, Oncology Tumor Board, “Indolent Non-

Hodkgin’s Lymphomas”, 16 March, 1995. 109. Albany Veterans Administration Hospital, Albany, NY, Hematology Conference,

“Indolent Non-Hodkgin’s Lymphomas”, 11 May, 1995. 110. Good Samaritan Hospital, San Jose, CA, Department of Medicine Grand Rounds,

“Indolent Non-Hodgkin’s Lymphomas”, 13 June 1995. 111. University of Chicago, Division of Hematology/Oncology Seminar, Chicago, IL,

“Indolent Non-Hodgkin’s Lymphomas”, 19 June 1995. 112. Providence Hospital, CME Conference, Washington, D.C., “Breast Cancer - Myths

and Reality”, 22 June 1995. 113. University Hospital, Staten Island, NY, Advances in Oncology Lecture Series,

“Indolent Non-Hodgkin’s Lymphomas”, 28 June 1995. 114. University of Southern California, Los Angeles, CA, Hematology Lecture Series,

“Indolent Non-Hodgkin’s Lymphomas”, 7 July 1995. 115. Monterey Peninsula Hospital, Monterey, CA, Hospital Grand Rounds, “Indolent

Non-Hodgkin’s Lymphomas”, 2 August 1995. 116. North Arundel Hospital, Glen Burnie, MD, Hospital Grand Rounds, “Indolent Non-

Hodgkin’s Lymphomas”, 14 September 1995.

Bruce D. Cheson, M.D. Page 156 Visiting Lectureships (Continued) 117. Windsor Regional Cancer Clinic, Windsor, Ontario, Canada, Hematology/Oncology

Seminar, “Indolent Non-Hodgkin’s Lymphomas”, 27 September 1995. 118. Hôtel-Dieu de Québec, Québec City, Canada, Hematology/Oncology Seminar.

“Autologous Stem Cell Transplantation for Indolent Non-Hodgkin/s Lymphomas”, 28 September 1995.

119. Québec City Regional Cancer Meeting, Québec CIty, Canada, “Indolent Non-

Hodgkin’s Lymphomas”, 28 September 1995. 120. Hôpital St. Sacrament, Québec CIty Canada, “Autologous Stem Cell

Transplantation for Indolent Non-Hodgkin/s Lymphomas”, 29 September 1995. 121. Oncology Board Review Course, offered by George Washington University,

Division of Hematology/Oncology, “Non-Hodgkin’s Lymphomas”, Fairfax, VA, 9 October 1995.

122. Cedars Hospital, Miami, FL, Department of Medicine Conference, “Indolent Non-

Hodgkin’s Lymphomas”, 13 October 1995. 123. Mercy Hospital, Miami, FL, Tumor Board, “Indolent Non-Hodgkin’s Lymphomas”,

13 October 1995. 124. Christ Hospital, Cincinatti, OH, Medical Grand Rounds, “Indolent Non-Hodgkin’s

Lymphomas”, 14 December 1995. 125. Kettering Medical Center, Dayton OH, Tumor Board, “Indolent Non-Hodgkin’s

Lymphomas”, 14 December 1995. 126. Washington Hospital Center Cancer Institute, Washington, D.C., “Indolent Non-

Hodgkin’s Lymphomas and Chronic Lymphocytic Leukemia”, 15 December 1995. 127. University of Washington, Seattle, WA, Oncology Grand Rounds, “Indolent Non-

Hodgkin’s Lymphomas”, 9 February 1996. 128. Fairfax Hospital, Fairfax, VA, Department of Medicine Grand Rounds, “Non-

Hodgkin’s Lymphomas”, 13 February 1996. 129. St. Louis University, St. Louis, MO, Lymphoma Conference, “Indolent Non-

Hodgkin’s Lymphomas”, 28 February 1996. 130. Boone Hospital, Colombia, MO, Tumor Board, “Indolent Non-Hodgkin’s

Lymphomas, 28 February 1996. 131. Washington University, Barnes Hospital, St. Louis, MO, Leukemia/Lymphoma

Conference, “Indolent Non-Hodgkin’s Lymphomas”, 28 February 1996. 132. Reading Blood Club, Reading, PA, “Indolent Non-Hodgkin’s Lymphomas and

Chronic Lymphocytic Leukemia”, 12 March 1996.

Bruce D. Cheson, M.D. Page 157 Visiting Lectureships (Continued) 133. Northeastern Regional Cancer Center, Hematology/Oncology Seminar, Ontario,

Canada, “Indolent Non-Hodgkin’s Lymphomas”, 10 May 1996. 134. Providence Hospital, Seattle WA, Medical/Surgical Conference, “Indolent Non-

Hodgkin’s Lymphomas”, 11 June 1996. 135. Georgetown University, Lombardi Cancer Center, Oncology Grand Rounds,

“Indolent Non-Hodgkin’s Lymphomas”, 19 June 1996. 136. Albert Einstein Cancer Center, Oncology Grand Rounds, “Indolent Non-Hodgkin’s

Lymphomas”, 26 June 1996. 137. Northshore University Hospital, Manhasset, NY, Hematology/Oncology Grand

Rounds, “Indolent Non-Hodgkin’s Lymphomas”, 12 September 1996. 138. Methodist Hospital of Thomas Jefferson University, Philadelphia, PA, Department

of Medicine Grand Rounds, “Indolent Non-Hodgkin’s Lymphomas”, 17 September 1996.

139. Kansas City Round Table of Hematology/Oncology, Kansas City, MO, “Indolent

Non-Hodgkin’s Lymphomas”, 19 September 1996. 140. Coney Island Hospital, Department of Medicine Grand Rounds, Coney Island, NY,

“Indolent Non-Hodgkin’s Lymphomas”, 3 October 1996. 141. Royal Victoria Hospital, Hematology Seminar, Montreal, Canada, “Chronic

Lymphocytic Leukemia: Biology and Therapy”, 3 October 1996. 142. Hospital Notre Dame, Hematology Conference, Montreal, Canada, “Chronic

Lymphocytic Leukemia: Biology and Therapy””, 4 October 1996. 143. Hôtel Dieu, Hematology Seminar, Montreal, Canada, “Chronic Lymphocytic

Leukemia: Biology and Therapy”, 4 October 1996. 144. Hospital Maison-Neuve-Rosemont, Monbtreal, Canada, “Chronic Lymphocytic

Leukemia: Biology and Therapy”, 3 October 1996. 145. University of Iowa, Hematology/Oncology Grand Rounds, “Indolent Non-Hodgkin’s

Lymphomas”, 9 October 1996. 146. Hoag Memorial Hospital, Laguna Beach, CA, Medical Staff Grand Rounds,

“Indolent Non-Hodgkin’s Lymphomas”, 24 October 1996. 147. George Washington University, Washington, D.C., Tumor Board, “Indolent Non-

Hodgkin’s Lymphomas”, 20 December 1996. 148. Portland Hematology Oncology Conference, Portland, OR, “Indolent Non-

Hodgkin’s Lymphomas”, 22 January 1997.

Bruce D. Cheson, M.D. Page 158 Visiting Lectureships (Continued) 149. City of Hope National Medical Center, Duarte, CA, Hematology Conference, “New

Drugs for Non-Hodgkin’s Lymphomas”, 6 February 1997. 150. Emory University, Hematology/Oncology Conference, Atlanta, GA, “Indolent Non-

Hodgkin’s Lymphomas”, 5 March 1997. 151. Tom Baker Cancer Center, Calgary, Canada, “Recent Advances in the Treatment

of Chronic Lymphocytic leukemia”, 12 March 1997. 152. Royal University Hospital, Saskatoon, Canada, “Recent Adances in the Biology

and Treatment of Chronic Lymphocytic Leukemia”, 12 March 1997. 153. Hematology Seminar, Regina, Canada, “Recent Advances in the Treatment of

Chronic Lymphocytic Leukemia”, 12 March 1997. 154. Lawrence Hospital, Bronxville, NY, Hospital Grand Rounds. “Indolent Non-

Hodgkin’s Lymphomas”, 8 April 1997. 155. University of Wisconsin, Madison, WI, Cancer Center Grand Rounds, “Indolent

Non-Hodgkin’s Lymphomas”, 23 April, 1997. 156. Cancer Medicine and Hematology 1997. Hematology and Oncology Board Review

Course, sponsored by Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Massachusetts General Hospital. “Chronic Lymphocytic Leukemia and Lymphoplasmacytic Disorders”, 23 September, 1997.

157. “Advances in Hematologic Malignancies”, Department of Medicine Grand Rounds,

Long Island Jewish Hospital, New Hyde Park, NY, 18 September 1998. 158. University of California, San Diego/American Cancer Society Lecture, “Current

Therapeutic Options in the Management of Indolent B-Cell Malignancies”, La Jolla, CA, 1 March 1999.

159. Toledo Hospital, Department of Medicine Grand Rounds. “Current Therapeutic

Options in the Management of Indolent B-Cell Malignancies”, Toledo, OH, 4 March 1999.

160. Halifax Hospital, Tumor Board. “Current Therapeutic Options in the Management

of Indolent B-Cell Malignancies”, Daytona, FL, 6 October 1999. 161. University of South Carolina Cancer Center, Hematology-Oncology Grand Rounds.

“New Therapeutic Options in the Management of Indolent B-Cell Malignancies”, Columbia, South Carolina, 6 March 2000.

162. University of Miami, Sylvester Cancer Center, Hematology Conference. “New

Therapeutic Options in the Management of Indolent Non-Hodgkin’s Lymphomas”, Miami, FL 29 March 2000.

Bruce D. Cheson, M.D. Page 159 Visiting Lectureships (Continued) 163. Howard University Cancer Center, Seminars in Oncology. “New Therapeutic

Options in the Management of Indolent Non-Hodgkin’s Lymphomas”, Washington, D.C., 19 April 2000.

164. Methodist Hospital, Oncology Grand Rounds, “New Therapeutic Options in the

Management of Indolent Non-Hodgkin’s Lymphomas”, Houston, TX, 26 July 2000. 165. M.D. Anderson Cancer Center, “New Drugs for the Management of NonHodgkin’s

Lymphomas”, Houston, TX, 26 July 2000. 166. Washington Hospital Center, Hematology/Oncology Grand Rounds. “New

Therapeutic Options in the Management of Indolent Non-Hodgkin’s Lymphomas”, Washington, D.C., 28 August 2000.

167. New York University, Hematology/Oncology Grand Rounds. “New Therapeutic

Options in the Management of Non-Hodgkin’s Lymphomas”, New York, NY, 6 September 2000.

168. Klinikum der Universität München, Hematology Grand Rounds. “New Therapeutic

Options in the Management of Non-Hodgkin’s Lymphomas”. Munich, Germany, 21 September 2000.

169. Akron General Hospital, James M. Perelman Visiting Professorship, “Monoclonal

Antibodies in the Treatment of Hematologic Malignancies”, Akron, OH, 11 October 2000.

170. University of Nebraska Lymphoma Study Group. “New Therapies for Indolent

Lymphomas and CLL”, Omaha, NE 19 January 2001. 171. Mt. Diablo Medical Center. “Immunotherapy for Non-Hodgkin’s Lymphoma in the

New Millennium”, Concord, CA, 25 January 2001. 172. University of California at San Francisco, Hematology/Oncology Grand Rounds.

“Immunotherapy for Non-Hodgkin’s Lymphoma in the New Millennium”, San Francisco, CA, 26 January 2001.

173. Memorial Sloan-Kettering Cancer Center, Department of Medicine Grand Rounds.

“New Agents for Non-Hodgkin’s Lymphomas”, New York, NY, 30 March 2001. 174. Northwestern University Cancer Center, Hematology Rounds. “Current

Approaches to the Treatment of Chronic Lymphocytic Leukemia”, Chicago, IL, 10 April 2001.

175. John Muir Cancer Center. “New Therapies for Indolent Non-Hodgkin’s

Lymphoma”, Walnut Creek, CA,13 April 2001. 176. Seventh Annual Jaffar Oncology Conference, “Innovative Therapies for CLL”,

Southfield, MI, 28 September 2001.

Bruce D. Cheson, M.D. Page 160 Visiting Lectureships (Continued) 177. Duke University Hematology/Oncology Seminar. “Emerging Therapies for Non-

Hodgkin’s Lymphomas”. Durham, NC, 8 November 2001. 178. Oncology Society of New Jersey. “Expanding Options in the Treatment of Indolent

B-cell Malignancies”. Princeton, NJ, 15 January 2002. 179. Medical Grand Rounds, Roswell Park Cancer Center. “New Therapies for Non-

Hodgkin’s Lymphomas:, Buffalo, NY, 18 January 2002. 180. Department of Internal Medicine Grand Rounds. East Virginia Medical School.

“Monoclonal Antibody Therapy of Non-Hodgkin’s Lymphomas”. Norfolk, VA, 10 April 2002.

181. Cancer Center Grand Rounds, Cleveland Clinic Foundation. “Emerging Therapies

for Indolent Non-Hodgkin’s Lymphomas”, Cleveland, OH, 10 May 2002. 182. Hematology/Oncology Grand Rounds, Dartmouth-Hitchcock Medical Center.

“Emerging Therapies for Indolent Non-Hodgkin’s Lymphomas: The Role of Radioimmunotherapy”. Dartmouth, NH, 23 May 2002.

183. University of Pittsburgh Cancer Center Grand Rounds. “Emerging Therapies for

Non-Hodgkin’s Lymphomas”, 30 May 2002. 184. University of Virginia, Hematology/Oncology Grand Rounds, “Expanding Options in

the Treatment of Indolent B-cell Malignancies”. Charlottesville, VA, 21 June 2002. 185.University of Rochester, Cancer Center Grand Rounds, “Expanding Options in the

Treatment of Indolent B-cell Malignancies”, Rochester, NY, 24 June 2002. 186. S.U.N.Y. Syracuse, Regional Oncology Center, Hematology-Oncology Grand

Rounds, “Emerging Therapies for Indolent B-Cell malignancies”, Syracuse, NY, 17 October 2002.

187. Leukemia and Lymphoma Society, ASH Reviews, “Indolent Non-Hodgkin’s

Lymphomas”, Pittsburgh, PA, 31 January 2003. 188. Leukemia and Lymphoma Society, ASH Reviews, “Aggressive Non-Hodgkin’s

Lymphomas”, Pittsburgh, PA, 31 January 2003 189. Leukemia and Lymphoma Society ASH Reviews, “Chronic Lymphocytic

Leukemia”, Pittsburgh, PA, 31 January 2003. 190. Brooke Army Medical Center, Hematology/Oncology Grand Rounds, “Treatment of

Aggressive Lymphomas’, San Antonio, TX, 7 March 2003. 191. Fairfax Hospital, Department of Medicine Grand Rounds, “New Approaches to the

Treatment of Non-Hodgkin’s Lymphomas”, Fairfax, VA, 18 March 2003.

Bruce D. Cheson, M.D. Page 161 Visiting Lectureships (Continued) 192. Maimonides Medical Center, Department of Medicine Grand Rounds, “Monoclonal

Antibody Therapy of Hematologic Malignancies”, Brooklyn, NY, 19 March 2003. 193. Maimonides Medical Center, Hematology/Oncology Grand Rounds, “Non-

Hodgkin’s Lymphoma and CLL:ASH Updatees”, Brooklyn, NY, 19 March 2003. 194. Leukemia and Lymphoma Society, Patient Education Program, “Clinical Trials and

New Advances in Leukemias and Lymphomas”, Uniondale, NY, 19 March 2003. 195. Washington Hospital Center, Cancer Center Research Conference, “New

Approaches to the Treatment of Non-Hodgkin’s Lymphomas”, Washington, D.C., 14 April 2003.

196. Emory University, Winship Cancer Center, Hematology/Oncology Grand Rounds.

“New Approaches to Indolent B-cell Malignancies”, Atlanta, GA, 30 April 2003. 197. West Virginia University, David Lee Medical Center, Didactic Tumor Board. “New

Therapeutic Approaches for Indolent B-cell Malignancies”, Charleston, WV, 6 June 2003.

198. University of Louisville, James Brown Cancer Center, Hematology Seminar, “New

Treatment Approaches for Chronic Lymphocytic Leukemia”, Louisville, KY, 20 June 2003.

199. The Valley Hospital Cancer Center, An Update on the Classification and

Management of Lymphoma and Multiple Myeloma, “Update on the Management of CLL and the Indolent Lymphomas”, Ridgewood, NJ, 15 October 2003.

200. The Ohio State University, Hematology/Oncology Grand Rounds, “New Drugs in

Lymphoma”, 19 Dec 2003. 201. West Virginia University, David Lee Medical Center, Tumor Board, “Current

Approaches to the Treatment of Chronic Lymphocytic Leukemia”, 2 April 2004. 202. University of Oklahoma, ASCO Review, “Non-Hodgkin’s Lymphoma”, 25 June

2004. 203. University of Rochester, Wilmot Cancer Center, “CLL: Progress Over the Past 25

Years”, Hematology/Oncology Grand Rounds, 1 November 2004. 204. Wayne State University, Karmanos Cancer Center, Hematology/Oncology Grand

Rounds, “Advances in the Treatment of Indolent Lymphoid Malignancies”, 18 November 2004, Detroit, MI.

205. Emory University, Winship Cancer Center, Hematology/Oncology Grand Rounds,

“Advances in the Treatment of Indolent Lymphoid Malignancies”, 5 January 2005, Atlanta, GA.

Bruce D. Cheson, M.D. Page 162 Visiting Lectureships (Continued) 206. Monmouth Hematology-Oncology Associates, “Advances in Chronic Lymphocytic

Leukemia”, 21 April 2005, West Long Branch, New Jersey. 207. East Orange Veterans Administration Hospital. Hematology/Oncology Grand

Rounds, “CLL: Advances Over the Past 25 Years”, East Orange, NJ, 25 May 2005.

208. New York Hospital of Flushing, Guest Lecture Series, “CLL: Advances Over the

Past 25 Years”, East Flushing, NY, 25 May 2005. 209. Broward Medical Center, Cancer Center Grand Rounds, “CLL: Advances Over the

Past 25 Years”, Ft. Lauderdale, FL, 16 August 2005. 210. Virginia Commonwealth University, Massey Cancer Center, Hematology/Oncology

Grand Rounds. “New Approaches To The Treatment of Follicular Lymphomas”, Richmond, VA, 18 October 2005.

211. Washington Hospital Center Cancer Institute, Hematology/Oncology Grand

Rounds, “New Drugs in Lymphoma”, Washington, D.C., 9 June 2006. 212. Pennsylvania Hematology/Oncology Associates. “CLL: The Role of Minimal

Residual Disease”, Philadelphia, PA, 22 June 2006. 213. Cancer Education Consortium, Clinical Pharmacology of Anticancer Agents,

“Monoclonal Antibodies”. Leesburg, VA, 16 October 2006. 214. Montgomery General Hospital, Medical/Surgical Grand Rounds, “B-cell

Malignancies”, Olney, MD, 9 November 2006. 215. Howard University Cancer Center, “Seminars in Oncology”. “B-cell Malignancies:

Focus on Follicular NHL”, Washington, D.C., 14 December 2006. 216. Halifax Medical Center, Hematology/Oncology Grand Rounds. “Diffuse Large B-

Cell Lymphomas: 2007”, Daytona Beach, FL, 10 January 2007. 217. British Columbia Cancer Agency-sponsored seminar. “How Do We Sequence

Available Tretment Options in Chronic Lymphocytic Leukemia”, Vancouver, British Columbia, Canada, 7 May 2007.

218. British Columbia Cancer Agency, “New Drugs on the Horizon in Non-Hodgkin’s

Lymphoma”, Vancouver, British Columbia, 8 May 2007. 219. LyFE Symposium, “Optimal management of Chronic Lymphocytic Leukemia”,

Vancouver, British Columbia, 9 May 2007. 220. Georgetown University Hospital, Department of Medicine Grand Rounds,

“Monoclonal Antibody Therapy of Non-Hodgkin’s Lymphomas”, 12 July 2007. 221. Cancer Education Consortium’s 15th Annual Pharmacology of Anti-Cancer Agents,

“Monoclonal Antibodies”, Leesburg, VA, 15 October 2007.

Bruce D. Cheson, M.D. Page 163 Visiting Lectureships (Continued) 222. Continuing Medical Education Seminar, UPMC, New Approaches to Relapsed and

Refractory Follicular Lymphoma, Uniontown, PA, 3 April 2008. 223. Update on B-cell Lymphomas. Chambersburg Hospital Grand Rounds,

Chambersburg, PA, 2 May 2008. 224. New Drugs for the Treatment of Chronic Lymphocytic Leukemia. CME Program,

Washington, D.C., 21 May 2008. 225. New Approaches to the Treatment of Chronic Lymphocyic Leukemia. Columbia

University, Hematology/Oncology Seminar, New York, NY, 22 May 2008. 226. New Approaches to the Treatment of Chronic Lymphocytic Leukemia, CME

Program, Charlottesville, VA, 10 July 2008. 227. New Approaches to the Treatment of Chronic Lymphocytic Leuykemia, CME

Program, San Jose, CA, 16 July 2008. 228. New Approaches to the Treatment of Chronic Lymphocytic Leukemia, CME

Program, San Francisco, CA, 17 July 2008. 229. PET Scans in Lymphoma. University Hospital Fleurimont, Sherbrooke, Quebec,

Canada, 4 September 2008. 230. PET Scans in Lymphoma. Dinner conference, Quebec City, Quebec, Canada, 4

September 2008. 231. PET Scans in Lymphoma. Hôpital Charles-Lemoyne, Hematology Grand Rounds,

Montreal, Canada, 5 September 2008. 232. New Treatments for Relapsed and Refractory Follicular Lymphomas. Delaware

Society of Clinical Oncology, Milford, DR, 25 September 2008. 233. Emerging Treatment Paradigms in the Management of CLL. Cooper Cancer

Center, Voorhees, NJ, 26 September 2008. 234. Cancer Education Consortium’s 15th Annual Pharmacology of Anti-Cancer Agents,

“Monoclonal Antibodies”, Leesburg, VA, 13 October 2008. 235. Lymphoma Update 2008, Holy Cross Hospital Grand Rounds, Silver Spring, MD,

11 October, 2008. 236. PET Scans in Lymphoma, Ottawa General Hospital, Ottawa, Ontario, Canada, 23

January 2009. 237. PET Scans in Lymphoma, Mount Stephen’s Club, Montreal, Canada, 23 January

2009. 238. PET Scans in Lymphoma and Visiting Professorship, Walter Reed Army Medical

Center, Washington DC, 6 March 2009.

Bruce D. Cheson, M.D. Page 164 Visiting Lectureships (Continued) 239. Therapy for Relapsed and Refractory Follicular Lymphoma, Hospital Grand

Rounds, Laurel Regional Hospital, Laurel, MD, 9 April 2009. 240. PET Scans in Lymphoma. Queens University, Cancer Research Institute,

Kinsgton, Ontario, Canada, 23 April 2009. 241. Pet Scans in Lymphoma, CME Lecture, Missisagua, Ontario, Canada, 23 April

2009. 242. PET Scans in Lymphoma, Princess Margaret Hospital, Hematology-Oncology

Grand Rounds, 24 April 2009. 243. Non-Hodgkin’s Lymphoma and Hodgkin’s Lymphoma: An Update. Leukemia and

Lymphoma Society Patient Education Meeting, Virginia Hospital Center, Arlington, VA, 29 April 2010.

244. Cancer Education Consortium’s 1st Annual Merrill Egorin Memorial Workshop on

Cancer Pharmacology, “Monoclonal Antibodies”, Leesburg, VA, 13 September 2010.

245. Is PET in Lymphoma the Emperor of all Modalities? George P. Canellos Honorary

Lectureship, Dana Farber Cancer Institute, 12 May 2011. 246. Targeting T-cell Lymphomas: Current Challenges, Recent Findings, and Emerging

Treatment Options. Howard University Cancer Center, Washington, D.C. 5 March 2012.

247. Cheson’s Rule of New Drug Development, Visiting Lecturer Series, Genentech Biooncology, San Francisco, CA, 9 March 2012.

248. New Treatments in Relapsed and Refractory Peripheral T-cell Lymphoma. T-Cell Expert Forum, Stockholm, Sweden, 20 March 2012.

249. New Treatments in Relapsed and Refractory Peripheral T-cell Lymphoma. Hematology-Oncology Conference, Rigshospitalet, Copenhagen, Denmark, 21 March 2012.

250. Clinical Trials and Tribulations: Cheson’s Rule of New Drug Development. Celgene, Summit, NJ, 24 September 2012.

251. Cancer Education Consortium’s 3rd Annual Merrill Egorin Memorial Workshop on Cancer Pharmacology, “Monoclonal Antibodies”, Leesburg, VA, 8 October 2012.

252. 9th Annual Mary Miklos Chupp Lecture, Tufts Cancer Center and Tufts University School of Medicine. “The Case Against Chemotherapy in Lymphoid Malignancies”. Boston, MA, 25 October 2012.

253. Change of Treatment Paradigm for Indolent Lymphoma: What is New? Croydon University Hospital, London, England, 1 November 2012.

Bruce D. Cheson, M.D. Page 165 Visiting Lectureships (Continued) 254. Change of Treatment Paradigm for Indolent Lymphoma: What is New? Royal

Society of Medicine, London England, 1 November 2012.

255. Response Criteria and Follow-up in Lymphoma. European School of Oncology, Ulm University, Certificate of Competence in Lymphoma, e-learning module, December, 2012 for 14 months.

256. Fondazione Italiana Linfomi – La Cantera – Milestones in Lymphoma, Modena, Italy, 5 March 2013.

257. Fondazione Italiana Linfomi – La Cantera – Current Standard Treatments for Malignant Lymphoma, Modena, Italy, 5 March 2013.

258. Fondazione Italiana Linfomi – La Cantera – New Drugs for Lymphoma, Modena, Italy, 5 March 2013.

259. Fondazione Italiana Linfomi – La Cantera – Harmonisation of Methods for Clinical Research in Lymphoma, Modena, Italy, 5 March 2013.

260. Fondazione Italiana Linfomi – La Cantera – How To Turn From Clinical Research to Clinical Practice, Modena, Italy, 6 March 2013.

261. Fondazione Italiana Linfomi – La Cantera – Response Criteria in Lymphoma, Modena, Italy, 6 March 2013.

262. Fondazione Italiana Linfomi – La Cantera – Case Presentations in Lymphoma, Modena, Italy, 6 March 2013.

263. The Use of PET Scans in Lymphoma, Hematology-Oncology Conference, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, 7 March 2013.

264. Chemotherapy for Follicular Lymphoma: The End Is In Sight. Department of Medicine Grand Rounds, Rochester General Hospital, Rochester, NY, 2 May 2013.

265. Chemotherapy for Follicular Lymphoma: The End Is In Sight. NCRI-UK Lymphoma Clinical Trials Group Meeting, Michael Bennett Memorial Lecture. London, England, 25 October 2013.

266. Case Studies in Lymphoma. St. James University Hospital, Leeds Cancer

Center, Leeds, England, 19 November 2013.

267. Advances in the Management of Follicular Lymphoma. Kingston Hospital, Kingston, England, 20 November 2013.

268. Lymphoma Case Studies. Royal Society of Medicine, London, England, 20 November 2013.

269. Lymphoma: Is Chemotherapy Dead? Georgetown University Department of Medicine Grand Rounds, 6 November 2014.

Bruce D. Cheson, M.D. Page 166 Visiting Lectureships (Continued) 270. Follicular Lymphoma: Is Chemotherapy Dead? Keynote Speaker, Weber

Lymphoma Lecture, Raleigh, NC, 11 December 2014.

271. Update on Lymphoma. Raleigh, NC, 12 December 2014. 272. Response Criteria and Follow-up in Lymphoma. European School of Oncology,

Ulm University, Certificate of Competence in Lymphoma, e-learning module, January, 2015.

273. Evaluation and Publication of Clinical Trials. European School of Oncology, Ulm

University, Certificate of Competence in Lymphoma, e-learning module, January, 2015.

274. CLL: Advances in Treatment and an ASH Update. George Washington University

Hematology Updates, Washington, D.C., 21 February 2015. 275. Lenalidomide in Non-Hodgkin Lymphoma. Investigator meeting. Baltimore, MD,

16 April 2015. 276. New Anti-CD20 Antibodies for CLL – Are They Better Than Rituximab? Great

Debates and Updates in Hematologic Malignancies. New York, NY, 17 April 2015. 277. The Role of Kinase Inhibitors for Multiple Relapsed CLL. Great Debates and

Updates in Hematologic Malignancies. New York, NY, 17 April 2015. 278. Single Agent Rituximab or Biological Doublets in the Management of Preiously

Untreated, Symptomatic, Low-Tumor Burden Follicular Lymphoma. Great Debates and Updates in Hematologic Malignancies. New York, NY, 18 April 2015.

279. New Drugs in Lymphoma: Is the End of Chemotherapy Near? Peijing Union

Medical College, Beijing, China, 11 May 2015. 280. Lymphomas 2015. Oncology Nursing Fellowship Lecture. Georgetown University

Hospital. Washington, D.C., 23 October 2015. 281. Case Presentations in Lymphoma and CLL. Sourasky Medical Center,

Hematology Oncology Division. Tel Aviv, Israel, 1 November 2015 282. Case Presentations in Lymphoma and CLL. Assula Medical Center, Hematology

Oncology Division. Tel Aviv, Israel. 1 November 2015. 283. Case Presentations in Lymphoma and CLL. Beillinson Cancer Center.Beillinson,

Israel. 1 November 2015. 284. Response Assessment in Lymphoma. What is New? Oncology Grand Rounds.

King Faisel Specialist Hospital and Research Center. Riyadh, Saudi Arabia 24 April 2016.

285. Emerging Therapies in Indolent Lymphoma. Adult Hematology Grand Rounds.

King Faisel Specialist Hospital and Research Center. Riyadh, Saudi Arabia 24 April 2016.

Bruce D. Cheson, M.D. Page 167 Visiting Lectureships (Continued) 286. Lymphoma and Lymphoproliferative Forum. Case Presentations. Marriott Hotel,

Riyadh, Saudi Arabia 24 April 2016. 287. Response Assessment in Lymphoma. What is New? Oncology Grand Rounds.

King Khalid University Hospital. Riyadh, Saudi Arabia 25 April 2016. 288. B-cell Malignanices: New Therapeutic Strategies for the Practicing Clinician.

Hematology Conference. University of Maryland, Greenbaum Cancer Center. Baltimore, MD, 20 May 2016.

289. CLL/SLL: New Therapeutic Strategies for the Practicing Clinician. Howard

University Faculty. Washington, D.C., 31 May 2016. 290. Follicular Lymphoma: Targeted, Maintained, and Cured. 14th Annual Indy

Hematology Conference (T. Howard Lee Keynote Lecture), Indianapolis, IN, 11 March 2017.

291. Non-Hodgkin Lymphomas: Unmet Needs and the Potential for MOR-208. Munich,

Germany, 25 October 2018. 292. Managing the CLL Patient After Ibrutinib. Lymphoma Research Foundation, D.C.

Rounds. Washington, D.C., 1 November 2018. 293. Making A Lymphoma Diagnosis. Lymphoma Research Foundation Lymphoma

Workshop. Washington, D.C., 10 November 2018. 294. Immunotherapy. Lymphoma Research Foundation Lymphoma Workshop.

Washington, D.C., 10 November 2018. 295. Follicular Lymphoma. Lymphoma Research Foundation Lymphoma Workshop.

Washington, D.C., 10 November 2018. 296. How to Manage and Treat iNHL. Sheik Khalifa Medical Center, Abu Dhabi, UAE,

24 January 2019. 297. CLL In View Of The Latest Updates. Sheik Khalifa Medical Center, Abu Dhabi,

UAE, 24 January 2019. 298. Emerging Strategies In The Tretment of Non-Hodgkin Lymphoma. Meet The

Expert in Hematology. Dubai, UAE, 25 January 2019. 299. Current And Emerging Treatment Standards For Patient With CLL. Meet The

Expert in Hematology. Dubai, UAE, 25 January 2019. 300. Prolonging Progression Free Survival In Follicular Lymphoma. Meet The Expert in

Hematology. Cairo, Egypt, 26 January 2019. 301. Newly Diagnosed CLL: Shared Decision Making. Meet The Expert in Hematology.

Cairo, Egypt, 26 January 2019.

Bruce D. Cheson, M.D. Page 168 Visiting Lectureships (Continued) 302. Tailoring Therapy For Relapsed/Refratctory NHL. Meet The Expert in

Hematology. Cairo, Egypt, 26 January 2019. 303. Prolonging Progression Free Survival In Follicular Lymphoma. Meet The Expert in

Hematology. Beirut, Lebanon, 27 January 2019. 304. Newly Diagnosed CLL: Shared Decision Making. Meet The Expert in Hematology.

Beirut, Lebanon, 27 January 2019. 305. Treatment Strategies for Follicular Lymphoma: Past, Present, Future. Tokyo,

Japan, 12 February 2019. 306. Treatment Strategies for Follicular Lymphoma: Past, Present, Future. Nagoya,

Japan, 13 February 2019. 307. Treatment Strategies for Follicular Lymphoma: Past, Present, Future. Osaka,

Japan, 14 February 2019. 308. Indolent and Hodgkin Lymphomas. 16th Annual Indy Hematology Review (Nurse

presentation). Indianapolis, IN, 9 March 2019. 309. Indolent and Hodgkin Lymphomas: Achieving Curability. 16th Annual Indy

Hematology Review. Indianapolis, IN, 9 March 2019. 310. Recommendations For Staging, Response and Follow-up of Lymphomas.

European School of Oncology Certificate of Competence in Lymphoma, e-learning module, 2019.

311. Evaluation and Publication of Clinical Trials. European School of Oncology

Certificate of Competence in Lymphoma, e-learning module, 2019. 312. NHL Advances. Reddy Lab Investigator Meeting. Rome, Italy, 11 April 2019.

313. The Journey of R2 in Indolent Non-Hodgkin Lymphomas. Celgene Augment

Launch, Keynote Speaker. San Diego, CA, 11 June 2019.

314. Key Updates in the Treatment of Chronic Lymphocytic Leukemia. PCE Oncology Conference. North Bethesda, MD, 5 October 2019.

315. Addressing Current Questions and Controversies in the Management of

Lymphomas and Chronic Lymphocytic Leukemia. 61st American Society of Hematology Annual Meeting, Orlando, FL, 6 December 2019.

316. New Treatments for Relapsed and Refractory Diffuse Large B-cell Lymphoma.

Israeli Hematology Group. 6 July 2020. 317. Response Assessment in Lymphoma, Past, Present and Future. Taimei

Corporation (virtual). 21 November 2020.

Bruce D. Cheson, M.D. Page 169 Visiting Lectureships (Continued) 318. Mantle Cell Lymphoma: Pathogenesis, Biology and Future Directions. George

Washington University, Hematology-Oncology Division Journal Club (virtual). 2 December 2020.

319. Emerging Treatments in the Therapy of R/R Diffuse Large B-cell Lymphoma.

Ascension Providence Hospital, Michigan (virtual). 15 December 2020. 320. Mantle Cell Lymphoma: Pathogenesis, Biology and Future Directions (virtual).

Beigene lecture. 15 December 2020. 321. Emerging Treatments in the Therapy of R/R Diffuse Large B-cell Lymphoma.

University of South Alabama Cancer Center, Mobile, AL (virtual). 16 December 2020.


Christiana Health Care, Christiana, DE (virtual). 17 December 2020. 323. Emerging Treatments in the Therapy of R/R Diffuse Large B-cell Lymphoma.

Medical University of South Carolina, Charleston, SC, Hematology-Oncology Seminar (virtual). 15 January 2021.


Summit Cancer Center, Spokane, WA, Hematology-Oncology Seminar (virtual). 19 January 2021.


Indianapolis Blood & Bone Marrow Group, Indianapolis, IN (virtual). 27 January 2021.

326. Response Criteria and Follow-up in Lymphoma. European School of Oncology,

Ulm University, Certificate of Competence in Lymphoma, e-learning module, February, 2021.

327. Evaluation and Publication of Clinical Trials. European School of Oncology, Ulm

University, Certificate of Competence in Lymphoma, e-learning module, February 2021.

328. Ukoniq: A New Treatment Option for Relapsed/Refractory (R/R) Marinal Zone

Lymphoma and Follicular Lymphoma. Cardinal Health Oncoloy Summit (virtual). 21 February 2021.

329. Ukoniq: A New Treatment Option for Relapsed/Refractory (R/R) Marinal Zone

Lymphoma and Follicular Lymphoma. New England Cancer Specialists (virtual). 23 February 2021.


Karmanos Cancer Institute at McLaren Flint, Flint, MI (virtual). 17 March 2021. 331. Emerging Treatments in the Therapy of R/R Diffuse Large B-cell Lymphoma.

California Cancer Associates for Research and Excellence. 18 March 2021.

Bruce D. Cheson, M.D. Page 170 Visiting Lectureships (Continued) 332. Follicular Lymphoma: An Introductory Overview, Standard of Care, and

Therapeutic Landscape. Beigene Corp. 25 March 2021. 333. Ukoniq: A New Treatment Option for Relapsed/Refractory (R/R) Marginal Zone

Lymphoma and Follicular Lymphoma. Texas Oncology (virtual). 30 March 2021. 334. Emerging Treatments in the Therapy of R/R Diffuse Large B-cell Lymphoma. St.

Joseph Mercy Health System, Michigan (virtual). 7 April 2021. 335. The Road to a Chemo-free World. Pioneer in Oncology Lecture, IJCR, 21 April

2021. 336. Emerging Treatments in the Therapy of R/R Diffuse Large B-cell Lymphoma.

Marshfield Clinic, WI (virtual). 28 April 2021. 337. The Road To A Chemo-Free World in Hodgkin Lymphoma. TessaCell Corp, 29

April 2021. 338. Mantle Cell Lymphoma: Pathogenesis, Biology and Future Directions. Fox Chase

Cancer Center, Philadelphia, PA (virtual), 3 May 2021. 339. Marginal Zone Lymphoma: A Primer. Beigene Corporation. 6 May 2021.

340. Monjuvi (tafasitamab-cxix) for Use as Second-Line Therapy in Adult Patients with R/R DLBCL, in Combination with Lenalidomide. Redding, CA (virtual), 19 May 2021.

341. Ukoniq: A New Treatment Option for Relapsed/Refractory (R/R) Marginal Zone Lymphoma and Follicular Lymphoma. Indianapolis, IN (virtual), 23 June 2021.


Green Bay Oncology Associates (Virtual). 9 July 2021. 343. Ukoniq: A New Treatment Option for Relapsed/Refractory (R/R) Marginal Zone

Lymphoma and Follicular Lymphoma. Dallas, TX (virtual), 28 July 2021.

Bruce D. Cheson, M.D. Page 171 Visiting Lectureships (Continued)


Meetings/Sessions Coordinated/Chaired 1. Suramin in the Treatment of AIDS and Related Illnesses. NCI, 5 November 1984. 2. National Cancer Institute Meeting on Suramin Trials. NIH, 7 October 1985. 3. Autologous Bone Marrow Transplantation Workshop. NCI, 10 April 1985. 4. Anti-viral Therapy in AIDS. NCI, 7 October 1985. 5. National Priorities for the Treatment of Aggressive Non-Hodgkin's Lymphomas.

NCI, 8 January 1986. 6. Workshop on Cutaneous T-Cell Lymphomas. NCI, 27 January 1986. 7. Workshop on Hairy Cell Leukemia II. NCI, 19 March 1986. 8. Workshop on Anti-Viral Agents in AIDS. INSERM, Paris, France, 13-14 March

1986. 9. National Strategy Meeting on Chronic Lymphocytic Leukemia. NCI, 17 April 1987. 10. Adult Leukemia and Lymphoma. American Society of Clinical Oncology, New

Orleans, LA, 24 May 1988. 11. Workshop on Diagnostic and Response Criteria in Acute Myeloid Leukemia. NCI,

26 August 1988. 12. Treatment Strategies for Kaposi's Sarcoma: Chemotherapy and the Treatment of

Kaposi's Sarcoma. Bethesda, MD, 4 October 1988. 13. National Strategy Meeting on Multiple Myeloma. NCI, 21 February 1989. 14. Future Directions in Biologic and Therapeutic Research in Multiple Myeloma.

Second International Workshop on Myeloma: Advances in Biology and Therapy. Houston, TX, 8 April 1989.

15. Workshop on Autologous Marrow Transplantation for Acute Myeloid Leukemia.

NCI, 11 May 1989. 16. NCI-sponsored National CLL Working Group, San Francisco, CA, 21 May 1989. 17. ASCO Educational Symposium - "Chronic Lymphocytic Leukemia - 1992",

American Society of Clinical Oncology Annual Meeting, Washington, D.C., 20 May 1990.

18. NCI-Sponsored CLL Working Group. NCI, 8 August 1990.

Bruce D. Cheson, M.D. Page 173 19. Educational symposium in conjunction with the American Society of Hematology

Annual Meeting - "Chronic Lymphocytic Leukemia: New Therapies and Future Prospects", Boston, MA, 30 November 1990.

20. Workshop on Biological Aspects of All-trans Retinoic Acid. National Cancer

Institute, 25 March 1991. 21. NCI/INSERM Conference on "The Use of Interleukin-2 in Hematologic

Malignancies". Bethesda, MD, 12-13 September 1991. 22. ASCO Educational Symposium - "Chronic Lymphocytic Leukemia: New

Perspectives on Biology and Therapy", American Society of Clinical Oncology Fall Meeting, Miami, FL, 9 November 1991.

23. AIDS Clinical Trials Group Meeting on HIV-associated lymphomas. Washington,

D.C., 4 December 1991. 24. Workshop on Multi-drug Resistance in Acute Myeloid Leukemia, National Cancer

Institute, Bethesda, MD, 30 March 1992. 25. Adult Leukemia and Lymphoma, American Society of Clinical Oncology, San

Diego, CA, 18 May 1992. 26. Educational symposium in conjunction with the American Society of Hematology

Annual Meeting - “New Concepts in the Biology and Therapy of Indolent B-cell Non-Hodgkin’s Lymphomas”, Anaheim, CA, 4 December 1992.

27. Leukemia slide presentations, American Society of Hematology, Anaheim, CA, 7

December 1992. 28. National Strategy Meeting on New Directions in the Therapy of Intermediate Grade

Non-Hodgkin’s Lymphomas, Bethesda, MD, 24 February 1993. 29. Myelodysplastic Syndromes/Chronic Lymphocytic Leukemia/Hairy Cell

Leukemia/Macroglobulinemia - “Leukemia: The Next Questions”, Houston, Texas, 25 March 1993.

30. Myeloproliferative Disorders and Myelodysplastic Syndromes: A Clinical Update.

Hilton Head, SC, 18-19 June 1993. 31. Consensus Conference on Chronic Lymphocytic Leukemia, Amelia Island, FL, 19-

20 February 1994. 32. “Hematologic Malignancies...New Strategies and Targets”, session on chronic and

acute leukemias, Atlanta, GA, 27 October 1994. 33. Acute Leukemias. 37th Annual Meeting of the American Society of Hematology, 4

December 1994.

Bruce D. Cheson, M.D. Page 174 34. Low Grade Lymphomas/Large Cell Lymphomas. “Lymphoma...the next questions”,

San Antonio, TX, 20 October 1995. 35. Chronic Lymphocytic Leukemia. 38th Annual Meeting of the American Society of

Hematology, Seattle, WA, 5 December 1995. 36. Consensus Conference on Non-Hodgkin’s Lymphomas, Phoenix, AZ, 17 February

1996. 37. Education Session on Multiple Myeloma, 33rd Annual Meeting of the American

Society of Clinical Oncology, Denver, CO, 17 and 18 May 1997. 38. International Workshop on Response Criteria in Non-Hodgkin’s Lymphomas, 26

February 1998. 39. Toward the Cure of Indolent B-cell Malignancies. 40th Annual Meeting of the

American Society of Hematology, Miami, FL, 4 December 1998. 40. International Workshop on Waldenström’s Macroglobulinemia. Rockville, MD, 7-8

September 2000. 41. International Workshop to Standardize Diagnosis and Response in Acute

Myelogenous Leukemia. Madrid, Spain, 23-25 March 2001. 42. National Cancer Institute State of the Science Meeting on Chronic Lymphocytic

Leukemia. Bethesda, MD, 11-12 June 2001. 43. Bendamustine in the Treatment of Hematological Malignancies. Lisbon, Portugal,

21 October 2001. 44. First Annual Conference: Targeted Therapies for the Treatment of Hematologic

Malignancies. Session chair. Kona, Hawaii, 17 July 2003. 45. International Harmonisation Workshop at the Sixth International Symposium on

Hodgkin’s Lymphoma, Cologne Germany, 18 September 2004. 46. Response Criteria in Lymphoma – Meeting of the International Harmonization

Project. 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 9 June 2005.

47. HDAC Inhibition – A Novel Approach to Cancer Treatment. 9th International

Conference on Malignant Lymphoma, Lugano, Switzerland, 7 June 2005. 48. Post-Lugano Lymphoma Symposium. Washington, D.C., 10 September 2005. 49. 2006 International Workshop on Lymphoid malignancies (co-chair), Laguna Beach,

CA, 21-22 January 2006.

Bruce D. Cheson, M.D. Page 175 50. FDG-PET Demonstration Project Invitational Workshop, NIH, Bethesda, MD, 20

March 2006. 51. Lymphoma Research Foundation North American Patient Education Forum. Los

Angeles, CA, 27-29 October 2006. 52. Current Trends in Leukemia, Lymphoma, and Myeloma. Arlington, VA, 9 February

2008. 53. Oncology Drug Development: Rethinking FDA Oversight, American Institute fior

Public Policy, Panel on Clinical Trials Design, Washington, D.C., 13 March 2008. 54. Hodgkin’s Lymphoma: Advancing Beyond Standard Management. 10th-

International Conference on Malignant Lymphoma, 3 June 2008, Lugano Switzerland.

55. The Evolving Role of Multifunctional Agents in Lymphoid Malignancies, 10th-

International Conference on Malignant Lymphoma, 3 June 2008, Lugano, Switzerland.

56. New Drugs. 10th-International Conference on Malignant Lymphoma, 7 June 2008,

Lugano, Switzerland. 57. Advances in the Clinical Management of Lymphoma: An Update of the Lugano

Meetings. 13 September 2008, Washington, D.C. 58. Current Trends in Leukemia, Lymphoma and Myeloma. 31 January 2009,

Washington, D.C. 59. Pipeline Drugs Become Clinical Reality, at American Society of Cliinical Oncology,

30 May 2009, Orlando, FL. 60. Defining a Standard of Care for Indolent NHL and CLL: A 2009 Perspective. Pan

Pacific Lymphoma Conference, 23 June 2009. 61. New Aspects of CLL Treatment. VIIIth International Workshop of the German CLL

Study Group in Cologne. Bonn, Germany, 4 September 2010.

62. Lymphoma Response Evaluation. 8th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 23 October 2010.

63. What are clinically meaningful endpoints in CLL? Lymphoma Research Foundation sponsored workshop. Crystal City, VA, 25-26 May, 2011.

64. Lymphoma Pretreatment Assessment and Response Criteria in the New Millennium: Beyond Ann Arbor. 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 14 June 2011.

65. Chronic Lymphocytic Leukemia session, iith International Conference on Malignant Lymphoma, Lugano, Switzerland, 17 June 2011.

Bruce D. Cheson, M.D. Page 176 66. 4th International Meeting on PET in Lymphoma, Poster Discussion on Interim PET.

Menton, France, 5 October 2012.

67. 17th Annual Lymphoma Research Foundation North American Forum on Lymphoma, Manhattan Beach, CA, 9-11 November 2012.

68. Advances in the Treatment of B-cell Malignancies. 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18 June 2013.

69. Advances in the Treatment of B-cell Malignancies. 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18 June 2013.

70. Workshop on International Guidelines on Follow-up and Survivorship, 9th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 12 October 2013.

71. Consensus Panel Meeting: Update from an international consensus panel: treatment recommendations for the optimal use of bendamustine in chronic lymphocytic leukaemia, non-Hodgkin lymphomas, and multiple myeloma, Richmond, England, 20 March 2014.

72. Redefining the therapeutic landscape for relapsed/refrafctory CLL. Pan Pacific Lymphoma Conference, Kona, HI 22 July 2014.

73. 1st Middle East and Sub-Saharan Africa (MENA/SSA) Oncology and Hematology

Summit. Moderator for Hematology sessions. Dubai, UAE, 6 March 2015. 74. 1st Postgraduate Lymphoma Conference, Scientific Committee, Rome, Italy, 26-27

March 2015. 75. 2012…2015. T-cell Lymphomas: We Are Illuminating the Darkest of Tunnels. PTCL-

the “combostep” of New Drugs. Bologna, Italy, 28 April 2015. 76. Imaging. 13th ICML, Lugano, Switzerland, 18 June 2015. 77. Immunotherapy Response Criteria for Hematologic Malignancies. Washington,

D.C. 20 November 2015. 78. Follicular Lymphoma. 2nd Postgraduate Lymphoma Conference. Rome, Italy, 17

March 2016. 79. Non-Hodgkin Lymphoma. New Drugs in Hematology. Bologna, Italy. 10 May

2016. 80. PET and Immunotherapy in Lymphoma: How to Report? 6th International

Workshop on PET in Lymphoma. Menton, France, 20 September 2016. 81. PET Workshop. 10th International Workshop on Hodgkin Lymphoma, Cologne,

Germany. 22 October 2016.

Bruce D. Cheson, M.D. Page 177 82. Lymphoma Research Foundation Lymphoma Workshop, Washington, D.C., 18

March 2017. 83. Session on Follicular Lymphoma. 3rd Postgraduate Lymphoma Conference.

Rome, Italy 24 March 2017. 84. Front-line Therapy for Follicular Lymphoma: How I Approach. Indolent Lymphoma

Workshop. Bologna, Italy, 15 May 2017. 85. Maintenance: To Be or Not To Be. Indolent Lymphoma Workshop. Bologna, Italy,

15 May 2017. 86. Improving Treatment Strategies for Patients With Follicular Lymphoma: How to

Translate Novel Study Data Into Clinical Practice. Lugano, Switzerland, 13 June 2017.

87. Follicular Lymphoma. 4th Postgraduate Lymphoma Conference, Rome, Italy 15

March 2018. 88. NHL oncoMAP Washington Meeting. Washington, D.C. 30 April 2018. 89. PTCL: Update on…2015…2018 T-cell Lymphomas: we are close to the

finalization. Bologna, Italy, 8 May 2018. 90. Regional Summit on B-Cell and Plasma Malignancies, Boston, MA 12 May 2018. 91. Prognostic Factors and Prediction of Response in Lymphomas. New Drugs in

Hematology. Bologna, Italy, 1 October 2018. 92. Clinical Trials: What, How and Why? Lymphoma Research Foundation North

American Patient Education Forum. Manhattan Beach, CA, 13 October 2018. 93. Immunotherapy. Lymphoma Research Foundation North American Patient

Education Forum. Manhattan Beach, CA, 13 October 2018. 94. Lymphoma Research Foundation, D.C. Rounds. Washington, D.C., 1 November

2018. 95. Lymphoma Research Foundation Lymphoma Workshop. Washington, D.C., 10

November 2018. 96. Follicular Lymphoma. 5th Postgraduate Course in Lymphoma. Rome, Italy, 14

March 2019. 97. Lymphoma Research Foundation, D.C. Rounds, Washington, D.C. 4 April 2019.

98. New Drugs. Aggressive Lymphomas. Bologna, Italy, 14 May 2019.

99. PET Imaging. 15th ICML, Lugano, Switzerland, 20 June 2019.

Bruce D. Cheson, M.D. Page 178 100. Lymphoma Resesarch Foundation Lymphoma Rounds, Washington, D.C. 3

October 2019. 101. Hodgkin Lymphoma. ICML-16 (virtual), 22 June 2021


Documents

Bruce D. Cheson, MD - ESCO